

## Speaker Abstracts

<b>Molecular Basis of Disease</b> .....	<b>9</b>
The rapid progress in next-generation genetics of ataxias: insights, challenges, and next steps .....	9
Elucidating the genetic background of childhood-onset ataxias.....	10
Genotype-phenotype correlation of mutant SLC25A46 disrupting mitochondrial fission in cerebellar degeneration .....	10
Genes that affect synaptic excitability and transmission identified by rare variant analyses in episodic ataxias .....	11
Novel SCA gene FAT Atypical Cadherin 2 is a regulator of autophagy .....	12
Afg3l2 missense mutation p.Met665Arg impairs m-AAA protease function: new hints into a therapeutic strategy for SCA28.....	13
The presence and relevance of autoantibodies to CNS proteins in patients with cerebellar ataxia.....	14
Ataxin-2 regulates mitochondrial precursors to maintain nutrient balance and cellular energetics.....	15
Understanding the pathophysiological and the molecular mechanisms underlying the recessive ataxia ARCA2.....	16
E3 ligase RNF126 directly ubiquitinates frataxin, promoting its degradation: identification of a potential therapeutic target for Friedreich Ataxia.....	16
Regulation of neuronal mRNA splicing by ATXN3 is disturbed in SCA3/MJD .....	17
Epigenetic silencing in Friedreich ataxia is caused by hypermethylation of the FXN CpG island shore....	18
Spinocerebellar ataxia type 1 (SCA1): molecular basis of neurodegeneration in the cerebellum (ataxia) and brainstem (lethality).....	18
Transcriptional profiling of isogenic iPSC-derived Friedreich's ataxia sensory neurons .....	19
Early cerebellar mitochondrial biogenesis deficits and OXPHOS complex I and II deficiency in the KIKO mouse model of Friedreich ataxia .....	20
Addressing mitochondrial function in a mouse model of Friedreich's Ataxia (FRDA).....	20
Mitofusin-dependent ER stress mediates degeneration in a Drosophila model of Friedreich's ataxia ....	21
<b>Translational Models of Disease</b> .....	<b>22</b>
Targeting repeat expansion in cellular models of Friedreich's Ataxia.....	22
Understanding Friedreich's ataxia neuropathophysiology using a new conditional neuronal mouse model. ....	23
A SCA7 mouse model showing multisystem phenotypes; new opportunities for pathomechanism studies and therapeutic development .....	23
Inducible and reversible phenotypes in a novel mouse model of Friedreich's Ataxia .....	24
Repeat disorders: models, markers and more. ....	25
Voluntary running prevents onset of symptomatic Friedreich's ataxia in mice.....	25
Using mouse models and BioID proteomic approach to understand ARSACS pathophysiology. ....	26
Let-7 activates autophagy and alleviates motor and neuropathological deficits in pre- and post-symptomatic Machado-Joseph disease mouse models .....	26
<b>Natural History, Biomarkers and Endpoints</b> .....	<b>27</b>
Natural history of Friedreich ataxia.....	27
Natural history of the spinocerebellar ataxias (SCAs).....	28
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: a natural history study over a two-year follow-up .....	29
Detailing the natural history of Friedreich's Ataxia – loss of ambulation in the CCRN-FA study .....	30
Long-term quality of life, depression and activities of daily living in the most common spinocerebellar ataxias (SCA1, SCA2, SCA3, SCA6) .....	31
Longitudinal MRS, MRI and DTI in the spinal cord in Friedreich's Ataxia: 24-month follow-up .....	33
Basal ganglia and Posterior fossa structural abnormalities in SCA3 stratified for disease stages.....	35
CCFS a quantitative score of cerebellar dysfunction and evolution in Friedreich ataxia .....	35
Cortical responses and change detection to auditory and somatosensory stimuli in Friedreich ataxia ...	36

Exercise stress testing on adaptive equipment is feasible and reliable in Friedreich Ataxia .....	38
Developing a clinically meaningful instrumented measure of upper limb function in Friedreich ataxia. .38	
Cardiac magnetic resonance T1 mapping as a window into the myocardium in Friedreich ataxia (FRDA) .....	39
Auditory dysfunction and it's remediation in individuals with spinocerebellar ataxia. ....	40
<b>Therapeutics and Clinical Trials .....</b>	<b>41</b>
Summary and lessons learned from ataxia trials .....	41
Innovative trial designs for rare diseases, with focus on use of innovative endpoints and potential use of registry data. ....	41
Activation of Frataxin expression by duplex RNAs and antisense oligonucleotides .....	41
Gene-targeted synthetic molecules stimulate transcription through repressive GAA-repeats in patient- derived Friedreich's Ataxia cells.....	42
Class-I HDAC inhibitors with improved potency and drug-like properties for de-repressing frataxin production in Friedreich's Ataxia .....	42
RNA/DNA hybrid interactome uncovers DHX9 as a novel regulator of pathological R-loops in Friedreich ataxia.....	43
Safety, Efficacy, and Pharmacodynamics of Omaveloxolone in Friedreich's Ataxia Patients (MOXIe Trial): Part 1 Results.....	43
Lessons learned from recent approvals of therapies for neuromuscular disorders. ....	44
Overview of viral gene therapy approaches for genetic diseases.....	45
Role of microRNAs in Machado-Joseph disease: from pathogenesis to therapy.....	45
Docosahexaenoic acid (DHA) supplementation as a therapy for Spinocerebellar Ataxia 38 (SCA38) .....	46
Neurotrophic factor and cytokine mimetics as new potential therapeutic agents for Friedreich's ataxia .....	47
Gene therapy for Friedreich's ataxia.....	48
Targeting the intracellular localization of ataxin-3 as novel treatment approach for Spinocerebellar Ataxia Type 3 (SCA3) .....	48
Ataxin-3 exon skipping as a treatment strategy for Spinocerebellar Ataxia type 3 .....	49
Nicotinamide Mononucleotide supplementation in a model of Friedreich's Ataxia cardiomyopathy improves cardiac function and bioenergetics in a SIRT3-dependent manner .....	50
Correction of sensory ataxia in a novel mouse model of Friedreich ataxia using gene therapy approach .....	51
TALEN and CRISPR gene editing for treatment of Machado-Joseph disease .....	51
Phenotypic and functional characterization of sensory neurons derived from human pluripotent stem cells and examining their in vivo capability to integrate into adult dorsal root ganglia. ....	52
Intravenous delivery of AAV gene therapy to cerebellum and peripheral tissues critical for the treatment of Friedreich's ataxia.....	53
Effects of acetyl-DL-leucine in cerebellar ataxias .....	54
<b>Molecular Basis of Disease .....</b>	<b>57</b>
1. Nuclear transport factors influencing pathogenic mechanisms induced by expanded ataxin-3.....	57
2. Addressing mitochondrial function in a mouse model of Friedreich's ataxia. ....	57
3. Analysis of GAA repeat interruptions in a large panel of Friedreich ataxia patient DNA samples ...	57
4. Frataxin deficiency leads to lipolysis alteration in skeletal muscle cells .....	58
5. Identification of specific brain metabolic dysfunctions in Friedreich's Ataxia using proteomic approach in an innovative Drosophila model .....	59
6. When ataxia is not just ataxia – why genetic testing matters .....	59
7. Defining the Frataxin G130V pathogenic mechanism in Friedreich's ataxia .....	60
8. Progressive cerebellar ataxia, parkinsonism and myoclonic epilepsy due to maternal segmental uniparental isodisomy and a novel mutation in MFSD8 .....	61
9. Mutations in NKX6-2 cause progressive spastic-ataxia and hypomyelination .....	62
10. HAX-1 is a potential molecular biomarker for cardiomyopathies in Friedreich's Ataxia.....	63

11.	Molecular mechanisms underlying the atypical mild phenotype in Friedreich's ataxia patients with missense mutations .....	63
12.	A510V variant in SPG7 is associated with a cerebellar phenotype .....	64
13.	An in vitro study of the network connectivity in a Friedreich's Ataxia-neuronal model.....	65
14.	CRISPR/Cas9 genome-wide screen to identify novel targets for the treatment of Friedreich's Ataxia	65
15.	Identification of p38 MAPK as a novel therapeutic target for Friedreich ataxia .....	66
16.	Identification of a novel autosomal dominant slowly progressive late onset ataxia co-segregating with a chromosome 14 deletion/duplication .....	67
17.	High-throughput sequencing and clinical data of a family presenting with autosomal dominant spinocerebellar ataxia that maps to the SCA25 locus .....	67
18.	Detecting known repeat expansions with standard protocol next generation sequencing .....	68
19.	NGS analysis for episodic ataxias expands the phenotypic spectrum of SCA27/FGF14.....	69
20.	Insights into the molecular pathogenesis of Spinocerebellar Ataxia 38 (SCA38).....	69
21.	Genes that affect synaptic excitability and transmission identified by rare variant analyses in episodic ataxias .....	70
22.	Mutations in a novel gene implicate cellular stress in a new form of Autosomal Recessive Cerebellar Ataxia .....	70
23.	Application of Next Generation Sequencing in a cohort of ataxic patients using a multi-gene panel approach .....	71
24.	Specific neuronal vulnerability in SCA1 is not associated with CAG instability between different brain regions .....	72
25.	Clinical and genetic characteristics of sporadic adult-onset ataxia.....	73
26.	Alteration of the growth cone dynamics in dorsal root ganglia neurons from the Friedreich ataxia YG8sR mouse .....	73
27.	Confirmation of ATP8A2-related disorders as recessive cerebellar ataxia .....	74
28.	Novel SCA gene FAT Atypical Cadherin 2 is a regulator of autophagy .....	75
29.	Elucidating the genetic background of childhood-onset ataxias.....	75
30.	Understanding the pathophysiological and the molecular mechanisms underlying the recessive ataxia ARCA2 .....	75
31.	Heart and nervous system pathology in compound heterozygous Friedreich ataxia .....	75
32.	Friedreich ataxia: developmental failure of the dorsal root entry zone .....	76
33.	Defining the effect of expanded GAA repeats on the kinetics of FXN transcription in Friedreich's Ataxia	76
34.	Time and region-specific glial pathology in mouse model of Machado-Joseph disease.....	77
35.	Synaptic pathology in in vitro and in vivo models of Friedreich's ataxia .....	78
36.	KIF1A motor domain variants and gene copy number variation in patients with spinocerebellar ataxia	78
37.	Functional studies of AFG3L2 mutations reveal haploinsufficiency as the pathogenetic mechanism of SCA28.....	79
38.	The c.1529C>T (p.Ala510Val) SPG7 missense mutation in sporadic cerebellar ataxias in Italy. ..	80
39.	ACO2 mutations: a novel phenotype associating severe optic atrophy, cerebellar atrophy and severe spastic paraplegia .....	81
40.	NMR analysis of the direct complex between the FeS clusters IscU scaffold protein and frataxin	82
41.	Investigating the role of FAST-1 in Friedreich ataxia.....	83
42.	Misregulation of microRNA expression in Friedreich's ataxia cells.....	84
43.	The role of salsin in autophagy offers novel therapeutic opportunities .....	84
44.	Autosomal recessive cerebellar ataxia type 3 (ARCA3): novel ANO10 gene mutations in 6 late-onset Italian patients.....	85
45.	Mitofusin-dependent ER stress mediates degeneration in a Drosophila model of Friedreich's ataxia. Juan Antonio Navarro Langa (See oral presentation) .....	85

46.	Identification of a pathogenic SCA1 allele with 38 repeats from a large UK cohort and improving SCA1 allele sizing methods.....	86
47.	Complexity of the genetics and clinical presentation of spinocerebellar ataxia 17.....	86
48.	mTOR is differentially activated in in vitro and in vivo models of Friedreich ataxia.....	87
49.	Evaluation of the posttranslational modification O-GlcNAcylation and its potential involvement on the pathogenesis of Machado-Joseph Disease.....	88
50.	Defective trafficking of inflammatory response factors exhibit hyposensitive immunogenic response in skin fibroblasts from Ataxia Telangiectasia patients.....	89
51.	Frataxin-deficient cardiomyocytes present an altered thiol-redox state.....	89
52.	Early dysregulated cardiac mitochondrial biogenesis and OXPHOS system in the KIKO mouse model of Friedreich Ataxia.....	90
53.	Late onset spinocerebellar ataxia and orofacial clefting in a case of interstitial 1q32.2q32.3 deletion encompassing the SYT14 and IRF6 genes.....	91
54.	Validation of common genetic modifiers for NDDs in SCA3.....	91
55.	A CRISPR approach for investigating epigenetic silencing in Friedreich ataxia.....	92
56.	Deletion of the ataxia protein saccin alters dynamics of the vimentin cytoskeleton and impairs cell migration.....	93
57.	Mitochondrial calcium transporter NCLX, the NFAT3 transcription factor and mitochondrial permeability transition pore become altered in cell models of Friedreich ataxia.....	93
58.	Lithium and cortical myoclonus; Is the cerebellum the key protagonist?.....	94
59.	Ataxin-2 regulates mitochondrial precursors to maintain nutrient balance and cellular energetics. Neslie Ece Sen (see oral presentations).....	95
60.	Dysregulated lipid homeostasis emerging as a prominent pathological feature in a mouse model of Autosomal Recessive Cerebellar Ataxia 2 (ARCA2).....	95
61.	Mutational analysis of ITPR1 in a Taiwanese cohort with cerebellar ataxia.....	96
62.	Genotype-phenotype correlation of mutant <i>SLC25A46</i> disrupting mitochondrial fission in cerebellar degeneration. Janos Steffen (see oral presentations).....	97
63.	Ataxin-3's interaction with the proteasome shuttle protein, Rad23: Implications for Spinocerebellar Ataxia Type 3.....	97
64.	Nitric Oxide prevents Aft1 activation and metabolic remodeling in frataxin- deficient yeast.....	97
65.	Deciphering metabolic dysfunctions in Friedreich's ataxia using quantitative proteomic approach.....	98
66.	Novel mutation in SETX causes a dominant pleiotropic Tremor-Ataxia phenotype across three generations.....	99
67.	Dissection of epigenetic mechanisms underlying the GAA-mediated FXN silencing in Friedreich's ataxia to identify FXN up-regulating compounds.....	100
68.	Activation of $\alpha$ 1 adrenergic receptors is required and sufficient for stress-induced attacks of motor dysfunction in a mouse model of Episodic Ataxia Type 2.....	100
69.	Physiological and pathophysiological functions of ataxin-3 isoforms and their impact on Machado Joseph Disease.....	101
70.	Clinical and genetic characterization of Spinocerebellar Ataxia Type 6.....	102
71.	De novo T362R mutation in MORC2 (Microorchidia 2) causes early onset cerebellar ataxia and axonal polyneuropathy with diaphragmatic involvement.....	102
198.	Repeat expansion at the interface between genomic instability and autophagy.....	103
201.	A novel mutation in the KCNA1 gene in a patient with episodic ataxia, myokymia, painful contractures and metabolic dysfunctions.....	104
	<b>TRANSLATIONAL MODELS OF DISEASE.....</b>	<b>105</b>
72.	Impaired mitochondrial function in SCA1 patient-derived cells.....	105
73.	Folate metabolism modifies disease progression in a mouse model for mitochondrial ataxia.....	105
74.	Sodium valproate is protective in a novel transgenic zebrafish model of Machado Joseph disease.....	106

75.	Cellular models of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) reveal mitochondrial dysfunction and cytoskeletal reorganisation.....	107
76.	Characterization of iPSC-derived Friedreich ataxia cardiomyocytes.....	108
77.	Understanding Friedreich’s ataxia neuropathophysiology using a new conditional neuronal mouse model.....	108
78.	A human iPSC-based cardiac model of Friedreich’s Ataxia for drug discovery and patient stratification using all-optical electrophysiology.....	109
79.	Let-7 activates autophagy and alleviates motor and neuropathological deficits in pre and post symptomatic Machado-Joseph disease mouse models.....	110
80.	Epigenetic editing of the Frataxin (FXN) locus by re-purposing CRISPR/CAS9 – targeted epigenetic editing with heterochromatin antagonists specifically reactivates the FXN gene in living cells? 110	
81.	Elovl5 knockout mice recapitulate SCA38 symptoms and cerebellar atrophy.....	111
82.	Application of nanotechnology in FRDA drug research.....	112
83.	A Drosophila cell-based assay for high-throughput screening of genetic modifiers of FXN transcriptional silencing mediated by the GAA repeat expansion.....	112
84.	Mouse models of Friedreich’s Ataxia.....	113
85.	Histological characterization and drug screening on a Drosophila cardiac model of Friedreich Ataxia	114
86.	New Drosophila models of Friedreich ataxia with GAA expansions.....	114
87.	Inactivation of the Grm5 gene improves motor coordination defects in the Grm1crv4 mouse model of SCAR13 ataxia.....	115
88.	Generation of Machado-Joseph disease induced pluripotent cell lines and isogenic controls using the CRISPR/Cas9 technology.....	116
89.	Comparison of two GAA repeat expansion-based Friedreich ataxia mouse models: YG8sR and YG8LR	117
90.	High Throughput Screen (HTS) using ARSACS fibroblast cytoskeletal bundling assay.....	117
91.	Development of an unbiased standardized gene therapy genotoxicity platform using induced pluripotent stem cells and their reprogrammed derivatives.....	118
92.	A human induced pluripotent stem cell (iPSC)-based model of cerebellar ataxia.....	118
93.	Voluntary running prevents onset of symptomatic Friedreich’s ataxia in mice.....	119
	<b>NATURAL HISTORY, BIOMARKERS AND ENDPOINTS</b> .....	<b>121</b>
94.	Systems biology approach to studies of mitochondrial dysfunction for the discovery of Friedreich’s ataxia biomarkers.....	121
95.	A study of personality, psychopathological features and social adaptation in subjects with the Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.....	121
96.	What do we know about personality and cognitive deficits in ARSACS: results from a pilot study 122	
97.	Applicability of neuropsychological and personality tests in ARSACS.....	123
98.	Impacts of cognitive deficits and social participation in ARSACS.....	123
99.	Investigating feasibility of use of an Android Smart Phone Application (MoveIt) as a clinical outcome measure.....	124
100.	How does performance of the Friedreich Ataxia Functional Composite compare to rating scales? 124	
101.	Sexual function, intimate relationships and Friedreich Ataxia.....	125
102.	Keeping the black dog at bay: understanding depression in Friedreich ataxia.....	126
103.	Transgenic mouse models of Machado-Joseph disease show cerebellar neurochemical profiles similar to that of patients.....	127
104.	A unique pattern of left ventricular remodeling in Friedreich ataxia (FRDA) related to frataxin deficiency?.....	128
105.	Monitoring progression of disease in Friedreich’s Ataxia: a multimodal electrophysiological approach.....	128

106.	CARFA (NCT02840669): A study to characterize the cardiac phenotype of individuals With Friedreich's Ataxia .....	129
107.	CCFS a quantitative score of cerebellar dysfunction and evolution in Friedreich ataxia .....	130
108.	Ambulatory status and quality of life in children with Friedreich ataxia .....	130
109.	SAOA vs. MSA-C: Structural analysis with VBM and TBSS .....	131
110.	Healthcare practices and socio-economic impact in Friedreich's Ataxia .....	131
111.	Validation of suitable reference genes for the normalization of qPCR gene expression data in spinocerebellar ataxia type 3. ....	132
112.	Autosomal recessive spastic ataxia of Charlevoix-Saguenay: a natural history study over a two-year follow-up .....	133
113.	Cognitive deficits in spinocerebellar ataxia type-3/Machado-Joseph disease. ....	133
114.	Baseline disease severity predicts longitudinal brain atrophy over 2-Years in Friedreich Ataxia: the IMAGE-FRDA Study .....	133
115.	Prediction of the age at onset in Spinocerebellar ataxia type 3 varies according to population of origin	134
116.	The progression rate of neurological deterioration in spinocerebellar ataxia type 2 changes according to stage of disease .....	135
117.	Neurological phenotypes in spinocerebellar ataxia type 2: role of mitochondrial polymorphism A10398G and other risk factors .....	136
118.	Validation of the Neurological Examination Score for the assessment of Spinocerebellar Ataxias (NESSCA) and responsiveness of several rating scales in Spinocerebellar Ataxia type 2 .....	137
119.	CAG repeat numbers seem to influence genetic fitness and meiotic drive of ATXN2 alleles ....	138
120.	Local gray matter changes in the cerebellum in MSA-C and SAOA: a multicenter VBM study..	138
121.	Assessing mobility, balance, coordination, and dexterity in ARSACS: Reliability and validity of 7 outcome measures.....	139
122.	Exercise stress testing on adaptive equipment is feasible and reliable in Friedreich ataxia.....	140
123.	Cardiac magnetic resonance T1 mapping as a window into the myocardium in Friedreich ataxia	140
198.	(FRDA) .....	140
124.	Body Mass Index and Stature in the Friedreich Ataxia Clinical Outcome Measure Study .....	140
125.	Acute effects of dietary glycemic index on lactate and glucose homeostasis in individuals with Freidreich's Ataxia and other disorders affecting mitochondria.....	141
126.	Motor GABA levels predict clinical impairment in children with Friedreich ataxia.....	142
127.	Biomarkers in FRDA cardiomyopathy to monitor disease progression.....	143
128.	Correlation between GAA expansion length and frataxin upregulation in Friedreich's ataxia ..	144
129.	Targeted quantitation of coenzyme A metabolites and serum apolipoprotein A-I by LC-MS for monitoring mitochondrial dysfunction in Friedreich's ataxia .....	145
130.	Living with Ataxia in Ireland 2016—a nationwide survey of 130 Irish patients with inherited Ataxia	145
131.	Longitudinal change of gait and balance in individuals with Friedreich ataxia .....	146
132.	Allelic CACNA1A disorders: a retrospective cohort analysis on clinical course and overlapping features .....	147
133.	The autonomic nervous system in Friedreich's Ataxia: preliminary findings.....	148
134.	Peripheral blood gene expression biomarkers in Friedreich's ataxia patients.....	148
135.	Corticokinematic coherence in patients with Friedreich ataxia correlates with GAA1 repeat expansion and SARA score .....	149
136.	Cortical responses and change detection to auditory and somatosensory stimuli in Friedreich ataxia	149
137.	Causal factors behind early- and late-onset Machado-Joseph disease patients do not interfere with the rate of neurological deterioration .....	151
138.	ARSACS in the UK .....	151
139.	Searching for neuroimaging biomarkers in SCA1 .....	152

140.	BCL2 and HSPB1 as potential molecular biomarkers of Spinocerebellar Ataxia Type 3 progression: results from a longitudinal study.....	153
141.	MR imaging of the spinal cord and brain in Friedreich's Ataxia .....	154
142.	Structural signature of classical vs late-onset Friedreich's ataxia by multimodality brain MRI .	155
143.	Differences in cognition between Spinocerebellar Ataxias and Multiple System Atrophy-Cerebellar Type .....	156
144.	Detailing the natural history of Friedreich's ataxia – loss of ambulation in the CCRN-FA study	156
145.	Analysis of correlations among four measures of disease progression in Friedreich's ataxia. ...	156
146.	Cognition in Friedreich Ataxia: a neuropsychological and RS-FMRI study. ....	157
147.	Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests	158
148.	Ataxia, 50 clinical case series.....	158
149.	Expression of GSK3B, BDNF, ENO2, and HDAC6 genes in patients with Machado-Joseph disease before and after lithium treatment.....	159
150.	Reduced cerebral white-matter integrity in Friedreich ataxia is associated with diminution in myelin integrity: The IMAGE-FRDA study.....	160
151.	Sleep and fatigue in Friedreich's Ataxia .....	161
152.	Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome (CANVAS), a novel vestibulo-cerebellar ataxia: clinical phenotype, pathology, imaging abnormalities, differential diagnoses and a quantitative bedside test.....	162
153.	A novel oculomotor biomarker in Friedreich's Ataxia.....	162
154.	Tracking progression in Friedreich's Ataxia (FRDA) to establish biomarkers for clinical trials...	163
155.	Swallowing function declines over 12 months in Friedreich ataxia .....	164
156.	Anti-MAG associated cerebellar ataxia .....	164
157.	Causes of cerebellar ataxia with sensory ganglionopathy .....	165
	<b>THERAPEUTICS AND CLINICAL TRIALS.....</b>	<b>166</b>
158.	Highly specific ubiquitin-competing molecules promote frataxin accumulation in Friedreich ataxia iPSC-derived neuronal cells. ....	166
159.	FDA-approved drug screening for Friedreich Ataxia: FDA11 promotes frataxin accumulation at near- physiological levels in FRDA patient-derived cells. ....	167
160.	TAT-MTScs-FXN protects frataxin-deficient neurons and is targeted, processed and functional in mice models of Friedreich ataxia. ....	168
161.	Physiotherapy management of the ataxias towards best clinical practice: 2016 guideline update	169
162.	Role of microRNAs in Machado-Joseph disease: from pathogenesis to therapy.....	169
163.	Clinical Trial Readiness for Friedreich's Ataxia Gene Therapy.....	169
164.	Friedreich's ataxia patients and mice have less mitochondria, and the EMA and FDA-approved drug dimethyl fumarate raises frataxin in cells and mice, and mitochondrial number in mice and humans	170
165.	Citalopram reduces aggregation of ATXN3 in a YAC transgenic mouse model of Machado-Joseph disease.....	171
166.	Calcitriol, the active form of Vitamin D, reduces apoptotic markers in a neuron model of Friedreich ataxia.....	172
167.	Long-term treatment with thiamine in Friedreich ataxia.....	173
168.	Riluzole spinocerebellar ataxia type 7: report on two families.....	174
169.	Patient Reported Outcomes in Friedreich's Ataxia after withdrawal from Treatment with ldebenone .....	175
170.	Morpholino directed alternative splicing of mismatch repair protein mMLH3 in an FRDA mouse model	176
171.	RT001 First-in human Clinical Trial Demonstrates Safety, Favorable Pharmacokinetics, and Early Signals of Efficacy in Friedreich's Ataxia.....	176
172.	Stimulating neural repair through bone marrow stem cell fusion in models of ataxia.....	177

173.	Evaluation of AMX0035, a novel combination therapy for the treatment of neurodegenerative diseases, in cellular models of Friedreich's Ataxia .....	177
199.	.....	178
174.	TALEN and CRISPR gene-editing for treatment of Machado-Joseph disease.....	178
175.	Rationale and Trial Design of a Study of the Efficacy and Safety of Omaveloxolone in Patients with Friedreich's Ataxia (MOXIe) .....	179
176.	Serotonergic signaling suppresses ataxin-3 proteotoxicity .....	180
177.	Docosahexaenoic acid (DHA) supplementation as a therapy for Spinocerebellar ataxia 3 (SCA38) 180	180
178.	Effect of Diazoxide on Friedreich ataxia models .....	180
179.	Ibuprofen improves neuropathology and increases neural progenitors proliferation, synaptic function and neurite growth in Machado-Joseph disease .....	181
180.	Rehabilitation improves health and well-being in individuals with Friedreich ataxia.....	182
181.	Non-invasive and allele-specific silencing of mutant ataxin-3 alleviates neuropathology and motor deficits of Machado–Joseph disease .....	183
182.	Clinical trials in Friedreich ataxia: pre-clinical evidence of efficacy is essential .....	183
183.	CAT-4001 improves mitochondrial function in a Friedreich's ataxia model .....	185
184.	Modification of Frataxin with BBB-shuttles to increase brain access .....	185
185.	Biophysical Characterization of the Recombinant Human Frataxin Precursor .....	186
186.	Autologous haematopoietic stem cell transplantation in a patient with paraneoplastic-related ataxia 187	187
187.	DAO inhibitor preclinical therapeutic studies for FRDA .....	188
188.	HMTase inhibitor preclinical therapeutic studies for FRDA .....	189
189.	BBB-shuttle decorated DNA nanocarriers to treat Friedreich's ataxia.....	189
190.	Ataxin-3 exon skipping as a treatment strategy for Spinocerebellar ataxia type 3.....	190
191.	Combining multiple therapeutic strategies for Friedreich's ataxia (FRDA): antioxidant metallic nanoclusters as coadjuvants for gene and stem cell therapy.....	190
192.	Increased frataxin expression induced in Friedreich ataxia cells by new TALEs fused with a transcription activation domain.....	191
193.	In vivo deletion of the GAA repeats from the intron 1 of the human frataxin gene using the CRISPR system delivered with PHP.B-serotyped AAV in the YG8R mouse model.....	191
200.	.....	192
194.	Combining transcranial direct current stimulation and intensive physiotherapy in patients with Friedreich's Ataxia: a pilot study. ....	192
195.	Speech Rehabilitation in Friedreich ataxia .....	193
196.	EPI-743 (Alpha-tocotrienol Quinone) Demonstrates Long-Term Improvement in Neurological Function and Disease Progression in Friedreich's Ataxia .....	193
197.	RNA therapeutics for Friedreich's Ataxia .....	194
199.	What to look for in a clinical trial? How clinical trials can be interpreted differently in reviews...	195
200.	Gene-targeted synthetic molecules stimulate transcription through repressive GAA-repeats in patient-derived Friedreich's ataxia cells. ....	196



# Speaker abstracts:

## Molecular Basis of Disease.

The rapid progress in next-generation genetics of ataxias: insights, challenges, and next steps

Matthis Synofzik, Hertie-Institute for Clinical Brain Research, Tübingen, Germany

Recent next-generation sequencing (NGS) techniques have allowed to identify an expanding number of novel ataxia genes, and to provide a large share of previously undiagnosed ataxia patients with a molecular diagnosis. This progress prompts several new insights, challenges, and next steps.

*Insights.* Panel and exome sequencing have revised frequency notions in recessive ataxias. *ARSACS*, *SYNE1* and *SPG7* (but not Ataxia Teleangiectasia) might be the most common recessive ataxias following Friedreich's Ataxia. These three recessive ataxias might thus now be selected as promising target diseases for natural history, biomarker and treatment studies. In parallel, these NGS techniques have started to dissolve the classical traditional classification system driven by clinical diagnosis, which might need to be replaced by an approach of dynamic *modular phenotyping*. For example, boundaries from ataxias to HSPs (see e.g. *SPG7*) or to epilepsies (see e.g. *KCNA2*) have become fluid. These disease groups share not only overlapping phenotypes and underlying genes, but also common cellular pathways and disease mechanisms, which in turn might offer shared hubs for targeted *across-disease* molecular treatments.

*Challenges.* NGS techniques have also unraveled a problem which might not yet have received sufficient critical appraisal in research and clinical practice: the identification of missense variants of unknown significance in dominant ataxia genes (like e.g. *AFG3L2/SCA28*, or *ITPR1/SCA29*), and partly also recessive ataxia genes (e.g. *SYNE1*). This emphasizes the need of functional confirmation of missense variants in ataxia genes - not just for research purposes, but in fact primarily also for daily clinical diagnosis.

*Next steps.* Current NGS techniques still solve an - astonishingly uniform - share of only 20-40% ataxia patients across different labs. This indicates the need to establish novel approaches to solve the still unsolved ataxia patients. The following approaches might be particularly promising: (i) trio analysis for *de novo* mutations (see e.g. *ITPR1*); (ii) large-scale exome sharing in joint ataxia NGS pipelines for identifying "second families" (e.g. in GENESIS); (iii) mutational burden analysis. Mutational burden analysis have so far been largely reserved to relatively frequent neurodegenerative diseases like ALS, but might also provide a promising approach in ataxias, if we jointly aggregate data-sets in worldwide common ataxia NGS pipeline.

Finally, the genetic progress achieved by ataxia NGS has now to be translated into systematic translational approaches. The genetic stratification of ataxia patients allowed by NGS is indeed the major bridgehead for identifying special causal pathway mechanisms and preparing targeted molecular treatments in ataxias. Multi-center consortia, like e.g. PREPARE, have now started to create a systematic translational pipeline, facilitating all the crucial translational steps from NGS to standardized preclinical trials, FDA-conform outcome measures, and registry-inventoried transnational trial-ready cohorts in genetic ataxias.

## Elucidating the genetic background of childhood-onset ataxias

Ignatius E1,2, Isohanni P1,2, Pohjanpelto M1, Palin E1, Brilhante V1, Ojanen S1, Suomalainen A1, Lönnqvist T2, Carroll CJ1

1Research Programs Unit, Molecular Neurology, University of Helsinki, 00290 Helsinki, Finland

2Department of Pediatric Neurology, Helsinki University Central Hospital, 00029 Helsinki, Finland

### Introduction

Despite available genetic testing, a large proportion of all documented ataxia cases remain genetically uncharacterized. Childhood-onset ataxias are clinically and genetically heterogeneous, which makes finding the molecular diagnosis challenging. Whole exome sequencing (WES) technology has become increasingly used in the diagnosis of neurodevelopmental and neurodegenerative disorders. The aim of this study was to characterize the genetic background of childhood-onset ataxias in Finland using WES technology.

### Methods

Our cohort includes all pediatric patients with ataxia as the primary symptom of disease evaluated in Helsinki University Central Hospital during the years 1999-2016. Patients with acute, infection related ataxias, ataxias that follow brain insult and patients with mild ataxia as a minor part of a disorder were excluded. 42 families lacked a genetic diagnosis and were investigated using WES.

### Results

A pathogenic or likely pathogenic mutation was found for 16 families (38 %). Known or novel autosomal recessive variants were found in known ataxia genes HIBCH, STUB1, ADCK3, B9D1, CLN5, PTRH2, TPP1 as well as in the novel ataxia gene SQSTM1, encoding autophagy receptor p62, we reported recently. De novo dominant or dominantly inherited variants explained approximately a third of genetic causes in our cohort, with variants identified in EBF3, ITPR1, NKX2-1 and ATP1A3. Furthermore, we report here subjects with de novo variants in genes not previously linked to ataxia.

## Genotype-phenotype correlation of mutant SLC25A46 disrupting mitochondrial fission in cerebellar degeneration

Steffen J1, Wan J2, Koehler CM1, Jen JC2,3.

Department of 1Chemistry & Biochemistry, 2Neurology, and 3Neurobiology, University of California, Los Angeles, California, U.S.A.

**Introduction:** Pontocerebellar hypoplasia is a heterogeneous group of autosomal recessive congenital disorders characterized by maldevelopment and degeneration of the cerebellum and brainstem with global developmental delay. We identified recessive mutations in SLC25A46 in patients with PCH with profound weakness and apnea at birth. In the meantime, biallelic mutations were identified in SLC25A46 encoding a mitochondrial protein in a cohort with optic atrophy variably associated with axonal neuropathy and cerebellar atrophy. We wish to understand how mutations in SLC25A46 may lead to cerebellar degeneration.

**Methods:** We performed biochemical and cellular analysis in expression studies of a spectrum of missense mutations and probed the function of the orthologous gene in zebrafish embryos by using morpholinos.

Results: We found that SLC25A46 is localized to the mitochondrial outer membrane. Gene-specific knockdown led to mitochondrial hyperfusion in both cell lines and zebrafish neurons, with hindbrain malformation and loss of spinal motor neurons in the morphant zebrafish embryos. This appears to be mediated by increased stability of MFN1 and MFN2 on mitochondria. There was variable stability and abundance of the mutant proteins harboring different missense mutations from our study and previously reported cases. For Leu341Pro associated with early death, we observed selective degradation through coordinated ubiquitylation by the E3 ubiquitin ligases MULAN and MARCH5 independent of the typical pathways involving mitophagy and apoptosis.

Conclusion: Mutations in SLC25A46 implicate the dysregulation of mitochondrial fission in a broad spectrum of clinical manifestations of cerebellar degeneration. The loss of SLC25A46 function is correlated with lethal congenital PCH with apnea as the most severe, while the greatest stability and abundance of the mutant protein is correlated with isolated mild optic atrophy as the mildest phenotype. The degradation of SLC25A46 is regulated by the ubiquitin-proteasome system independent of mitophagy and promotes oligomerization of MFN1/2 to lead to mitochondrial hyperfusion.

#### REFERENCES:

1. Abrams AJ, Hufnagel RB, Rebelo A, et al. Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. *Nat Genet.* 2015;47(8):926-32. doi: 10.1038/ng.3354. Epub 2015 Jul 13. PubMed PMID: 26168012; PubMed Central PMCID: PMC4520737.
2. Wan J, Steffen J, Yourshaw M, et al. Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. *Brain.* 2016 Aug 20. pii: aww212. [Epubahead of print] PubMed PMID: 27543974.
3. Steffen J, Vashisht AA, Wan J, Jen JC, Claypool SM, Wohlschlegel JA, Koehler CM. Rapid degradation of mutant SLC25A46 by the ubiquitin-proteasome system results in MFN1/2-mediated hyperfusion of mitochondria. *Mol Biol Cell.* 2017 Mar 1;28(5):600-612. doi: 10.1091/mbc.E16-07-0545. Epub 2017 Jan 5. PubMed PMID:28057766; PubMed Central PMCID: PMC5328619.

#### [Genes that affect synaptic excitability and transmission identified by rare variant analyses in episodic ataxias](#)

Stephanie Efthymiou<sup>1</sup>, Vincenzo Salpietro<sup>1</sup>, Marisol Sampedro-Castañeda<sup>1</sup>, Andreea Manole<sup>1</sup>, Thomas Bourinaris<sup>1,2</sup>, Emer O'Connor<sup>1</sup>, Liana Veneziano<sup>3</sup>, Elide Mantuano<sup>3</sup>, Marina Frontali<sup>3</sup>, Paola Giunti<sup>1</sup>, Richard Boles<sup>4,5,6</sup>, Elena Dominguez Garrido<sup>7</sup>, Conceicao Bettencourt<sup>1</sup>, Juan A. Botia<sup>1</sup>, Mina Ryten<sup>1</sup>, Jana Vandrovцова<sup>1</sup>, Samuel McCall<sup>8</sup>, Robyn W. Labrum<sup>8</sup>, Sameer Zuberi<sup>9</sup>, Alfons Macaya<sup>10</sup>, Dimitri M. Kullmann<sup>11</sup>, Roope Manniko<sup>1</sup>, Henry Houlden<sup>1</sup>, Michael G. Hanna<sup>1,12</sup>, SYNAPS Study Group

<sup>1</sup>Department of Molecular Neuroscience, Institute of Neurology, University College London, London WC1N 3BG, United Kingdom <sup>2</sup>Department of Neurology, Papageorgiou Hospital, Thessaloniki 56429, Greece <sup>3</sup>Institute of Translational Pharmacology, National Research Council, Rome 00044, Italy <sup>4</sup>Division of Medical Genetics, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA <sup>5</sup>Department of Pediatrics, Keck School of Medicine at USC, Los Angeles, CA 90033, USA <sup>6</sup>Courtagen Life Sciences, 12 Gill St, Ste. 3700, Woburn, MA 01801, USA <sup>7</sup>CIBIR - Centro de Investigación Biomédica de La Rioja, 26006, Logrono, Spain <sup>8</sup>Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK <sup>9</sup>Royal Hospital for Children, Glasgow G51 4TF, UK <sup>10</sup>Hospital Universitari Vall d'Hebron,

Autonomous University of Barcelona, 08035 Barcelona, Spain 11Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London WC1N 3BG, United Kingdom 12MRC Center for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery, London WC1N 3BG, United Kingdom

## Introduction

The episodic ataxias are a heterogeneous group of paroxysmal neurological disorders characterized by intermittent attacks of unsteadiness and incoordination, often associated with additional neurological features including migraine or hemiplegic migraine, epilepsy, fluctuating weakness, or progressive ataxia. There are at least ten causative genes reported, with some of these only identified in isolated cases or families. Although separate screening studies have been carried out on each of the episodic ataxia genes, so far there has been no report of large study using a next generation sequencing approach in the analysis of these disorders, thus little is known about their molecular heterogeneity.

## Methods

We investigated a cohort of 231 families or patients with episodic ataxia, mostly referred to a tertiary neurology center in London. Using a combination of Sanger sequencing, multiplex ligation-dependent probe amplification and next generation sequencing (panel and whole-exome sequencing), we identified the likely genetic cause of the disease in 94 families from our cohort (40.6%), including rare variants in genes associated with different paroxysmal neurological disorders.

## Results

The most frequent genes carrying variants in the positive families were CACNA1A (n=49, 52.1%) and KCNA1 (n=25, 26.5%), followed by PRRT2 (n=4, 4.2%), PNKD (n=4, 4.2%), SLC2A1 (n=3, 3.1%), SCN2A (n=3, 3.1%), SLC1A3 (n=2, 2.1%), ATP1A2 (n=1%), SCN1A (n=1%), ATP1A3 (n=1, 1%) and SCN8A (n=1%). In the majority of patients episodes of ataxia started in childhood or adolescence (mean age of onset 7.8 years) and a number of paroxysmal (epileptic and non-epileptic) symptoms preceded many years the cerebellar signs in some cases. We used whole-transcriptome gene expression data from human brain samples to generate weighted co-expression networks of the identified mutated genes, which resulted enriched in synaptic transmission modules. Of importance, we identified new causative genes encoding channels (SCN1A), transporters (ATP1A2) and synaptic regulators (PNKD), based on our knowledge of existing pathophysiology of episodic ataxias, and tested in vitro some of these rare variants using electrophysiological methods.

## Conclusion

The identification in the present study of rare variants in genes implicated in synaptic excitability and transmission highlight overlapping molecular pathways and pleiotropic clinical presentations in paroxysmal neurological disorders.

**Keywords:** Episodic ataxia; Paroxysmal neurological disorders; Channelopathies; Synaptopathies; Transportopathies

## [Novel SCA gene FAT Atypical Cadherin 2 is a regulator of autophagy](#)

B.M. Hofstra<sup>1</sup>, M.R. Fokkens<sup>1</sup>, G.B. Bampi<sup>1</sup>, R.J. Sinke<sup>1</sup>, B van de Sluis<sup>2</sup>, and [D.S. Verbeek<sup>1</sup>](#)

<sup>1</sup>Dept of Genetics, University Medical Center Groningen, Groningen, The Netherlands

<sup>2</sup>Dept of Pediatrics, section Molecular Genetics, University Medical Center Groningen, Groningen, The Netherlands

**Introduction** We identified missense mutations in FAT2 to cause spinocerebellar ataxia. FAT2 encodes for FAT Atypical Cadherin 2 and is the second identified human homolog of the *Drosophila* fat gene. Fat is a multifunctional protein, and in addition to modifying cell adhesion, has been shown to regulate autophagy in the photoreceptors and loss of fat contributed to neurodegeneration through defective autophagy in DRLPA flies. In this project, we explored the role of FAT2 as a regulator of autophagy.

**Methods** Using CRIPR-Cas9, we generated Fat2<sup>-/-</sup> N2A cells and Fat2<sup>-/-</sup> mouse. We investigated autophagy and autophagic flux during starvation and treatment with chloroquine. LC3 and p62 levels were determined via Western blotting. Autophagy was also assessed by quantifying LC3:EGFP and LC3-T50A:EGFP puncta using fluorescent microscopy. Formation of autophagosomes and their fusion with lysosomes was studied by immunocytochemistry using RAB5/7 and LAMP2 antibodies.

**Results** Ablation of Fat2 in N2A cells significantly increased LC3II levels and p62 levels compared to wild type cells. Upon starvation and chloroquine treatment, LC3II and p62 levels further increased in both wild type and Fat2<sup>-/-</sup> cells. This coincided with an increase in LC3:EGFP puncta in Fat2<sup>-/-</sup> cells compared to wild type cells under basal conditions. Notably, no further increase in LC3:T50A puncta was detected in Fat2<sup>-/-</sup> cells under basal conditions, whereas this was observed in wild type cells. Additionally, RAB5/7 co-localized with LAMP2 in both wild type and Fat2<sup>-/-</sup> cells.

**Conclusions** Fat2 is a negative regulator of autophagy as increased autophagy activity, increased autophagic flux, and properly formed autolysosomes were observed in Fat2<sup>-/-</sup> cells. Currently, we are investigating where Fat2 acts on the autophagy pathway including Hippo signaling. Additionally, we are introducing the human FAT2 mutation c.10758G>C; p.Lys3586Asn using CRISPR-Cas9 in N2A cells, and are characterizing Fat2<sup>-/-</sup> mouse. Thus, autophagy deficits due to mutant FAT2 likely cause spinocerebellar ataxia.

[Afg3l2 missense mutation p.Met665Arg impairs m-AAA protease function: new hints into a therapeutic strategy for SCA28.](#)

C.Mancini<sup>1</sup>, E.Hoxha<sup>2,3</sup>, L.Iommarini<sup>4</sup>, U.Richter<sup>5</sup>, C. Cagnoli<sup>1</sup>, A.Brussino<sup>1</sup>, E.Giorgio<sup>1</sup>, S.Cavaliere<sup>6</sup>, E.Pozzi<sup>1</sup>, E.Di Gregorio<sup>6</sup>, M.Ferrero<sup>1</sup>, E.Riberi<sup>1</sup>, E.Turco<sup>7</sup>, F.Altruda<sup>7</sup>, G. Gasparre<sup>8</sup>, B.Battersby<sup>5</sup>, A.M. Porcelli<sup>4</sup>, F. Tempia<sup>2,3</sup>, A. Brusco<sup>1,6</sup>.

1) Department of Medical Sciences, University of Torino, Italy

2) Neuroscience Institute Cavalieri Ottolenghi, Torino, Italy

3) Department of Neuroscience, University of Torino, Italy

4) Department of Pharmacy and Biotechnologies (FABIT), University of Bologna, Italy

5) Institute of Biotechnology, University of Helsinki, Finland

6) Medical Genetics Unit, "Città della Salute e della Scienza" Hospital, Torino, Italy

7) Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy

8) Department Medical and Surgical Sciences, Medical Genetics, University of Bologna, Italy

**Introduction:** SpinoCerebellar Ataxia type 28 (SCA28, OMIM#610246) is a rare autosomal dominant cerebellar ataxia, accounting for ~1.5% of the European cases. The causative gene, AFG3L2, encodes for a mitochondrial protein that assembles into homo- or hetero-hexamers with paraplegin, to form the matrix-ATPase Associated with various cellular Activities (m-AAA) protease. The m-AAA protease is a crucial component of the mitochondrial protein quality-control system, exerts chaperone-like activity and participates in mitochondrial protein processing and maturation. We generated a knockin (KI) mouse model harboring the

p.Met665Arg mutation in the peptidase M-41 domain of Afg3l2. Afg3l2KI/KI (KI-ho) were embryonically lethal, whereas Afg3l2KI/+ mice (KI-hz) were viable and developed a late-onset ataxia, starting at 18 months of age.

Methods: We evaluated: i) mitochondrial morphology and function, studying both homo- and heterozygous Mouse Embryonic Fibroblasts (MEF) obtained at E14.5; ii) mitochondrial dynamics (Opa1 immunoblot and mt-RFP vector transfection); iii) bioenergetics (Seahorse assay and ATP synthesis). Results: We detected a complete loss of long Opa1 isoforms in KI-ho, with a fragmented mitochondrial network. A similar imbalance of Opa1 isoforms was present in cerebellum homogenates derived from KI-hz mice. Mitochondrial bioenergetics revealed a reduction of basal oxygen consumption and decreased ATP synthesis in both KI-ho and KI-hz, indicating a general mitochondrial dysfunction. We speculated that the excess of Opa1 processing, and consequent mitochondrial fragmentation, might be directly linked to the impairment of Afg3l2 function in mt-protein quality control. To investigate this hypothesis, we inhibited mt-protein synthesis with chloramphenicol and found a rescue in mitochondrial dynamics and Opa1 processing.

Conclusions: We propose that Afg3l2 missense mutations alter mitochondrial proteostasis in SCA28. Our initial data suggest mutant p.Met665Arg negatively affects the m-AAA quality control function. The m-AAA complex, unable to regulate mt-protein degradation, leads to a toxic engulfment of mitochondria by de novo synthesized proteins. Our findings propose a novel option for a therapeutic strategy.

### [The presence and relevance of autoantibodies to CNS proteins in patients with cerebellar ataxia](#)

Angela Vincent

Emeritus Professor of Neuroimmunology, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford OX3 9DU, UK

There are three main types of autoantibodies that are highly relevant to neurological diseases. Over the last 50 years, a number of antibodies have been identified that bind intracellular (nuclear and cytoplasmic) proteins in neuronal cells, that are shared by remote tumours, most often cancers of lung, ovary or breast. The “onconeural” antigens (usually called Hu, Yo, Ma2 etc) are typically expressed by the tumours, and although the antibodies are good biomarkers for the presence of the tumour, they are not thought to be pathogenic. T cell-mediated immunity directed at the tumour but also attacking the neuronal cells is thought to be responsible for neural damage and clinical presentations. A smaller number of antibodies to other (non-tumour) intracellular proteins (eg. glutamic acid decarboxylase, GAD) are not commonly paraneoplastic but their pathogenic role is not clear. Finally, the most recent discoveries have been of antibodies to proteins, usually membrane-expressed, on the surface of neurons or glia. These antibodies are not necessarily associated with tumours and are thought to be directly pathogenic since the patients respond to immunotherapies such as plasma exchange, steroids, intravenous immunoglobulins and immunosuppressant drugs.

This new area of “antibody-mediated CNS diseases” has become relevant to many neurological presentations. Typically antibodies to neuronal receptors or ion-channel associated proteins can be identified in patients with different forms of limbic encephalitis (seizures, amnesia, psychiatric disturbance). Antibodies to the NR1 subunit of the glutamate (NMDA) receptor are found in patients, usually children and young women, with a complex and life-threatening syndrome which includes movement disorders. Glycine receptor antibodies are associated

with brainstem and spinal cord disturbance. In addition antibodies to the water channel aquaporin-4 or to myelin oligodendrocyte glycoprotein are found in patients with relapsing demyelinating syndromes that can affect optic nerve, spinal cord and brain regions.

Cerebellar ataxia is not (yet) strongly associated with any one specific antibody. The best known is Yo antibody with breast or ovarian/uterine tumours; these patients usually have a relentlessly progressive disease. GAD antibodies are found in some patients often with other systemic autoimmune disorders; treatment responses are not clear. Calcium channel antibodies may be relevant to some cancer-related ataxias. In addition, cerebellar disturbance can be found in a proportion of cases with the membrane antibodies mentioned above (eg CASPR2), and these cases may respond well to immunotherapies. Overall, there are patients who have potentially treatable forms of ataxia and antibody testing should be considered. The presentation will summarise the current information, the evidence for pathogenicity and the treatment responses.

### Ataxin-2 regulates mitochondrial precursors to maintain nutrient balance and cellular energetics

Sen NE 1, Meierhofer D 2, Gispert-Sanchez S 1, Basak AN 3, Auburger G 1.

1 Experimental Neurology, Goethe University Medical School, 60590, Frankfurt am Main, Germany

2 Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany

3 Neurodegeneration Research Laboratory, Boğaziçi University, 34342, Istanbul, Turkey

#### Introduction:

Repeat expansions in the polyglutamine domain of Ataxin-2 (ATXN2 gene) beyond 34 CAG triplets result in an autosomal dominant cerebellar atrophy, called Spinocerebellar ataxia type 2 (SCA2). In contrast, the loss of Ataxin-2 protein leads to a series of metabolic problems like obesity, insulin resistance and diabetes mellitus. Ataxin-2 is known to regulate different steps of RNA and protein metabolism in the cell, ranging from pre-mRNA processing to mRNA translation and decay. Under stress conditions, Ataxin-2 is localized to stress granules and coordinates cellular adaptation to altered bioenergetics conditions. Although the involvement of Ataxin-2 in various subcellular mechanisms was discovered over the past decade, the exact function of this protein is yet to be defined.

#### Methods:

In order to understand the native physiological function of Ataxin-2 and the molecular mechanisms underlying disease, we performed label-free proteomic analyses in Atxn2 knock-out (KO) mouse tissues and high-throughput RNA-sequencing in SCA2 patient blood samples. Data were validated with quantitative immunoblots and qPCR analyses in different experimental setups.

#### Results:

In addition to the expected dysregulations of the RNA metabolism pathways in SCA2 blood transcriptome, significant dysregulations of Parkinson's and Huntington's disease pathways were also observed, both resulting from mitochondrial dysfunction. Likewise, the cerebellum and liver proteome of the Atxn2-KO mice showed dysregulations in branched chain amino acid degradation, general amino acid and fatty acid metabolisms and citric acid cycle pathways, all of which take place in mitochondria. Further validations confirmed the modulation of several mitochondrial transcripts (Pink1, Ghitm, Opa1) and proteins (ACADS, ALDH6A1, ALDH7A1, IVD, MCCC2, PCCA, OTC) by Ataxin- 2.

## Conclusions:

Our findings show Ataxin-2 to act on mitochondrial precursors to determine leucine levels as key factor for mTORC1 signaling and growth control, as well to govern mitochondrial quality control.

## Understanding the pathophysiological and the molecular mechanisms underlying the recessive ataxia ARCA2

Jaeg-Ehret T.1,2, Singh P.K. 1, Licitra F. 1,2, Reutenauer L. 1, Puccio H. 1,2

1Department of Translational Medicine and Neurogenetics, IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), INSERM U596, CNRS UMR 7104, 67400 Illkirch, France, 2 Université de Strasbourg, France

ARCA2, a rare form of autosomal recessive ataxia, is characterized by early onset progressive cerebellar ataxia, cerebellar atrophy and a mild deficiency in Coenzyme Q10 (CoQ). A large proportion of the patients show additional neurological signs such as epilepsy and exercise intolerance. A variety of loss of function mutations have been identified in the COQ8A gene leading to ARCA2. COQ8A was recently suggested to have a regulatory role in CoQ biosynthesis in mammals through an unorthodox protein kinase like activity (Stefely J.A. et al, Molecular Cell 2016). To understand the pathological mechanisms of ARCA2 and study the function of COQ8A, a constitutive Coq8a knock-out (KO) mouse model was generated. Our results showed that Coq8a KO mice recapitulate many of the symptoms observed in patients including the development of a slowly progressive loss of coordination, a mild CoQ deficit and exercise intolerance, suggesting that they are a good model to study ARCA2. More specifically, Purkinje neurons presented morphological and functional impairment and a mild mitochondrial defect was detected in skeletal muscle. Here we report the use of cellular models of the affected tissues (cerebellum and muscle) to uncover the molecular signature of COQ8A loss and CoQ deficit. Despite CoQ deficit in the muscle no mitochondrial bioenergetics defect was uncovered. In parallel, RNAseq analyses of cerebellum at late stages implicate COQ8A in novel cellular processes including vesicular trafficking, lipid metabolism and ion channels. Interestingly, we have identified, by RT-qPCR, a key set of genes that are dysregulated very early on in the pathology. We are currently investigating these pathways to uncover the link with COQ8A function. Altogether, our experiments will shed light on the early molecular events that lead to ARCA2 and may help draw a link between COQ8A function, CoQ pools and the symptoms observed in patients.

## E3 ligase RNF126 directly ubiquitinates frataxin, promoting its degradation: identification of a potential therapeutic target for Friedreich Ataxia.

Benini M.1,2, Fortuni S.1, Condò I.1, Alfedi G.1, Malisan F.1, Toschi N.3,4, Serio D.1,2, Massaro D.S.1, Arcuri G.1, Testi R.1,2, Rufini A.1,2,\*.

1. Laboratory of Signal Transduction, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy;
2. Fratagene Therapeutics Srl, Viale dei Campioni 8, 00144 Rome, Italy.
3. Medical Physics Section, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy;
4. Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging and Harvard Medical School, Boston, MA 02115, USA.

\* email: [rufini@med.uniroma2.it](mailto:rufini@med.uniroma2.it)



**Introduction:** Friedreich ataxia (FRDA) is a severe neurodegenerative genetic condition, currently lacking an adequate therapy, characterized by reduced expression levels of the mitochondrial protein frataxin. Patients live with a reduced and insufficient amount of frataxin protein, therefore the main goal of a specific treatment for FRDA would be to restore physiological frataxin levels. Since frataxin levels are controlled by the ubiquitin-proteasome system, inhibition of the frataxin E3 ligase, the enzyme responsible for frataxin ubiquitination, may represent a strategy to achieve an increase in frataxin levels by preventing its degradation. **Methods:** In order to identify the E3 ligase that ubiquitinates frataxin, we have performed a functional screening of a siRNA library targeting more than 600 E3 ligases, to search for genes whose siRNA-mediated suppression would result in an increase in frataxin levels. **Results:** Here we report the identification of the RING E3 ligase RNF126 as the enzyme that specifically mediates the ubiquitination of frataxin precursor, targeting it for proteasomal degradation. RNF126 interacts with frataxin precursor and promotes its ubiquitination in a catalytic activity-dependent manner, both in vivo and in vitro. Most importantly, RNF126 depletion results in frataxin accumulation in cells derived from FRDA patients, highlighting the relevance of RNF126 as a new therapeutic target for Friedreich ataxia (Benini et al., 2017). **Conclusions:** Taken together, these results indicate that the E3 ligase RNF126 controls frataxin abundance in cells derived from patients and open the way for the development of a specific therapy aimed at inhibiting RNF126-mediated frataxin degradation.

Benini M, Fortuni S, Condo I, Alfedì G, Malisan F, Toschi N, Serio D, Massaro DS, Arcuri G, Testi R, Rufini A. 2017. E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia. *Cell Rep* 18:2007-2017.

### [Regulation of neuronal mRNA splicing by ATXN3 is disturbed in SCA3/MJD](#)

Neves-Carvalho A<sup>1,2</sup>, Almeida B<sup>1,2</sup>, Duarte-Silva S<sup>1,2</sup>, Silva JM<sup>1,2</sup>, Heetveld S<sup>3</sup>, Sotiropoulos I<sup>1,2</sup>, Heutink P<sup>3</sup>, Li KW<sup>4</sup> and Maciel P<sup>1,2</sup>

<sup>1</sup> Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal

<sup>2</sup> ICVS/3B's – PT Government Associate Laboratory, Braga/Guimarães, Portugal

<sup>3</sup> German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

<sup>4</sup> Vrije University Medisch Centrum (VUMC), Amsterdam, The Netherlands

**Introduction:** Deubiquitylating (DUB) enzymes have been recognized as central players in the maintenance of the correct ubiquitylation/deubiquitylation balance in cells. Ataxin-3 (ATXN3) is a protein with DUB activity mutated in Machado-Joseph disease (MJD) (also known as Spinocerebellar ataxia type 3 – SCA3). To date, besides the involvement of ATXN3 in the Ubiquitin-proteasome pathway (UPP) its physiological function remain elusive and no substrates for its DUB activity have been identified. **Methods:** To identify potential candidates of the DUB activity of this protein, we characterized the ubiquitome of neuronal cells lacking ATXN3 (ATXN3shRNA cells) by mass-spectrometry. We found that a large proportion of the proteins with altered polyubiquitylation in ATXN3shRNA cells were proteins involved in RNA post-transcriptional modification. **Results:** By transcriptomic analysis and using reporter minigenes we confirmed that splicing was globally altered in cells lacking ATXN3. Among the targets with altered splicing was SRSF7(9G8), a regulator of tau exon 10 splicing. Here we show that loss of function of ATXN3 leads to a deregulation of tau exon 10 splicing resulting in a decreased 4R/3R tau ratio. The fact that similar alterations were found

in the brain of a mouse model of MJD, suggests that this mechanism might be contributing for the pathogenesis of MJD. Conclusions: This work establishes a link between two key proteins involved in different neurodegenerative disorders, and suggests a new function for ATXN3 in the regulation of splicing.

### Epigenetic silencing in Friedreich ataxia is caused by hypermethylation of the FXN CpG island shore

Bidichandani S.I., Rodden L.N. and Chutake Y.K.

Department of Pediatrics, University of Oklahoma Health Sciences Center, USA

Introduction: Friedreich ataxia (FRDA) is caused by an expanded GAA triplet-repeat (GAA-TR) mutation in intron 1 of the FXN gene that results in epigenetic silencing of the FXN promoter. DNA methylation of CpG island shores, regions that flank human gene promoters when they are embedded in CpG islands, is a known mechanism of epigenetic silencing.

Results: Deep sequencing revealed that DNA hypermethylation spreads from the expanded GAA-TR mutation to the FXN CpG island shore. The CpG island shore is hypermethylated in FRDA, but it remains unmethylated in the non-disease state, and becomes unmethylated when the expanded GAA-TR is reverted to the normal size in isogenic cell lines, thus functioning as a FRDA-specific differentially methylated region (FRDA-DMR). The hypermethylated FRDA-DMR was detected in various patient derived cell types, and also in tissues from the humanized mouse model of FRDA that carries an expanded GAA-TR. Analysis of individual DNA molecules revealed a variegated pattern of DNA methylation within the FRDA-DMR, the magnitude and extent of which was dependent on the length of the expanded GAA-TR mutation. Knockdown of DNMT3A in patient-derived cells reduced methylation of the FRDA-DMR and increased levels of FXN transcript, indicating that DNA methylation contributes to FXN epigenetic silencing in FRDA. Furthermore, treatment with 5-aza-2'-deoxycytidine enhanced the ability of a class I histone deacetylase inhibitor that is known to ameliorate epigenetic promoter silencing in FRDA, to further increase FXN transcript levels in patient-derived cells.

Conclusion: Hypermethylation of the FXN CpG island shore plays a key role in epigenetic silencing in FRDA, and is a novel therapeutic target for reactivation of the epigenetically silenced FXN gene.

### Spinocerebellar ataxia type 1 (SCA1): molecular basis of neurodegeneration in the cerebellum (ataxia) and brainstem (lethality)

Emily Leathley<sup>1,2,\*</sup>, Zhao Chen<sup>1,3,\*</sup>, Melissa Ingram<sup>1,4</sup>, Tyler Tschumperlin<sup>1,3</sup>, Jillian Friedrich<sup>1,3</sup>, Lisa Duvick<sup>1,3</sup>, Maxime W. C. Rousseaux<sup>5</sup>, Huda Y. Zoghbi<sup>5</sup>, Christine Henzler<sup>6</sup>, and Harry T. Orr<sup>1,3</sup>

\*Contributed equally to this work.

<sup>1</sup>Institute of Translational Neuroscience, <sup>2</sup>Department of Neuroscience, <sup>3</sup>Department of Laboratory Medicine and Pathology, <sup>4</sup>Department of Genetics, Cell Biology, and Development, <sup>6</sup>RISS Bioinformatics, Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455. <sup>5</sup>Departments of Molecular and Human Genetics, Pediatrics, and Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030

SCA1, a fatal neurodegenerative disorder, is caused by a CAG expansion encoding a polyglutamine (polyQ) stretch in the protein ATXN1. Upon mutating two residues in Ataxin-1 that are critical for its interaction with the transcriptional regulator Capicua (CIC) abrogates the cerebellar toxicity of polyQ-ATXN1. These results demonstrate that gain-of-function of the ATXN1-CIC complex is a predominant driver of SCA1 cerebellar disease. We used RNA sequencing to profile cerebellar and brainstem (medulla) gene expression in the SCA1 mouse models. Weighted Gene Coexpression Network Analysis of cerebellar expression data revealed a gene network that significantly correlated with disease progression in *ATXN1[82Q]* and *Sca1<sup>154Q/2Q</sup>* cerebellum. In *Sca1<sup>154Q/2Q</sup>* mice, onset of disease is considerably later in the medulla than in the cerebellum. While molecular pathways altered in the medulla have some similarities to those affected in the cerebellum, there are considerable differences between the medulla and the cerebellum. Additionally, we found that upregulation of cholecystinin (*Cck*) and subsequent interaction with the Cck1 receptor (Cck1R) underlies the lack of progressive Purkinje cell pathology in *Pcp2-ATXN1[30Q]D776* mice. A Cck1R agonist, A71623, administered IP beginning at six weeks-of-age via osmotic minipumps to *ATXN1[30Q]D776;Cck<sup>-/-</sup>* mice, *ATXN1[82Q]*, and *ATXN2[127Q]* mice, protected against progressive ataxia and Purkinje cell pathology/degeneration. These latter results suggest that manipulation of the Cck-Cck1R pathway may be a therapeutic target for treatment of ataxias involving Purkinje cell degeneration.

Support: NIH grants R37NS022920 and R01NS045667 and the National Ataxia Foundation

#### [Transcriptional profiling of isogenic iPS-derived Friedreich's ataxia sensory neurons](#)

Lai J.1, Nachun D.2, Petrosyan L.1, Throesch B.3, Baldwin K. 3, Coppola G.2, Gottesfeld J. M.1 and Soragni E.1

1 Department of Molecular Medicine, 3 Department of Neuroscience, The Scripps Research Institute, La Jolla, CA, USA

2 Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, CA, USA

Introduction: Friedreich's ataxia (FRDA) is caused by the transcriptional silencing of the FXN gene and consequent loss of frataxin protein. How the reduced expression of this essential mitochondrial protein leads to neurological and other systemic symptoms in FRDA patients remains unclear. Similarly to other triplet repeat disorders, it is not known why only specific cell types seem to be affected in the disease, namely large sensory neurons and cardiomyocytes. We seek to uncover the gene expression signature due to GAA·TCC repeat expansion in FRDA neuronal cells, that would help explain the FRDA pathophysiology in affected organs.

Methods: The combination of induced pluripotent stem (iPS) cell technology and genome editing techniques offers the unique possibility of addressing these questions in a relevant cell model of the disease, without the confounding effect of different genetic backgrounds. We derived a set of isogenic iPS cell lines that differ only in the length of the GAA·TCC repeats, using "scarless" gene-editing methods (helper-dependent adenovirus mediated homologous recombination) and performed transcriptomic analysis of iPS-derived CNS and PNS neurons by RNA sequencing.

Results: Three datasets were obtained, two from isogenic lines (comparing FRDA and unaffected CNS and PNS neurons) and one using non-isogenic CNS neurons (comparing two FRDA and two unaffected lines). Differential gene expression analysis showed a remarkable overlap among the three datasets in the pathways identified, which include regulation of cell adhesion, neuronal differentiation, synaptic transmission

and gated channel activity. Gene co-expression network analysis performed on the nonisogenic dataset identified modules which, in addition, include genes related to metabolism of lipid and lipoprotein and lysosome.

Conclusions: Using isogenic iPS-derived neurons we find that multiple cellular pathways are commonly affected by the loss of frataxin in CNS and PNS neurons

### Early cerebellar mitochondrial biogenesis deficits and OXPHOS complex I and II deficiency in the KIKO mouse model of Friedreich ataxia

Lin H.1, Magrane J.2, Rattelle A.1, Clark, E.M.1,3, Dong Y.1, Halawani S. M.1 and Lynch D.R.1,3

1Departments of Pediatrics and Neurology, The Children's Hospital of

Philadelphia, 2Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New

York, NY, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, 19104

#### Introduction

Friedreich Ataxia (FRDA) is the most common recessive inherited ataxia resulting from deficiency of frataxin, a highly conserved mitochondrial protein crucial for Fe/S cluster formation and ATP production. Frataxin deficiency is associated with mitochondrial dysfunction in FRDA patients and mouse models. However, early mitochondrial pathophysiology in FRDA cerebellum remains elusive.

#### Methods

Using the frataxin knock-in/knockout (KIKO) mice and KIKO mice carrying a mitoDendra transgene, a mouse model with neurobehavioral deficits analogous to clinical manifestations in FRDA patients, we examined if the mitochondrial biogenesis PGC-1 /NRF1/Tfam pathways and OXPHOS complex are altered in cerebellum of presymptomatic and symptomatic KIKO mice by immunohistochemistry, Western blotting and OXPHOS complex activity microplate assay kits.

#### Results

In KIKO mice at presymptomatic ages, levels of mitochondrial biogenesis master regulator PGC-1 $\alpha$  and its downstream effectors NRF1 and Tfam are significantly decreased in cerebellar homogenates compared with age-matched controls, suggesting early impairment of cerebellar mitochondrial biogenesis pathways. Early mitochondrial deficiency is further supported by significant reduction of mitochondrial markers GRP75 and mitofusin-1 (MFN1) levels and immunoreactivities in cerebellar homogenates and cortex respectively. Furthermore, the levels and number of mitoDendra are significantly decreased in cerebellar cortex of mitoDendra-KIKO mice, confirming cerebellar mitochondrial biogenesis deficits. Moreover, the OXPHOS complex I and II markers and enzyme activities are significantly decreased in cerebellar homogenates, suggesting complex I and II deficiency in cerebellum of presymptomatic KIKO mice.

#### Conclusions

Our findings identify early cerebellar mitochondrial biogenesis deficits and OXPHOS complex I and II deficiency as a potential mediator of cerebellar dysfunction and ataxia, thereby providing a potential therapeutic target for early intervention in FRDA patients.

### Addressing mitochondrial function in a mouse model of Friedreich's Ataxia (FRDA)

R Abeti,<sup>1</sup> M H Parkinson,<sup>1</sup> I P Hargreaves,<sup>2</sup> P R Angelova,<sup>3</sup> C Sandi,<sup>4,5</sup> M A Pook,<sup>4</sup> A

Y Abramov<sup>3</sup> and P Giunti<sup>1</sup>

<sup>1</sup>Ataxia Centre, Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK

2National Hospital, Neurometabolic Unit, London UK

3Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK

4Ataxia Research Group, Division of Biosciences, Department of Life Sciences, College of Health & Life Sciences, and Synthetic Biology Theme, Institute of Environment, Health & Societies, Brunel University London, Uxbridge, UK

5Current Address: Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.

**Background.** Friedreich's ataxia (FRDA) is an inherited neurodegenerative disease. The mutation consists of a GAA repeat expansion within the FXN gene, which downregulates the levels of frataxin, leading to abnormal mitochondrial iron accumulation, which may in turn cause changes in mitochondrial function. Although, many studies of FRDA patients and mouse models have been conducted in the past two decades, the role of frataxin in mitochondrial pathophysiology remains elusive. Therefore, we have investigated mitochondrial abnormalities in order to understand the role of frataxin in pathophysiology.

**Methods.** By using confocal microscopy we assessed an array of functional assays to characterize the possible difference in mitochondrial activity between control and FRDA cells. Here we studied mitochondrial membrane potential ( $\Delta \psi$ ) and its maintenance, mitochondrial NADH redox state, FAD<sup>+</sup> pool, and lipid peroxidation in cerebellar granule neurons of FRDA mouse model. The FRDA mouse model used was generated by the Pook laboratory based upon expression of human FXN transgene containing GAA repeat expansions within a mouse frataxin null background.

**Results.** Our results show that mitochondria are deregulated in FRDA-like neurons, causing a decrease in mitochondrial membrane potential ( $\Delta \psi$ ) due to an inhibition of Complex I, which is partially compensated by an overactivation of Complex II. This complex activity imbalance leads to ROS generation in both mitochondrial matrix and cytosol, which results in increased lipid peroxidation. Preventing this increase in lipid peroxidation, in neurons, protects against cell death.

**Conclusions.** This work describes the pathophysiological properties of the mitochondria in neurons from a FRDA mouse model and shows that lipid peroxidation could be an important target for novel therapeutic strategies in FRDA. By establishing that FRDA is another clinical presentation of a group of disorders due to complex I deficiency, this work may shed a light to a common therapeutic pathway amongst several degenerative disorders.

### Mitofusin-dependent ER stress mediates degeneration in a *Drosophila* model of Friedreich's ataxia

Oliver Edenharter, Stephan Schneuwly, [Juan Antonio Navarro](#)  
Institut für Zoologie, Universität Regensburg, Germany

**Introduction.** Frataxin downregulation is responsible for Friedreich's Ataxia (FRDA), a rare neurodegenerative disorder that currently lacks an effective treatment. *Drosophila* models of FRDA have been shown to reproduce the main biochemical and physiological features of this disease. A forward genetic screening performed in our lab identified *Drosophila* mitofusin (Marf) as an important element in the pathology. Marf knockdown completely suppressed locomotor dysfunction, brain vacuolization and lipid accumulation in frataxin-deficient flies. In mammals and flies, Mitofusins play key roles in mitochondrial fusion/fission as partner of Opa1

and Drp1, in mitophagy as substrate of Parkin and in the interphase between mitochondria and endoplasmic reticulum (ER). Our aim was to unravel the rescue mechanism underlying Marf knockdown.

**Methods.** Using different histological and molecular markers such as p62, ATG8a, LAMP1, Xbp1 and BiP/GRP78, we have studied effects of frataxin knockdown on mitochondrial morphology, mitophagy and ER function and dissected the roles of Marf in our fly FA model.

**Results.** We have found that frataxin silencing modified mitochondrial morphology, stimulated mitophagy and altered the endoplasmic reticulum (ER) stress response. Remarkably, our results highlighted that the role of Mitofusin in the ER-Mitochondria axis is underpinning the Marf-silencing mediated protection. In agreement, TUDCA, a chemical chaperone that reduces ER stress, was able to partially ameliorate FRDA defects. Defects in the ER stress response are more than a downstream effect of frataxin depletion. They seem to be necessary to disturb lipid homeostasis and trigger cellular degeneration.

**Conclusions.** Our results might define a new pathological mechanism in FRDA and suggest that mitochondrial dysfunction and ER stress represent a crucial convergence point in the pathology of the disease. This new relationship between mitochondria and ER in FRDA through mitofusin brings new perspectives towards a better understanding of the complete pathological picture in the disease and towards improvements in FRDA therapy.

## Translational Models of Disease

### [Targeting repeat expansion in cellular models of Friedreich's Ataxia](#)

Marek Napierala

Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham

Expansions of simple repeat sequences lead to several inherited ataxias. Friedreich's ataxia is unique amongst them as it is caused by large expansions of intronic GAA trinucleotide repeats. The number of expanded GAA repeats correlates with the extent of transcription silencing of the FXN gene and consequently with the extent of frataxin deficiency, however, the exact mechanisms leading to repeat expansion and decreased FXN transcription remain unclear. Inhibiting somatic expansions, stimulating contractions of the already expanded GAAs or removing the repeat tract altogether are considered ultimate therapeutic strategies for FRDA that target the primary defect underlying this disorder. Human cell lines derived from FRDA patients ensure the natural genomic and epigenomic context of the pathogenic GAA repeats, and therefore serve as excellent models to elucidate roles of various cis elements and trans acting factors that affect repeat expansions. We employed a set of FRDA and control primary fibroblasts, induced pluripotent stem cells (iPSCs) as well as cardiomyocytes terminally differentiated from the iPSCs to investigate the role of interplay between transcription and replication at the FXN locus on both GAA expansions and transcriptional silencing. Using single-molecule analysis we discovered that expanded GAA repeats present a substantial obstacle for the replication machinery at the FXN locus in FRDA cells. We confirmed that aberrant origin activation and the lack of a proper stress response to rescue stalled replication forks in FRDA cells cause an increase in 3'-5' progressing forks, which could enhance repeat expansion and hinder FXN transcription by inducing head-on collisions with RNA polymerases. Unexpectedly, our analyses of the expanded GAA tracts during prolonged culturing of the FRDA iPSCs demonstrated that increasing transcription of the FXN gene through the use of epigenetic modulators stimulated progressive expansions. Taken together, these results indicate that alleviating replication fork stalling and preventing replication/transcription collision rather than exclusively reactivating FXN transcription might be a more optimal therapeutic strategy for

FRDA. Finally, as a complementary approach to pharmacologic intervention, we have demonstrated that precise excision of the expanded GAAs reverses epigenetic changes associated with transcriptional silencing and restores frataxin expression to the levels observed in unaffected cells. Importantly, removal of the expanded GAA repeats also corrected the molecular phenotypes of FRDA iPSC-derived neuronal and cardiac cell models.

### [Understanding Friedreich's ataxia neuropathophysiology using a new conditional neuronal mouse model.](#)

de Montigny C., Piguet F., Diedhiou N. and Puccio H.

Department of Translational Medicine and Neurogenetics, IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), INSERM U596, CNRS UMR 7104, 67400 Illkirch, France, Université de Strasbourg, France.

Friedreich's ataxia (FA), the most common recessive ataxia, is characterized by sensory and spinocerebellar ataxia and hypertrophic cardiomyopathy. Proprioceptive neurons within the dorsal root ganglia (DRG) are one of the primary affected cells in FA patients. FA is caused by reduced levels of frataxin (FXN), an essential mitochondrial protein involved in the biosynthesis of iron-sulfur (Fe-S) clusters. FXN depletion leads to a Fe-S cluster protein deficit, mitochondrial dysfunction, iron dysregulation and cellular dysfunction. The molecular mechanism underlying neuronal degeneration has not been well established. To decipher the pathological mechanisms in proprioceptive neurons, a new conditional neuronal mouse model (cKO), based on the Cre/LoxP technology, was generated, using the Cre Recombinase expressed under the parvalbumin promoter. Parvlb cKO mice present a FXN depletion in DRG proprioceptive neurons, starting at E17.5, in Purkinje cells of the cerebellum at p40 and in interneurons of the brain at 21.5 weeks. Interestingly, we showed that proprioceptive neurons, which represent only 7.5% of the DRG cell population, express between 50 and 70% of the total FXN of the DRG. Moreover, lumbar DRG express more FXN than cervical DRG. Parvlb cKO mice develop a severe and progressive ataxic phenotype assessed by different behavioural tests and a specific decrease of the sensory wave, revealed by electrophysiological studies. At the molecular level, we identified a deficit of a Fe-S protein, the Succinate Dehydrogenase, in proprioceptive neurons and in Purkinje cells, followed by cellular iron dysregulation, in agreement with elements observed in non-neuronal mouse models. To decipher the downstream events following FXN depletion, RNAseq analysis of DRG was performed and an upregulation of genes known to be expressed by sensory neurons following axonal damage (Regeneration Associated Genes) was identified. Further molecular analyses are ongoing to elucidate the mitochondrial and cellular defects in neurons. Understanding FA neuropathophysiology is critical to develop therapeutical strategies and to identify biomarkers that are essential to validate therapeutical approaches such as gene therapy.

### [A SCA7 mouse model showing multisystem phenotypes; new opportunities for pathomechanism studies and therapeutic development](#)

Trottier Y, Niewiadomska-Cimicka A, Hache A, Weber C, Karam A, Messaddeq N, Piguet F.  
1Institute of Genetic and Molecular and Cellular Biology, CNRS, Inserm, University of Strasbourg, UMR7104, Illkirch

Introduction. In SpinoCerebellar Ataxia type 7 (SCA7), polyglutamine (polyQ) expansion in ATXN7 primarily causes neurodegeneration in the cerebellum and associated structures and in

the retina. However, extremely large polyQ expansions cause infantile forms with multisystem disorder that could include cardiac and renal failure.

**Methodology.** We performed a detailed characterization of a new SCA7140Q/5Q knock-in mouse line - obtained through intergenerational deletion of the original Sca7266Q/5Q line - in collaboration with the Mouse Clinical Institute of Illkirch. This included first-line behavioural, motor and sensory tests, and non-invasive telemetry, electrocardiography and echography. Correlation was made with neuropathological and molecular data.

**Results.** SCA7140Q/5Q line remarkably recapitulates the cardinal features of juvenile and infantile forms of SCA7 in the CNS and non-CNS tissues. This includes an early and progressive dystrophy of the photoreceptors and a late atrophy of the pons and Purkinje neurons of the cerebellum. SCA7140Q/5Q mice have hearing dysfunction, as found in 24% of SCA7 patients. Importantly, SCA7140Q/5Q mice also show cardiac hypertrophy, heart failure and renal dysfunction. Furthermore, we uncovered an early and severe metabolic dysfunction including defects in the homeostasis of iron and cholesterol, impaired glucose tolerance and low energy expenditure. The multisystem dysfunction in SCA7140Q/5Q mice causes a deficit in body weight from 16 weeks of age, muscle weakness at 18 weeks, and several behavioral and motor dysfunction already starting at 9 weeks.

The mice die after 1 year of disease duration, likely from hypotonia and respiratory failure.

**Conclusion.** The SCA7140Q/5Q mice represent a powerful model to study degenerative and developmental components of the disease. Although the study of neurodegeneration still constitute a major focus, analysis of other affected tissues in SCA7 shall reveal critical pathomechanisms of the disease. The multisystem dysfunctions of SCA7140Q/5Q mice also offer new opportunities for translational development of therapeutic strategies.

[Inducible and reversible phenotypes in a novel mouse model of Friedreich's Ataxia Vijayendran Chandran<sup>1, #</sup>, Kun Gao<sup>1</sup>, Vivek Swarup<sup>1</sup>, Revital Versano<sup>1</sup>, Hongmei Dong<sup>1</sup>, Maria C. Jordan<sup>3</sup> & Daniel H. Geschwind<sup>1,2</sup>](#)

<sup>1</sup>Program in Neurogenetics, Department of Neurology, <sup>2</sup>Department of Human Genetics, <sup>3</sup>Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.

<sup>#</sup>Present address: Department of Pediatrics, School of Medicine, University of Florida, Gainesville, FL 32610-0296, USA.

Correspondence should be addressed to D.G. (dhg@mednet.ucla.edu) or V.C. (vijayendran@ufl.edu).

Friedreich's ataxia (FRDA), the most common inherited ataxia in humans, is caused by recessive mutations that lead to a substantial reduction in the levels of frataxin (FXN), a mitochondrial iron binding protein. FRDA is a multi-system disease, involving multiple neurological, cardiac, and metabolic manifestations whose study would be substantially advanced by animal models that faithfully recapitulate human disease features. We developed an inducible mouse model of Fxn deficiency that enabled us to control the onset, progression and potential rescue of disease phenotypes by the modulation of Fxn levels using RNA interference. We found that systemic knockdown of Fxn in adult mice led to multiple features paralleling those observed in human patients, including electrophysiological, cellular, biochemical and structural phenotypes associated with cardiomyopathy, as well as dorsal root ganglion and retinal neuronal degeneration and reduced axonal size and myelin sheath thickness in the spinal cord. Fxn knockdown mice also exhibited other abnormalities similar to patients, including weight loss,



reduced locomotor activity, ataxia, reduced muscular strength, and reduced survival, as well as genome-wide transcriptome changes. The reversibility of knockdown also allowed us to determine to what extent observed phenotypes represent neurodegenerative cell death, or reversible cellular dysfunction. Remarkably, upon restoration of near wild-type FXN levels, we observed significant recovery of function, pathology and associated transcriptomic changes, even after significant motor dysfunction was observed. This inducible model of FRDA is likely to be of broad utility in therapeutic development and in understanding the relative contribution of reversible cellular dysfunction to the devastating phenotypes observed in this condition.

#### [Repeat disorders: models, markers and more.](#)

Leonard Petrucelli, Mayo Clinic.

Our lab has successfully used AAV-mediated somatic brain transgenesis to model C9orf72-associated ALS/FTD and have used these mice to tease out cellular mechanisms important for disease pathogenesis. Intriguingly, a remarkably similar hexanucleotide expansion results in spinocerebellar ataxia type 36. Like C9-ALS/FTD, this disease is also characterized by the formation of RNA foci, and we have evidence suggesting that repeat-associated non-ATG (RAN) translation also occurs in SCA36 patient tissue. And yet unlike C9-ALS/FTD, SCA36 is not associated with the formation of phospho-TDP43 aggregates and the two diseases primarily affect different brain regions, despite widespread expression throughout the CNS. We have recently generated mice that express the SCA36-associated hexanucleotide repeat. Preliminary data demonstrates that at 6 months of age, these mice show neuronal loss, RNA foci formation, and RAN translation products, but do not show any evidence of TDP-43 mislocalization. To our knowledge, this is the first mouse model of SCA36 generated to date. Furthermore, the similarities between SCA36 and C9-ALS/FTD allow us to use our existing C9-ALS/FTD model as a unique disease control as we investigate the mechanisms underlying the neuronal loss observed in our SCA36 mice. These models will allow us explore potential disease modifiers, in particular spt4, which may have implications for these repeat disorders and others.

#### [Voluntary running prevents onset of symptomatic Friedreich's ataxia in mice](#)

Zhao H<sup>1,2</sup>, Lewellen BM<sup>2</sup>, Zhang M<sup>2,3</sup>, Yan Z<sup>2,3,4,5</sup>

Dalian Medical University<sup>1</sup>, Dalian, China; Departments of Medicine<sup>2</sup>, Pharmacology<sup>3</sup>, Molecular Physiology and Biological Physics<sup>4</sup>, Center for Skeletal Muscle Research at Robert M. Berne Cardiovascular Research Center<sup>5</sup>, Charlottesville, Virginia, USA

Introduction: The most common clinical symptoms of Friedreich's ataxia (FRDA) include ataxia, muscle weakness, type 2 diabetes and heart failure, which are caused by impaired mitochondrial function due to loss of frataxin (FXN) expression. Endurance exercise is the most powerful intervention to promote mitochondrial function; however, the impact of endurance exercise on FRDA has not been studied. Methods: We assessed exercise intolerance (treadmill running), cardiac function (echocardiogram), whole body glucose metabolism (glucose tolerance test) and protein levels of Fxn, mitochondrial respiratory proteins and antioxidant enzymes (western blot analysis) in a mouse model of FRDA (knockout and knock-in of Fxn, KIKO) at 2,4 and 6 months of age. We also investigated the impact of long-term (4 months) endurance exercise (voluntary wheel running) in KIKO mice. Results: KIKO mice showed reduced Fxn protein expression (-49-69%) in the skeletal muscle, heart and liver compared with wild type mice at all ages, but displayed exercise intolerance, glucose intolerance, and

moderate cardiac dysfunction only at 6 months. These functional abnormalities are not due to reduced mitochondrial respiratory proteins and antioxidant enzymes, but impaired mitochondrial respiratory function. KIKO mice heart showed increased protein expression in the fibrosis pathway. Importantly, long-term voluntary running completely prevented these abnormalities and the onset of symptoms in the absence of restoration of Fxn protein expression.

Conclusions: KIKO mice recapitulate human FRDA with age-dependent onset of symptoms along with biochemical abnormalities. Long-term endurance exercise starting at a young age can completely prevent the onset of the disease without correcting the defect of Fxn expression in mice. This is the first study to demonstrate a profound protection of endurance exercise in FRDA in mice, raising exciting possibility of effectively prevention of FRDA by endurance exercise.

Acknowledgement: The studies were funded by FARA 183 General Research Grant to ZY.

### [Using mouse models and BioID proteomic approach to understand ARSACS pathophysiology.](#)

Larivière R., Sgarioto N., Gentil B, Choquet K., Durham H.D., Shoubridge E.A., Brais B.

Department of Neurology and Neurosurgery and Department of Human Genetics, Montreal Neurological Institute, McGill University, Montreal, Canada

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset neurodegenerative disorder caused by mutations in the SACS gene. Over 170 mutations have now been identified worldwide in SACS and are thought to cause a loss of saccin function. To better understand the course of the disease, we generated and characterized two ARSACS mouse models, one with a complete loss of saccin protein (Sacs KO) and a second expressing the R272C

mutation (Sacs KI). Both mouse models display a balance deficit, loss of coordination and motor deficit accompanied with a Purkinje cell loss and neuronal cytoskeletal disruption reminiscent of the human pathology. One of the most striking features of ARSACS's pathophysiology is the presence of abnormal neurofilament protein bundles in numerous neuronal populations, observable in both ARSACS mouse models, but also in an autopsied brain of an affected

patient. These results strongly suggest a role for saccin in the maintenance of proper cytoskeletal network. Using the BioID technique, we were able to identify saccin proximity partners and, as predicted, the majority of the interacting proteins are associated to the cytoskeleton. These genetically modified mice are excellent models for ARSACS and can be used to explore the impact of neuronal cytoskeletal bundling in the pathophysiology of this increasingly diagnosed recessive ataxia.

### [Let-7 activates autophagy and alleviates motor and neuropathological deficits in pre- and post-symptomatic Machado-Joseph disease mouse models](#)

Duarte, S.1,2, Miranda, C.O.1,2, Cunha-Santos, J.1,3, Barata, J.1, Estremores, B. 1, La Spada, A.R.4, de Almeida, L.P. 1,3

1 CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, 3004-504 Coimbra, Portugal; 2 IIIUC - Instituto de Investigação Interdisciplinar, University of Coimbra, 3030-789 Coimbra, Portugal; 3 Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal; 4 Institute for Genomic Medicine, University of California, San Diego; La Jolla, CA 92093, USA.

Machado-Joseph disease or spinocerebellar ataxia type 3 (MJD/SCA3) is a genetic neurodegenerative disorder associated with expansion of the number of CAGs in the coding region of the MJD1/ATXN3 gene, which translates into an expanded polyglutamine tract within ataxin-3 protein. MJD patients have severe clinical manifestations and premature death and there is no treatment available to modify disease progression. We and others provided evidence that autophagy impairments contribute to MJD pathogenesis with autophagosome accumulation, reduction of autophagy-associated protein levels, accumulation of mutant ataxin-3 and neurodegeneration. Recently, we also brought evidence that the let-7 microRNA is a key regulator of autophagy with particular relevance in polyglutamine disorders. In this work we aimed at investigating let-7 potential as a new therapeutic approach in a lentiviral-based and in a transgenic mouse model of MJD.

To overcome reduced Let-7 levels in a lentiviral MJD mouse model, we injected lentiviral vectors encoding for let-7 in the mouse striata. A 20% increase of let-7 levels was observed in the transduced region. LC3 immunoblot analysis revealed increased levels of LC3-II relative to actin upon let-7 treatment. A significant let-7-mediated reduction of ubiquitin-positive inclusions and neuronal dysfunction was observed in the lentiviral-based model at 4 weeks. Transduction of the cerebella of transgenic MJD mice with let-7 vectors significantly reduced motor incoordination and imbalance.

Hence, let-7 activates autophagy in the mammalian brain, promotes increased turnover of mutant ataxin-3 protein in mouse CNS, reduces neuronal dysfunction and ameliorates motor deficits. Therefore, autophagy activation mediated by let-7 may represent a new therapeutic approach for MJD.

#### Acknowledgements:

This work was financed by the European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Programme under project CENTRO-01-0145-FEDER-000008:BrainHealth 2020, and through the COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation and Portuguese national funds via FCT – Fundação para a Ciência e a Tecnologia, I.P., under projects POCI-01-0145-FEDER-007440 and P2020-PTDC/NEU-NMC/0084/2014, and EU Joint Programme - Neurodegenerative Disease Research (Transnational call) projects SynSpread Ref. JPND-CD/0001/2013 and ModelPolyQ; and the National Ataxia Foundation. Sónia Duarte, was supported by a FCT fellowship (SFRH/BPD/87552/2012).

## Natural History, Biomarkers and Endpoints

### Natural history of Friedreich ataxia

Jörg B. Schulz (on behalf of the EFACTS study group)

Department of Neurology, RWTH Aachen University Hospital, Aachen, Germany

Friedreich ataxia (FRAD) is a chronically progressing neuromuscular disorder starting in childhood, adolescents or young adulthood. It is caused by GAA repeat extensions in the first intron of the FXN gene which encodes the mitochondrial protein frataxin. GAA repeat

extensions suppress the transcription of the FXN gene leading to frataxin deficiency. The well-known pathophysiology of FRDA allows to identify treatment targets with the aim to stop its progression and modify the course of the disease. To design such studies knowledge of the natural history of the disease, identification of scales and biomarkers which capture the progression of the disease is of uttermost importance. To prospectively and longitudinally study the natural progression of FRDA the European Friedreich Ataxia Consortium for Translational Studies (EFACTS) set-up a registry. The cross-sectional and 2-year longitudinal data of about 600 patients have been published (1, 2). A similar approach has been taken by an American/Australian registry with published data up to a 5-year follow-up. (3). In the EFACTS registry, the Scale for the Assessment and Rating of Ataxia (SARA) and an ADL scale showed the highest sensitivity to monitor disease progression. The annual progression rate for SARA is  $0.77 \pm 0.06$  (mean  $\pm$  SEM) with a standard response mean (SRM) of 0.33 for one-year and 0.55 for two-year follow-up. If patients are limited to an age below 50 years and a SARA lower than 28 the annual progression is  $1.18 \pm 0.08$  (mean  $\pm$  SEM) with a SRM of 0.83. The data also show that FRDA shows slower progression than reported from retrospective data and imply that a study duration of at least 2 years is necessary in interventional studies aiming at disease modification without a direct symptomatic effect of the drug. These natural history data will now allow to design future treatment trials and select certain patient populations with faster disease progression.

#### References:

1. Reetz K et al. Lancet Neurol. 2015;14(2):174-82.
2. Reetz K et al. Lancet Neurol. 2016;15(13):1346-54.
3. Patel M et al. Annals of Clinical and Translational Neurology. 2016;3(9):684-94.

#### Natural history of the spinocerebellar ataxias (SCAs)

T. Klockgether

German Center for Neurodegenerative Diseases (DZNE) and Department of Neurology,  
University of Bonn, Germany

As potential treatments for SCAs are being developed, there is a need to characterise the natural history of these diseases by assessing the functional decline in each type and to identify factors that determine disease progression. An additional need is validation of markers that can be used as outcome measures in future early clinical trials.

The EUROSCA natural history study, a European multicentre longitudinal cohort study of 526 patients with SCA1, SCA2, SCA3 or SCA6, was initiated in 2005. Severity of ataxia, measured with SARA, served as the primary outcome measure. At baseline, an analysis of covariance with SARA as dependent variable led to multivariate models that explained 60.4% of the SARA score variance in SCA1, 45.4% in SCA2, 46.8% in SCA3 and 33.7% in SCA6. In SCA1, SCA2 and SCA3, SARA was mainly determined by repeat length of the expanded allele, age at onset and disease duration. A first analysis of longitudinal data after 2 years allowed to determine genotype-specific progression rates that were confirmed in a final analysis after an 8 year follow-up period. Annual SARA increase was  $2.11 \pm 0.12$  in SCA1,  $1.49 \pm 0.07$  in SCA2,  $1.56 \pm 0.08$  in SCA3, and  $0.80 \pm 0.09$  in SCA6. These values allow reliable calculation of sample sizes required for trials with drugs that are hypothesized to retard disease progression. In SCA1, longer repeat expansions ( $0.06 \pm 0.02$  per unit), and in SCA2, lower age at onset ( $-0.02 \pm 0.01$  per year) were associated with faster progression.

Activities of daily living measured with UHDRS-IV, quality of life (EQ-5D VAS) and mood (PHQ-9) steadily deteriorated over the observation period of 8 years, but the effect sizes were smaller than the effects size of SARA. The rate of deterioration of these measures did not differ between genotypes, but there was a trend that worsening was fastest in SCA1 and slowest in SCA6. In addition to SARA and repeat length, non-ataxia symptoms, in particular cognitive impairment and dysphagia affected the outcome.

The EUROSCA imaging substudy revealed genotype-specific patterns of atrophy progression with effect sizes that were in the same range or even superior to SARA. In the ongoing JPND-funded ESMI project, we are applying an automated brain segmentation pipeline to a large number of MRIs of SCA3 patients in an attempt to assess longitudinal size changes of brain structures and validate such measures as markers of disease progression. In addition, we attempt to develop new functional and biochemical markers based on quantitative motor assessment, transcript profiling and disease protein (ataxin-3) measurement. As part of the ESMI project, we have created a web-based, highly versatile SCA Registry that is used for prospective evaluation of study participants, but contains all existing data from the EUROSCA and RISCA cohorts and allows to import data from other cohorts, such as CRC-SCA. We wish to establish the SCA Registry as an open platform to clinical researchers worldwide.

#### [Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: a natural history study over a two-year follow-up](#)

Gagnon, C; Lessard, I. Lavoie, C., Brais, B., Mathieu, J.

**Introduction:** Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is characterized by pyramidal (spasticity, muscular weakness), cerebellar (ataxia) and distal neuropathic (amyotrophy). This study aimed to quantify the progression of the coordination, dexterity, balance, mobility, daily activities, and disease severity over a two-year period.

**Methods:** A total of 18 ARSACS patients were assessed two years apart. Coordination was assessed using the Lower Extremity Motor Coordination Test (LEMOCOT), Standardized Finger-to-Nose Test (SFNT) and Nine-Hole Peg Test (NHPT). Balance was assessed with the Berg Balance Scale (BERG). Mobility was documented using the 10- Meter Walk Test (10mWT) and Six-Minute Walk Test (6MWT). The Barthel Index assessed performance in daily activities. The Scale for the Assessment and Rating of Ataxia (SARA) was administered for disease severity.

**Results:** Mean age of participants was 38.8 years at baseline and 41.3 at follow-up. One participant switched from using a walking aid to a wheelchair within the two years. No significant difference was observed between baseline and follow-up for the SFNT, NHPT, and Barthel. Lower limb coordination deteriorated significantly, as demonstrated by the decrease of 3.8 targets at the LEMOCOT ( $p = 0.01$ ). Mobility was also affected, with a decrease in walking speed during the 10mWT ( $-0.194$  m/s,  $p = 0.005$ ) and a decrease of distance walked at the 6MWT ( $-31.7$ m,  $p = 0.028$ ). Balance decreased significantly (BERG,  $-2.9$ ,  $p = 0.016$ ) and disease severity assessed by the SARA worsened over time ( $+2.5$ ,  $p = 0.001$ ).

**Conclusions:** Although ARSACS is a slow degenerative disease, a significant decline was seen over the two-year period. This study will be pursued with a larger sample to be able to describe the rate of progression.

## Detailing the natural history of Friedreich's Ataxia – loss of ambulation in the CCRN-FA study

Christian Rummey (PhD),<sup>1</sup> Jennifer M. Farmer (MS)<sup>2</sup> and David R. Lynch (MD PhD),<sup>3</sup> for the CCRN-FA study network.


<sup>1</sup>Clinical Data Science GmbH, Basel, Switzerland, <sup>2</sup>Friedreich Ataxia Research Alliance, Downingtown, Pennsylvania, <sup>3</sup>Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Introduction - With >900 subjects across 12 centers in the US, Canada and Australia, the Collaborative Clinical Research Network (CCRN) hosts the largest natural history study in Friedreich's Ataxia (FA) to date. Presently, the maximum follow up time is 13y, and the study is continuously recruiting.

Loss of independent ambulation (LoA) is a major event in FA. With a tremendous burden on quality of life, it's relevance for drug development strategy is obvious. Available estimates for age/disease duration of LoA in FA span a broad range<sup>1,2,3</sup> and depend highly on characteristics of the respective cohort, due to disease-related diversity.

Methods – To understand the process of LoA in detail, we studied the age reaching relevant thresholds including gait/stance subscales of FARS, walking/falling problems in (ADL/QOL) questionnaires, timed 25-foot walk and disability staging, using time-to-event analyses. The influence of potential biases was explored and background factors evaluated using cox proportional hazards models.

Figure: Subject Years and Survival Distribution Function for LoA in the CCRN-FA Study.



Results – Exemplarily, a subset of 389 subjects (ambulatory, typical onset), report initial mild problems with walking at 14.6y (95%CI 11.6, 18.9, ADL questionnaire), the first requirement for a cane/walker at 19.1y (95%CI, 18.4, 20.2, FARS-gait item) and eventually LoA at 25.7y (95%CI 24.6, 31.7), defined as stage 5 in functional staging for ataxia. The most apparent predictor of progression to LoA remains the age of first ataxic symptoms.

**Conclusion** – Using data of 610 ambulatory subjects (1990 patient-years), we report the most comprehensive analysis of the process of LoA in FA. Beyond that, the ideal structure of the cohort (i.e. the recruitment strategy) will allow continuously more precise estimates. The CCRN-FA natural history study provides an unprecedented opportunity to guide future design of clinical trials in FRDA and will facilitate the use of LoA as an endpoint.

## References:

- 1 Harding AE, Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. *Brain* 1981.
- 2 Dürr A, Clinical and genetic abnormalities in patients with Friedreich's Ataxia. *NEJM* 1996.
- 3 Parkinson MH, Clinical features of Friedreich's ataxia: classical and atypical phenotypes. *J Neurochem* 2013.

## Long-term quality of life, depression and activities of daily living in the most common spinocerebellar ataxias (SCA1, SCA2, SCA3, SCA6)

Heike Jacobi, MD, Sophie Tezenas du Montcel, PhD, Peter Bauer, MD, Paola Giunti, PhD, Arron Cook, MBBS, Robyn Labrum, MD, Michael H. Parkinson, MBBS, Alexandra Durr, PhD, Alexis Brice, MD, Perrine Charles, MD, Cecilia Marelli, MD, Caterina Mariotti, MD, Lorenzo Nanetti, MD, Marta Panzeri, MD, Maria Rakowicz, PhD, Anna Sulek, PhD, Anna Sobanska, MD, Tanja Schmitz-Hübsch, MD, Ludger Schöls, MD, Holger Hengel, MD, Laszlo Baliko, MD, Bela Melegh, PhD, Alessandro Filla, MD, Antonella Antenora, MD, Jon Infante, MD, José Berciano, MD, Bart P. van de Warrenburg, PhD, Dagmar Timmann, MD, Sandra Szymanski, MD, Sylvia Boesch, MD, Jun-Suk Kang, MD, Massimo Pandolfo, MD, Jörg B. Schulz, MD, Audrey Tanguy, MScPH, Thomas Klockgether, MD.

Heike Jacobi, MD, German Center for Neurodegenerative Diseases (DZNE), Bonn and Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany

Sophie Tezenas du Montcel, PhD, Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, UMR S 1136, INSERM U 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France and AP-HP, Biostatistics Unit, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France

Peter Bauer, MD, Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

Paola Giunti, PhD, Department of Molecular Neuroscience, UCL, Institute of Neurology, London, United Kingdom

Arron Cook, MBBS, Department of Molecular Neuroscience, UCL, Institute of Neurology, London, United Kingdom

Robyn Labrum, MD, Neurogenetic Laboratory, National Hospital of Neurology and Neurosurgery, UCLH, London, United Kingdom

Michael H. Parkinson, MBBS, Department of Molecular Neuroscience, UCL, Institute of Neurology, London, United Kingdom

Alexandra Durr, PhD, INSERM, U 1127, F-75013, Paris, France, CNRS, UMR 7225, F-75013, Paris, France, Sorbonne Universités, UPMC Univ Paris 06, UMRS\_1127, F-75013, Paris, France, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France and APHP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, F-75013, Paris, France

Alexis Brice, MD, INSERM, U 1127, F-75013, Paris, France, CNRS, UMR 7225, F-75013, Paris, France, Sorbonne Universités, UPMC Univ Paris 06, UMRS\_1127, F-75013, Paris, France, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France and APHP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, F-75013, Paris, France

Perrine Charles, MD, APHP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, F-75013, Paris, France

Cecilia Marelli, MD, Service de Neurologie – CMRR, CHRU Gui de Chauliac, 80, av. A. Fliche, 34295 - Montpellier CEDEX 05, France

Caterina Mariotti, MD, SOSD Genetics of Neurodegenerative and Metabolic Diseases, Fondazione- IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Lorenzo Nanetti, MD, SOSD Genetics of Neurodegenerative and Metabolic Diseases, Fondazione- IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Marta Panzeri, MD, SOSD Genetics of Neurodegenerative and Metabolic Diseases, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Maria Rakowicz, PhD, Department of Clinical Neurophysiology, Institute of Psychiatry and Neurology, Warsaw, Poland

Anna Sulek, PhD, Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland

Anna Sobanska, MD, Department of Clinical Neurophysiology, Institute of Psychiatry and Neurology, Warsaw, Poland

Tanja Schmitz-Hübsch, MD, Charité Universitätsmedizin Berlin, Klinik für Neurologie, Berlin, Germany

Ludger Schöls, MD, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), D- 72076 Tübingen, Germany

Holger Hengel, MD, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), D- 72076 Tübingen, Germany

Laszlo Baliko, MD, Department of Neurology, Zala County Hospital, H-8900 Zalaegerszeg, Zrinyi M. Str. 1., Hungary

Bela Melegh, PhD, Department of Medical Genetics, and Szentagothai Research Center, University of Pécs, Pécs, Hungary

Alessandro Filla, MD, Department of Neuroscience, and Reproductive and Odontostomatological Sciences, Federico II University Naples, Italy

Antonella Antenora, MD, Department of Neuroscience, and Reproductive and Odontostomatological Sciences, Federico II University Naples, Italy

Jon Infante, MD, Service of Neurology, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria (UC) and Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Santander, Spain

José Berciano, MD, Service of Neurology, University Hospital "Marqués de Valdecilla (IDIVAL)", "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)", University of Cantabria (UC), Santander, Spain

Bart P. van de Warrenburg, PhD, Radboud University Medical Center, Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, PO Box 9101, 6500 HB Nijmegen, The Netherlands

Dagmar Timmann, MD, Department of Neurology, University Clinic Essen, University of Duisburg- Essen

Sandra Szymanski, MD, Department of Neurology, St. Josef Hospital, University Hospital of Bochum, Bochum, Germany

Sylvia Boesch, MD, Department of Neurology, Medical University, Innsbruck, Innsbruck Austria

Jun-Suk Kang, MD, Department of Neurology, University of Frankfurt, Frankfurt/M, Germany

Massimo Pandolfo, MD, Université Libre de Bruxelles (ULB), Neurology Service - ULB Hôpital Erasme, ULB Laboratory of Experimental Neurology, Brussels, Belgium

Jörg B. Schulz, MD, Department of Neurology, RWTH Aachen University, Pauwelsstraße 30, 52074 Aachen, Germany and JARA - Translational Brain Medicine, Aachen-Jülich, INM 11, Germany



Audrey Tanguy, MScPH, Biostatistics Unit, Groupe Hospitalier Pitié-Salpêtrière and Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, UMR S 1136, INSERM U 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France  
Thomas Klockgether, MD, Department of Neurology, University Hospital of Bonn, Bonn, Germany and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

**Introduction:** The spinocerebellar ataxias (SCAs) are a heterogeneous group of autosomal dominantly inherited progressive ataxia disorders. The most common SCAs which together account for more than half of all affected families are SCA1, SCA2, SCA3 and SCA6. In the last years many efforts have been made to characterize clinical manifestations and disease progression, but less is known about the health-related living conditions.

**Methods:** To obtain quantitative data on the evolution of health-related quality of life (EQ- 5D), depression (PHQ) and activities of daily living (UHDRS) as well as to identify factors that influence evolution we analysed the long term data of the EUROSCA natural history study, a multicentric longitudinal cohort study of 526 patients with either SCA1, SCA2, SCA3 or SCA6. The study was performed over 8 years at 17 European centers which together form the EUROSCA Clinical Group.

**Results:** Analyses were performed in a subgroup of 462 patients (SCA1:107, SCA2:146, SCA3:122, SCA6:87) who had at least one follow-up visit. Quality of life ( $p=0.241$ ), depression ( $p=0.139$ ) and activities of daily living ( $p=0.892$ ) did not differ between the genotypes at baseline. Quality of life (EQ-5D: SCA1:-2.88 $\pm$ 0.72; SCA2:-1.97 $\pm$ 0.49; SCA3:- 2.06 $\pm$ 0.55; SCA6:- 1.03 $\pm$ 0.57) and activities of daily living (UHDRS: SCA1:-1.35 $\pm$ 0.12; SCA2:- 1.15 $\pm$ 0.11; SCA3:- 1.16 $\pm$ 0.11; SCA6:-0.99 $\pm$ 0.12) decreased linearly and rates of decline did not differ between the genotypes (EQ-5D: $p=0.360$ ; UHDRS: $p=0.304$ ). Main determinants of decline were greater severity of ataxia and other neurological signs, the presence of depression, cognitive impairment, double vision and duration of follow-up. Evolution of depression was more complex and not linear in the most genotypes (SCA1:6.97- 0.28T+0.12T<sup>2</sup>; SCA2:5.54+0.91T- 0.09T<sup>2</sup>; SCA3:6.83+0.23T; SCA6:5.67-0.59T+0.14T<sup>2</sup>). The evolution of depression was additionally influenced by gender, dysphagia and urinary dysfunction.

**Conclusions:** Our study gives a comprehensive overview about the long-term evolution of quality of life, depression and activities of daily living in the most common SCA disorders SCA1, SCA2, SCA3 and SCA6, as well as the main determining factors.

### Longitudinal MRS, MRI and DTI in the spinal cord in Friedreich's Ataxia: 24-month follow-up

Pierre-Gilles Henry, James Joers, Dinesh Deelchand, Lynn Eberly, Diane Hutter, Khalaf Bushara, Gulin Oz, Christophe Lenglet

#### **Purpose**

There are very few MR data available in the spinal cord in Friedreich's Ataxia (FRDA). Recently, cross-sectional MR data were reported in the spinal cord, showing structural, microstructural and neurochemical changes [1,2]. Here we report the first *longitudinal* MRS, structural MRI, and diffusion MRI data in the cervical spinal cord of subjects with FRDA.

#### **Methods**

Subjects: Twenty-eight patients with FRDA (age 19.0  $\pm$  7.3 years, 15F, 13M) and 20 healthy age-

and gender-matched controls participated in the study. In addition, 17 patients returned for 12-month follow-up and 10 patients returned for 24-month follow-up. Most patients were at a relatively early stage of the disease (disease duration  $5.6 \pm 3.8$  years, FARS score  $42.7 \pm 10$  at baseline).

**MRS:** Proton MR spectra (TR/TE=5000/28ms, 256 averages) were acquired in the spinal cord at 3 Tesla using a modified semi-LASER sequence [3] from an  $8 \times 6 \times 30 \text{ mm}^3$  voxel positioned along the C4-C5 vertebrae. Spectra were quantified with LCModel using water as an internal reference.

**DTI:** DTI was acquired to cover C2 to C7 using a readout-segmented echo-planar sequence [4] with: TR/TE = 4500/66ms; voxel size =  $1.1 \times 1.1 \times 3.3 \text{ mm}^3$ ; iPAT=2; 30 axial slices; 30 diffusion gradients with b-value= 650 s/mm<sup>2</sup> and 6 additional b=0 volumes. DTI was acquired in two opposite phase encoding directions (A-P and P-A) and combined to correct for geometric and eddy current distortions [5]. The spinal cord was manually segmented at the C4-C5 level over 10 mm to obtain average values for fractional anisotropy, and axial and radial diffusivity.

**Morphometry:** MP-RAGE  $T_1$  images were obtained with 1 mm isotropic resolution. Cervical spinal cord was manually segmented with an ellipse on  $T_1$  images using Spineseg [1] to determine average spinal cord area and eccentricity on three contiguous slices at C2-C3 level.

## Results

### Cross-sectional:

MRS showed significant cross-sectional differences in tNAA (-40%,  $p < 1e-10$ ), mIns (+30%,  $p < 1e-4$ ), and tNAA/mIns ratio (-47%,  $p < 1e-13$ ). DTI showed significant differences in fractional anisotropy (-15%,  $p < 1e-6$ ), mean diffusivity (+15%,  $p < 0.0005$ ), axial diffusivity (AD, +6%,  $p = 0.05$ ) and radial diffusivity (RD, +25%,  $p < 1e-5$ ). Morphometry showed reduced spinal cord area (-28%,  $p < 1e-7$ ) and increased eccentricity in FRDA (+13%,  $p < 1e-6$ ), consistent with atrophy of dorsal and lateral columns of the spinal cord.

### Longitudinal (24-month follow-up):

The tNAA/mIns ratio decreased by 17% on average over 24 months ( $p = 0.02$ ). Fractional anisotropy decreased by 11% ( $p < 0.005$ ) and mean diffusivity increased by 26% ( $p < 0.0005$ ). Spinal cord area decreased by 18% over 24 months ( $p < 0.0001$ ) and eccentricity increased by 3% over 24 months ( $p < 0.01$ ). Similar trends were already apparent at 12 months, with p-values in the 0.01-0.1 range.

## Conclusion

Even though MR in the spinal cord is technically more challenging than in the brain, we detected significant longitudinal alterations in the cervical spinal cord of patients with FRDA at 12 and 24 months. With multiple therapeutic trials currently being planned in FRDA, including gene therapy trials, these data support a role for MRS and MRI as potential markers to assess therapeutic efficacy in clinical trials.

## Acknowledgements

This work was supported by the Friedreich's Ataxia Research Alliance, CureFA Foundation, Ataxia UK, GoFAR, the Bob Allison Ataxia Research Center, and NIH grants P41 EB015894 and P30 NS076408.

## References

[1] Chevis, C.F., et al. Spinal cord atrophy correlates with disability in Friedreich's ataxia. *Cerebellum*, 2013. 12(1):43-7 [2] Henry P.G. et al. MRS and diffusion MRI of the spinal cord in Friedreich's Ataxia. *Proc ISMRM 2014*, 571 [3] Öz, G., Tkáč, I., Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: validation in the cerebellum and brainstem. *Magn Reson Med*, 2011. 65(4):901-10 [4] Porter,

D.A., Heidemann, R.M., High resolution diffusion-weighted imaging using readout-segmented echo-planar imaging, parallel imaging and a two-dimensional navigator-based reacquisition. *Magn Reson Med*, 2009. 62(2):468-75 [5] Andersson, J. et al. A comprehensive Gaussian Process framework for correcting distortions and movements in diffusion images, *Proc ISMRM 2012*

### Basal ganglia and Posterior fossa structural abnormalities in SCA3 stratified for disease stages

Jean Levi Ribeiro de Paiva<sup>1</sup>, Thiago Junqueira R. Rezende<sup>1</sup>, Msc, Alberto Rolim M. Martinez<sup>1</sup>, MD, Iscia Lopes-Cendes<sup>2</sup>, MD PhD, Marcondes C. França Jr<sup>1</sup>, MD PhD.

<sup>1</sup> Department of Neurology and Neuroimaging Laboratory, School of Medical Sciences, University of Campinas (UNICAMP), Campinas SP, Brazil

<sup>2</sup> Department of Medical Genetics, School of Medical Sciences, University of Campinas (UNICAMP), Campinas SP, Brazil

**Introduction:** Spinocerebellar Ataxia Type 3 (SCA3) is the most common dominantly inherited ataxia and is characterized by widespread CNS damage. Despite this, there are still very few neuroimaging studies looking at the progression of such damage. Thus, our main objective is to characterize, through a volumetric approach, the basal ganglia and posterior fossa structural abnormalities in SCA3, and to determine its progression stratified for disease stages.

**Methods:** Eighty two patients with molecular confirmation and 82 healthy controls were enrolled. Patients were divided into 4 groups, according to disease duration (0 – 5 years, n=14; 5 – 10 years, n=26; 10 – 15 years, n=28; 15 years or more, n=14). We used 3D T1-weighted images obtained in a 3T scanner to segment deep gray matter and posterior fossa structures using an atlas-based approach. A generalized linear model was used for statistical analysis, and corrected p-values < 0.05 were considered significant.

**Results:** The comparison between patients (n=82; Age = 48.5 ± 12.6; (CAG)n = 71.9 ± 3.7; 38 men) and controls (n=82; Age = 48.0 ± 12.5; 38 males) showed significant atrophy in many structures, such as pons, midbrain, medulla, cerebellum, caudate, putamen and globus pallidus, all with p < 0,001. The comparison between the short duration group and their respective controls also showed a similar significant widespread atrophy. The comparison of results stratified for disease stages showed a linear pattern of progression in various structures. The estimated annual rate of volumetric reduction was more pronounced for the pons (R = 0,85; p < 0,001) and middle cerebellar peduncles (R = 0,83; p < 0,001).

**Conclusion:** Posterior fossa and basal ganglia damage progress linearly in SCA3. Volumetry of the pons and middle cerebellar peduncles are promising neuroimaging biomarkers for clinical follow-up and therapeutic trials.

### CCFS a quantitative score of cerebellar dysfunction and evolution in Friedreich ataxia

A Tanguy<sup>1</sup>, C Mariotti<sup>2</sup>, S Benaich<sup>1,3</sup>, A Durr<sup>1,3</sup>, S Tezenas du Montcel<sup>1,4</sup> on behalf of the EFACTS consortium

<sup>1</sup> AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

<sup>2</sup> Unit of Genetics of Neurodegenerative and Metabolic Disorders, Istituto Neurologico C Besta, Milan, Italy

<sup>3</sup> ICM (Institut du cerveau et de la moelle épinière), Sorbonne Universités, UPMC Université Paris 06 UMR\_S1127, and INSERM U1127, CNRS UMR 7225 Paris, France

<sup>4</sup> Sorbonne Universités, UPMC Université Paris 06 UMR\_S1136, and INSERM UMR\_S 1136,

Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France

**Introduction:** To evaluate cerebellar impairment clinical scales have been proposed, such as the Scale for the Assessment and Rating of Ataxia (SARA), or the composite cerebellar functional severity (CCFS) score, a quantitative performance-based scale validated in autosomal dominant cerebellar ataxias (SCA) and not in Friedreich ataxia (FRDA). Our objectives were to assess how specific are the CCFS and the SARA for FRDA compared to SCA and controls and what drives the values of these scores.

**Methods:** FRDA patients were recruited prospectively from 2010 to 2015 through the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS). The other subjects were recruited in Paris and in Milan.

**Results:** 383 FRDA patients, 205 SCA patients and 168 controls were consecutively recruited. FRDA patients had lower CCFS and SARA scores after adjustment for disease duration than SCA subjects. In FRDA subjects, CCFS and SARA were both independently associated with the disease duration, the age at onset and the shorter allele repeat size. In both FRDA and SCA subjects, CCFS increased with SARA but with a sigmoid relation: linear relation for SARA scores between 10 and 24, not linear outside these thresholds. The 199 subjects who did not the CCFS and were scored with the SARA had more severe disease characteristics than the subjects scored both scales.

**Conclusions:** In order to monitor disease severity, SARA is suitable for both diseases. Similarly to other clinical scales used for Friedreich ataxia ceiling effects in late stages of the disease may occur. CCFS, as a rater-independent continuous measure, is usable in a multicenter context, since it is simple, fast and fully automated. It is however hard to perform in the most severe patients.

### Cortical responses and change detection to auditory and somatosensory stimuli in Friedreich ataxia

Naeije G1, Marty B2, Wens V2, Goldman S2, Pandolfo M1, De Tiège X2

1 Service of Neurology, ULB-Hôpital Erasme, Belgium

2 Laboratoire de Cartographie fonctionnelle du Cerveau (LCFC), ULB Neuroscience Institute, Belgium

#### Introduction

Neurophysiological assessment of the proprioceptive and cerebellar systems, whose dysfunction and degeneration underlie the afferent and cerebellar ataxia characterizing Friedreich ataxia (FRDA), may define the severity and timing of their involvement, guide the identification of therapeutic targets, and provide biomarkers reflecting disease status, progression and response to treatments.

Previous studies on evoked potentials (EPs) in FRDA proposed that impairment in somatosensory EPs (SSEPs) correlates with GAA1 and does not change with disease progression, while impairment in brainstem auditory EPs (BAEPs) was reported to correlate with disease duration, suggesting an early and stable deficit in somatosensory processing and a progressive involvement of the auditory system. However, a limitation of SSEP studies is the complete loss of these responses in most FRDA subjects, even at a young age, a finding we could confirm with our patients.

#### Methods

We used magnetoencephalography (MEG) to study cortical evoked responses of FRDA subjects to somatosensory and auditory stimuli, with the assumption that this technology might allow

to detect responses even when traditional EPs cannot be measured, and add temporal and spatial resolution to the analysis. We also explored MEG signals generated by sensory change detection, which are thought to be modulated by the cerebellum. In traditional EP protocols, an increased evoked response, called mismatch negativity (MMN), is observed when a deviant stimulus occurs amongst a sequence of repeated standard stimuli. MMN is the correlate of pre-attentive change detection in sensory cortices. An equivalent signal can be measured by MEG. Of notice, unilateral cerebellar lesions lead to near absent MMN for ipsilateral deviant somatosensory stimuli, but have no effect on auditory change detection.

We studied 16 FRDA patients (10 females, 6 males), with a mean age of 30 years (range 9-53) and a mean SARA score of 23.4 (range 9.5-37.5), and 16 healthy controls (9 females, 7 males), with a mean age of 29 years (range 10-55). We recorded whole-scalp MEG (Elekta, Oy) while undergoing (1) a tactile oddball paradigm where standard stimuli consisted of pneumatic stimulation of the right forefinger fingertip and deviant stimuli of simultaneous stimulation of the first two phalanges; and (2) a monaural auditory oddball paradigm where standard stimuli consisted of audible tones of 540 Hz and deviant stimuli were 600 Hz tones, presented in the right ear. Inverse modelling was done using the Minimum Norm Estimate (MNE). For group analysis, individual source power time series were normalized by the maximum amplitude of standard responses before group averaging, to exclude individual subjects' amplitude effect. We temporally realigned time series on the first peak activation to control for individual response latencies. We used non-parametric permutation statistical tests to assess significance of evoked responses.

## Results

Cortical somatosensory evoked responses were found in all subjects at left primary somatosensory cortex (S1). In FRDA subjects their mean latency was significantly longer (53 vs 28 ms;  $p < 0.001$ ), and their mean amplitude was significantly smaller (0.285 vs 0.513;  $p = 0.0041$ ) than in controls. GAA1 negatively correlated with the amplitude of individual S1 responses ( $r = -0.74$ ,  $p = 0.0032$ ). Cortical auditory evoked responses were found in all subjects at primary auditory cortex (A1), bilaterally. In FRDA patients their mean latency was significantly longer than in controls (107 vs 87 ms;  $p < 0.001$ ), but their amplitude was comparable in FRDA and controls (0.507 vs 0.45;  $p = 0.25$ ). GAA1 negatively correlated with individual A1 responses ( $r = -0.56$ ,  $p = 0.036$ ) of FRDA subjects. Larger amplitude responses to deviant stimuli, the MEG equivalent of MMN, were found in controls and FRDA patients at left secondary somatosensory cortex (S2), with a delay of 100-200 ms; but also at left S1 in FRDA patients, with a delay of 50-78ms.

The normalized magnitude of deviant stimuli responses was significantly smaller for FRDA patients, and negatively correlated with GAA1 ( $r = -0.6$ ,  $p = 0.023$ ). Similarly, responses to deviant auditory stimuli were found in patients and controls over the left superior temporal lobe, with a delay between 150-200ms and comparable normalized magnitudes for both groups.

## Conclusions

MEG allows to detect cortical responses to tactile stimuli in all FRDA patients, even when SSEPs are absent. These responses are delayed and reduced in amplitude. Cortical auditory responses are not decreased in amplitude, but show increased latency. In both cases, impairment is seemingly unrelated to disease progression and only correlates with mutation severity, indicating that these parameters are biomarkers of early sensory damage. Cortical responses to deviant somatosensory stimuli (corresponding to MMN) are normally measured at S2 only, as it was the case with our controls, but in FRDA subjects they occurred in S1 as well.

## Exercise stress testing on adaptive equipment is feasible and reliable in Friedreich Ataxia

1,2Lin KY, 1McBride M, 1,2Paridon S, 1,3Lynch DR. 1The Children's Hospital of Philadelphia, 2Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 3Department of Neurology, Perelman School of Medicine at the University of Pennsylvania.

**Introduction:** Outcome measures which reflect clinically relevant changes in neurologic and cardiac function are needed in Friedreich Ataxia (FRDA). Traditional exercise equipment is not suited for most patients with significant gait and balance problems. We aimed to test whether exercise stress test (EST) performance on adaptive equipment is feasible and reliable in FRDA patients.

**Methods:** Subjects with genetically confirmed FRDA underwent incremental cardiopulmonary exercise testing on either an arm (ACE) or recumbent leg (RLCE) cycle ergometer at up to 4 visits (baseline, 2 wks, 4 wks, 1 yr). The ramp protocol was continued while subjects were advised to pedal at a constant rate until maximal volition or until limiting symptoms occurred. Maximum work rate, oxygen consumption (VO<sub>2</sub>max), oxygen (O<sub>2</sub>) pulse, and anaerobic threshold (AT) were ascertained. Test-retest reliability was assessed by intraclass coefficient (ICC) from visits 2 and 3.

**Results:** 23 subjects enrolled with mean FARS  $59 \pm 16$ , age  $19 \pm 8$  yrs, age of onset  $9 \pm 4$  yrs, GAA1  $741 \pm 195$  (except 2 with G130V point mutations). 21 (91%) completed a maximal EST; 2 subjects (FARS 82 and 89, GAA1 900 for both) could not keep a steady cadence to reach maximal volition on either ACE or RLCE attempts. ICC for work rate was excellent for ACE [0.98 (95%CI 0.86,0.998)] and RLCE [0.97(0.76,0.997)], while ICC was low on other parameters for ACE but high for RLCE: O<sub>2</sub> pulse 0.94 (0.52, 0.993), VO<sub>2</sub>max 0.93 (0.47, 0.992), AT 0.96 (0.69, 0.996).

**Conclusions:** Maximal EST on adaptive equipment is feasible for FRDA patients with high test-retest reliability. Clinical trials enrolling subjects who can complete arm cycle ergometry testing should consider maximum work as an outcome measure, while trials enrolling subjects who can complete recumbent leg ergometry testing can also use VO<sub>2</sub>max, O<sub>2</sub> pulse and AT as outcome measures.

## Developing a clinically meaningful instrumented measure of upper limb function in Friedreich ataxia.

Corben LA<sup>1, 2, 3</sup>, Tai G<sup>1</sup>, Szmulewicz D<sup>4,5,6</sup>, Horne MK<sup>6</sup>, Pathirana PN<sup>7</sup>, Delatycki MB<sup>1, 2, 3, 8</sup>.  
1Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Vic., Australia  
2School of Psychological Sciences, Monash University, Clayton, Vic., Australia  
3Department of Paediatrics, University of Melbourne, Parkville, Vic., Australia  
4Royal Victorian Eye and Ear Hospital, East Melbourne, Vic., Australia  
5Alfred Hospital, Prahran, Vic., Australia.  
6Florey Institute, Parkville, Vic., Australia.  
7School of Engineering, Deakin University, Geelong, Vic., Australia  
8Victorian Clinical Genetics Service, Parkville, Vic., Australia.

**Introduction:** Friedreich ataxia (FRDA) has a significant effect on upper limb function which in turn, compromises independence and quality of life. The most common measure of upper limb function in FRDA is the Nine Hole Peg Test (9HPT). Increasingly, regulatory bodies are calling for outcome measures to reflect changes in functional status however the capacity for the

9HPT to reflect functional capacity is uncertain. The aims of this study were twofold: 1) to identify the functional upper limb tasks that individuals with FRDA found most challenging and 2) and use these results, to develop and pilot an instrumented measure of upper limb function that captures burden of disease and potentially clinically meaningful change.

Methods: We analysed the upper limb component of the Friedreich Ataxia Impact Scale (FAIS) in 120 individuals with FRDA. In addition, we examined performance on the Jebsen Taylor Hand Function Test (JHFT) and 9HPT in 73 individuals with FRDA correlating both measures with clinical parameters of FRDA. Based on this analysis we developed an instrumented motion capture functional upper limb measure for FRDA.

Results: Intricate tasks such as taking a spoon to the mouth proved to be most problematic in 88% of participants, significantly correlating with age at disease onset ( $r=-0.229$ ,  $p<0.05$ ), disease duration ( $r=0.53$ ,  $p<0.00$ ), the dominant 9HPT ( $r=0.37$ ,  $p<0.00$ ) and all items in the upper limb section of the Friedreich Ataxia Rating Scale (FARS). Simulated feeding with the dominant hand on the JHFT significantly correlated with disease duration ( $\rho=0.40$ ,  $p<0.00$ ) and the 9HPT ( $\rho=0.58$ ,  $p<0.00$ ).

Conclusion: We have systematically identified a functional task that has provided the genesis for development of a true measure of upper limb function. This novel instrumented measure aims to accurately reflect upper limb function in individuals with FRDA and as such will be of significant utility in future clinical trials.

#### Cardiac magnetic resonance T1 mapping as a window into the myocardium in Friedreich ataxia (FRDA)

Lin KY, 2Delatycki M, 2Corben L, 3Cheung M, 4Ferrari V, 1Fogel M, 5Moir S, 5Peverill R.

1Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania and Children's Hospital of Philadelphia, , 2Murdoch Children's Research Institute, 3Department of Pediatrics, University of Melbourne, Heart Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, and 5 Monash Cardiovascular Research Centre, Monash Heart and Department of Medicine (School of Clinical Sciences at Monash Medical Centre), Monash University and Monash Health

Introduction: Left ventricular (LV) concentric remodeling or hypertrophy is common in FRDA and is associated with poorer prognosis. However, the nature of the underlying myocardial ultrastructural change in FRDA is unknown. The aim of this study was to investigate cardiac magnetic resonance (CMR) T1 mapping, a technique used to assess the fibrous tissue burden of the myocardium.

Methods: A standardized CMR protocol including T1 mapping and measurements of LV mass, LV end-diastolic volume, the native T1 time, post gadolinium (PostGad) T1 time, calculation of the LV mass/volume ratio (LVMVR) and the partition coefficient (PC) was performed on individuals from Melbourne and Philadelphia who were homozygous for GAA repeats in the FXN gene.

Results: Fifty-seven subjects (55% males) with FRDA were recruited from both sites; the median (range) age was 24 (10-51) years, age at onset 10 (2-28) years, disease duration 11 (3-36) years and GAA1 repeat length 694 (241-1050). Four subjects had an LV ejection fraction (EF)  $<55\%$  and 31 had an increased LVMVR ( $>1.20$ ). The native T1 time was similar in both cohorts, but the Philadelphia cohort was younger and had a higher PostGad T1 time and PC than the Melbourne cohort ( $p<0.01$  for all). On multivariate analysis, after adjusting for sex, age and site, there were positive correlations of GAA1 with native T1 time ( $\beta=0.47$ ,  $p=0.001$ )

and PC ( $\beta=0.52$ ,  $p<0.001$ ), but no relation of GAA1 with PostGad T1 time. LVMVR was also positively correlated with native T1 ( $\beta=0.30$ ,  $p<0.02$ ), but when LVMVR was combined with GAA1, only GAA1 remained a significant correlate of native T1.

Conclusion: T1 mapping demonstrates positive correlation of myocardial fibrous burden with GAA1, and provides information about the LV myocardium in FRDA which is independent of the presence of LV remodeling/hypertrophy. Information is required regarding the relationship of T1 variables with cardiac outcomes

### Auditory dysfunction and its remediation in individuals with spinocerebellar ataxia.

Uus K, 1, Rance G, 2.

1: The University of Manchester, 2: The University of Melbourne

Introduction: The spinocerebellar ataxia's (SCAs) are a heterogeneous group of neurological disorders caused by varying degrees of degeneration of the cerebellum, brainstem neurons and spinocerebellar tracts. In this study we investigated the auditory consequences of SCA types 1, 2 & 6 and explored the capacity of remote-microphone listening devices to alleviate everyday listening and communication difficulties in affected individuals.

Methods: Fourteen adults with SCA (Type 1: N=7; Type 2: N=2; Type 6: N=5) underwent a comprehensive evaluation of peripheral hearing mechanisms (sound detection, cochlear mechanics), auditory neural activity (auditory brainstem response) and functional hearing (monosyllabic speech perception, self-reported communication disability). Findings were compared with data obtained from 130 healthy controls.

Each SCA participant was subsequently fit with an ISense FM listening device and underwent a 6 week take-home trial.

Results: Sound detection thresholds were within age-corrected norms for 13/14 of the SCA participants. None-the-less, the majority of participants (in each SCA category) showed evidence of severe auditory dysfunction. Twelve individuals presented with abnormal VIIIth nerve/brainstem activity, with absent ABRs, delayed neural conduction or abnormal stimulus-rate sensitivity. Speech discrimination was affected, particularly for signals presented in background noise (0 dB SNR) with 12/14 participants performing at levels below the normal (95% confidence) range. Everyday listening ability was also impaired in most cases. Ten of 14 reported extreme difficulty understanding conversation in background noise and 9/14 felt that their hearing challenges adversely affected communication ability.

The use of an FM-listening system did, however, alleviate these difficulties. For 13/14 individuals speech perception scores improved to within the normal range when wearing the device and 11/14 reported significant improvement in everyday listening and communication over the course of the 6- week trial.

Conclusions: Auditory dysfunction is common in SCA1, SCA2 and SCA6, but remote-microphone listening devices appear to be a viable intervention option for many patients.



## Therapeutics and Clinical Trials

Summary and lessons learned from ataxia trials

Francesco Sacca

Innovative trial designs for rare diseases, with focus on use of innovative endpoints and potential use of registry data.

Prof Dr Kit CB Roes

University Medical Center Utrecht

In clinical trials that aim to provide confirmatory evidence for new treatments for rare diseases, the available sample size is often the crucial limitation. In a regulatory (drug approval) setting decision making based on evidence from a limited number of small trials is challenging. The totality of evidence is commonly taken into account, although in an informal fashion. To improve underlying methods as well as decision making our research followed different pathways, amongst which (1) how to optimize methods for (flexible) designs in case of finite and small sample sizes, (2) appropriate methods for meta-analysis of small number of small trials to support decision making and (3) investigate new patient centered outcomes that capture the often heterogeneous disease course efficiently (such as mitochondrial diseases, Duchenne's muscular dystrophy, e.g.). A brief general overview of potential methods will be given, with subsequent focus on development of individualized outcomes, goal attainment scaling, and the use of registry data as potential basis for (historical control) data and to better design clinical trials.

Activation of Frataxin expression by duplex RNAs and antisense oligonucleotides

David Corey, University of Texas Southwestern.

Friedreich's Ataxia (FRDA) is an incurable genetic disorder caused by a mutant expansion of the trinucleotide GAA within an intronic *FXN* RNA. This expansion leads to reduced expression of frataxin (FXN) protein and evidence suggests that transcriptional repression is caused by an R-loop that forms between the expanded repeat RNA and complementary genomic DNA. Synthetic agents that increase levels of FXN protein might alleviate the disease. We demonstrate that introducing anti-GAA duplex RNAs or single-stranded locked nucleic acids (LNAs) into patient-derived cells increases FXN protein expression to levels similar to analogous wild-type cells. Our data are significant because synthetic nucleic acids that target GAA repeats can be lead compounds for restoring curative FXN levels. Both antisense oligonucleotides (ASOs) and duplex RNAs (dsRNAs) were shown to activate FXN expression, providing two starting points for therapeutic development. Our results demonstrate that interfering with R-loop formation can trigger gene activation and reveal a new strategy for up-regulating gene expression. Current studies are focusing on exploring how chemical modifications affect the potency of activation. We are also examining the potency of activation in patient-derived cell lines that contain diverse numbers of mutant repeats. The purpose of this research is to identify the best compounds for animal studies and the prospects for these studies will be evaluated. The outstanding question is whether the promising results in cell culture can be translated successfully in vivo.

## Gene-targeted synthetic molecules stimulate transcription through repressive GAA-repeats in patient-derived Friedreich's Ataxia cells

Matthew P. Grieshop<sup>1</sup>, Graham S. Erwin<sup>1</sup>, Asfa Ali<sup>1</sup>, Jun Qi<sup>2</sup>, Matthew Lawlor<sup>2</sup>, Deepak Kumar<sup>3,4</sup>, Ishtar Ahmad<sup>3,4</sup>, Anna McNally<sup>5</sup>, Natalia Teider<sup>5</sup>, Katie Porringer<sup>5</sup>, Rajeev Sivasankaran<sup>5</sup>, Asuka Eguchi<sup>1</sup>, Mousheng Xu<sup>2</sup>, Achal K. Srivastava<sup>3</sup>, Mohammed Faruq<sup>4</sup>, James E. Bradner<sup>2,5</sup>, Aseem Z. Ansari<sup>1,6</sup> \*

<sup>1</sup> Department of Biochemistry, University of Wisconsin–Madison, Madison, Wisconsin 53706.

<sup>2</sup> Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, 02215. <sup>3</sup> Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

<sup>4</sup> Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India <sup>5</sup> Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139

<sup>6</sup> The Genome Center of Wisconsin, University of Wisconsin–Madison, Madison, Wisconsin 53706

Regulated release of paused RNA polymerase II (Pol II) into productively elongating state is a critical rate-limiting step in the expression of genes involved in development, differentiation and disease. Based on recent mechanistic insights, we designed molecules that function as synthetic transcription factors at targeted genomic loci. We apply this design to generate a molecule that enables transcriptional elongation through GAA microsatellites that silence Frataxin expression and lead to incurable Friedreich's ataxia. The molecule restores expression in primary cells from multiple patients bearing a range of GAA-repeat expansions. Our portable design provides a framework to generate a class of molecules that license Pol II to overcome repeat-induced repressive barriers to transcription elongation at other genomic loci.

## Class-I HDAC inhibitors with improved potency and drug-like properties for de-repressing frataxin production in Friedreich's Ataxia

Shripad S. Bhagwat, Helen Hua, Greg Luedtke, Alex Bridges, Michael Robinson, Doug Boatman, Elizabeth Soragni, Joel Gottesfeld, David Jacoby

Friedreich's Ataxia (FA) is a fatal genetic disease caused by production of insufficient amounts of frataxin protein in humans. Release of frataxin (*FXN*) gene silencing is a promising approach to treat FA. Class I histone deacetylase (HDAC) inhibitors that have a characteristic amino-benzamide as the substructure that binds zinc in the active site of HDAC, are found to be effective in cellular and animal models of FA. One such drug, RGFP109, was found to increase frataxin after a single oral dose in humans. However, 109 was discontinued from clinical development because of metabolic liabilities.

BioMarin has evaluated a large number of the amino-benzamide class of HDAC inhibitors in order to identify compounds that have increased potency for upregulating *FXN* expression, increased drug exposure in the disease specific tissues (brain and heart), a longer half-life in the body, and lower potential to form the undesired metabolites. An update on our search for an improved compound for the treatment of FA will be discussed during the presentation.

## RNA/DNA hybrid interactome uncovers DHX9 as a novel regulator of pathological R-loops in Friedreich ataxia

Matthias Groh, Agnese Cristini, Maiken Søndergaard Kristiansen, [Natalia Gromak](#)  
Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK

Friedreich ataxia (FRDA) is the most common inherited recessive ataxia, characterised by progressive sensory ataxia, cardiomyopathy, diabetes and premature death. It is caused by an expanded GAA repeat sequence in intron 1 of the frataxin (*FXN*) gene, resulting in frataxin mRNA and protein deficiency. Using methodology established in the lab (Skourti-Stathaki et al., 2011), we recently demonstrated that *FXN* silencing involves formation of unusual RNA/DNA structures, R-loops, over the expanded repeats (Groh et al., 2014). These R-loops are stable and trigger formation of repressive chromatin marks over the *FXN* gene. To elucidate the molecular mechanism of R-loop-mediated transcriptional silencing in FRDA, we designed an affinity purification approach coupled to mass spectrometry to identify R-loop-binding proteins (R-loop interactome) in an unbiased way. Based on this approach, the R-loop interactome consists of known R-loop factors SRSF1, FACT and Top1 and yet uncharacterised interactors, including RNA-/DNA-binding proteins, DNA repair and chromatin factors, and helicases. We investigated the function of the top R-loop interactome candidate, helicase DHX9, *in vivo*. We found that DHX9 recruitment to *FXN* gene is compromised in FRDA cells, resulting in increased R-loop accumulation over the expanded repeats. Interestingly, DHX9 overexpression promoted the resolution of disease-associated R-loops. These data suggest that DHX9 represents a novel regulator controlling R-loop metabolism in FRDA disease. Thus, RNA/DNA hybrid interactome provides a powerful resource to study R-loop biology in health and disease and reveals potential targets for future therapeutic interventions of FRDA.

Skourti-Stathaki K, Proudfoot NJ, Gromak N. 2011. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. *Molecular cell* **42**: 794-805.

Groh M, Lufino MM, Wade-Martins R, Gromak N. 2014. R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. *PLoS genetics* **10**: e1004318.

## Safety, Efficacy, and Pharmacodynamics of Omaveloxolone in Friedreich's Ataxia Patients (MOXle Trial): Part 1 Results

Authors: Lynch, D1; Farmer, J2; Meyer, C3; Boesch, S4.; Chin, M.3; Delatycki, M5; Giunti, P6; Goldsberry, A3; Hoyle, JC7; McBride, M1.; O'Grady, M.3; Perlman, S8; Subramony, S9; Wilmot, G10; Zesiewicz, T11

Institution

1. Children's Hospital of Philadelphia, Philadelphia, PA
2. Friedreich's Ataxia Research Alliance, Downingtown, PA
3. Reata Pharmaceuticals, Irving, TX
4. Innsbruck Medical University, Innsbruck, Austria
5. Murdoch Children's Research Institute, Melbourne, Australia
6. University College of London, London, England
7. The Ohio State University, Columbus, OH

8. University of California Los Angeles, Los Angeles, CA
9. University of Florida, Gainesville, FL
10. Emory University, Atlanta, GA
11. University of South Florida, Tampa, FL

#### INTRODUCTION:

Previous studies have demonstrated that suppression of Nrf2 in Friedreich's ataxia patients contributes to excess oxidative stress, mitochondrial dysfunction, and reduced ATP production. Omaveloxolone, an Nrf2 activator and NF- $\kappa$ B suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways. The initial dose-ranging portion of a Phase 2 study of the safety, efficacy, and pharmacodynamics of omaveloxolone in Friedreich's ataxia patients (MOXIe, NCT02255435) sought to evaluate the optimal omaveloxolone dose for further study.

#### METHODS:

Sixty-nine Friedreich's ataxia patients were randomized 3:1 to either omaveloxolone or placebo administered once daily for 12 weeks. Patients were randomized in cohorts of 8 patients, at dose levels of 2.5, 5, 10, 20, 40, 80, 160, and 300 mg. Eligible Friedreich's ataxia patients must have had a modified Friedreich's Ataxia Rating Scale (mFARS) score  $\geq 10$  and  $\leq 80$ , be between 16 to 40 years of age (inclusive), and be able to complete maximal exercise testing.

#### RESULTS:

Optimal pharmacodynamic and efficacy changes were observed at omaveloxolone doses of 80 and 160 mg. At the 160mg dose, omaveloxolone improved mFARS by 3.8 points versus baseline ( $p=0.0001$ ) and by 2.3 points versus placebo ( $p=0.06$ ). Omaveloxolone produced greater improvements in mFARS in patients that did not have preexisting musculoskeletal foot deformity (pes cavus). In patients without this foot deformity at the 160mg dose level, omaveloxolone improved mFARS by 6.0 points from baseline ( $p<0.0001$ ) and by 4.4 points versus placebo ( $p=0.01$ ). Omaveloxolone was well tolerated, and adverse events were generally mild in severity.

**CONCLUSIONS:** Treatment of Friedreich's ataxia patients with omaveloxolone at the optimal dose level led to improvements in neurological function (mFARS). Therefore, omaveloxolone treatment will be examined in greater detail at the optimal dose level in Part 2 of the MOXIe study.

#### [Lessons learned from recent approvals of therapies for neuromuscular disorders.](#)

Jane Larkindale, Friedreich's Ataxia Research Alliance and Duchenne Regulatory Science Consortium, Critical Path Institute.

Several drugs for neuromuscular disorders have been approved by the US Food and Drug Administration (FDA) and/or the European Medicines Authority (EMA) in recent years. These include Spinraza for spinal muscular atrophy (SMA), Exondys51, Emflaza and Translarna for Duchenne Muscular Dystrophy and Radicava for Amyotrophic Lateral Sclerosis (ALS). Each drug has taken a different path to approval: several are approved by only one authority and several have utilized accelerated approval pathways. Trials have varied significantly in size and design, and many protocols have utilized biomarkers and natural history data to support their cases for approval. Many of these therapies have generated controversy around their supportive data, the populations of patients they should be approved for and around the pricing of such therapies. This talk will review the

work that led to approval of these therapies and lessons learned from those approvals that can be applied to future studies of potential therapeutics for ataxias.

### [Overview of viral gene therapy approaches for genetic diseases](#)

Nicholas Muzyczka  
University of Florida College of Medicine  
Gainesville, FL 32608

We now have over 30 years of experience with a variety of gene therapy vectors for the correction of genetic diseases. Although we have yet to see a successful gene therapy drug enter the marketplace, two gene delivery systems have proven to be capable of efficient delivery of genes to somatic cells in animal models. Both are capable of long-term correction of disease symptoms in animal models and in humans. These are Adeno-associated virus (AAV) and retroviruses. We will compare the biology of these two delivery systems, with a particular focus on AAV. Safety issues, the current production and downstream processing issues associated with these vectors and quality control issues that need to be considered will be outlined. We will also discuss the routes of administration that can be used for both peripheral (systemic) and CNS delivery. In addition, we will briefly discuss the immune response to these vectors and methods that are being tried to minimize the immune response. Finally, we will outline approaches that are currently being used to develop the next generation of vectors, which promise to be more efficient and more cell and organ specific. These vectors are likely to deliver not just replacement genes, but also elements that knock down endogenous genes (miRNA), site specific endonucleases that modify mutant genes or constructs that correct mutant genes by homologous recombination.

### [Role of microRNAs in Machado-Joseph disease: from pathogenesis to therapy.](#)

Vitor Carmona<sup>1,2</sup>, Janete Cunha-Santos<sup>1,2</sup>, Isabel Onofre<sup>1,2</sup>, Ana Teresa Simões<sup>1</sup>, Udaya Vijayakumar<sup>1</sup>, Beverly Davidson<sup>3,4</sup> and Luís Pereira de Almeida<sup>1,2</sup>

<sup>1</sup>CNC—Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, Coimbra 3004-504, Portugal

<sup>2</sup>Faculty of Pharmacy, University of Coimbra, Coimbra 3000-548, Portugal

<sup>3</sup>The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA;

<sup>4</sup>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Introduction: Machado-Joseph disease (MJD) is the most common dominantly-inherited ataxia worldwide. Although several studies contributed to the understanding its pathogenesis, the pathogenic events underlying neurodegeneration are not completely understood. Importantly, transcriptional dysregulation has been recognized as an important disease pathway in MJD and our group has already provided evidence implicating endogenous microRNAs (miRNAs) in the regulation of ataxin-3 (ATXN3) mRNA. Methods: To evaluate their ability to regulate mutATXN3 expression *in vitro*, miRNAs targeting ATXN3 were cloned into a lentiviral expression system. Expression levels of miRNAs targeting ATXN3 were evaluated *in vitro* by qPCR, in SH-SY5Y cell lines expressing either wild-type or mutant ATXN3, and in neural stem cells and neurons differentiated from human induced pluripotent stem cells. The expression levels of these miRNAs were also

evaluated *in vivo*, in post-mortem human brain samples and in the cerebellum of MJD transgenic mice. MiRNAs validated *in vitro* were lentivirally overexpressed *in vivo*, together with mutATXN3, through stereotaxic injection.

Results: Our results show that miRNAs targeting ATXN3 mRNA directly reduce the expression of mutATXN3 at the mRNA and protein levels. Moreover, qPCR analysis revealed a general downregulated profile for these miRNAs across different MJD models, particularly in MJD transgenic mice. Accordingly, different genes encoding for miRNA machinery were also found to be downregulated in these samples. Moreover, *in vivo* overexpression of these miRNAs reduced: a) mutATXN3 mRNA levels, b) aggregate counts, and c) associated DARPP32- depleted volume.

Conclusion: All in all, this study identified and validated different miRNAs targeting ATXN3 mRNA, which were found to be downregulated in MJD models and whose overexpression ameliorated disease manifestations *in vivo*, providing an opportunity for the development of novel therapeutic interventions for this disorder.

This work was supported by funds FEDER and the Competitive Factors Operational Program – COMPETE and by national funds through the Portuguese Foundation for Science and Technology (FCT: PTDC/SAU-NMC/116512/2010, E- Rare4/0003/2012 and EU Joint Programme - Neurodegenerative Disease Research (JPND) projects SynSpread, ESMI and ModelPolyQ); by the Richard Chin and Lily Lock Machado Joseph Disease Research Fund; and the National Ataxia Foundation to LPA. VC, JCS, ATS have grants from FCT. Geetha Vijayakumar was funded by the Marie Curie ITN –Treat PolyQ network.

### [Docosahexaenoic acid \(DHA\) supplementation as a therapy for Spinocerebellar Ataxia 38 \(SCA38\)](#)

Manes M1, Alberici A1, Di Gregorio E2,3, Boccone L4, Mitro N5, Premi E1, Pasolini MP6, Pani C4, Paghera B7, Perani D8, Orsi L9, Costanzi C10, Tempia F11, Caruso D5, Padovani A1, Brusco A2,3, Borroni B1

1 Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

2 Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy

3 Department of Medical Sciences University of Turin, Turin, Italy

4 Ospedale Regionale Microcitemie, ASL 8, Cagliari, Italy

5 Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy,

6 Neurophysiology Unit, "Spedali Civili", Brescia, Italy

7 Department of Nuclear Medicine, University of Brescia, Brescia, Italy

8 Vita-Salute San Raffaele University, Milano, Italy; Nuclear Medicine Unit, San Raffaele Hospital, Milano, Italy; Division of Neuroscience, San Raffaele Scientific Institute, Milano, Italy.

9 Neurologic Division 1 Department of Neuroscience and Mental Health AOU Città della Salute e della Scienza di Torino Turin Italy.

10Neurology Unit, Cremona Hospital, Cremona, Italy

11 Neuroscience Institute Cavalieri Ottolenghi (NICO) and Department of Neuroscience, University of Turin, Turin, Italy

Introduction: Spinocerebellar Ataxia 38 (SCA38) is caused by mutations within the *ELOVL5* gene, which encodes an enzyme involved in the synthesis of long-chain fatty acids. As a

consequence, SCA38 patients have significantly reduced synthesis of serum docosahexaenoic acid (DHA). We evaluated the safety and efficacy of DHA supplementation on clinical symptoms and brain FDG-PET imaging in SCA38 patients. Methods: We enrolled 10 SCA38 patients, and we carried out a) a double-blind randomised placebo- controlled study for 16 weeks, and b) a single-blind open-label study for 24 weeks. At baseline, and at each visit, patients underwent blood sampling for ELOVL5 dosages, standardised clinical assessment, brain FDG- PET study, and electroneurography (ENG). Results: After 16-week DHA vs. placebo treatment, repeated measures ANOVA performed on Scale for the Assessment and Rating of Ataxia (SARA) scores revealed a TIME×TREATMENT interaction, with significant clinical improvement in DHA-group ( $p=0.042$ ). Prolonged DHA treatment for 24-weeks determined significant expression revealed a significant time effect, with reduced serum levels at T2 as compared to baseline ( $p=0.001$ ), improved scores of both SARA ( $p=0.008$ ) and International Cooperative Ataxia Rating Scale (ICARS,  $p=0.02$ ), along with significant improvement of cerebellar metabolism (statistical parametric mapping analyses, False Discovery Rate corrected). No adverse events were recorded. Conclusions: DHA supplementation is a safe and effective treatment in improving clinical symptoms and cerebellar metabolism in patients with SCA 38.

#### Neurotrophic factor and cytokine mimetics as new potential therapeutic agents for Friedreich's ataxia

Y. Katsu-Jiménez, M. Agró & J. Díaz-Nido

Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid. Instituto de Investigaciones Sanitarias Hospital Puerta de Hierro-Majadahonda. Madrid, SPAIN

Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by recessive mutations that produce a deficiency of frataxin. Research in our lab and others has demonstrated that neurotrophic factors like Brain-Derived Neurotrophic Factor (BDNF) and cytokines like Erythropoietin (Epo) can prevent neurodegeneration triggered by frataxin deficit and increase frataxin expression in different experimental models. However the therapeutic application of these protein factors is seriously limited because of their poor pharmacokinetics and their inability to effectively cross the blood brain barrier. In order to address these limitations, we have explored the therapeutic potential of smaller molecules which can activate BDNF or Epo receptors.

One of these molecules, 7,8-dihydroxyflavone (7,8-DHF) is known to activate TrkB BDNF receptors. Our results indicate that 7,8-DHF decreases the levels of apoptotic markers and increases frataxin expression in primary neuronal cultures from both wild-type and FRDA model YG8 mice. Moreover 7,8-DHF also leads to a significant increase in frataxin in cultures of FRDA patient- derived olfactory mucosa stem cells. Interestingly, the systemic administration of 7,8-DHF to YG8 mice in vivo enhances frataxin expression in the cerebellum but not in the heart of treated animals (which is consistent with the higher expression of TrkB in the cerebellum). Another molecule, the helix B surface peptide (HBSP), has been reported to activate the cytoprotective Epo receptor without stimulating erythropoiesis. HBSP also increases frataxin expression in primary neuronal cultures from both wild-type and YG8 mice, as well as in FRDA patient-derived olfactory mucosa stem cells. More interestingly, the systemic administration of HBSP to YG8 mice in vivo increases frataxin both in cerebellum and heart of treated animals. In view of these data we suggest that neurotrophic factor and cytokine mimetics such as 7,8-DHF and HBSP

should be considered as a novel strategy to increase frataxin expression and delay neurodegeneration in FRDA.

### Gene therapy for Friedreich's ataxia

Barry J. Byrne, M.D., Ph.D. and Manuela Corti, PhD  
University of Florida, College of Medicine, Gainesville, FL, USA.

AAV-mediated gene therapy has gained significant momentum over the past few years with an increasing number of subjects enrolled in clinical studies. In this presentation, I will review the pathway to launching clinical gene therapy studies. Initial studies have been aimed at demonstrating safety in open-label studies using several routes of administration. New FDA and EMEA guidelines which support product development in rare disease will facilitate the drug development path for gene therapy approaches. These new pathways have been reinforced by the 21<sup>st</sup> Centuries Cures Act, recently approved legislation in the USA.

In addition to new regulatory pathways, there are opportunities for improved access to clinical trial material and innovative clinical trial design which may be of value in Friedreich's ataxia. Supply of sufficient high quality clinical product is an important part of the clinical study plan. The latest observations from a novel clinical AAV production strategy will be reviewed to establish the basis for sufficient clinical supply to meet broad clinical demand in current and future gene therapy studies.

Lastly, the management of preexisting immune response and the ability to re-dose AAV vectors remains a critical barrier in clinical implementation of AAV-mediated gene therapy. Findings from recent IND-enabling studies will be reviewed to consider the options for management of this issue in FA gene therapy.

### Targeting the intracellular localization of ataxin-3 as novel treatment approach for Spinocerebellar Ataxia Type 3 (SCA3)

Sowa, A.S.1,2,3; Wang, Z.1,2,3; Martins, M.I.1,2; Schmidt, J.1,2; Abedi, M.1,2,3; Weishäupl, D.1,2,3; Teixeira de Castro, A.4; Weber, J.J.1,2; Maciel, P.4; Tricoire, H.5; Riess, O.1,2 and Schmidt, Th.1,2

1 Institute of Medical Genetics & Applied Genomics, Eberhard Karls University of Tuebingen, Tuebingen, Germany

2 Center for Rare Diseases (ZSE), University Hospital Tuebingen, Tuebingen, Germany

3 Graduate School of Cellular & Molecular Neuroscience, Tuebingen, Germany

4 Life and Health Science Research Institute, University of Minho, Braga, Portugal

5 Degenerative Processes, Stress and Aging, Université Paris Diderot - Paris 7, Paris, France

Introduction: Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is a neurodegenerative disorder caused by a CAG expansion in the *ATXN3* gene leading to a polyglutamine expansion in the encoded ataxin-3 protein. In controls, ataxin-3 is predominantly located in the cytoplasm but forms protein aggregates in the nucleus of neurons in SCA3 patients. We already demonstrated *in vivo* that the toxicity of expanded ataxin-3 is linked to its intracellular localization: Only nuclear ataxin-3 gave rise to a phenotype with protein aggregates, purely cytoplasmic ataxin-3, however, even with a



highly expanded polyglutamine repeat, remained harmless and did not aggregate. We further dissected the nucleocytoplasmic transport mechanisms of ataxin-3 and identified a transport protein whose critical importance for the nuclear import of ataxin-3 we confirmed *in vitro* and *in vivo*.

**Methods:** As pathologically ataxin-3 remains harmless as long as it is kept in the cytoplasm, we anticipated the intracellular localization of ataxin-3 as a target for a possible therapeutic intervention. For this reason, we generated an assay allowing us to easily monitor the intracellular localization of normal or expanded ataxin-3. As it was demonstrated before that heat shock leads to a nuclear translocation of ataxin-3 we used heat shock treatment to validate the efficacy of our assay.

**Results:** We used our assay to screen a library of FDA-approved compounds and indeed identified compounds impacting the nuclear translocation of ataxin-3. We further validated the identified compounds *in vivo*. As the compounds we identified are already FDA-approved and on the market, they could be transferred to the clinics comparatively fast.

**Conclusions:** We believe that our results will improve the understanding of pathological mechanisms influencing the progression of the disease and are an important contribution towards a treatment of SCA3.

#### Acknowledgement:

This study was supported by the National Ataxia Foundation (Pioneer SCA Translational Grant to T.S.), the European Commission (Seventh Framework Programme FP7/2012 under Grant Agreement No. 264508, "TreatPolyQ") and the German Federal Ministry of Education and Research (E-Rare consortium PPPT-MJD).

#### [Ataxin-3 exon skipping as a treatment strategy for Spinocerebellar Ataxia type 3](#)

[L.J.A. Toonen](#)<sup>1</sup>, F. Rigo<sup>2</sup>, H. van Attikum<sup>1</sup> and W.M.C. van Roon-Mom<sup>1</sup>

<sup>1</sup> Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

<sup>2</sup> Ionis Pharmaceuticals, Carlsbad, CA, USA

#### Introduction

Spinocerebellar ataxia type 3 (SCA3) is one of nine neurodegenerative polyglutamine (polyQ) disorders caused by a CAG triplet expansion in the coding region of a gene. In SCA3, the CAG repeat expansion is located in exon 10 of the ATXN3 gene. The expanded polyQ stretch in the mutant ataxin-3 protein causes a gain of toxic function, over time leading to neurodegeneration. We make use of antisense oligonucleotides (AONs) to mask exons from the splicing machinery, resulting in exclusion of targeted exons from the transcript and subsequent translation of a modified protein. The major advantage of this exon skipping approach is that the toxic ataxin-3 protein region can be removed whilst maintaining normal protein expression levels. This is important, because ataxin-3 is known to function in the proteasomal protein degradation and DNA damage response pathways.

#### Methods

In our study we made use of 2'-O-methoxyethyl (MOE) modified AONs to induce exon 10 skipping of ATXN3 pre-mRNA. Repeated *in vivo* intracerebroventricular injections of the AONs were performed in transgenic MJD84.2 SCA3 mice. AONs were administered as repeated 250 µg bolus injections for a total dose of 1 mg.

## Results

AON injections in mouse brain was tolerated well and resulted in efficient ATXN3 exon 10 skipping at RNA level in all tested brain regions (brainstem, cerebellum and cortex) of the SCA3 mice. The resulting truncated ataxin-3 protein lacking the toxic polyQ domain was detected in the same brain regions. AON treatment led to reduction of mutant ataxin-3 nuclear localisation observed in substantia nigra. Additionally, we are able to show in vitro that truncated ataxin-3 retained its ubiquitin binding and cleavage function.

## Conclusions

We conclude that *ATXN3* exon 10 skipping using AONs is a promising approach for the treatment of SCA3, as the toxic polyQ region is removed from the ataxin-3 protein.

### Nicotinamide Mononucleotide supplementation in a model of Friedreich's Ataxia cardiomyopathy improves cardiac function and bioenergetics in a SIRT3-dependent manner

Martin, AS<sup>1,2</sup>, Abraham, DM<sup>3</sup>, Hershberger, KA<sup>1,2</sup>, Mao, L<sup>3</sup>, Cui, H<sup>1</sup>, Liu, J<sup>2</sup>, Liu, X<sup>2</sup>, Muehlbauer, MJ<sup>1</sup>, Locasale, JW<sup>1,2</sup>, Payne, RM<sup>4</sup>, and Hirschey, MD<sup>1,2,5</sup>

<sup>1</sup>Duke Molecular Physiology Institute, Duke University Durham, NC; <sup>2</sup>Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC; <sup>3</sup>Department of Medicine, Division of Cardiology and Duke Cardiovascular Physiology Core, Duke University Medical Center, Durham, NC; <sup>4</sup>Department of Medicine, Division of Pediatrics, Indiana University, Indianapolis, IN; <sup>5</sup>Department of Medicine, Division of Endocrinology, Metabolism, & Nutrition, Duke University Medical Center, Durham, NC

**Background/Hypothesis:** Increasing NAD<sup>+</sup> levels by supplementing with the precursor nicotinamide mononucleotide (NMN) improves cardiac function in multiple mouse models. While NMN influences several aspects of mitochondrial metabolism, the molecular mechanisms by which increased NAD<sup>+</sup> enhances cardiac function are poorly understood. A putative mechanism of NAD<sup>+</sup> therapeutic action is via activation of the mitochondrial NAD<sup>+</sup>-dependent protein deacetylase sirtuin 3 (SIRT3). We assessed the therapeutic efficacy of NMN and the role of SIRT3 in the Friedreich's Ataxia cardiomyopathy mouse model (FXNKO).

**Methods/Results:** At baseline, the FXNKO heart has mitochondrial protein hyperacetylation, reduced SIRT3 mRNA expression, and increased demand for NAD<sup>+</sup>. Remarkably, NMN administered to FXNKO mice restored cardiac function to levels near normal. To determine whether SIRT3 is required for NMN therapeutic efficacy, we generated SIRT3KO and SIRT3KO/FXNKO (dKO) knockout models. The improvement in cardiac function upon NMN treatment in the FXNKO is lost in the dKO model, demonstrating that the effects of NMN are dependent upon cardiac SIRT3. Coupled with cardioprotection, SIRT3 mediates NMN-induced improvements in both cardiac and extra-cardiac metabolic function and energy metabolism.

**Conclusions:** Taken together, these results serve as important preclinical data for NMN supplementation or SIRT3 activator therapy in Friedreich's Ataxia patients.

## Correction of sensory ataxia in a novel mouse model of Friedreich ataxia using gene therapy approach

Françoise Piguet, Nadège Vaucamps, Charline de Montigny, Aurélie Eisenmann, Laurence Reutenauer and Hélène Puccio.

Department of Translational Medicine and Neurogenetics, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France; INSERM, U596, Illkirch, France; CNRS, UMR7104, Illkirch, France; Université de Strasbourg, Strasbourg, France.

Friedreich's ataxia (FA), the most common autosomal recessive ataxia, is characterized by a sensory and spinocerebellar ataxia, hypertrophic cardiomyopathy and increase incidence of diabetes. FA is caused by reduced levels of frataxin (FXN), an essential mitochondrial protein involved in the biosynthesis of iron-sulfur (Fe-S) clusters. Impaired mitochondrial oxidative phosphorylation, bioenergetics imbalance, deficit of Fe-S cluster enzymes and mitochondrial iron overload occur in individuals with FA. Proprioceptive neurons within the dorsal root ganglia (DRG) and cardiomyocytes are the most affected tissues in FA patients. To date there are not effective treatment for FA.

We have previously established the primary proof-of-concept for developing gene therapy of FA cardiomyopathy and showed that adeno-associated virus (AAV) rh.10 vector expressing human FXN injected intravenously rapidly and completely reversed the cardiac disease (Perdomini et al, 2014). We recently generated a novel mouse model that recapitulates faithfully the sensory ataxia associated to FA using the conditional approach to delete frataxin specifically in the parvalbumin expressing cells, including the proprioceptive neurons of the DRG. Using this mouse model, we have developed an AAV gene therapy approach based on an intravenous delivery of AAV9-CAG-hFXN-HA vector and shown at an early symptomatic stage of the disease a complete prevention of the ataxic phenotype and electrophysiological analysis showed maintenance of the sensory wave in the treated animals. Histological studies revealed a complete prevention of neuronal loss in the DRG.

We then evaluated the therapeutical approach at a post symptomatic stage of the disease with a combination of an intravenous delivery of AAV9-CAG-hFXN-HA vector and 3 intracerebral deliveries of AAVrh10-CAG-hFXN-HA. Treated animals displayed a complete reversion of the proprioceptive phenotype evaluated by gait analysis, coordination test and EMG as well at the histological levels with a full preservation of neurons within DRG and a complete regeneration of axons within peripheral nerves. Together, our results provide a proof-of-concept for developing gene therapy for the sensory ataxia in FA.

## TALEN and CRISPR gene editing for treatment of Machado-Joseph disease

Lopes, S. M.<sup>1,2,3</sup>, Nobre, R.<sup>2,3</sup>, Nóbrega, C.<sup>3,4,5</sup>, Lopes, M.M.<sup>3</sup>, Matos, C. A.<sup>2,3</sup>, Sanjana, N.<sup>6</sup>, Hsu, P.<sup>6</sup>, Ran, F.A.<sup>6</sup>, Cong, L.<sup>6</sup>, Zhang, F.<sup>6</sup>, Pereira de Almeida, L.<sup>3,7</sup>

<sup>1</sup>PhD Programme in Experimental Biology and Biomedicine (PDBEB), CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; <sup>2</sup>Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Portugal; <sup>3</sup>CNC – Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; <sup>4</sup>Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal; <sup>5</sup>Center for Biomedical Research, CBMR, University of Algarve, Faro, Portugal.; <sup>6</sup>Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA; <sup>7</sup>Faculty of Pharmacy, University of Coimbra, Portugal.

Introduction: Machado-Joseph disease (MJD) is a fatal and untreatable, dominant neurodegenerative disorder. It is caused by an unstable expansion of a CAG tract in the coding region of the ATXN3 gene, resulting into a polyglutamine repeat expansion (1). This confers a toxic gain-of-function to the resultant ataxin-3, leading to the formation of neuronal intranuclear inclusions and to cell death (2). Specific gene correction or inactivation can be achieved through engineered nucleases, such as TALENs and CRISPR/Cas systems (3). Upon the introduction of targeted double strand breaks, genome editing is attained through the activation of endogenous machinery, facilitating the generation of knock-out and knock-in models (4).

Material and Methods: In order to suppress ATXN3 gene expression through the insertion of a loss-of-function mutation, a panel of sequences (TALENs and CRISPR), directed against an early exon of the human gene, were designed and constructed. Functional characterization was performed in HEK 293T cells, through the surveyor mutation detection assay. One sequence of each system was selected and intra-cranially delivered to an in vivo lentiviral mouse model of MJD, using adeno-associated viral particles. The neuropathological markers were assessed 4 weeks after surgery.

Results: Surveyor mutation detection assay revealed the editing capability of our customized nucleases both in HEK 293T cells, and in striatal samples of the mouse model. We observed a reduction in the levels of wild-type ataxin-3 in human cells and a drastic reduction of the mutant protein in the animal model, in a dose-dependent manner. Immunohistochemical analysis of mouse brain sections revealed the same tendency for the reduction of aggregates in the striatum.

Conclusions: Genome editing technologies based on programmable nucleases opened up the possibility of treating diseases that are caused by gene mutations at their source. Accordingly, our results suggest that both TALEN and CRISPR systems are able to efficiently target and modify the ATXN3 gene, leading to the insertion of a loss-of-function mutation, and consequently to its knock-out.

1 – Kawaguchi, Y et al. Nat Genet. 1994; 8(3): 221-8; 2 – Bettencourt, C et al. Orphanet J Rare Dis. 2011; 6:35; 3 – Cox DB et al. Nat Med. 2015; 21(2):121-31; 4 – Gaj T et al. Trends Biotechnol. 2013; 31(7):397-405.

This work was supported by the funds FEDER through Programa Mais Centro (CENTRO-07-ST24- FEDER-002006) and the Competitive Factors Operational Program – COMPETE; by national funds through the Portuguese Foundation for Science and Technology (PTDC/NEU-NMC/0084/2014, E- Rare4/0003/2012 and EU Joint Programme - Neurodegenerative Disease Research (JPND) project ModelPolyQ); by the Richard Chin and Lily Lock Machado Joseph Disease Research Fund; and the National Ataxia Foundation. Sara Lopes was supported by FCT fellowship SFRH / BD / 51673 / 2011.

Phenotypic and functional characterization of sensory neurons derived from human pluripotent stem cells and examining their in vivo capability to integrate into adult dorsal root ganglia.

Serena Viventi<sup>1, 2</sup>, Abdullah Alshawaf<sup>1, 5</sup>, Stefano Frausin<sup>4</sup>, Wayne Ng<sup>3</sup>, Jason Ivanusic<sup>6</sup>, Lachlan Thompson<sup>4</sup>, and Mirella Dottori<sup>1, 2</sup>

<sup>1</sup> Centre for Neural Engineering, The University of Melbourne, Australia.

<sup>2</sup> Department of Biomedical Engineering, The University of Melbourne, Australia.

<sup>3</sup> Austin Hospital, Heidelberg, Victoria, Australia.

4 The Florey Institute of Neuroscience and Mental Health, Australia.

5 Department of Psychiatry, The University of Melbourne, Australia.

6 Department of Anatomy and Neuroscience, The University of Melbourne, Australia.

**Introduction:** Friedreich ataxia (FRDA) is a disease characterised by neurodegeneration and cardiomyopathy. FRDA is due to insufficiency of the mitochondrial protein, FRAXIN, which leads to mitochondrial dysfunction, cell toxicity and cell death, particularly within the nervous system and cardiac tissue. The sensory dorsal root ganglia (DRG) is one of the primary and most significant sites of degeneration occurring in FRDA. Sensory neurons derived from human pluripotent stem cells (hPSC) are a valuable resource to develop regenerative therapies to treat FRDA either for drug discovery platforms and/or cell replacement transplants.

**Methods:** We have developed an efficient system for deriving DRG sensory neurons from hPSC. Here we phenotypically and functionally characterize the hPSC-derived sensory neuronal subtypes using Q-PCR, immunostaining and multi-electrode array analyses. Furthermore, hPSC-derived sensory neurons were transplanted in the adult rat DRG regions to examine their capacity to mature and functionally integrate in vivo.

**Results:** Our data shows that hPSC-derived cultures consist of heterogeneous population of sensory neuronal subtypes, including proprioceptors, mechanoreceptors and nociceptors. We demonstrate their functionality in vitro using multi-electrode arrays and also their ability to mature and integrate in vivo when transplanted into the adult DRG region. Some in vitro and in vivo analyses have also been performed using FRDA induced pluripotent stem cells (iPSC).

**Conclusions:** These studies show promising outcomes for using FRDA iPSC to treat peripheral sensory neurodegeneration.

### [Intravenous delivery of AAV gene therapy to cerebellum and peripheral tissues critical for the treatment of Friedreich's ataxia.](#)

Martin Goulet, Holly Lindgren, Allyse Mazzarelli, Emily Christensen, Ada Felix-Ortiz, Justin Aubin, Peter Pechan, Eric Horowitz, Yanqun Shu, Xiaochuan Zhou, Jeff Thompson, Qingmin Chen, Todd Carter, Jenna Carroll, Dinah Sah, [Holger Patzke](#)  
Voyager Therapeutics, 75 Sidney St, Cambridge, MA 02139, USA.

#### Introduction

Adeno-associated viral (AAV) vectors have great potential for therapeutic gene delivery. A major challenge of AAV gene therapy is delivering the transgene to target cells at levels that result in expression that is safe and effective. In larger mammals including primates, only relatively limited gene transfer to the adult CNS has been achieved to-date following systemic administration. For FA, primary sites of pathology are the dentate nucleus of the cerebellum, dorsal root ganglia (DRG) and heart. Here, we describe studies with novel AAV capsids in non-human primates to evaluate the potential of intravenous (IV) administration for frataxin gene delivery to the cerebellum, PNS and peripheral organs for the treatment of FA.

#### Methods

AAV vectors comprising novel capsids and a HA-tagged frataxin transgene were administered IV to non-human primates and approximately 1 month later, frataxin-HA gene transfer to target tissues was assessed. Bio-distribution and cellular tropism were evaluated

by HA-tag immunohistochemistry, whereas vector genome levels were quantified with digital PCR. Frataxin-HA levels were determined by ELISA.

#### Results

Significant gene transfer to the dentate nucleus of the cerebellum was observed. Staining for the HA-tag labelled considerable numbers of neurons. Gene transfer was also high to DRG and heart, and accompanied by high exogenous frataxin expression evident by ELISA and HA- staining.

#### Conclusions

Studies in the non-human primate support intravenous dosing with a novel capsid as a potential approach for the treatment of central and peripheral FA with AAV gene therapy.

### Effects of acetyl-DL-leucine in cerebellar ataxias

Tatiana Bremova, Katharina Feil, Michael Strupp

Dept. of Neurology and German Center for Vertigo, University Hospital LMU Munich, Germany

**Background.** Acetyl-DL-leucine (AL) is a modified amino acid which has been used to treat vertigo since 1957. It may act due to its direct effect on neurons, as was shown in the vestibular nuclei. Due to the phylogenetical and electrophysiological similarities and close interactions between vestibular and deep cerebellar neurons, we had hypothesized that there may also be a positive effect on ataxic symptoms in cerebellar disorders.

**Results.** In 2013, in a first case series on 13 patients with different types of cerebellar ataxia we showed that AL (5 g/ day for 1 week) significantly improved the symptoms in terms of SARA, SCAFI and Qo [4]. Mean total SARA ( $\pm$  SD) decreased from a baseline of  $16.1 \pm 7.1$  to  $12.8 \pm 6.8$  on medication ( $p = 0.002$ ). There were also significant improvements in sub-scores for gait, speech, finger-chase, nose-finger-test, rapid alternating movements and heel-to-shin. Furthermore, patients showed a significantly better performance in the SCAFI consisting of the 8-m-walking-time, 9HPTD and the PATA rate. QoL increased during treatment ( $p = 0.003$ ). No side effects were reported. (Videos: [www.dgn.org](http://www.dgn.org)).

In 2015 we reported in a case series on 12 patients with Niemann-Pick type C (NPC) that AL (5 g per day for one month with a one-month titration) significantly improved the clinical symptoms, measured by SARA, SCAFI, modified disability rating scale (mDRS) and EQ-5D-5L Quality of Life [1]. The total SARA-score changed significantly from a baseline of  $10.8 \pm 11.2$  to  $7.0 \pm 10.7$  after one month on medication and  $10.5 \pm 11.5$  post 1 month of washout, indicating an improvement of cerebellar signs on medication ( $p = 0.000412$ ). The total mDRS score was  $10.0 \pm 5.35$  at baseline,  $9.0 \pm 5.3$ , on medication and  $10.0 \pm 5.4$  after one month of washout. The 9HPTD changed significantly on medication. In terms of QoL, the visual analog scale of EQ-5D-5L also changed significantly on medication (videos: [www.neurology.org](http://www.neurology.org)).

A third case series demonstrated an improved so-called coefficient of variation of stride time in the gait analysis of 14 patients with cerebellar ataxia during a treatment with AL [3]. The improvement of variability was restricted to the condition of slow walking, where walking stability is thought to critically rely on the sensory integration function of the cerebellum. It should be mentioned that in another case series with 10 patients with degenerative cerebellar ataxia, no improvement in SARA was observed [2]. However, 7 out of 10 patients described a subjective improvement on medication.

**Conclusions and limitations.** Acetyl-DL-leucine significantly improved ataxic symptoms without side effects and therefore showed a good risk-benefit profile. The added value of

the above-mentioned case series is the demonstrated safety and tolerability of the agent in various medical conditions with the common symptom of cerebellar ataxia. The obvious limitations of these studies are a) the lack of reference agent (placebo), b) the non-blinded design, and c) the small sample size.

#### Reference List

1. Bremova T, Malinova V, Amraoui Y, Mengel E, Reinke J, Kolnikova M, Strupp M (2015) Acetyl- dl-leucine in Niemann-Pick type C: A case series. *Neurology* 85:1368-1375
2. Pelz JO, Fricke C, Saur D, Classen J (2015) Failure to confirm benefit of acetyl-DL-leucine in degenerative cerebellar ataxia: a case series. *J Neurol* 262:1373-1375
3. Schniepp R, Strupp M, Wuehr M, Jahn K, Dieterich M, Brandt T, Feil K (2016) Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series. *Cerebellum Ataxias* 3:8
4. Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg BP, Klopstock T, Feil K (2013) Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. *J Neurol* 260:2556-2561

# Poster Abstracts

## POSTER SESSION ONE

**Thursday 28 September**  
**h. 5.30 – 7.30 pm**



## Molecular Basis of Disease

### 1. Nuclear transport factors influencing pathogenic mechanisms induced by expanded ataxin-3

Abeditashi M.<sup>1,2,3</sup>, Martins M.I.<sup>1,2</sup>, Riess O.<sup>1,2</sup> and Schmidt T.<sup>1,2</sup>

<sup>1</sup>Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany

<sup>2</sup>Centre for Rare Diseases (ZSE), University Hospital Tübingen, Tübingen, Germany

<sup>3</sup>Graduate Training Centre of Neuroscience, University of Tübingen, Tübingen, Germany

**Introduction:** Spinocerebellar ataxia type 3 (SCA3) is the most common autosomal dominant cerebellar ataxia. The disease is caused by the expansion of CAG trinucleotide repeat within the ATXN3/MJD1 gene that encodes the ataxin-3 protein. The expansion results in the elongation of the polyQ tract within ataxin-3 which leads to the generation of insoluble aggregates. SCA3 is characterized by ataxia, clumsiness and difficulty with speech and swallowing.

Previous studies indicated that the nucleus is the main site of the toxicity and aggregation of expanded ataxin-3. Moreover, it is found that nuclear localization of ataxin-3 plays an important role in the manifestation of symptoms in SCA3. The main aim of this study is to investigate the mechanisms which are involved in nuclear transport of ataxin-3 and to find how nuclear transporters (karyopherins) affect and contribute to the nucleocytoplasmic shuttling of mutant ataxin-3.

**Methods:** In order to investigate the effect of karyopherins overexpressing on the localization and aggregates formation of ataxin-3, ataxin-3 knockout HEK293 cells were co-transfected with expanded ataxin-3 and karyopherins. Localization and aggregate formation of expanded ataxin-3 were evaluated using nucleocytoplasmic fractionations, western blots and filter trap assays.

**Results:** Our results indicate that specific karyopherins lead to less amount of ataxin-3 in both the cytoplasm and the nucleus of HEK293 cells, and to the reduction of aggregate formation.

**Conclusion:** In conclusion, karyopherins could be involved in the toxicity, formation of expanded ataxin-3 aggregates and pathophysiology of SCA3. Thereby, they are interesting candidates for the development of treatment approaches for SCA3.

### 2. Addressing mitochondrial function in a mouse model of Friedreich's ataxia. Rosella Abeti (see oral presentation)

### 3. Analysis of GAA repeat interruptions in a large panel of Friedreich ataxia patient DNA samples

Al-Mahdawi, S.<sup>1,2,\*</sup>, Ging, H.<sup>3,\*</sup>, Bayot, A.<sup>3</sup>, Cavalcanti, F.<sup>4</sup>, La Cognata, V.<sup>5</sup>, Cavallaro, S.<sup>5</sup>, Giunti, P.<sup>3</sup> and Pook, M.A.<sup>1,2,\*</sup>

<sup>1</sup>Ataxia Research Group, Biosciences, Department of Life Sciences, CHLS, and

<sup>2</sup>SBTheme, IEHS, Brunel University London, Uxbridge, UB8 3PH, UK; <sup>3</sup>Department

of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, WC1N 3BG, UK; 4 Institute of Neurological Sciences, National Research Council, Contrada Burga, 87050 Mangone, Cosenza, Italy; 5 Institute of Neurological Sciences, National Research Council, Via Paolo Gaifami, 18, 95126, Catania, Italy. \* = Joint first author.

Friedreich ataxia (FRDA) is a multi-system autosomal recessive inherited disorder primarily caused by homozygous GAA repeat expansion mutations within intron 1 of the frataxin (FXN) gene. The GAA repeat expansions may be pure (GAA) $_n$  in sequence or may be interrupted with regions of non-GAA sequence, such as (GAAGGA) $_n$ . To our knowledge there has been no large-scale study of FRDA patient DNA samples to determine the frequency of interruptions in GAA repeat expansions. Therefore, we have investigated a large panel of 258 FRDA patient and carrier DNA samples using GAA repeat PCR amplification and MbolI restriction enzyme digestion, together with GAA repeat TP-PCR analysis. Our results demonstrate that the vast majority (87%) of FRDA GAA repeat expansions do not contain significant sequence changes that would result in abnormal MbolI digestion profiles, indicating that they are primarily pure GAA repeats. However, a large number of samples (65%) do show small sequence variations at the 3' end of the GAA repeat sequence as detected by TP-PCR. These results have specific implications in our understanding of FRDA disease progression and the more general understanding of trinucleotide repeat disease characteristics.

#### 4. Frataxin deficiency leads to lipolysis alteration in skeletal muscle cells

Lettieri Barbato D., Tortolici F., Tatulli G., Aquilano K.

Dept. Biology, University of Rome Tor Vergata, Rome, Italy

Type 2 diabetes (T2D) represents the major complication in Friedreich's ataxia (FRDA), however, the upstream events responsible for T2D remain to be determined. Skeletal muscle of FRDA patients show the same features of T2D including Impaired mitochondrial function, accumulation of intracellular lipids and insulin resistance. In this study we have analysed some of the possible mechanisms responsible for the increased risk of developing T2D in FRDA focusing our attention on the lipolytic system.

To generate a FRDA cellular model, we have used murine C2C12 myocytes silenced for frataxin (FXN). Also skeletal muscles obtained from a FRDA mouse model (KIKO) were analysed to corroborate the results obtained in vitro.

We have firstly analysed some of the main hallmarks of FRDA to validate the cellular model. We found that FXN mRNA expression and protein content was efficiently downregulated. FXN deficient cells displayed increased level of oxidatively damaged proteins as well as decreased mitochondrial activity. These events were also accompanied by up-regulated expression of atrogin and murf1, which are involved in the degeneration of myofibers. We found a significant accumulation of intracellular lipids that was associated with altered level of key components of the lipolytic pathway. In particular, we detected a lowered activity of protein kinase A that resulted in the inhibition of hormone sensitive lipase (HSL). Moreover, we found decreased level of ABDH5 and adipose tryglyceride lipase (ATGL) that represent the enhancer and the rate-limiting enzyme of the lipolytic cascade respectively.

Our results indicate that impaired lipolysis in skeletal muscle could contribute to the development of T2D and suggest that therapeutic strategies aimed at targeting lipolytic enzymes could mitigate metabolic disturbances in FRDA.

## 5. Identification of specific brain metabolic dysfunctions in Friedreich's Ataxia using proteomic approach in an innovative *Drosophila* model

Jessica Ayache<sup>1</sup> and Sophie Halliez<sup>1</sup>, Elodie Rousseau<sup>2</sup>, Laetitia Colomb<sup>3</sup>, Camille Garcia<sup>3</sup>, Hervé Tricoire<sup>4</sup> and Jean-Michel Camadro<sup>1</sup>, Véronique Monnier<sup>4</sup> and Valérie Serre<sup>1</sup>  
(1) « Mitochondria, Metals and Oxidative Stress » group and (3) Structural and Functional Proteomics Facility, Jacques Monod Institute, UMR7592 CNRS – Paris Diderot University, 15 rue Hélène Brion, 75013 Paris; (2) Department of Life Sciences – Paris Diderot University; (4) Unit of Functional and Adaptive Biology – BFA, EAC4413 CNRS, Paris Diderot, Sorbonne Paris Cite, Paris, France.

Friedreich's ataxia (FA) is the most common inherited recessive ataxia. In 98% of cases, FA is caused by an abnormal GAA trinucleotides repeat in the first intron of the frataxin gene. This mutation leads to a complex DNA structure formation, which sequesters the RNA polymerase, disabling frataxin expression at a basal level in cells. This is responsible for mitochondria decreased activity, lying at the root of severe metabolic disorders. This leads ultimately to cardiomyopathy, being the most frequent cause of premature death. There is an urgent need to better understand the molecular process involved in the pathology, to allow the development of effective therapeutic strategies.

Our study is based on the powerful *Drosophila* FA model. In fact, the frataxin *Drosophila* homologue fh shares a high degree of sequence homology with the human frataxin. Moreover, some phenotypes like cardiac dysfunction induced in Fh-depleted *Drosophila* can be rescued by the human frataxin expression, supporting conserved role of frataxin through evolution and between the two species.

By in vivo targeted RNA-interference methodology, we generated lineages that carry the constitutive transcriptional activator GAL4 through two drivers, used alone or combined and that trigger neurons or glia. We generated protein extracts from L3 larvae brains and analysed them by quantitative proteomic approach. We monitored proteins whose expression varies in these *Drosophila* FA models, allowing to look after specific biochemical pathways and precise biomarkers of the disease. This analysis could provide new clues and hypothesis about FA molecular mechanism, allowing to work on new genetic or pharmacologic strategies. We could test these new strategies on our *Drosophila* models first, before being validated in rodent models.

## 6. When ataxia is not just ataxia – why genetic testing matters

Caglayan, AO<sup>1</sup>; Sandford E<sup>2</sup>; Gumus, H<sup>3</sup>; Kubisiak T<sup>2</sup>, Soma D<sup>4</sup>; Cornell SE<sup>5</sup>; Burmeister, M<sup>26</sup>  
1 Dept of Genetics, Bilim University, Istanbul, Turkey; 2 Molecular & Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, USA; 3 Private practice, Kaysera, Turkey; 4 Dept of Human Genetics, University of Chicago, USA; 5 Amherst, MA; 6 Dept of Computational Medicine & Bioinformatics, Psychiatry and Human Genetics, University of Michigan, Ann Arbor, USA.

Introduction: Traditionally, genetic testing for ataxia has been primarily used to explain symptoms, test pre-symptomatically in patients with relatives, and for family planning purposes. Once the most common forms of ataxia have been excluded, exome sequencing can identify additional ataxia genes.

Methods: Next generation whole exome sequencing was analyzed primarily for research purposes.

Results: Mutations in genes causing metabolic disorders were identified that lead to specific treatments.

Case 1 is a child was diagnosed at 16 months with ataxia and hypotonia. Numerous blood tests, chromosome breakage and microarray analysis and two MRIs of both brain and body scans were initially reported to the family as normal. Exome sequencing identified Pro428Leu and Asp327Val in the Arylsulfatase (ARSA) gene, causing metachromatic leukodystrophy (MLD), which if untreated leads to rapid lethal neurological deterioration. Sanger sequencing and pathologically low ARSA enzyme activity, as well as re-analysis of the MRI and body scan (decompressed gall bladder) confirmed MLD. A stem cell transplant was initiated. One year later, the child's neurological and intellectual development is normal.

Case 2 are siblings from a consanguineous marriage with adolescent onset of ataxia. Linkage analysis under consanguinity modeling identified one 1 Mb linkage peak, on Chr. 9 with LOD score >1, under which a homozygous conservative mutation in COQ4, Gly55Val was identified. Severe mutations in COQ4 cause primary COQ10 deficiency with fatal neonatal epileptic encephalopathy and seizures. Blood of our patients showed borderline/low COQ10 levels. High dose (3000 mg) COQ10 treatment was initiated in one of the siblings, who significantly improved (SARA score of 30 before to 10 after treatment). After treatment discontinuation due to cost, the patient's condition deteriorated with seizures.

Conclusion: Exome sequencing can identify treatable causes of ataxia and should be considered an essential aspect in the diagnosis of ataxia, not just a research or experimental tool.

## 7. Defining the Frataxin G130V pathogenic mechanism in Friedreich's ataxia

Yu-Yun Chen<sup>1</sup>, Ashlee Long<sup>1</sup>, Elisia Clark<sup>2</sup>, David R. Lynch<sup>2</sup>, Marek Napierala<sup>1</sup>, and Jill Sergesketter Butler<sup>1</sup>

<sup>1</sup>Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA; <sup>2</sup>Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA

Introduction: Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by reduced expression of the mitochondrial protein frataxin (FXN). Most FRDA patients are homozygous for large expansions of GAA repeats in intron 1 of the FXN gene, while a fraction of patients is heterozygous for a point mutation and GAA expansion). The most prevalent missense mutation changes a glycine to valine at position 130 (G130V). FRDA G130V patients exhibit different clinical symptoms than patients with homozygous GAA expansions, including retained reflexes and slower disease progression. We and others have demonstrated that the level of mature FXN protein is more prominently reduced in FRDA G130V samples compared to samples harboring homozygous expansions. Moreover, mitochondrial maturation processing of FXN to its final form is perturbed by the G130V mutation, resulting in accumulation of the intermediate isoform. We hypothesize that the FXN-G130V intermediate isoform is functional and contributes to the atypical FRDA G130V clinical presentation.

Methods: We employed mammalian expression systems along with RNA sequencing of FRDA G130V fibroblasts.

Results: FXN-G130V displays a punctate subcellular distribution and only partially co-localizes with FXN-WT, suggesting independent functions. We also confirmed that the reduced level of FXN protein observed in FRDA G130V fibroblasts occurs via a post-transcriptional mechanism, as steady-state FXN mRNA levels are comparable to those of unaffected carriers and nuclear export and splicing of FXN mRNA are unchanged.

Conclusions: No models or reagents exist to distinguish FXN-WT and FXN-G130V proteins in FRDA G130V patient specimens, and it remains unknown if FXN-G130V is processed and/or functional in disease-relevant tissues. We are using CRISPR/Cas9 to generate G130V cell line and mouse models to address these questions. Realization of this project will provide a mechanistic basis to specify the contribution of FXN-G130V isoforms to FRDA pathogenesis, necessary to develop therapeutic strategies tailored to FRDA G130V patients.

#### 8. Progressive cerebellar ataxia, parkinsonism and myoclonic epilepsy due to maternal segmental uniparental isodisomy and a novel mutation in MFSD8

Carnevale A1, Moro F2, Langburt W3, Meschino W4, Parkinson N5, Stavropoulos DJ5, Santorelli FM2, Yoon G1,3

1 Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

2 Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa

3 Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

4 Genetics Program, North York General Hospital, Toronto, Canada

5 Department of Paediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada

**BACKGROUND:** Neuronal ceroid lipofuscinoses (NCL) are a genetically heterogeneous group of neurodegenerative disorders commonly inherited in an autosomal recessive manner. Mutations in the MFSD8 gene are associated with variant late-infantile-onset forms of NCL (vLINCL).

**CASE PRESENTATION:** We report an 18-year-old male born to non-consanguineous parents of Jamaican origin. He had normal development until 7 years of age, at which time he developed seizures and subsequently severe developmental regression and progressive ataxia. Initial brain MRI at age 14 years was normal; however follow up imaging at 16 years revealed diffuse cerebral and marked cerebellar atrophy. Serial neurological evaluations revealed progressive cerebellar symptoms, spasticity, myoclonus, bradykinesia, rigidity and postural instability. Lysosomal storage disorders, including the NCLs were suspected given the patient's presentation.

**RESULTS:** Genetic analysis revealed a novel homozygous (c.863+4A>G) variant in MFSD8 interpreted as being of uncertain clinical significance. The variant was not present in the ESP, 1000G or ExAC databases. A conjunctival biopsy was negative for curvilinear bodies, fingerprint inclusions, crystalloid inclusions, membrane-bound collections of glycogen or zebra bodies. Parental testing revealed the mother was heterozygous for the variant and it was absent in the father. Identity studies confirmed parental relationships and lack of paternal contribution at 4q28. Microarray (743,000 SNP probes) demonstrated a region of homozygosity on chromosome 4, encompassing the MFSD8 gene, suggesting segmental maternal uniparental isodisomy (UPD). PCR- amplification of RNA from patient fibroblasts detected multiple transcripts including a shorter transcript due to skipping of exons 8 and 9 (c.698\_864del) in addition to the wildtype.

**CONCLUSION:** To our knowledge, this is the first report of vLINCL associated with a MFSD8 mutation due to maternal UPD. The relatively mild symptoms observed in our patient are likely due to the presence of wildtype MFSD8 protein in addition to the abnormally spliced

transcript. This case expands the phenotypic spectrum of MFSD8- related disorders and illustrates the molecular and clinical variability of vLINCL due to a splicing mutation in this gene.

### 9. Mutations in NKX6-2 cause progressive spastic-ataxia and hypomyelination

Viorica Chelban<sup>1,7</sup>, Nisha Patel<sup>2</sup>, Jana Vandrovцова<sup>1</sup>, Natalia Zanetti<sup>3</sup>, David S Lynch<sup>1</sup>, Mina Ryten<sup>9,10</sup>, Juan A Botía<sup>9,11</sup>, Oscar Bello<sup>3</sup>, Eloise Tribollet<sup>1</sup>, Stephanie Eftymiou<sup>1</sup>, SYNaPS study group, Indran Davagnanam<sup>8</sup>, Fahad Bashiri<sup>6</sup>, Nicholas Wood<sup>1,4</sup>, Fowzan S Alkuraya<sup>2,5</sup> and Henry Houlden<sup>1,4</sup>

<sup>1</sup>Department of Molecular Neuroscience, <sup>3</sup>Department of Clinical and Experimental Epilepsy, <sup>8</sup>Department of Brain Repair & Rehabilitation, <sup>9</sup>Reta Lila Weston Research Laboratories, Institute of Neurology, University College London, London WC1N 3BG, UK. <sup>2</sup>Developmental Genetics Unit, Department of Genetics, King Faisal Specialist Hospital and Research Center, MBC 03, PO Box 3354, Riyadh 11211 Saudi Arabia. <sup>4</sup>Neurogenetics Laboratory, The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK. <sup>5</sup>Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. <sup>6</sup>Department of Pediatrics, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia. <sup>7</sup>Department of Neurology and Neurosurgery, Institute of Emergency Medicine, Chisinau, Republic of Moldova. <sup>10</sup>Department of Information and Communications Engineering, University of Murcia, Spain <sup>11</sup>Department of Medical & Molecular Genetics, King's College London, Guy's Hospital, London, UK

#### Introduction:

The combination of progressive limb spasticity and cerebellar ataxia are frequently found in clinical practice and form a heterogeneous group of degenerative disorders that are classified as either pure spastic ataxia, or complex with additional neurological signs. Inheritance is either autosomal dominant or recessive. Hypomyelinating features on MRI are not uncommonly seen with spastic-ataxia but this is usually mild in adults, and severe and life limiting in children. Here, we describe for the first time a human phenotype associated with mutations in the NKX6-2 gene in seven individuals from three families of different ethnic background with an early onset spastic-ataxia phenotype.

#### Methods:

Using a combination of homozygosity mapping and exome sequencing we mapped this phenotype to deleterious nonsense or homeobox domain missense mutations in the NKX6-2 gene.

#### Results:

Two families had childhood onset disease with very slow progression, and are still alive in their 30s/40s with predominant ataxia and cerebellar atrophy features on imaging. The third family had a similar but very early onset presentation associated with brain hypomyelination. NKX6-2 is a transcriptional repressor with early high general and late focused CNS expression. Deficiency of its mouse ortholog results in widespread hypomyelination in the brain and optic nerve, and poor motor coordination in a pattern consistent with the observed human phenotype.

#### Conclusions:

Our results support a non-redundant developmental role of NKX6-2 in humans and imply that NKX6-2 mutations should be considered in the differential diagnosis of spastic-ataxia and hypomyelination.

## 10. HAX-1 is a potential molecular biomarker for cardiomyopathies in Friedreich's Ataxia

F. Cherubini<sup>1,8</sup>, S. Fortuni<sup>1</sup>, S. Maletta<sup>2</sup>, F. Tiano<sup>1</sup>, A. Rufini<sup>1,8</sup>, N. Toschi<sup>3</sup>, I. Condò<sup>1</sup>, G.P. Ussia<sup>4</sup>, M. Frontali<sup>5</sup>, S. Romano<sup>6</sup>, C. Marcotulli<sup>7</sup>, C. Casalli<sup>7</sup>, G. Novelli<sup>2</sup>, R. Testi<sup>1,8</sup>, F. Amati<sup>2</sup> and F. Malisan<sup>1</sup>

1. Dept. of Biomedicine and Prevention; University of Rome "Tor Vergata", Italy; 2. Section of Medical Genetics, Dept. of Biomedicine and Prevention, University of Rome "Tor Vergata", Italy; 3. Medical Physics Section, Dept. of Biomedicine and Prevention, University of Rome "Tor Vergata", Italy; 4. Cardiovascular Disease Unit, Dept. of Systems Medicine, University of Rome "Tor Vergata", Italy; 5. CNR Institute of Translational Pharmacology Rome, Italy; 6. Neurosciences, Mental Health, and Sensory Organs (NESMOS), Sapienza University of Rome; Italy 7. Dept. of Medical Surgical Sciences and Biotechnologies, Polo Pontino- Sapienza University of Rome, Italy, 8. Fratagene Therapeutics Srl, Rome, Italy.

Frataxin deficiency, responsible for the disease Friedreich's Ataxia (FRDA), is crucial for cell survival since it critically affects survival of neurons, pancreatic beta cells and cardiomyocytes. The heart is frequently affected with typical manifestation of hypertrophic cardiomyopathy, which can progress to heart failure and death. Microarray analysis targeted at investigating FRDA pathogenesis revealed that frataxin overexpression correlates with overexpression of HS-1 associated protein X-1 (HAX-1), a family of proteins involved the protection of cardiomyocytes from apoptosis. Interestingly, HAX-1 heterozygous-deficient hearts exhibit increases in infarct size. Furthermore, HAX-1 coordinates network assembly of actin structures with KV3.3 channel, the dysfunction of which is correlated with Spinocerebellar ataxia 13 (SCA13). Frataxin and HAX-1 are therefore both involved in apoptosis regulation, a mechanism underlying the progression of cardiomyopathies.

Microarray analysis performed on lymphoblastoid cells derived from a FRDA patient stably reconstituted with wild type frataxin indicated HAX-1 as the highest up-regulated transcript (FC=+2, p<0.05). This result was further assessed at protein level by western blot analysis of I) HEK293 stably

transfected with empty vector compared to wild type frataxin, II) lymphoblasts and primary fibroblasts from FRDA patients compared to clinically unaffected heterozygous parents as well as healthy fibroblasts, and III) peripheral blood mononuclear cells of FRDA patients, heterozygous parents and non-correlated healthy controls. Moreover, qRT-PCR analysis revealed that frataxin and HAX-1 expression are correlated (r= 0.95, p<0.05) in a group of FRDA patients.

Our results suggest HAX-1 as an important gene possibly involved in the pathogenesis of a cardiac phenotype in FRDA. HAX-1 will be considered as a candidate for further evaluation as a potential biomarker for cardiomyopathies, potentially providing insight into their pathogenesis as well as prognostic information in these patients.

## 11. Molecular mechanisms underlying the atypical mild phenotype in Friedreich's ataxia patients with missense mutations

Elisia M. Clark (EMC) <sup>1,2</sup>, David R. Lynch (DRL)<sup>1,2</sup> <sup>1</sup>University of Pennsylvania, Philadelphia, PA <sup>2</sup>Children's Hospital of Philadelphia, Department of Neurology, Philadelphia, PA

Friedreich's ataxia (FRDA) is a recessive neurodegenerative disease caused by GAA trinucleotide repeats within intron 1 of the FXN gene, resulting in reduced levels of Frataxin

(FXN) expression. 3-4% of FRDA patients are heterozygous carrying missense point mutations on one allele and GAA repeats on the other allele. Patients with G130V have significantly lower FXN levels than typical FRDA patients, yet present with an atypical mild phenotype. While FXN is present in multiple forms including FXN1-210, FXN42-210, and FXN81-210, FXN81-210 has been the most studied. However, patients with G130V, have higher ratio of FXN42-210 to FXN81-210 levels in both overexpression studies and patient fibroblasts, which may play a role in explaining milder phenotype. Cellular growth rate and phase contrast imaging was used to compare fibroblasts from control, typical FRDA, and G130V patients. Western blotting and confocal imaging was performed to compare FXN, mitochondrial ferritin, and aconitase levels. Cell iron content was quantified using a colorimetric assay, measuring absorbance at 593nm. Isotopologue analysis was used to label and follow Krebs cycle intermediates to study mitochondrial Krebs cycle flow. Finally, in-gel activity assays and NADPH absorbance at 340nm was used to measure cytosolic and mitochondrial aconitase activity. Fibroblasts from patients with G130V, compared to typical FRDA patients, are healthier as measured by growth rate and cell morphology. They have increased mitochondrial ferritin and decreased total iron, suggesting absence of mitochondrial iron overload associated with typical FRDA, as well as increased mitochondrial Krebs Cycle flow. Furthermore, there is also increased cytosolic and mitochondrial aconitase activity, which is usually low in typical FRDA patients. Functional studies with FXN42-210-G130V are undergoing to investigate its functional capacity in iron-sulfur cluster biogenesis. Taken together, these findings provide insight into the pathogenic mechanisms associated with the atypical mild phenotype in FRDA patients with G130V missense mutation.

## 12. A510V variant in SPG7 is associated with a cerebellar phenotype

Coarelli G1,2, Banneau G3, Monin ML1,3, Ewencyk C1,3, Fontaine B4, Azulay JP5, Ollagnon-Roman E6, Brice A1,3, Stevanin G1,3,7, Durr A1,3

1 ICM (Institut du Cerveau et de la Moelle Épineière), unit INSERM/UPMC 1127 and CNRS 7225, 75013, Paris, France

2 APHP, Department of Neurology, Avicenne Hospital, 93000, Bobigny, France

3APHP, Department of Genetics, Pitié-Salpêtrière Charles-Foix University Hospital, 75013, Paris, France

4 APHP Department of Neurology, Pitié-Salpêtrière Charles-Foix University Hospital, 75013, Paris, France

5Movement Disorders Unit, Aix-Marseille University, 13385, Marseille, France 6Department of Genetics, Croix-Rousse University Hospital, 69004, Lyon, France 7Ecole Pratique des Hautes Etudes, PSL Research University, 75014, Paris, France

**Introduction:** The first identified gene among the hereditary spastic paraplegia (HSP) was SPG7, encoding paraplegin. Clinical presentations linked to this gene are varied, ranging from complicated form of HSP to hereditary ataxia. To investigate phenotype-genotype correlations, we collected a large series of patients with two pathogenic variants.

**Methods:** We analysed clinical and genetic data from 95 SPG7 patients.

**Results:** Transmission was predominantly autosomal recessive (n= 57), isolated (n = 28), but also dominant in 9, although all patients carried two mutations. There were 43 women and 52 men, with a mean age at examination of  $49.2 \pm 15.1$  years; mean age at onset of  $33.2 \pm 15.2$  years ranging from birth up to 70. Cerebellar ataxia was the presenting sign in 58 patients, spastic gait in 30. The A510V variant was frequent, in a heterozygous state (n=53) and in a homozygous state (n=11). The presence of at least one A510V variant was associated with later age at onset ( $35.7 \pm 13.4$  years versus  $28.3 \pm 17.3$ ,  $p = .02$ ), characterized by more often ataxic



onset (74% versus 50%,  $p=.03$ ) and cerebellar signs at examination (75% versus 43%,  $p=.003$ ). In contrast, extensor plantar reflexes were equally frequent in both groups, but increased reflexes were more often found in the absence of the A510V variant ( $p=.03$ ). Intellectual deficiency was more frequently associated with the spastic phenotype and without the A510V variant ( $p=.01$ ). No gender difference was found regarding clinical presentation at onset, but there was a faster disease progression in women (shorter disease duration but similar functional stage,  $p < .001$ ).

Conclusion: In SPG7 the predominantly cerebellar phenotype is driven by the presence of at least one A510V variant.

### 13. An in vitro study of the network connectivity in a Friedreich's Ataxia-neuronal model

Codazzi F 1, Menegon A 1, Beccalli O 1, Rai M 2, Donatello S 2, Bettegazzi B 1, Bellani S1, Zacchetti D 1, Grohovaz F 1 and Pandolfo M 2

1 San Raffaele Scientific Institute and University, Milano, Italy

2 Laboratory of Experimental Neurology, Université Libre de Bruxelles (ULB), Brussels, Belgium

Introduction: Friedreich's Ataxia (FRDA) is an autosomal recessive ataxia caused by reduced expression of the mitochondrial protein frataxin. Although several mechanisms leading to neurodegeneration have been elucidated, alterations of neuronal activity and connectivity are still to be investigated. Neuronal function is highly sensitive to perturbed cellular homeostasis, including altered iron metabolism as found in frataxin-deficient cells.

Methods: We transfected hippocampal primary neurons, obtained from P2 rats, with validated siRNA against frataxin. We estimated frataxin expression (DIV) by western blot analysis. To evaluate neuronal excitability and network properties, cells were plated on Microelectrode Array (MEA) chips, where 60 electrodes allow the electrophysiological recordings of activity across the neuronal network, either under basal or treated conditions. Concomitantly, we investigated by fluorescence microscopy other neuronal parameters such as iron handling, ROS production, mitochondrial membrane potential, etc...

Results and Conclusion: In order to study how frataxin deficiency affects neuronal network activity, we established a neuronal model characterized by reduced level of frataxin and by the capability to form a mature and highly connected network. By RNA interference technology we induced a partial frataxin deficiency (about 50%) in primary neuronal cultures, which was maintained for 10-12 DIV. Validation of this model by analyzing the cellular parameters already characterized in human iPSC-derived neurons (Codazzi et al., 2016) is ongoing.

Preliminary MEA analyses revealed that control hippocampal neurons are highly active. Mild oxidative conditions (acute H<sub>2</sub>O<sub>2</sub> treatment, 50  $\mu$ M) resulted in increased burst activity and spike synchronization within the network. These experiments will be extended to siRNA-treated neurons and to iPSC-derived neuronal cells. This approach would offer a very sensitive in vitro assay to better understand neuronal functional alteration in FRDA and to evaluate the effects of therapeutic molecules.

### 14. CRISPR/Cas9 genome-wide screen to identify novel targets for the treatment of Friedreich's Ataxia

Corda G.1, del Molino del Barrio I.1, Hadzic A.1, Lufino M.1 and Wade-Martins R1.

1 Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, UK

Friedreich's Ataxia (FRDA) is the most common form of inherited ataxia and is caused by a GAA expansion in the intron 1 of the Frataxin gene. This expansion results in the depletion of the protein frataxin (FXN), leading to progressive neurodegeneration and severe gait and coordination impairments. Diabetes and cardiomyopathy are also commonly observed in patients, with the latter being the primary cause of premature death. Although progress has been made to elucidate the molecular mechanisms underlying the illness, only a few drugs, which do not cure the disease but only ameliorate the symptoms, are used in the clinic. It is therefore of paramount importance to find new molecular targets that can pave the way to the pharmacological upregulation of FXN.

#### Methods

Genome-wide knock-down or knock-out approaches have been extensively used to discover molecular pathways involved in physiological processes and disease. Here we propose a CRISPR/Cas9 genome-wide knock-out approach coupled with quantification of FXN expression to identify novel regulators of FXN expression.

#### Results

We have optimized an assay to detect with high sensitivity the endogenous levels of FXN in both healthy and patient cells. This assay can be exploited to identify cells that present an increase of FXN following a CRISPR/Cas9 genome-wide knock-out screen.

#### Conclusions

With this work we present a promising high throughput approach that aims to identify new regulators of FXN expression that could be exploited to develop a targeted therapy for FRDA.

### 15. Identification of p38 MAPK as a novel therapeutic target for Friedreich ataxia

Cotticelli, M.G.<sup>1,2</sup>, Xia, S.<sup>1,2</sup>, Kaur, A.<sup>3</sup>, Lin, D.<sup>1,2</sup>, Wang, Y.<sup>1</sup>, and Wilson, R.B.<sup>1,2</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, PA

<sup>2</sup>The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research

<sup>3</sup>Marian University College of Osteopathic Medicine

**Introduction:** Friedreich ataxia (FA) is an autosomal recessive neuro- and cardio- degenerative disorder caused by decreased expression of frataxin, a protein that localizes to mitochondria and is required for iron-sulfur-cluster (ISC) assembly.

**Methods:** We screened a random shRNA library and identified a synthetic shRNA (clone gFA11) that reverses the growth defect of FA cells in culture.

**Results:** Clone gFA11 decreases cytokine secretion in primary FA fibroblasts and reverts other changes associated with cell senescence. Using the Ingenuity software package, we found that the gene-expression profile induced by gFA11 is remarkably similar to the gene-expression profile induced by the p38 MAPK inhibitor SB203580. We found that p38 phosphorylation, indicating activation of the p38 pathway, is higher in FA cells than in normal control cells. Furthermore, siRNA knockdown of frataxin in normal fibroblasts also increases p38 phosphorylation. Treatment of FA cells with p38 inhibitors recapitulates the reversal of the slow-growth phenotype induced by clone gFA11.

**Conclusions:** These data highlight the involvement of the p38 MAPK pathway in the pathogenesis of FA and the potential use of p38 inhibitors as a treatment for FA.

## 16. Identification of a novel autosomal dominant slowly progressive late onset ataxia co-segregating with a chromosome 14 deletion/duplication

M Bahlo<sup>1,2</sup>, R Tankard<sup>1,2</sup>, RJM Gardner<sup>3</sup>, E Storey<sup>4,5</sup>, T Burgess<sup>6</sup>, A Boys<sup>6</sup>, M Fahey<sup>4,7</sup>, G Gillies<sup>8</sup>, S Robertson<sup>3</sup>, MB Delatycki<sup>2,4,6,8</sup>, P Lockhart<sup>2,8</sup>

1. Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
2. University of Melbourne, Parkville, Victoria, Australia
3. University of Otago, Dunedin, New Zealand
4. Monash University, Clayton, Victoria, Australia
5. Alfred Hospital, Prahran, Victoria, Australia
6. Victorian Clinical Genetics Services, Parkville, Victoria, Australia
7. Monash Medical Centre, Clayton, Victoria, Australia
8. Murdoch Childrens Research Institute, Parkville, Victoria, Australia

**Introduction-** Autosomal dominant spinocerebellar ataxias are a group of disorders that present with largely adult onset ataxia with variable speed of progression, and variable associated neurological symptoms. At least 42 types with an associated chromosomal locus have been described and in a number of these, the underlying genetic basis has been identified.

**Methods-** We have identified a family with at least 22 individuals affected by a relatively pure cerebellar ataxia. Onset of ataxia is generally beyond 40 years and does not limit lifespan. The disease is very slowly progressive with individuals often ambulant many years after symptom onset. MRI of brain revealed atrophy of the superior and dorsal cerebellar vermis and mild atrophy of the cerebellar hemispheres. The brain stem was normal.

**Results-** Eight individuals with ataxia from the family, separated by a total of 20 meioses, have been shown to have a novel deletion/duplication of 14q32.13 using chromosomal microarray. The deletion and duplication each include four OMIM genes. None of the eight genes are known disease genes and none are obvious candidates for the phenotype. Linkage mapping within a branch of the family shows that the del/dup co-segregates with the phenotype.

**Conclusion-** It is most likely that one of the deleted genes is responsible for the phenotype in this family. RNA-seq and assessment of the eight genes in WES/WGS data from individuals with unsolved ataxia are underway. Microarray can occasionally identify the cause of ataxia and should be included in the work up of individuals with this presentation.

## 17. High-throughput sequencing and clinical data of a family presenting with autosomal dominant spinocerebellar ataxia that maps to the SCA25 locus

Tankard R<sup>1,2</sup>, Amor DJ<sup>2,3,4,5</sup>, Howell KB<sup>3,5</sup>, Gillies G<sup>3</sup>, Pope K<sup>3</sup>, Storey E<sup>6,7</sup>, Gardner RJM<sup>8</sup>, Leventer RJ<sup>2,3,5</sup>, Lockhart PJ<sup>2,3</sup>, Delatycki MB<sup>2,3,4,7</sup>, Bahlo M<sup>1,2</sup>

- 1 Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
- 2 The University of Melbourne, Parkville, Victoria, Australia
- 3 Murdoch Childrens Research Institute, Parkville, Victoria, Australia
- 4 Victorian Clinical Genetics Services, Parkville, Victoria, Australia
- 5 Royal Children's Hospital, Parkville, Victoria, Australia
- 6 Alfred Hospital, Prahran, Victoria, Australia
- 7 Monash University, Clayton, Victoria, Australia
- 8 University of Otago, Dunedin, New Zealand

**Introduction:** Dominant spinocerebellar ataxias (SCA) are a heterogeneous group of progressive, degenerative genetic disorders affecting coordination and movement.

**Methods:** Here we present a family with seven members affected by an autosomal dominant SCA with variable age of onset suggestive of anticipation. At least one affected individual from this family tested negative for each of the repeat-expansion disorders SCA1, 2, 3, 6, 7, 8 and 17 and Friedreich ataxia, which are the most common causes of SCA. SNP-chip linkage was performed. Whole exome and whole genome sequencing was undertaken on three family members to try to identify the causative mutation.

**Results:** The phenotype in the family is characterised by marked variability in expressivity from one individual with an onset at 5 years with rapid progression to requirement for a walking aid through to subtle incoordination with minimal functional impact at 56 years in another. Sensory neuropathy on nerve conduction study was found in most affected individuals. Linkage mapping in the family identified four candidate regions, of which one overlapped with the locus for SCA25 (Online Mendelian Inheritance in Man (OMIM) 608703, 2p21-p15). Exome and genome sequencing were performed on three members of the family. In addition to standard single-nucleotide variant and indel analysis of this data, we performed copy-number variation and short tandem repeat analysis but were unable to find any plausible disease-causing genetic variants.

**Conclusion:** Previously, only one family has been linked to the SCA25 locus (Stevanin et al Ann Neurol 2004), but the genetic basis remains unknown. Both the initial family, and the one described here are characterised by marked variability in age at onset and clinical severity and prominent sensory neuropathy, raising the possibility of the causative mutation being an unstable repeat expansion. Ongoing studies will aim to identify the causative mutation.

#### 18. Detecting known repeat expansions with standard protocol next generation sequencing

R Tankard<sup>1,2</sup>, MB Delatycki<sup>2,3,4</sup>, PJ Lockhart<sup>2,4</sup>, M Bahlo<sup>1,2</sup>

1. Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
2. University of Melbourne, Parkville, Victoria, Australia
3. Victorian Clinical Genetics Services, Parkville, Victoria, Australia
4. Murdoch Childrens Research Institute, Parkville, Victoria, Australia

**Background-** Repeat expansions cause over 20 neurogenetic disorders that can present with overlapping clinical phenotypes, making molecular diagnosis challenging. Ataxias are the most common of these including SCAs 1, 2, 3, 6, 7, 8, 10, 12, 17, 36, Friedreich ataxia (FRDA) and DRPLA. Single gene or small panel PCR-based methods are employed to identify the precise genetic cause, but can be slow and costly, and often yield no result. Genomic analysis via whole exome and whole genome sequencing (WES and WGS) is being increasingly performed to diagnose genetic disorders. However, until recently analysis protocols could not identify repeat expansions in these datasets.

**Methods-** A new method for the identification of repeat expansions using either WES or WGS was developed. Four retrospective cohorts of individuals with eight different known repeat expansion disorders, including SCA 1, 2, 6, 7 and FRDA, were analysed with the new method. Results were assessed by comparing to the known disease status. Performance was also compared to a recently published genotyping-based method, ExpansionHunter.

**Results-** Expansion repeats were successfully identified in WES and WGS datasets. The new method demonstrated very high predictive capabilities, achieving a median area under the curve (AUC) of 0.9. The new robust method achieved a median specificity and sensitivity of

0.99 and 0.75 respectively, compared to ExpansionHunter (median specificity = 0.99, median sensitivity = 0.56). These results were achieved regardless of whether the library preparation was PCR-free or not. Conclusions- The new method, called exSTRa (expanded STR algorithm), is available from <https://github.com/bahlolab/exSTRa>. It can be applied to existing WES or WGS data to identify likely repeat expansions. We demonstrate that exSTRa can be effectively utilised as a screening tool to interrogate WES and WGS sequencing data generated with PCR-based library preparations which can then be followed up with specific diagnostic tests.

### 19. NGS analysis for episodic ataxias expands the phenotypic spectrum of SCA27/FGF14

Di Bella D1, Sarto E1, Moroni I2, Estienne M2, Nanetti L1, Mariotti C1, Magri S1, Taroni F1  
1Unit of Genetics of Neurodegenerative and Metabolic Diseases, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy; 2Unit of Child Neurology, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy.

**Introduction:** Episodic ataxias (EAs) are a clinically and genetically heterogeneous group of autosomal dominant neurological disorders characterized by recurrent episodes of ataxia and incoordination lasting minutes to hours. To date, five EA genes are known. Mutations in KCNA1 and CACNA1A account for the majority of cases worldwide, but many patients remain undiagnosed after genetic testing.

**Methods:** An NGS panel covering >100 known genes associated with cerebellar ataxia including EA genes was used to screen 17 individuals (14 sporadic) with EA. A coverage analysis was performed to identify gene copy-number variation.

**Results:** We identified pathogenic mutations in CACNA1A (EA2) in two early-onset patients (2/17=12%). One sporadic case (35y) was heterozygous for the known mutation p.Arg1857Ter. In one family, the proband (18y) and his father were heterozygous for a 2-exon intragenic deletion confirmed by MLPA. The 3 patients presented acetazolamide-responsive ataxia episodes since infancy. Interestingly, coverage analysis revealed a heterozygous 1-exon deletion in the FGF14 gene in one patient (18y) presenting, since the age of 11 months, fever-induced ataxic attacks characterized by disequilibrium, dysmetria, worsening of horizontal nystagmus. Since the age of 7y, the patient also reported paroxysmic episodes of headache often accompanied by phono- and photophobia and disequilibrium. Treatment with acetazolamide was discontinued due to nonresponsiveness and adverse effects. The deletion is not present in proband's parents and appear to have arisen de novo. Mutations in FGF14 are known to cause spinocerebellar ataxia type 27 (SCA27). Recently, FGF14 null-mutations have been associated with an EA form or a variable phenotype characterized by mild ataxia and abnormal eye movements worsening during fever attacks.

**Conclusion:** Mutations in known EA genes can explain only a minority of cases in our cohort. Interestingly, an FGF14 gene mutation is associated with an early-onset EA form in one patient, thus further expanding the phenotypic spectrum of SCA27.

### 20. Insights into the molecular pathogenesis of Spinocerebellar Ataxia 38 (SCA38)

Di Gregorio E.1,2, Ferrero M.1, Manes M.3, Costanzi C.3, Boccone L.4, Orsi L.5, Cavalieri S.1, Giorgio E.1, Mancini C.1, Pozzi E.1, Riberi E.6, Mitro N.7, Caruso D.7, Tempia F.8, Borroni B.3, Brusco B.1,2.

1 Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy  
2 Department of Medical Sciences, University of Turin, Turin, Italy

3 Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

4 Ospedale Regionale Microcitemie, ASL 8, Cagliari, Italy

5 Neurologic Division 1, Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy

6 University of Turin, Department of Public Health and Pediatrics, Turin, Italy

7 Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy

8 Neuroscience Institute Cavalieri Ottolenghi, Orbassano, Italy

ELOVL5 gene is associated with autosomal dominant Spinocerebellar Ataxia 38 (SCA38, MIM#611805), a rare adult-onset cerebellar neurodegeneration. This gene encodes for an elongase, an enzyme localized in the endoplasmic reticulum (ER) where it is involved in the synthesis of a subset of polyunsaturated fatty acids. We explored pathogenic mechanism of SCA38, studying aberrant ELOVL5-p.Gly230Val protein. We demonstrated a subcellular mislocalization in the Golgi apparatus of p.Gly230Val ELOVL5 protein in different cellular models. Based on these data, we hypothesized p.Gly230Val-ELOVL5 is a misfolded protein able to activate the cellular unfolded protein response (UPR). We showed a significant increase of ELOVL5 protein in SCA38 fibroblasts after a treatment with the proteasome inhibitor MG-132, supporting the idea of an unfolding protein due to p.Gly230Val mutation. A significant increase of UPR markers CHOP, ATF-4 and XBP1 demonstrated the activation of ER-stress response in COS7 cells stably expressing aberrant ELOVL5. We reasoned that the use of the chemical chaperone PBA might act on misfolded ELOVL5 reverting to physiological ER distribution of the protein and to cellular rescue from ER-stress. Our data on COS7 cells, stably expressing p.Gly230Val ELOVL5, demonstrated that PBA treatment relocalized the protein into ER.

Due to the aberrant ELOVL5 accumulation in the Golgi apparatus we looked at this organelle size and the ER- Golgi protein trafficking. Our preliminary data demonstrated a significant increase in the Golgi size and a slow- down of vesicular stomatitis virus G glycoprotein (VSVG) transport from ER to the Golgi in COS7 cells stably expressing p.Gly230Val ELOVL5. These data might suggest a Golgi dysfunction likely due to misfolded ELOVL5 accumulation in this apparatus.

In conclusion, our results support a role for altered ER-stress response in SCA38 pathogenesis, suggesting chemical chaperones might be useful in the treatment, and disclose Golgi dysfunction as part of the disease mechanism.

## 21. Genes that affect synaptic excitability and transmission identified by rare variant analyses in episodic ataxias

Stephanie Efthymiou (see oral presentations)

## 22. Mutations in a novel gene implicate cellular stress in a new form of Autosomal Recessive Cerebellar Ataxia

Eidhof I1,6, Baets J2-4,6, Kamsteeg EJ1, Deconinck T3,4, van Nijnhuys L1, Martin JJ3, De Jonghe P2-4, Schenck A1,7, van de Warrenburg B5,7\*

1. Department of Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands
2. Neurogenetics Group, Center for Molecular Neurology, VIB, Antwerp, Belgium
3. Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium
4. Department of Neurology, Antwerp University Hospital, Antwerp, Belgium

5. Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands

6 Shared first authors

7 Shared senior authors

## Introduction

Autosomal Recessive Cerebellar Ataxia (ARCA) is a group of rare neurodegenerative disorders that share progressive degeneration of the cerebellum and associated tracts as the main hallmark. Although more than 100 genes have been identified in ARCA many ARCA patients remain without a genetic diagnosis, suggesting the existence of even more ARCA genes. The large clinical and genetic heterogeneity, and the rare nature of individual ARCA forms challenge the identification of novel ARCA genes.

## Methods

At both the Nijmegen and Antwerp sites, whole exome sequencing (WES) is applied in patients with (presumed) genetic ataxia. In two independent patients, variants in a gene not previously implicated in ataxia were identified. To gain further independent support for the implication of this gene in ARCA pathophysiology, the role of its *Drosophila* orthologue was investigated in lifespan, motor behavior and stress treatments.

## Results

In the two unrelated ataxia patients, we identified three different variants in a novel ARCA gene: compound heterozygous (nonsense/frameshift) in one and homozygous (frameshift) in the other. Both patients had onset of ataxia in the fourth decade. Other common features that evolved included spasticity and dystonia, as well as dementia in later stages of disease in one case. Ubiquitous knockdown of the *Drosophila* orthologue of the novel gene resulted in shortened lifespan and motor behavior anomalies such as righting defects, reduced and uncoordinated walking behavior and compromised flight. In addition, we showed that normal expression levels of the novel gene protected against deleterious effects of stress such as Reactive Oxygen Species and, to a minor degree, nutrient deprivation.

## Conclusions

We define a new subtype of ARCA caused by loss-of-function mutations in a novel ARCA gene. Our data from *Drosophila* independently support a role of the gene in motor behavior and suggest that cellular stress may contribute to the phenotypes observed in the *Drosophila* model and patients. We will present the novel ARCA gene and our data at the meeting.

### 23. Application of Next Generation Sequencing in a cohort of ataxic patients using a multi-gene panel approach

Galatolo D.<sup>1</sup>, Antenora A. <sup>2</sup>, Natale G. <sup>2</sup>, Tessa A.<sup>1</sup>, Fico T. <sup>2</sup>, Filla A.<sup>2</sup>, Santorelli F.M.<sup>1</sup>

<sup>1</sup>Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, and <sup>2</sup>Department of Neurosciences, Federico II University, Naples, Italy

Introduction: Hereditary ataxias (HA) are clinically and genetically heterogeneous conditions. Sanger sequencing in routine clinical investigation of HA patients has been replaced because the modern Next Generation Sequencing (NGS) approaches have proved to be more time- and cost- effective. Moreover, the clinical use of NGS has also broadened the etiologies in HA. With NGS applications, the diagnostic rate in HA is about 35% when using exome sequencing (ES), and about 20% when target resequencing panels (TRP) are applied. There are no studies

examining naïve patients with TRP strategies, however. In this study, we applied a TRP strategy in a cohort of ataxic patients as a first tier diagnostic approach.

**Methods:** We studied a consecutive group of 30 index cases with congenital, degenerative, or late onset ataxias. DNA sequencing adopted a TRP Haloplex platform, capturing 82 genes, and was performed on a MiSeq Illumina sequencer. All patients had been tested for pathological expansions in SCA1, 2, 3, 6, 7, 17 and for the intronic GAA expansion in FXN. Genotypes were analyzed using Ingenuity Variant Analysis. Probable and possible pathogenetic mutations were confirmed by traditional Sanger sequencing.

**Results:** We found pathogenetic mutations in 8 patients (27%), including 8 new variants (72%), detected in 5 different genes (PRKCG, SYNE1, PNPLA6, SPG7, SETX). SPG7, often mutated in hereditary spastic paraplegias (HSP), was the most common (38%) followed by PNPLA6 (25%).

**Conclusions:** In this study applying TRP to analyze naïve HA patients we observed a diagnostic rate of 27%, a finding as yet less informative than ES which remains a method of choice in clinical diagnostic settings. Our study also confirmed that HA and HSP share several disease genes and could represent two extremes on a continuous spectrum.

#### 24. Specific neuronal vulnerability in SCA1 is not associated with CAG instability between different brain regions

Ging, H.1, Pigazzini, M.L.1, Pemble, S.2, Sweeney, M.G.2, Nethisinghe, S.1, Giunti, P.1  
1London Ataxia Centre, Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.

2Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, United Kingdom.

**Introduction:** SCA1 results from an expanded polyglutamine tract, encoded by CAG trinucleotides, within ATXN1, with symptoms due to cerebellar degeneration, specifically degeneration of the Purkinje cells and neurons within the brainstem and spinal cord. A major determinant of SCA1 pathology is the repeat size, which has an inverse relationship to disease age of onset and severity. We have previously shown that interruption of the expansion by missense (CAT) mutations is a significant modulator of the disease phenotype, with interruptions delaying the age at onset such that the length of the longest contiguous stretch of pure CAG repeats inversely correlates with age at onset (Menon et al., 2013). This study aims to understand the somatic differences between human blood and various brain regions from two SCA1 patients, differentially involved in the neurodegenerative process, and their phenotypic effect.

**Methods:** DNA was extracted from the brain and blood of two SCA1 patients. This DNA was fragment sized, cloned and sequenced, as previously described (Menon et al., 2013).

**Results:** Somatic mosaicism was investigated in eight brain regions of two SCA1 patients by fragment analysis, sizing both the mode and largest expansions, and confirmed by cloning and DNA sequencing. Sequencing analysis established the exact size and configuration of the CAG repeats and found them to be largest in the caudate nucleus and shortest in the cerebellum. This argues against a direct association between the degree of somatic mosaicism and the selective neurodegeneration in SCA1.

**Conclusions:** Peripheral blood DNA CAG repeat size is a good indicator of repeat size in the cerebellum and validates its use in the diagnostic setting. Furthermore, this work



demonstrates that selective neuronal vulnerability correlates poorly with the observed somatic instability throughout the different tissues examined.

## 25. Clinical and genetic characteristics of sporadic adult-onset ataxia

I Giordano<sup>1,2</sup>, S Tezenas du Montcel<sup>3,4</sup>, S Roeske<sup>2</sup>, S Vielhaber<sup>5,6</sup>, J Machts<sup>5</sup>, P Bauer<sup>7</sup>, T Klockgether<sup>1,2</sup> on behalf of the SPORTAX consortium

1Department of Neurology, University Hospital of Bonn, Bonn, Germany

2German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

3Pierre Louis Institute of Epidemiology and Public Health, Pierre and Marie Curie University (UPMC), Paris, France

4Biostatistics Unit, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

5German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany

6Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

7Centogene AG, Rostock, Germany

**Background:** Sporadic adult onset ataxia is often caused by multiple system atrophy cerebellar type (MSA-C), but many patients do not fulfil MSA-C criteria and are designated sporadic adult onset ataxia (SAOA).

**Objective:** To study disease characteristics, define natural history and identify disease causing genetic mutations.

**Methods:** In the SPORTAX registry, we enrolled 249 ataxia patients with progressive adult onset ataxia and negative family history. All known acquired causes of ataxia were ruled out. All subjects were tested negative for repeat mutations. SARA was the primary outcome. DNA samples were screened for mutations using a high-coverage ataxia-specific gene panel.

**Results:** 95 of the 249 subjects met diagnostic criteria of clinically probable MSA-C at baseline or during follow-up. 48 participants with negative MSA-C criteria and disease duration of >10 years were designated SAOA/non-MSA. Hyperreflexia, rigidity, and urinary dysfunction were more frequent in MSA-C. Compared to MSA-C, SAOA/non-MSA patients had lower SARA scores ( $13.6 \pm 6.0$  vs.  $16.0 \pm 5.8$ ,  $p=0.0200$ ) and slower annual SARA increase ( $1.1 \pm 2.3$  vs.  $3.3 \pm 3.2$ ,  $p=0.0013$ ). The cognitive ability assessed with MoCA was similar ( $22.14 \pm 3.1$  vs.  $22.76 \pm 3.8$ ), but compared to a healthy group, MSA patients had worse results ( $22.8 \pm 3.8$  vs.  $28.3 \pm 1.7$ ,  $p=0.000$ ). Likewise, pHQ9 ( $6.63 \pm 4.89$  vs  $7.81 \pm 5.00$ ,  $p=0.2407$ ) and HADS-D sum score ( $13.2 \pm 5.7$  vs.  $12 \pm 6.6$ ,  $p=0.677$ ) did not differ between SAOA/non-MSA and MSA-C. In 11 of 194 subjects (6%), a definitive or probable genetic diagnosis was made.

**Conclusions:** Our study provides quantitative data on the clinical phenotype and progression of sporadic ataxia with adult onset. Screening for causative mutations with a gene panel approach yielded a genetic diagnosis in 6% of the cohort.

## 26. Alteration of the growth cone dynamics in dorsal root ganglia neurons from the Friedreich ataxia YG8sR mouse

D.C. Muñoz Lasso<sup>1</sup>, J. Sáenz<sup>2</sup>, M.A. Pook<sup>3</sup>, M. de la Iglesia Vayá<sup>2,4</sup>, B. Mollá<sup>5</sup>, F. Pallardó<sup>1, 6</sup>, F. Palau<sup>5,6</sup>, P. González-Cabo<sup>1, 6</sup>

1. Department of Physiology, Faculty of Medicine and Dentistry. University of Valencia – INCLIVA, Valencia, Spain

2. Brain Connectivity Lab. Neurological Impairment Program. Joint Unit FISABIO & Prince Felipe Research Center (CIPF), Valencia, Spain

3. Ataxia Research Group, Division of Biosciences, Department of Life Sciences, College of Health & Life Sciences, Brunel University London, Uxbridge, UB8 3PH, UK

4. Centre of Excellence in Technological Innovation in Bioimaging, Health Regional Ministry of Valencia (CEIB-CS) Instituto de Biomedicina de Valencia (IBV) CSIC, Valencia, Spain
5. Department of Genetic and Molecular Medicine, Hospital Sat Joan de Due and Institut de Recerca Pediatrica (IRP-HSJD), Barcelona, Spain
6. CIBER de Enfermedades Raras (CIBERER), Valencia, Spain

Introduction: Appropriate levels of ATP and reactive oxygen species (ROS) generate a normal axonal growth, and together with the intracellular Ca<sup>2+</sup> signaling, control the motility of growth cones and the axonal pathfinding. Based on the fact that Friedreich's ataxia (FRDA) cells have altered mitochondrial ATP production, increased oxidative stress and calcium dysregulation, our hypothesis is that the deficit of frataxin affects the morphology and dynamics of the growth cones (GCs) in adult DRG neurons.

Methods: Morphometric and computer-based analysis of the GCs were performed in primary culture of DRG neurons from male Y47R and YG8sR mice at 2, 6 and 9 months of age and analyzed by Time-Lapse phase-contrast microscopy.

Results: The morphometric analysis from 2 month-old-mice exhibited a smaller area of GCs in YG8sR-DRG neurons than Y47R mice (91.24 vs. 69.69  $\mu\text{m}^2$ ; \*\* $p=0.0013$ ). In addition, two-customized computer-based analysis identified aberrant patterns in the dynamics of the GCs from YG8sR-DRG neurons. GCs from YG8sR-DRG neurons built shorter neurites (32.34 vs. 24.97  $\mu\text{m}$ , \* $p=0.0491$ ), at lower velocity (0.01 vs. 0.007

$\mu\text{m}\cdot\text{sec}^{-1}$ , \* $p=0.0187$ ), and with smaller axon turning angles ( $-68.14^\circ$  vs.  $-42.97^\circ$ , \*\*\* $p=0.0006$ ). The changes in morphology and the aberrant motion patterns present in the dynamics of the GCs of 2 month-old-mice were no longer evident for 6 and 9 month-old-mice.

Conclusions: The aberrant changes in the morphology and dynamics of the growth cones of adult DRG neurons from YG8sR mice suggest that the intrinsic ability to grow and to regenerate axons of DRG neurons would be altered as part of neuropathological process involved in FRDA pathophysiology.

## 27. Confirmation of ATP8A2-related disorders as recessive cerebellar ataxia

Guissart C1, Larrieu L1, Oncel I2, Topaloglu H2, Calvas P3, Koenig M1

1 Laboratoire de Génétique de Maladies Rares, Institut Universitaire de Recherche Clinique, EA7402 Université de Montpellier, CHU Montpellier, 34093 Montpellier, France

2 Department of Pediatrics, Hacettepe University, Ankara, Turkey

3 Department of Clinical Genetics, Purpan University Hospital, Toulouse, France.

Introduction: ATP8A2-related disorders are autosomal recessive conditions that associate encephalopathy with or without hypotonia, psychomotor delay, abnormal movements, chorea, tremor, intellectual disability, optic atrophy and cerebellar atrophy. To date, only four families have been described: one case is affected by a presumed dominant de novo balanced translocation of chromosomes 10 and 13, disrupting the ATP8A2 coding sequence, while the three other families have homozygous or compound heterozygous missense mutations located in the catalytic cytoplasmic domain and adjacent transmembrane segment VI [amino acids 364 to 877] of the Phospholipid-transporting ATPase IB which is a 1188 amino-acid protein involved in the maintenance of asymmetric distribution of phospholipids of various membranes.

Methods and results: Here we report the identification by exome sequencing of novel homozygous ATP8A2 (NM\_016529) mutations in two consanguineous families with ataxia and hypotonia. Both mutations are located in exon 20 and cause non-conservative missense changes (p.Gly585Val and p.Arg588Trp) predicted to be pathogenic. Two siblings with the

p.Gly585Val mutation originated from Turkey and were affected by 1 year of age with head titubation, ataxic gait and tremor. Both of these siblings have borderline intellectual functioning with IQ: 70-80. In the second family from Algeria, with the p.Arg588Trp mutation, a girl was affected by delayed walking, disequilibrium, severe hypotonia, dysmetria, multidirectional nystagmus, mild deafness, and cerebellar atrophy. All three patients were still ambulant, with unilateral aid, by ages ranging from 8 to 11 years.

Conclusions: The phenotypic spectrum related to ATP8A2 mutations includes a less severe form characterized by cerebellar ataxia. ATP8A2 should therefore be included in screening panels for the diagnosis of syndromic inherited ataxias. It appears that all recessive ATP8A2 mutations identified so far are missense mutations located in a specific domain of the protein, which suggests a partial loss of function mechanism irrespective of severity.

Keywords: ataxia; ATP8A2

### [28. Novel SCA gene FAT Atypical Cadherin 2 is a regulator of autophagy](#)

B.M. Hofstra, M.R. Fokkens, G.B. Bampi, R.J. Sinke, B van de Sluis, and [D.S. Verbeek](#)

### [29. Elucidating the genetic background of childhood-onset ataxias](#)

Erika Ignatius (see oral presentation)

### [30. Understanding the pathophysiological and the molecular mechanisms underlying the recessive ataxia ARCA2](#)

Tiphaine Jaeg Ehret (see oral presentation)

### [31. Heart and nervous system pathology in compound heterozygous Friedreich ataxia](#)

1Becker AB, 2Qian J, 3Yang M, 4Bauer P, 5Gelman B, 1,2Koeppen AH

- (1) Research Service, Veterans Affairs Medical Center, Albany, NY, USA
- (2) Department of Pathology, Albany Medical College, Albany, NY, USA
- (3) Children's Hospital Colorado, Aurora, CO, USA
- (4) CENTOGENE, Rostock, Germany
- (5) University of Texas Medical Branch, Galveston, TX, USA

Introduction: In a small percentage of Friedreich ataxia (FA) patients, the pathogenic mutation is heterozygous, consisting of a guanine-adenine-adenine (GAA) trinucleotide repeat expansion on one allele, and a deletion, point mutation, or insertion on the other. We report the heart and nervous system pathology of two compound heterozygous FA patients.

Methods: Patient 1, an 11-year-old boy (GAA, 825/c.11\_12TCdel), had chorea, cardiomyopathy, and diabetes mellitus. He died from cardiorespiratory arrest. His heart weighed 288 g (expected normal: 122 g). Patient 2, a 28-year-old man (GAA, 707/exon 5 del), had cardiomyopathy and diabetes mellitus. He died from an intracerebral hemorrhage. The heart weighed 439 g (expected normal: 270-360 g).

Results: Microscopy of the left ventricular wall (LVW) of the heart showed cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs. The cardiac lesions were similar to those in age-matched homozygous FA patients with cardiomyopathy and diabetes mellitus (boy, 10, GAA 1016/1016; woman, 25, GAA 800/1100). The neuropathology was also similar, including atrophy of the large neurons of the dentate nuclei (DN), hypoplasia of spinal cord and dorsal root ganglia, and loss of large axons in dorsal roots (DR). The DR in the 2 young FA patients and the adult FA heterozygote showed bizarre balloon-like expansions that

reacted with antibodies to S100 and glial fibrillary acidic protein, indicating a central nervous system origin. Enzyme-linked immunosorbent assays of LVW and DN extracts of the 4 cases showed frataxin levels at or below the detection limits of the method ( $\leq 10$  ng/g wet weight) (normal DN:  $195 \pm 55$  ng/g; normal LVW:  $235 \pm 75$  ng/g).

Conclusions: Disease manifestations in compound heterozygotes do not follow a uniform pattern but depend on the expression level of frataxin. Low tissue frataxin levels, rather than the specific type of mutation in the frataxin gene, also determine the pathological phenotype in FA (Supported by FARA).

### 32. Friedreich ataxia: developmental failure of the dorsal root entry zone

1,2Koeppen AH, 1Becker AB, 2Qian J, 3Gelman B, 4Mazurkiewicz JE

(1) Research Service, Veterans Affairs Medical Center, Albany, NY, USA

(2) Department of Pathology, Albany Medical College, Albany, NY, USA

(3) University of Texas Medical Branch, Galveston, TX, USA

(4) Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, NY, USA

Introduction: Dorsal root ganglia (DRG), dorsal roots (DR), and dorsal root entry zones (DREZ) of the spinal cord are vulnerable in Friedreich ataxia (FA). The depletion of myelinated fibers in the dorsal columns, more moderate loss of axons in the dorsal spinocerebellar tracts, and absence of nerve cells in the dorsal nuclei are fully explained by insufficient prenatal and perinatal centripetal growth of axons arising from DRG.

Methods: Segments of formalin-fixed upper lumbar spinal cord of 12 homozygous and 2 compound heterozygous FA patients were sectioned longitudinally to represent DREZ and stained for the glial fibrillary acidic protein (GFAP), S100, vimentin, the central nervous system (CNS)-specific myelin protein PLP, the peripheral nervous system (PNS) myelin proteins PMP-22 and P0, and the Schwann cell proteins alpha-dystroglycan, periaxin, and laminin. Additional methods were confocal microscopy and electron microscopy.

Results: Normal DREZ show a short dome-like extension of GFAP-, S100-, and vimentin-reactive CNS tissue into DR and sharp demarcation of CNS and PNS myelin proteins. Alpha-dystroglycan, periaxin, and laminin form tight caps around these domes. In FA, CNS tissue extends into DR over much longer distances, reaching up to 3 mm. The transition between CNS and PNS myelin is irregular. The ultrastructure of the CNS extensions into the DR shows heterogeneous fibrillary bundles.

Conclusions: These observations provide indirect evidence that frataxin deficiency in FA leads to incomplete demarcation between spinal CNS and PNS. During prenatal and perinatal development, neural-crest derived boundary cap cells provide guidance to DRG axons growing into the dorsal spinal cord and at the same time block the inappropriate intrusion of CNS glia into DR. It is likely that frataxin is required during a critical period of permissive (axons) and non-permissive (astroglia) border-control (Supported by Friedreich's Ataxia Research Alliance and New York State Department of Health).

### 33. Defining the effect of expanded GAA repeats on the kinetics of FXN transcription in Friedreich's Ataxia

Yanjie Li and Marek Napierala

Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294

Introduction: Friedreich's ataxia (FRDA) is caused by reduced levels of the mitochondrial protein frataxin (FXN) as a result of large expansions of GAA trinucleotide repeats located in the first intron of the FXN gene. Transcriptional silencing of FXN is one of the primary targets for therapeutic intervention, therefore, understanding the exact molecular mechanism governing the GAA-induced silencing is essential for developing a precise therapeutic strategy. The expanded GAAs have been demonstrated to perturb both initiation and elongation of FXN transcription, however, high resolution analyses of the transcriptional kinetics in FRDA cells are lacking.

Methods: Analyses were conducted in FRDA and control iPSCs due to relatively high expression of FXN in these cells. Precision nuclear run-on sequencing (PRO-seq) assay was used to define nascent transcription with single nucleotide resolution. Inhibitors of transcription initiation and elongation were used to investigate the effect of the expanded GAAs. PRO-seq and RNA polymerase II ChIP-seq data were overlapped. Antibodies specific for total RNAPII, as well as Ser2 and Ser5 phosphorylated polymerase were utilized for immunoprecipitation.

Results: A comprehensive, high resolution transcription landscape of the FXN locus in FRDA and control iPSCs was determined. Strand-specific PRO-seq profiles demonstrated decreased transcription elongation in the FRDA cells. In addition, preliminary data indicate a decrease in recruitment of RNAPII machinery to the FXN promoter region accompanied by significant perturbations of the transition from initiation to productive elongation in FRDA cells. No significant antisense transcription initiation could be observed at the FXN locus in iPSCs.

Conclusion: Results of our transcription kinetics analyses in control and FRDA iPSCs indicate that interplay between transcription initiation-elongation of the FXN gene and especially the transition into processive elongation is affected in FRDA iPSCs. Therefore, simultaneous targeting of both initiation and elongation defects maybe required to achieve a therapeutically significant increase of FXN mRNA synthesis.

#### 34. Time and region-specific glial pathology in mouse model of Machado-Joseph disease

Sara Duarte-Silva<sup>1,2</sup>, Andreia Neves-Carvalho<sup>1,2</sup>, Nogueira-Gonçalves G<sup>1,2</sup>, Anabela Silva-Fernandes<sup>1,2</sup>, Andreia Teixeira-Castro<sup>1,2</sup> and Patrícia Maciel\*<sup>1,2</sup>

- 1) Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal;
- 2) ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal;

Introduction: Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3, is a genetically determined neurodegenerative disease of adult onset, caused by expansion of a polyglutamine (PolyQ) tract within the protein ataxin-3. Astrogliosis is observed in MJD patients' brains post-mortem, but it has classically been interpreted as a reaction to neuronal demise. Our goal in this study was to determine the contribution of glial cells for disease initiation and progression in MJD. Methods: For that, we used a well characterized animal model of the disease, the CMVMJD135 transgenic mouse model at different disease stages, together with histological and molecular analysis techniques. Results: We found a region-specific astrocytic pathology in symptomatic mice (34 weeks of age): while in the substantia nigra and spinal cord (two affected regions) a classical astrocytic reactivity was observed, in the pontine nuclei (another affected region) we found a general hypotrophy of the astrocytes. Nevertheless, we found no differences in the expression levels of the glutamate transporter EEAT2 in the brainstem and spinal cord suggesting functional astrocytes. Expression analysis in young symptomatic mice (22 weeks) of inflammation-related molecules revealed an up-regulation of anti-inflammatory molecules such as arginase-1 and IL4. Interestingly, as the

disease progresses, we observed a shift towards a mixed profile: in 34 weeks-old animals, an up-regulation of Tnfa, Il1b, Ccl2, CD86 and Il10 (pro and anti-inflammatory cytokines) was detected in the brainstem and spinal cord of these mice. Intriguingly, the expression levels of arginase 1 and peroxiredoxin- 2, anti-inflammatory-related enzymes, were significantly decreased at this age. No differences were found in other inflammation-related molecules such as Il-6, iNOS, Cxcl10, Cxcl12, Cxcl14, Cxcl17, Il4, Tgfb1, Cx3cr1, Mac2, MHCII and Nfkb1. Conclusions: Altogether, these results point to the importance of glial cells in the pathogenesis of MJD, and suggests a bi-modal pattern of neuroinflammation in this disorder.

### 35. Synaptic pathology in in vitro and in vivo models of Friedreich's ataxia

Cristina Lao-Peregrín<sup>1</sup>, Giuseppe Yañez<sup>1</sup>, Irene Bolea<sup>1</sup>, Joriene C. de Nooij<sup>2</sup>, Peter A. Goldstein<sup>3</sup>, and Jordi Magrané<sup>1</sup>

<sup>1</sup>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine; <sup>2</sup>Department of Neurology, Columbia University Medical Center; <sup>3</sup>Department of Anesthesiology, Weill Cornell Medicine. New York, NY, USA

Proper distribution and supply of mitochondria are necessary for the normal maintenance of neuronal architecture and activity, including synaptic plasticity and function. Mitochondrial dysfunction in Friedreich's ataxia (FA) is likely to impact on some of these neuronal aspects. Although synaptic pathology in FA is largely unexplored, immunohistochemical studies in autopsy specimens from FA patients have provided evidence supporting the existence of synaptic abnormalities.

We aim to investigate synaptic abnormalities in cultured sensory neurons and in a mouse model of FA (KIKO mouse). We use molecular and cellular techniques, including fluorescence microscopy and electrophysiology recordings, and immunohistochemistry of spinal cords and muscles to study synaptic dysfunction in FA.

We have identified altered synapses and electrophysiological properties in KIKO sensory neurons, as compared to controls. Synaptic alterations are also present in the adult KIKO mouse, at both ends of the sensory neuron (that is, the spinal cords and the muscle spindles). We are currently testing the effects of therapeutic approaches aimed to correct Fxn-induced mitochondria dysfunction.

Our data suggests that synaptic dysfunction is an early, initiating event in FA pathogenesis.

### 36. KIF1A motor domain variants and gene copy number variation in patients with spinocerebellar ataxia

Magri S<sup>1</sup>, Sarto E<sup>1</sup>, Pareyson D<sup>2</sup>, Alfei E<sup>3</sup>, Nanetti L<sup>1</sup>, Mariotti C<sup>1</sup>, Di Bella D<sup>1</sup>, Taroni F<sup>1</sup>.

<sup>1</sup>Unit of Genetics of Neurodegenerative and Metabolic Diseases, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy; <sup>2</sup> Unit of Central and Peripheral Degenerative Neuropathies, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy; <sup>3</sup>Unit of Developmental Neurology, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy.

Introduction: KIF1A is a neuron-specific kinesin that functions as an anterograde motor protein along axonal microtubules. Recessive missense mutations of KIF1A are associated with a complicated form of spastic paraplegia with cerebellar involvement and peripheral neuropathy (SPG30), while recessive truncating mutations are associated with hereditary sensory/autonomic neuropathy (HSAN2). Moreover, dominant de- novo mutations in the motor domain may cause a complex neurologic phenotype characterized by cognitive

impairment variably associated with cerebellar atrophy, spastic paraparesis, optic nerve atrophy, peripheral neuropathy, and epilepsy.

Methods: NGS analysis of 135 ataxia and 94 spastic paraplegia patients using a probe-based customized panel containing >200 genes associated with spastic paraplegia (112) or ataxia (139). Coverage analysis was performed to identify copy-number variations (CNV).

Results: We identified de-novo known pathogenic mutations (p.Arg216Cys and p.Arg254Gln) in 2/135 patients. Both patients presented with a predominantly ataxic phenotype with cerebellar atrophy, prevalent in the vermis, and mild intellectual disability with an infantile/juvenile onset. Moreover, we identified 3 novel missense variants of unknown significance affecting conserved residues of the motor domain in two sporadic patients with ataxia and intellectual disability and one familial case with spastic paraplegia and neuropathy (3/229 in the ataxia/spastic paraplegia group vs 0/247 in a peripheral neuropathy group). Finally, we identified a partial duplication of KIF1A (exons 16-49) in 3/135 (2%) ataxia patients, two of whom negative for pathogenic mutations in other genes and one positive for a homozygous null mutation in SETX. Conclusion: Our results indicate that KIF1A dominant mutations can cause a predominantly ataxic phenotype with cognitive deficit. Furthermore, the frequency of a partial KIF1A duplication in our cohort of ataxic patients vs that in a reference sample (ExAC: 142/52322) is significantly higher ( $P=0.0005$ ) to suggest a possible role in the pathogenesis of the disease as modifier or susceptibility factor. (MoH RF-2011-02351165 grants to FT).

### 37. Functional studies of AFG3L2 mutations reveal haploinsufficiency as the pathogenetic mechanism of SCA28

Tulli S. 1, Del Bondio A. 1, Mancini C. 2, Mazza D. 3, Codazzi F. 4, Nolte D. 5, Goizet C. 6, De Jonghe P. 7, Brusco A. 2, Casari G. 8,9 and Maltecca F. 1,9

1 Ospedale San Raffaele, Division of Genetics and Cell Biology, Milan, Italy;

2 Department of Medical Sciences, University of Turin, Italy;

3 Ospedale San Raffaele, Center of Experimental Imaging, Milan, Italy;

4 Ospedale San Raffaele, Division of Neuroscience, Milan, Italy;

5 Institute for Human Genetics, Justus-Liebig-University, Giessen, Germany;

6 Laboratoire MRGM, INSERM U1211, Université Bordeaux and Service de Génétique, Hôpital Pellegrin, CHU Bordeaux, France;

7 VIB-Department of Molecular Genetics, University of Antwerp, Belgium;

8 Telethon Institute of Genetics and Medicine, Pozzuoli, Italy;

9 Università Vita-Salute San Raffaele, Milan, Italy.

Introduction: Among autosomal dominant spinocerebellar ataxias, SCA28 is the only form caused by mutations in a mitochondrial resident protein, AFG3L2. The latter forms oligomeric complexes in the inner mitochondrial membrane, the m-AAA proteases, which play a crucial role in mitochondrial quality control and in the regulation of mitochondrial morphology. Most SCA28-causing mutations are heterozygous missense changes clustering in exon 15 and 16 of AFG3L2, which encode the key peptidase domain of the protein. Whether the pathogenetic mechanism of SCA28 is haploinsufficiency or negative-dominance exerted by mutant AFG3L2 has not been clarified.

**Methods:** We derived primary skin fibroblasts from SCA28 patients carrying missense mutations (F664S, M666T, G671R, Y689H) or a deletion involving the C-terminal part of AFG3L2 (G555GfsX11). We analysed the amount of AFG3L2 as a monomer by WB and as assembled m-AAA complex by BN- PAGE. We evaluated mitochondrial physiology by live imaging examination of the mitochondrial network morphology, cytofluorimetric analysis of mitochondrial membrane potential ( $\Delta\psi_m$ ) and FRET-based measurement of mitochondrial calcium buffering.

**Results:** We found that the analysed missense changes do not affect the ability of AFG3L2 to assemble into m-AAA complexes, whose amount is instead halved in the presence of G555GfsX11 mutation. We disclosed increased mitochondrial fragmentation in patient cells, which interestingly correlated with reduced amount of proteins mediating

mitochondrial fusion, indicating that this is a primary event in SCA28 pathogenetic cascade. As a consequence, mitochondrial calcium buffering is reduced in patients, despite unchanged  $\Delta\psi_m$ . We observed that these phenotypes are milder in Y689H cells, in agreement with the less severe clinical features of the patient.

**Conclusions:** Altered mitochondrial morphology and reduced calcium buffering directly correlates with disease progression, representing reliable markers for future clinical trials. The analysed missense mutations resulted in phenotypes similar to G555GfsX11 mutation, definitely indicating haploinsufficiency as the pathogenic mechanism of SCA28.

### 38. The c.1529C>T (p.Ala510Val) SPG7 missense mutation in sporadic cerebellar ataxias in Italy.

C. Mancini<sup>1</sup>, S. Cavalieri<sup>1</sup>, E. Giorgio<sup>1</sup>, E. Di Gregorio<sup>2</sup>, M. Ferrero<sup>1</sup>, E. Pozzi<sup>1</sup>, E. Riberi<sup>1</sup>, L. Pradotto<sup>3</sup>, S. Bagnolis<sup>4</sup>, S. Piacentini<sup>4</sup>, P. Ferrero<sup>5</sup>, E. Rubino<sup>5</sup>, L. Orsi<sup>5</sup>, P. Prontera<sup>6</sup>, M. Zibetti<sup>5</sup>, A. Tessa<sup>7</sup>, M. Barghigiani<sup>7</sup>, F.M. Santorelli<sup>7</sup>, A. Antenora<sup>8</sup>, A. Filla<sup>8</sup>, A. Brusco<sup>1,2</sup>.

- 1) Department of Medical Sciences, University of Torino, Turin, Italy;
- 2) Medical Genetics Unit, "Città della Salute e della Scienza" Hospital, Turin, Italy;
- 3) Division of Neurology and Neurorehabilitation, San Giuseppe Hospital, IRCCS-Istituto Auxologico Italiano, Piancavallo (VB), Italy;
- 4) Dep. of Neuroscience, Psychology, Drug Research and Child's Health, University of Florence, Florence, Italy;
- 5) Dep. of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy
- 6) Medical Genetics Unit, Hospital 'S. Maria della Misericordia', Perugia, Italy.
- 7) Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy
- 8) Department of Neurosciences, Federico II University, Naples, Italy

#### INTRODUCTION:

Hereditary Ataxias are clinically, genetically, and etiologically heterogeneous groups of neurodegenerative disorders, characterized by a cerebellar syndrome often associated with dysarthria and oculomotor signs. More than 150 genes have been reported so far, with overlapping pathogenic mechanisms however the genetic cause remains unknown in >40% of patients.

A recent report suggested that SPG7 mutations, causing the most common form of autosomal recessive spastic paraplegia (MIM#607259), account for approximately 18.6% of cases with unexplained ataxia in UK. All were homozygotes or compound heterozygotes for the c.1529C>T (p.Ala510Val) missense mutation.

#### METHODS:



We set up a rapid assay for c.1529C>T/p.Ala510Val using restriction enzyme analysis after PCR amplification, and screened 1000 ataxic patients of Italian origin, collected since 2005 at Genetics Unit in “Città della Salute e della Scienza” Hospital Torino and the Neurogenetic Unit, IRCCS Stella Maris, Pisa. Heterozygous carriers were further analyzed by Sanger sequencing to find the second variant.

#### RESULTS:

We identified nine homozygotes and 17 heterozygotes for the c.1529C>T mutation. We further extended mutation analysis by sequencing the entire SPG7 coding region to the heterozygous carriers. We found 15 cases with a second mutation, two were novel variants (splicing mutation c.1553-2delAG and c.287-1G>C).

Positive patients showed a pure cerebellar ataxia at onset, evolving in mild spastic ataxia alternatively associated with dysarthria (~80% of patients), urinary contingency (~30%), and mild cognitive impairment (~40%).

#### CONCLUSIONS:

SPG7 p.Ala510Val mutants account for 2.4% of sporadic cerebellar ataxias in Italy. The high frequency of the SPG7 allele c.1529C>T in the ataxic patients suggests it should be considered as priority test in the presence of pure ataxia, even with absent or subtle pyramidal signs. Moreover, these findings further highlight the heterogeneity of disease spectrum linked to mutations in components of the mitochondrial AAA protease.

### 39. ACO2 mutations: a novel phenotype associating severe optic atrophy, cerebellar atrophy and severe spastic paraplegia

C. Marelli<sup>1</sup>, C Guissart<sup>2</sup>, M Quiles<sup>3</sup>, B. Carlander<sup>1</sup>, D. Chretien<sup>4</sup>, P. Rustin<sup>4</sup>, C. Hamel<sup>3</sup>, and M. Koenig<sup>2</sup>

1. Department of Neurology, Gui de Chauliac Montpellier University Hospital, France
2. EA7402 Institut Universitaire de Recherche Clinique, and Laboratoire de Génétique Moléculaire, University Hospital, Montpellier, France
3. Maladies Sensorielles Génétiques, CHRU, Montpellier, France; INSERM U1051, Institute for Neurosciences of Montpellier; Université Montpellier, Montpellier, France.
4. INSERM UMR 1141, PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.

**Introduction:** Aconitase 2 (ACO2) encodes the mitochondrial aconitase (ACO2), an enzyme catalysing interconversion of citrate into isocitrate in the tricarboxylic acid (TCA) cycle. ACO2 mutations have been initially associated with isolated retinitis pigmentosa (Hartong et al. 2008) and subsequently to isolated (Metodiev et al. 2014) or syndromic optic atrophy, combining retinal degeneration, encephalopathy, epilepsy, and cerebellar ataxia (Spiegel et al. 2012).

**Methods:** Mini-exome sequencing by exon capture with the Trusight One sequencing panel kit (Montpellier NGS platform) in a patient with familial syndromic optic atrophy **Results:** A 54-years-old lady presented with severe optic atrophy, mild cerebellar ataxia, and severe spastic paraplegia. Her symptoms began in infancy, with delayed motor development and moderately delayed mental development. Her sister has the same clinical presentation with ocular problems, spasticity, and more severe mental retardation. Cerebral MRI showed moderate cerebellar atrophy and T2 and FLAIR hyper-intensities in cerebellar dentate nuclei and in supratentorial white matter. Neurological examination revealed severe visual impairment, mild upper limb ataxia, tetra-hyperreflexia and severe spastic paraplegia. Ophthalmological evaluation confirmed the presence of optic atrophy (without retinal involvement), globally stable since first examination at the age of 38.

Mini-exome analysis identified compound heterozygous mutations in ACO2 (c.940+5G>C; p.Pro712Leu); the first mutation involves an intronic splicing site with a splice score reduction from 1.17 to 0.21 (transcript analysis is in progress). Aconitase enzymatic activity on the patient cultured skin fibroblast showed a 50% decrease in presence of citrate, and a 40% decrease in presence of cis-aconitase (compared to the isocitrate deshydrogenase activity as a reference), consistent with deficiencies observed in previously reported cases (Metodiev et al. 2014).

Conclusion: In addition to severe ocular, ataxic, and encephalopathic phenotypes, ACO2 mutations should also be investigated in the presence of recessive predominant spastic paraplegia and optic atrophy, associated with radiological and mild clinical cerebellar involvement.

#### 40. NMR analysis of the direct complex between the FeS clusters IscU scaffold protein and frataxin

Maso Lorenzo<sup>1</sup>, De Rosa Edith<sup>1,2</sup>, Santos Javier<sup>3</sup>, Bellanda Massimo<sup>2</sup> and Costantini Paola<sup>1</sup>

<sup>1</sup>Department of Biology, University of Padova, Viale G. Colombo 3, 35121 Padova, Italy

<sup>2</sup>Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35121 Padova

<sup>3</sup>Instituto de Química y Físicoquímica Biológicas (IQUIFIB), Universidad de Buenos Aires, Junín 956, (C1113AAD), Buenos Aires, Argentina

Introduction: mutations of genes coding for proteins involved in the assembly of FeS clusters cause several human mitochondrial pathologies, including Freidreich's Ataxia (FRDA) [1]. The majority of FRDA patients are homozygous for an abnormal expansion of a GAA trinucleotide repeat in the first intron of the frataxin gene (FXN), leading to a severe reduction of protein expression levels [2]. A small but significant proportion of patients (i.e. 4%) are compound heterozygous for the GAA expansion on one FXN allele and for a mutation on the other. These patients present either the classical FRDA phenotype or an atypical, less severe clinical picture [3]. All clinically important mutations described in heterozygous FRDA patients affect highly conserved residues of frataxin [3]. On the other hand, the primary function of this protein is still under debate, and the specific contribution of its deficiency to the pathogenesis of both classical and atypical FRDA is unknown. One open issue is the involvement of frataxin in the FeS clusters assembly machinery. In this work, we explored by NMR the direct complex of wild type as well as several mutant frataxin proteins with IscU, the scaffold upon which the FeS clusters are assembled.

Methods: recombinant human (90-210) frataxin and IscU proteins were expressed in *E. coli* and purified to homogeneity by double-steps chromatographies. Their interaction was investigated by monitoring the changes in the sofast-HMQC spectra of <sup>15</sup>N-labeled FXN upon addition of unlabeled IscU, either in the presence or in the absence of iron (as Fe<sup>3+</sup> or Fe<sup>2+</sup>). The experiments were performed with wild type frataxin as well as with the pathological mutants G130V (associated to an atypical clinical presentation) and W155R (which results in the classical FRDA phenotype).

Results: we found that 1) wild type frataxin is able to directly interact with the scaffold IscU, as assessed by chemical shift perturbation of peaks associated to residues belonging to the Fe-binding region, and to a  $\beta$ -sheet portion of the protein; 2) this interaction is strictly dependent on iron (either Fe<sup>3+</sup> or Fe<sup>2+</sup>); 3) several residues involved in the interaction are mutated in the heterozygous patients. Based on these results, we explored the complex of IscU with the two frataxin clinical mutant G130V and W155R. Both mutants, upon addition of IscU in the

presence of iron, showed a chemical shift perturbation for residues in the Fe-binding region, as the wild type FXN. Anyway, subtle but significant differences, with respect of the wild type FXN, were observed in the  $\beta$ -sheet portion: only the G130V mutant, and not W155R, showed small shifts for peaks in this region, as the wild type FXN. Moreover, for G130V additional peaks were found to be influenced by the interaction, suggesting a larger plasticity of this mutant.

Conclusions: our data support the conclusion that the two investigated mutations of FXN have an influence of its interaction with IscU in vitro. Whether this finding could be related to their different clinical outcome requires further investigations, which are currently under way in our laboratories.

[1] Campuzano V. et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. *Hum. Mol. Genet.* 6, 1771-1780

[2] Cossée M. et al. (1999) Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. *Ann. Neurol.* 45, 200-206

[3] De Castro M. et al. (2000) Genotype and phenotype analysis of Friedreich's ataxia compound heterozygous patients. *Hum. Genet.* 106, 86-92

#### 41. Investigating the role of FAST-1 in Friedreich ataxia

Mikaeili, H., Sandi, M., Bayot, A., Al-Mahdawi, S. and Pook, M.A.

Division of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Synthetic Biology Theme, Institute of Environment, Health and Societies, Brunel University London, Uxbridge, UK

Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a GAA trinucleotide repeat (TNR) expansion within the first intron of the FXN gene, leading to severe deficiency of FXN transcript. FRDA patients have disease-related epigenetic changes, which may be the underlying cause of FXN gene silencing. Furthermore, it has previously been shown in other TNR diseases that increased levels of antisense RNA expression can induce heterochromatin formation and epigenetic silencing of the corresponding sense gene.

The frataxin antisense transcript, FAST-1, is overexpressed in FRDA patient-derived fibroblasts, associated with depletion of CTCF, a chromatin insulator protein, and heterochromatin formation. We have overexpressed FAST-1 in both HEK293 and HeLa cell lines and we have identified a corresponding 30-70% decrease of FXN expression levels compared to control cells. Additionally, we identified a significant positive correlation between FAST-1 copy number and FAST-1 expression level ( $R^2 = 0.7$ ,  $P = 0.04$ ) and a negative correlation between FAST-1 copy number and FXN expression level ( $R^2 = -0.58$ ,  $P = 0.04$ ). Chromatin immunoprecipitation (ChIP) of FAST-1 overexpressing HeLa cells showed reduced occupancy of CTCF at the 5'UTR of the FXN gene. It is plausible that increased antisense transcription displaces CTCF from the 5'UTR and results in heterochromatin formation and FXN gene silencing.

To further investigate the role of FAST-1 in FXN gene silencing, we have used a small hairpin RNA (shRNA) to knock down FAST-1 in FRDA fibroblast cells. We found that knocking down FAST-1 increases FXN expression, but not to the level of control cells.

Since FAST-1 is associated with FXN gene silencing, inhibition of FAST-1 expression may be an effective approach for FRDA therapy.

#### 42. Misregulation of microRNA expression in Friedreich's ataxia cells

Julia O. Misiorek<sup>1</sup>, Martyna O. Urbanek<sup>1</sup>, David R. Lynch<sup>2</sup>, Jill Butler<sup>3</sup>, Marek Napierala<sup>1,3</sup>

<sup>1</sup> Department of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland

<sup>2</sup> Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA

<sup>3</sup> Department of Biochemistry and Molecular Genetics, UAB Stem Cell Institute, University of Alabama at Birmingham, Birmingham, Alabama

**Introduction:** Friedreich's ataxia (FRDA) is an inherited neurodegenerative disorder mainly characterized by muscle weakness, loss of coordination and heart muscle abnormalities. FRDA is caused by expansion of GAA nucleotide repeats in the first intron of the Frataxin gene (FXN), which leads to decreased protein production. Frataxin is involved in biogenesis of iron-sulfur clusters and heme, thus its diminished levels disrupt iron and heme homeostasis. Interestingly, imbalanced heme and iron levels affect maturation of microRNAs (miRNAs), small non-coding RNAs that control target gene expression. Recently, misregulation of miRNA processing has been observed in neurodegenerative diseases indicating miRNA involvement in the pathogenesis of these disorders. Since miRNA levels are changed in FRDA, we hypothesize that reduced frataxin levels disturb expression and processing of miRNAs through impaired iron/heme metabolism. **Methods and results:** To verify this hypothesis, miRNA sequencing was conducted on 15 fibroblast lines from FRDA patients and 15 unaffected control lines. Based on the outcome, a set of 10 aberrantly expressed miRNAs in FRDA patients was selected. Further RT-PCR analysis narrowed down this set to two significantly changed miRNAs in FRDA fibroblasts, namely 10a-5p and 148a-3p, which showed over two-fold increase in expression compared to unaffected controls. Next, luciferase assays were used to evaluate how these selected miRNAs affect the expression of their target genes. Among analyzed candidate genes were those associated with heme and iron metabolism as well as those involved in neurodegeneration. To further establish the miRNA signature in FRDA, fibroblasts from several patients and controls were reprogrammed to induced pluripotent stem cells. Neurons and cardiomyocytes will be differentiated from these cells for comprehensive studies to establish the interplay between miRNA and heme/iron metabolism at the molecular level. **Conclusions:** These results reveal aberrant miRNA processing in FRDA cells, indicating a new therapeutic target for FRDA treatment.

#### 43. The role of saccin in autophagy offers novel therapeutic opportunities

Morani F.<sup>1</sup>, Doccini S.<sup>1</sup>, Nesti C.<sup>1</sup>, Tessa A.<sup>1</sup>, Santorelli F. M.<sup>1</sup>

<sup>1</sup>Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa.

**Introduction:** Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a childhood-onset neurological disease resulting from mutations in SACS encoding saccin. The complex architecture of saccin suggests that it may operate in protein quality control. Molecular chaperones, classically associated with protein folding, unfolding and assembling, have been revealed as important modulators of selectivity during the autophagic process. **Methods:** To investigate the role of saccin in autophagy we studied protein KD (knockdown) in SH-SY5Y cells, protein KO (Knockout) in Hek-293T cells, and the function in primary skin fibroblasts from ARSACS patients. We performed immunofluorescence assay and Western Blotting (WB) to study localization and expression levels of classical autophagic and mitochondrial markers in the presence or absence of specific autophagy inducers (i.e., EBSS medium, Rapamycin) or inhibitors (i.e., 3MA, Spautin1, Bafilomycin A1).

Results: The autophagic pathway results defective in saccin KD or KO cells, and ARSACS skin fibroblasts as shown by LC3 and p62 expression levels in WB, and by reduced co-localization of the autophagosome marker LC3 with lysosomal marker Lamp1, suggesting fusion inhibition of autophagic compartments and subsequent failed cargo degradation.

Conclusions: The multi-domain structure of saccin indicates an essential role for the protein in the delicate regulation of autophagy to promote neuronal survival. Our results corroborate the hypothesis that recognition of impaired autophagy in ARSACS might not only improve our biological understanding on the ways saccin operates in disease conditions but, through possible chemical manipulation of the autophagic pathway, it might also offer new pharmacological opportunities. Pharmacological up-regulation of autophagy might hopefully alleviate clinical and pathological symptoms and delay the processes of neurodegeneration. This study was partially funded by Ataxia Charlevoix-Saguenay Foundation.

#### 44. Autosomal recessive cerebellar ataxia type 3 (ARCA3): novel ANO10 gene mutations in 6 late-onset Italian patients

Nanetti L, Di Bella D, Sarto E, D'Amico MC, Magri S, Mariotti C, Taroni F.

Unit of Genetics of Neurodegenerative and Metabolic Diseases, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy

Introduction: Autosomal recessive cerebellar ataxia type 3 (ARCA3) is a rare inherited neurodegenerative disorder characterized by a juvenile-adult age of onset. The disease is predominantly caused by truncating mutations in the ANO10 gene.

Methods: Patients were analyzed, for genetic diagnosis, on an NGS platform either by a probe-based customized panel covering >100 known genes associated with cerebellar ataxia or by a single-gene ultradeep amplicon sequencing using Nextera-XT method (Illumina).

Results: We identified 5 novel causative ANO10 gene mutations in 6 Italian patients. One sporadic case (age 62), presented ataxia at age 38, and was compound heterozygote for the c.518delT and c.289delA ANO10 mutations. A second sporadic case manifested spastic-ataxia at the age of 40 and was compound heterozygote for the c.1418delA and c.337+1G>A mutations. In one family, two affected siblings, (age 50 and 54), were homozygous for the c.1088\_1093delinsTCCTT mutation. They manifested disequilibrium and dysarthria at the age of 41 and 45. In the second family, two sisters (age 61 and 57) were homozygous for c.289delA mutation, and manifested ataxia and dysarthria at age 51 and 55. Disease duration ranged from 5 to 22 years. In all cases the disease course was slowly progressive, with a score at Scale for the Assessment and Rating of Ataxia ranging from 7 to 17. All patients presented mild vertical ophthalmoparesis, 5/6 had nystagmus, 5/6 dysphagia, 5/6 pyramidal signs (increased deep tendon reflexes, Babinski sign, and lower limb spasticity), 3/5 urinary urgency. Executive syndrome was observed in 5/6 cases. Brain MRI revealed cerebellar atrophy, and in one case hyperintensity in the dentate nuclei. Two sisters had epileptic EEG abnormalities and giant somato-sensory evoked potentials, but no seizures.

Conclusion: The present study describes 5 novel ANO10 gene mutations associated with a late disease onset. In addition to the classical ARCA3 spastic-ataxia phenotype, we consistently found vertical gaze ophthalmoparesis and mild cognitive impairment.

#### 45. Mitofusin-dependent ER stress mediates degeneration in a Drosophila model of Friedreich's ataxia. Juan Antonio Navarro Langa (See oral presentation)

#### 46. Identification of a pathogenic SCA1 allele with 38 repeats from a large UK cohort and improving SCA1 allele sizing methods

Nethisinghe, S.1, Pigazzini, M.L.1, Pemble, S.2, Sweeney, M.G.2, Labrum, R.2, Manso, K.1, Moore, D.3, Warner, J.3, Davis, M.B.2 and Giunti, P.1

1London Ataxia Centre, Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.

2Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, United Kingdom.

3Molecular Genetics Laboratory, South East Scotland Genetics Service, Western General Hospital, Edinburgh, United Kingdom.

**Introduction:** Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant progressive neurodegenerative disorder resulting from an expansion of a polyglutamine tract within the ATXN1 gene. Normal alleles have a tract size of 6-35 CAG repeats whilst pathogenic alleles have at least 39 repeats and intermediate, sub-pathogenic alleles lie in-between. Here we examine 3189 diagnostic tests and use this data for redefining the repeat ranges associated with SCA1. We also investigate two methods for improving the accuracy of CAG repeat sizing.

**Methods:** Genomic DNA was extracted from patient blood and SCA1 alleles were fragment analysed using capillary electrophoresis of PCR amplified CAG repeat tracts, as previously described (Menon et al., 2013). Plasmids containing cloned CAG repeat tracts of known sequence (Menon et al., 2013) were analysed alongside a triplet repeat primed PCR (TP PCR) CAG repeat ladder (Warner et al., 1996). Fragment analysis was also performed on 100 plasmids containing CAG repeats of known sequence (Menon et al., 2013).

**Results:** 3189 SCA1 diagnostic tests were performed (6378 discrete chromosomes). The majority (n=5953) were normal alleles with 14-34 repeats. There were 58 pathogenic alleles in the range 39-71 repeats. We identified an individual with an ADCA type I phenotype and a pathogenic allele of 38 repeats, the smallest yet reported. Interestingly, out of 367 intermediate range alleles (35-38 repeats), only this allele lacked CAT interruptions. Using a TP PCR ladder to calibrate fragment analysis via capillary electrophoresis we are able to accurately size the CAG repeat tract irrespective of repeat composition or length. Fragment analysis of 100 plasmids of known CAG repeat configuration sequence was used to generate a new model for calculating repeat size from capillary electrophoresis migration.

**Conclusions:** We recommend fragment analysis calibration using a TP PCR CAG repeat ladder or a series of plasmids containing cloned CAG repeats to improve repeat sizing accuracy. We also recommend the reduction of the pathogenic range to include uninterrupted alleles of 38 repeats.

#### 47. Complexity of the genetics and clinical presentation of spinocerebellar ataxia 17

Nethisinghe, S.1, Lim, W.N.1, Ging, H.1, Abeti, R.1, Pemble, S.2, Sweeney, M.G.2, Labrum, R.2, Cervera, C.2, Davis, M.B.2 and Giunti, P.1

1London Ataxia Centre, Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.

2Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, United Kingdom.

**Introduction:** Spinocerebellar ataxia 17 (SCA17) is a rare, autosomal dominant neurodegenerative disease caused by a CAG repeat expansion in the TATA-box binding protein gene (TBP). It is distinct from other SCAs for its association with dementia and psychiatric symptoms. Here we perform a phenotype-genotype correlation, examining the repeat structure of the TBP gene in a cohort of 20 SCA17 subjects and how this relates to age at disease onset and other clinical observations.

**Methods:** Genomic DNA was extracted from patient blood and SCA17 alleles were fragment analysed using capillary electrophoresis of PCR amplified CAG repeat tracts. CAG repeat tracts were PCR amplified and cloned into plasmids for sequencing, similar to SCA1 alleles previously described (Menon et al., 2013).

**Results:** We found no correlation between total CAG repeat length and age at disease onset. We observe identical repeat patterns and similar phenotypes in two monozygotic twins. However, there is variable penetrance or anticipation in a family where a father and son have similar sized CAG repeats, but the father is asymptomatic whilst the son is severely affected with an age at onset of 21 years old.

**Conclusions:** The CAG repeat configuration of the TBP gene is complex and analysis shows no definitive correlation between total CAG repeat length and age at disease onset. There is variability in the presentation and penetrance of the SCA17 phenotype, with monozygotic twins with similar repeat patterns presenting with similar phenotypes, whereas in another family striking anticipation was shown only phenotypically.

#### [48. mTOR is differentially activated in in vitro and in vivo models of Friedreich ataxia.](#)

Donatello S, Hu A, Rosety I, Rai M, Pandolfo M

Laboratory of Experimental Neurology, Université Libre de Bruxelles (ULB), Brussels, Belgium

##### Introduction

To find pathogenic pathways that may represent therapeutic targets for Friedreich ataxia (FRDA), we investigated the possible involvement of the mechanistic target of rapamycin (mTOR). A systematic study of this pathway in FRDA has never been performed, so it is unknown if and how frataxin (Fxn) and mTOR are connected. mTOR is involved in key metabolic processes known to be affected in FRDA, such as energy metabolism and iron homeostasis.

##### Methods

mTOR activation was assessed by Western blotting by quantifying phosphorylation of its substrates (S6K, S6, 4EBP1) in in vitro models, such as Fxn knock-down SH-SY5Y and 293T cells and patient iPSC-derived neurons; and in vivo models, such as KIKO mice and liver and heart Fxn conditional KO mice. The expression level of genes positively regulated by mTOR, such as mevalonate kinase (MVK) and glucose-6-phosphate dehydrogenase (G6PD) was also measured by qPCR.

##### Results

In cell models with reduced Fxn expression, mTOR activation appeared to be overall downregulated.

However, in in vivo models mTOR activation was tissue-specific. In conditional KO

mice, mTor activation was increased in liver and heart. In KIKO mice, mTor activation was increased in the cerebellum, while it was decreased in skeletal muscle. Significantly reduced MVK expression was observed only in patient IPS-derived neurons.

#### Conclusions

Our preliminary data suggest that in in vitro models, mTOR activation is down-regulated when Fxn expression is decreased. Conversely, in in vivo models of FRDA its regulation is highly tissue-specific. In vivo, different tissue-specific compensatory mechanisms absent in the cell culture models, including homeostatic responses involved in iron metabolism, could be responsible for differential mTOR activation.

#### 49. Evaluation of the posttranslational modification O-GlcNAcylation and its potential involvement on the pathogenesis of Machado-Joseph Disease

Sena P.P.<sup>1,2,3</sup>, Weisäupl D.<sup>1,2,3</sup>, Harmuth T.<sup>1,3</sup>, Riess O.<sup>1,3</sup>, Schmidt T.<sup>1,3</sup>

1 Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

2 Graduate Training Center of Neuroscience, Tübingen, Germany

3 Centre for Rare Diseases, Tübingen, Germany

**Introduction:** Machado-Joseph Disease (MJD) is caused by an expanded polyglutamine (polyQ) repeat in ataxin-3 protein, culminating in neurodegeneration. One disease hallmark is the formation of toxic fragments that aggregate. How those aggregates are formed and its role for the disease condition remains unknown. The impairment of the protein posttranslational modification (PTM) O-linked N- acetyl-D-glucosamine (O-GlcNAc) by the O-GlcNAc transferase (OGT) enzyme has been associated to protein aggregation in neurodegeneration. This PTM consists on the attachment of a monosaccharide to a target protein and is responsive to the cellular glucose uptake. The group of modified proteins ranges from gene transcription to autophagic flux and apoptosis. The cerebellum of MJD patients shows a pronounced glucose hypometabolism and it was already demonstrated that a cohort of early onset patients presents higher insulin sensitivity. A recent work proposed a moderate caloric restriction for improving the motor coordination in a MJD animal model. Altogether, these data suggest a potential role of glucose metabolism and protein O-GlcNAcylation in MJD. Therefore, our study aimed to evaluate this PTM responsive to glucose in cells expressing expanded ataxin-3.

**Methods:** A transiently-transfected cell model and patient-derived cells were maintained under different glucose concentrations and studied for the aggregation of expanded ataxin-3, its subcellular localization and the levels of soluble protein.

**Results:** The modulation of OGT in the transiently transfected cell model alters the localization, the soluble levels and the aggregation pattern of expanded ataxin-3, thus being OGT and O-GlcNAcylation worth studying in MJD and its disease protein. Patient-derived cells were also analyzed for this PTM in different time points.

**Conclusion:** Our work shows for the first time that a protein posttranslational modification responsive to the cellular glucose metabolism may be influencing the turnover of polyQ toxic fragments in Machado- Joseph disease. Therefore this pathway is a potential target for novel therapeutical approaches.



## 50. Defective trafficking of inflammatory response factors exhibit hyposensitive immunogenic response in skin fibroblasts from Ataxia Telangiectasia patients

E.Pozzi<sup>2</sup>, S.Cannito<sup>3</sup>, M.Parola<sup>3</sup>, S.Augeri<sup>4</sup>, S.Morone<sup>4</sup>, C.Mariotti<sup>5</sup> E.Giorgio<sup>2</sup>, C.Mancini<sup>2</sup>, E.DiGregorio<sup>1</sup>, M.Ferrero<sup>2</sup>, E.Riberi<sup>2</sup>, A.Brusco<sup>1,2</sup>, S.Cavaliere<sup>1</sup> 1S.C.D.U. Medical Genetics, A.O.U. San Giovanni Battista, Torino, Italy, 2 Department of Medical Sciences, genetic Unit, University of Torino, 3 Department of Clinical and Biological sciences, Unit of Experimental Medicine and Clinical pathology, University of Turin, 4 Department of Medical Sciences, Immunogenetic Unit, University of Turin, Italy 5 Unit of Genetics of Neurodegenerative and Metabolic Diseases, IRCCS Neurologic Institute Carlo Besta, Milan, Italy

**Background:** Ataxia-Telangiectasia (A-T) is a rare autosomal recessive multisystemic disease affecting cerebellum, immune system, lungs, liver and characterised by an enhanced risk of leukemia and other solid tumors. ATM protein plays a major role in controlling the double-strand breaks (DSBs) response and cellular homeostasis. Despite the cerebellar ataxia is the prominent symptom, the major cause of mortality in A-T is due to respiratory failure due to recurrent bacterial infections of the upper-respiratory tract and oral tissues. Since oxidative stress and inflammation are emerging as important hallmarks in A-T, we hypothesized that A-T patients could exhibit impaired innate immune response due to defective pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) by microbes. Oxidized phospholipids on the cytoplasmic membrane of A-T patients could contribute to impaired innate immune response. **Methods:** Primary skin fibroblasts from A-T and healthy controls were assessed for genes encoding inflammatory response factors using RT-qPCR and citofluorimetric analysis, before and after stimulation with with E. Coli lipopolysaccharide (LPS). LPS and TNF- mediated was measured by western blot analysis.

**Results:** A-T cells were less responsive than controls as shown by the expression of TLR- 4 and CD-14 receptors and by IL-6 gene expression both at basal level and after LPS or TNF- $\alpha$  stimuli. In the same conditions, the activation pathway was less activated in A-T cells respect to healthy LCLs.

**Conclusions:** Our studies indicate for the first time a defective trafficking of TLR-4 and CD14 in response to LPS stimuli. This defect could contribute to hyposensitive response of A-T patients to immunogenic challenge. Further investigations in this pathway could provide a potential target for therapeutic clinical intervention in A-T.

## 51. Frataxin-deficient cardiomyocytes present an altered thiol-redox state

Purroy R, Alsina D, Ros J and Tamarit J.

Dept. Ciències Mèdiques Bàsiques, Fac. Medicina, Universitat de Lleida. Lleida. Spain

**Introduction:** Friedreich ataxia is a neurodegenerative disease accompanied by hypertrophic cardiomyopathy. This disease is caused by deficient expression of frataxin, a mitochondrial protein that has been related to iron homeostasis, energy metabolism, and oxidative stress. We have recently set up a cardiac cellular model of Friedreich Ataxia based on neonatal rat ventricular myocytes (NRVMs) and lentivirus-mediated frataxin RNA interference. As these frataxin-deficient NRVMs present signs of oxidative stress, we decided to explore the presence of protein thiol modifications in this model.

**Methods:** The presence of reversible oxidized cysteine residues was investigated using the thiol-reactive fluorescent probe Bodipy-iodoacetamide and 2D-gel electrophoresis. The presence of glutathionylated proteins was analyzed using antibodies against glutathione. Modified proteins were identified by mass spectrometry.

Results: We identified three proteins with altered redox status in frataxin-deficient NRVMs: Electron transfer flavoprotein-ubiquinone oxidoreductase (ETFD), Dihydrolipoyl dehydrogenase (DLDH) and ATP synthase subunit alpha (ATPA). As DLDH is involved in lipoic acid turnover, we investigated the status of this cofactor in more detail. We found that total protein-bound lipoic acid levels are not affected in frataxin-deficient NRVMs, but their redox status is compromised as it is found in a more oxidized form. We also analyzed the presence of glutathionylated proteins and we found that actin was glutathionylated in frataxin-deficient NRVMs.

Conclusions: These results are indicative of an altered thiol-redox state in frataxin-deficient NRVMs that could contribute to the cardiac pathology. Therefore, we are currently exploring the potential protective effect of thiol-containing antioxidants on this model.

## 52. Early dysregulated cardiac mitochondrial biogenesis and OXPHOS system in the KIKO mouse model of Friedreich Ataxia

Rattelle, A.1, Lin, H.1, Clark, E.M.1,2, Lynch, D.R.1,2

1Departments of Pediatrics and Neurology, Children's Hospital of Philadelphia,

2Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, 19104

### Introduction

Friedreich Ataxia (FRDA), an autosomal recessive neurodegenerative disease, is the most common form of inherited ataxia resulting from deficiency of frataxin, a highly conserved mitochondrial protein crucial for Fe/S cluster formation and ATP production. The mean age at death is 38 years old due to coexistence of cardiomyopathy. Frataxin deficiency is associated with mitochondrial dysfunction in FRDA patients and models. However, early mitochondrial pathophysiology in FRDA heart remains elusive.

### Methods

Using the frataxin knock-in/knockout (KIKO) mice of FRDA, we sought to investigate if mitochondrial biogenesis and OXPHOS complex are altered in KIKO heart at presymptomatic age by examining the levels of a master mitochondrial biogenesis regulator, PGC-1 $\alpha$  and OXPHOS complex markers using Western blotting and OXPHOS complex enzyme activity microplate assay kits.

### Results

At presymptomatic age, levels of PGC-1 $\alpha$  are increased by 51% in heart homogenates of KIKO mice compared with age-matched controls, while the frataxin levels are reduced by 90%, suggesting early dysregulation of mitochondrial biogenesis in response to frataxin-deficiency-induced mitochondrial stress. The protein levels of OXPHOS Complex III, IV and V markers UQCRC2, MTCO1 and ATP5A, are decreased by 20%-33 % respectively, whereas levels of Complex I core subunit NDUF8 are increased by 44% and Complex II subunit SDHB remains unaltered. Furthermore, enzyme activities of Complex II and IV are compromised, whereas Complex I activity remains unaltered, suggesting dysregulated cardiac mitochondrial OXPHOS systems in presymptomatic KIKO mice.

### Conclusions

Our findings identify early dysregulation of cardiac mitochondrial biogenesis and the OXPHOS system as a potential mediator of cardiomyopathy, thereby providing a potential therapeutic target for in FRDA patients.

### 53. Late onset spinocerebellar ataxia and orofacial clefting in a case of interstitial 1q32.2q32.3 deletion encompassing the SYT14 and IRF6 genes

Ricca I.1, Bini P.2, Cereda C.3, Ceroni M.2,4

1 Molecular Medicine, Stella Maris Foundation, IRCCS, Pisa, Italy

2 Neurological Department, C. Mondino National Institute of Neurology Foundation, IRCCS, Pavia, Italy

3 Center of Genomics and post-Genomics, C. Mondino National Institute of Neurology Foundation, IRCCS, Pavia, Italy

4 Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

**Introduction:** The SYT14 gene encodes synaptotagmin 14, a membrane-trafficking protein highly expressed in human and mouse brain. Mutations in SYT14 were identified in two brothers born from consanguineous parents affected by mild-to-moderate psychomotor retardation and late-onset autosomal recessive spinocerebellar ataxia (SCAR11, MIM 614229). In addition, it has been reported a 12-year-old girl with developmental delay, cerebral and cerebellar atrophy and seizures and a de novo balanced translocation disrupting intron 3 of the SYT14 gene. **Methods** We performed array-CGH (Human Genome CGH+SNP Microarray kit 4x180K, Agilent) in a 41-year-old man with cleft lip and palate and progressive cerebellar ataxia. He was born from nonconsanguineous parents after an uneventful pregnancy. Psychomotor development was normal. He showed mild school difficulties and worked as a laborer. At age 31 he developed mental deterioration, bradykinesia and progressive gait ataxia, followed by dysarthria, mild dysphagia, nystagmus, saccadic dysfunction and mild pyramidal signs. Brain MRI showed diffuse cerebral and cerebellar atrophy, prominent in the cerebellar vermis, frontal lobes and brainstem. Tibial SEPs latencies were prolonged. EMG/ENG analyses were normal. FXN gene testing was negative. **Results** Array-CGH showed a 5.77 Mb interstitial deletion of the chromosome bands 1q32.2-q32.3, encompassing about 11 disease causing genes. The deleted region contains SYT14 and IRF6, whose mutations cause an orofacial clefting syndrome (Van der Woude syndrome, MIM 119300). **Conclusions** This report broadens the spectrum of neurological features associated with SYT14 disruption and highlights the role of array-CGH for investigating patients with a syndromic form of cerebellar ataxia that do not fit into a known syndrome.

### 54. Validation of common genetic modifiers for NDDs in SCA3

Eva Haas<sup>1,2</sup>, Christine Ehrhardt<sup>1,2</sup>, Nicolas Casadei<sup>1,2</sup>, Sven Poths<sup>1,2</sup>, Jakob Matthes<sup>1,2</sup>, James Mills<sup>3</sup>, Eleonora Aronica<sup>3</sup>, Joerg Gsponer<sup>4</sup>, Jeannette Hübener-Schmid<sup>1,2</sup>, Olaf Riess<sup>1,2</sup>

1 Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany

2 Center of Rare Diseases, University of Tuebingen, Tuebingen, Germany

3 University of Amsterdam, Academic Medical Center, Department of (Neuro)Pathology, Amsterdam, Netherlands

4 University of British Columbia, Vancouver, Canada

**Introduction:** The neurodegenerative disease Spinocerebellar ataxia type 3 (SCA3) is the most common autosomal dominantly inherited ataxia worldwide. Genetic origin of the disease is a mutation in the MJD1 gene, causing an expansion of the CAG repeat and a prolonged polyglutamine (polyQ) tract in the resulting protein ataxin-3 (ATX3). This expanded polyQ tract leads to increased aggregation of the mutated protein and finally causing neuronal cell damage and cell death, leading to the patients' symptoms. The formation of aggregates is a feature

SCA3 shares with other neurodegenerative disease (NDD), e.g. Alzheimer's disease (AD) and Parkinson's disease (PD). Therefore, it is more than likely that this group of diseases share generic modifiers and downstream pathways that might offer targets for new therapeutic strategies.

In our study we aim to identify modifiers common in different neurodegenerative disease including AD, PD and SCA3. This shall help to elucidate the general processes in neurodegeneration and furthermore point out new intervening possibilities to delay the disease progression or at least alleviate the symptoms. Modifier candidates will be validated for SCA3 in cell culture and double-mutant mouse models.

The main questions addressed are: What proteins interact with aggregation causing proteins? Which downstream pathways are involved? Are mutated proteins of different NDDs regulated by common generic modifiers?

Methods: To address the above mentioned questions we use an RNASeq based approach to identify genes differentially regulated in SCA3, PD and AD. Therefore, we sequence different brain areas of rodent disease models at different time points as well as human brain samples of disease patients to identify common modifiers by integrational analysis. Shortlisted candidate genes are validated in cell culture experiments using RNAi as well as biochemical approaches. Mouse models of the final candidates will be cross bred with mouse models for SCA3 to confirm the effects for this disease in vivo.

Results: Preliminary data integration of lower model organisms (*Drosophila*, *S. Cerevisiae*) together with first data generated of mouse models provided a first list of potential generic modifiers. Comparison of this preliminary gene list with the results of RNASeq data from human SCA3 patient cerebellar samples, revealed an overlap of a few candidate genes, which will now be further validated in vitro and in vivo.

In conclusion, NDDs like AD, PD and SCA3 share the common feature of protein aggregation, independent of the disease causing mutation. Therefore, RNASeq data of different model organism and patient brain samples show dysregulation in the same genes. Further investigation of these possible generic modifiers will lead us to a better understanding of common pathways in NDDs and moreover, provide us with new strategies on how to intervene with these diseases.

## 55. A CRISPR approach for investigating epigenetic silencing in Friedreich ataxia

Rodden, L.N.<sup>1</sup> and Bidichandani, S.I.<sup>1,2</sup>

<sup>1</sup>Oklahoma Center for Neuroscience, <sup>2</sup>Department of Pediatrics University of Oklahoma Health Sciences Center, USA

Introduction: Friedreich ataxia (FRDA) is caused by an expanded GAA repeat in intron 1 of the FXN gene that induces heterochromatin formation and silencing of the promoter. The FXN promoter is unmethylated in both FRDA and non-FRDA cells.

However, the CpG island shore (CGI shore), an area adjacent to the promoter, becomes hypermethylated in FRDA. Because hypermethylation of CGI shores is known to negatively regulate gene expression, we hypothesized that FXN CGI shore methylation contributes to epigenetic silencing in FRDA.

Methods: shRNA-mediated knockdown of DNMT3A and DNMT3B was carried out in patient-derived lymphoblastoid cells. qRT-PCR was used to measure FXN transcript levels. Methylation-specific qPCR (MS-qPCR) was used to measure DNA methylation. Furthermore, to modify DNA methylation specifically at the FXN locus, we designed a CRISPR-Cas9 strategy to target DNMT3A to the FXN CGI shore via nine different guide RNAs. HEK293T cells were transfected with these and deactivated Cas9 tethered to DNMT3A. DNA methylation was measured at CpG

sites within the CGI shore with MS- qPCR, methylation-sensitive high-resolution melting (MS-HRM), and bisulfite sequencing.

Results: Knockdown of DNMT3A and DNMT3B reduced DNA methylation at the FXN CGI shore, and increased FXN transcript levels. Targeting dCas9-DNMT3A to the FXN CGI shore significantly increased DNA methylation at the FXN locus.

Conclusions: DNMT3A and DNMT3B facilitate DNA hypermethylation of the FXN CGI shore, which contributes to silencing of the FXN gene in FRDA. CRISPR-Cas9 is a powerful tool to investigate the molecular mechanism of epigenetic silencing in FRDA.

## 56. Deletion of the ataxia protein saccin alters dynamics of the vimentin cytoskeleton and impairs cell migration

Lisa E.L. Romano, Teisha Y. Bradshaw, Suran Nethisinghe, Emma J. Duncan and J. Paul Chapple  
William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, EC1M 6BQ, United Kingdom

### Introduction

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is an early onset neurodegenerative disease that may also have a neurodevelopmental component. ARSACS results from mutations in the SACS gene that encodes saccin, a modular protein with conserved domains that indicate a molecular chaperone linked function. Saccin's role is unknown, but consequences of loss of function include reduced mitochondrial health and neurofilament abnormalities.

### Methods

In this study we investigate consequences of saccin loss in ARSACS patient fibroblasts, and SHSY5Y cells, by targeting SACS with siRNA silencing or using CRISPR/Cas9 genome editing. Fibroblasts and SH-SY5Y cells express vimentin instead of neurofilament. We therefore investigated vimentin localisation and dynamics in these cellular models using confocal imaging and fluorescence recovery after photobleaching (FRAP). We also test if cytoskeletal abnormalities in saccin null cells impact on cell migration.

### Results

ARSACS patient fibroblasts and saccin null SH-SY5Y cells have a collapsed vimentin filament network. This includes abnormal perinuclear accumulation of vimentin. FRAP analyses revealed that vimentin dynamics is reduced in saccin knockdown cells. In addition, saccin null cells showed reduced proliferation and loss of directional migration compared to wild-type controls. Vimentin is known to regulate focal adhesions. Consistent with this we observed localisation of focal adhesion proteins, relative to cytoskeletal proteins, was altered in saccin null cells.

### Conclusions

Our data shows that loss of saccin disrupts the vimentin cytoskeleton, which in turn impacts on cellular migration. Vimentin is initially expressed by nearly all neuronal precursors in vivo, so these findings may be relevant to understanding neurodevelopmental aspects of ARSACS.

## 57. Mitochondrial calcium transporter NCLX, the NFAT3 transcription factor and mitochondrial permeability transition pore become altered in cell models of Friedreich ataxia.

Purroy R., Britti E., Delaspre F., Alsina D., Tamarit J. and Ros J.\*.

Dept. of Ciències Mèdiques Bàsiques. Fac. Medicina. University of Lleida. Lleida.

Spain

(\*) Correspondence to: Joaquim.ros@cmb.udl.cat

**Introduction:** Previous results from our group showed that decreased frataxin levels in DRG neurons provoked an alteration of calcium homeostasis, neurite degeneration and apoptotic cell death (1). In cardiac myocytes, frataxin deficiency lead to mitochondrial swelling (2) suggesting the opening of mitochondrial permeability transition pore (MPTP). Therefore, we have analysed the downstream effects of frataxin deficiency by studying the relationship between MPTP, mitochondrial calcium transporters (MCU and NCLX) and NFAT, a transcription factor that, upon dephosphorylation by calcineurin (a calcium-dependent phosphatase) becomes active, travels to nucleus and promotes cardiac hypertrophy (3) and neurodegeneration of dopaminergic neurons (4).

**Methods:** We used primary cultures of cardiac myocytes and dorsal root ganglia (DRG) neurons from newborn rats. Reduction of around 80% of frataxin levels in these cells is achieved by transduction with lentivirus containing shRNA silencing sequences. MPTP opening was checked by Cobalt-CalceinAM quenching method.

**Results:** After frataxin depletion, we observed that, in cardiac myocytes, calcein fluorescence inside mitochondria was quenched by CoCl<sub>2</sub> treatment indicative of the MPTP opening. These cells also displayed reduced levels of NCLX, a mitochondrial transporter for calcium efflux. Interestingly, DRG neurons and lymphoblastoid cell lines obtained from Friedreich Ataxia patients also display reduced levels of the transporter. We also show that, after frataxin depletion, NFAT becomes dephosphorylated in both cardiomyocytes and neurons. Finally, cyclosporin A, a drug that closes MPTP, is able to reverse the mitochondrial disarrangements observed in cardiac myocytes, promotes NFAT phosphorylation and restores cell viability in DRG neurons.

**Conclusion:** The connection between decreased NCLX levels, induction of MPTP opening and NFAT dephosphorylation provides new molecular clues to understand the deleterious downstream effects of frataxin deficiency. These results open a possibility for repurposing cyclosporin A or compounds targeting MPTP as an approach to FA treatment.

**Acknowledgments:** This project has been funded by SAF-2013-44820-R from Ministerio de Economía y Competitividad (Spain) and by Federacion Española de Enfermedades Raras (FEDER) grant.

1. Mincheva-Tasheva S. et al. 2014. Hum Mol Genet. 23:1829-41
2. Obis E. et al. 2014. Free Radic Biol Med. 73:21-33
3. Houser SR, Molckentin JD. 2008. Does contractile Ca<sup>2+</sup> control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes?. Sci Signal. 1(25):pe31.
4. Luo J. et al. 2014. A calcineurin- and NFAT-dependent pathway is involved in  $\alpha$ -synuclein-induced degeneration of midbrain dopaminergic neurons. Hum Mol Genet. 23:6567-6574

## 58. Lithium and cortical myoclonus; Is the cerebellum the key protagonist?

Sarrigiannis PG, Zis P, Unwin Z, Hoggard N\*, Hadjivassiliou M.  
Academic Department of Neurosciences and Neuroradiology\*. Royal Hallamshire Hospital, Sheffield, UK.

### Introduction

Lithium is used in the treatment of bipolar disorders and has been trialed as treatment in a mouse model of SCA1. Lithium toxicity, can affect the central nervous system and can cause

ataxia. Such toxicity resolves with reduction or withdrawal of lithium. There are case reports of lithium-induced myoclonus which is cortical in origin and can improve by stopping lithium. None of these reports have implicated the cerebellum in the development of myoclonus. It remains unclear as to why only a small proportion of patients on lithium develop cortical myoclonus described as “myoclonic tremor” and what is the role of cerebellar involvement in such cases.

#### Methods

We identified 4 patients referred to the Sheffield Ataxia Centre on lithium with suspected cortical myoclonus and ataxia. All patients were clinically and neurophysiologically assessed and underwent brain MRI including spectroscopy of the cerebellum.

#### Results

2/4 patients presented primarily with cerebellar ataxia but all 4 had action myoclonus (myoclonic tremor). In three the tremor persisted at rest. Mean age at presentation (3 females, one male) was 67 years (range 57-78). Mean duration on lithium treatment was 14 years (range 8-30). None of the patients had lithium levels above the recommended range during routine monitoring.

The tremor developed several years after commencing lithium. All 4 patients had cerebellar dysfunction clinically and on MR spectroscopy. Gluten sensitivity was the cause of the ataxia in 3. In addition 2 of these 3 patients had previous history of prolonged exposure to high levels of alcohol. Neurophysiological polygraphy demonstrated a cortical generator of the myoclonus with no stimulus sensitivity. Only the non-gluten sensitive patient showed giant SEPs.

#### Conclusions

Lithium induced myoclonic tremor is frequently associated with cerebellar ataxia. We postulate that cerebellar dysfunction may be a prerequisite for the development of cortical myoclonus in patients on lithium.

59. [Ataxin-2 regulates mitochondrial precursors to maintain nutrient balance and cellular energetics.](#) Neslie Ece Sen (see oral presentations)

60. [Dysregulated lipid homeostasis emerging as a prominent pathological feature in a mouse model of Autosomal Recessive Cerebellar Ataxia 2 \(ARCA2\)](#)

Pankaj Kumar SINGH 1, Laurence REUTENAUER 1 and Hélène PUCCIO 1

1- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch 67404, France.

#### Introduction-

The ‘Aarf domain containing family of kinase’ ADCK3 (COQ8A) is a putative mitochondrial kinase proposed to be involved in the biosynthesis of the redox active lipid ubiquinone or coenzyme Q (CoQ). Mutation in Coq8A gene leads to autosomal recessive cerebellar ataxia 2 (ARCA2) characterized by ataxia, cerebellar atrophy, ubiquinone deficiency in muscle and exercise intolerance. We generated Coq8A knockout mice that successfully reproduce these clinical features. In addition, the mice show a mild dyslipidaemia. Since muscle biopsy of ARCA2 patients show lipid accumulation and biosynthesis of CoQ shares intermediate precursor to that with cholesterol, we investigated lipid metabolism in these mice to identify

underlying aspects of the molecular pathology that could impact disease progression, severity and clinical heterogeneity seen in ARCA2 patients.

Methods-

The approaches involve several in-vivo and in-vitro biochemical, enzymatic and metabolic assays, coupled with transcripts and proteins analysis on different model systems, including mice tissues and human cell lines.

Results-

Our results provide a definite evidence of hypercholesterolemia in Coq8A KO mice, with the dynamics of lipoprotein particles being majorly affected. Furthermore, distinct steps of lipid metabolism are severely affected in a tissue specific manner, suggesting a global dysregulation of lipid metabolism in these mice. Dysregulation of glucose homeostasis is also seen in these mice, perhaps secondary to dyslipidaemia. In context of the role of COQ8A in ubiquinone biosynthesis, we observed that COQ8A resides as part of large protein complex/s within the mitochondria and provides the first in-vivo evidence of the role of COQ8A in the stabilizing ubiquinone biosynthetic protein complex.

Conclusion-

Dyslipidaemia along with ubiquinone deficiency emerge as major pathological hallmarks in a mouse model of ARCA2.

#### 61. Mutational analysis of ITPR1 in a Taiwanese cohort with cerebellar ataxia

Hsiao CT,<sup>1,2,3</sup> Liu YT,<sup>2,4</sup> Liao YC,<sup>2,4</sup> Hsu TY,<sup>2,4</sup> Lee YC,<sup>2,4,5</sup> Soong BW<sup>2,4,5,6</sup>

<sup>1</sup>Division of Neurology, Department of Internal Medicine, Taipei Veterans General Hospital Taoyuan Branch, Taoyuan, Taiwan, Republic of China (ROC)

<sup>2</sup>Department of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC

<sup>3</sup>Graduate Institute of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC

<sup>4</sup>Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

<sup>5</sup>Brain Research Center, National Yang-Ming University, Taipei, Taiwan, ROC

<sup>6</sup>Institute of Neuroscience, National Yang-Ming University, Taipei, Taiwan, ROC

Introduction:

The inositol 1,4,5-triphosphate (IP<sub>3</sub>) receptor type 1 gene (ITPR1) encodes the IP<sub>3</sub> receptor type 1 (IP<sub>3</sub>R1), which modulates intracellular calcium homeostasis and signaling. Mutations in ITPR1 have been implicated in inherited cerebellar ataxia. The aim of this study was to investigate the role of ITPR1 mutations, including both large segmental deletion and single nucleotide mutations, in a Han Chinese cohort with inherited cerebellar ataxia in Taiwan.

Methods:

Ninety-three unrelated individuals with molecularly unassigned spinocerebellar ataxia after extensive genetic analyses, selected from 585 pedigrees with autosomal dominant cerebellar ataxias, were recruited into the study with elaborate clinical evaluations. The quantitative PCR technique was used to survey large segmental deletion of ITPR1 and the targeted sequencing approach was applied to sequence all the 61 exons and their flanking regions of ITPR1.

Results:

A novel ITPR1 mutation, c.7721T>C (p.V2574A), was identified in a family with dominantly inherited cerebellar ataxia. The proband has an adult-onset non-progressive pure cerebellar ataxia and her daughter is afflicted with a childhood onset cerebellar ataxia with intellectual sub-normalities.

Conclusions:



ITPR1 mutation is an uncommon cause of inherited cerebellar ataxias, accounting for 0.2% (1/585) of patients with dominantly inherited cerebellar ataxias in Taiwan. This study broadens the mutational spectrum of ITPR1 and also emphasizes the importance of considering ITPR1 mutations as a possible cause of inherited cerebellar ataxias.

62. Genotype-phenotype correlation of mutant *SLC25A46* disrupting mitochondrial fission in cerebellar degeneration. Janos Steffen (see oral presentations)

63. Ataxin-3's interaction with the proteasome shuttle protein, Rad23: Implications for Spinocerebellar Ataxia Type 3

Joanna R. Sutton<sup>1</sup>, Jessica R. Blount<sup>1</sup>, Sokol V. Todi<sup>1</sup>

<sup>1</sup> Department of Pharmacology, Wayne State University School of Medicine, USA

**Introduction:** Polyglutamine (polyQ) repeat expansion in the deubiquitinase ataxin-3 causes neurodegeneration in Spinocerebellar Ataxia Type 3 (SCA3), one of nine inherited, incurable diseases caused by similar mutations. Ataxin-3's degradation is inhibited by its binding to the proteasome shuttle, Rad23, through ubiquitin-binding site 2 (UbS2) on ataxin-3. Disrupting this interaction decreases levels of ataxin-3. Since reducing levels of polyQ proteins can decrease their toxicity, we tested whether genetically modulating the ataxin-3-Rad23 interaction regulates its toxicity in vivo.

**Methods:** Using the phiC31-mediated integration system, we generated new *Drosophila* models of SCA3 that express human, full-length pathogenic ataxin-3 with all domains intact or with UbS2 mutated. We expressed these constructs in specific tissues of the fly using the Gal4-UAS system to characterize the effect of decreased Rad23 binding to ataxin-3 on the SCA3 phenotype.

**Results:** We found that exogenous Rad23 increases the toxicity of pathogenic ataxin-3, coincident with increased levels of the disease protein. Conversely, reducing Rad23 levels alleviates toxicity in this SCA3 model. Unexpectedly, pathogenic ataxin-3 with a mutated Rad23-binding site at UbS2, despite being present at lower levels, is more pathogenic than its counterpart with intact UbS2. Additional studies established that increased toxicity upon mutating UbS2 stems from disrupting the autoprotective role that pathogenic ataxin-3 has against itself, which depends on the co-chaperone, DnaJ-1.

**Conclusions:** Our data reveal a novel balance between pathogenic and potentially therapeutic properties of the ataxin-3-Rad23 interaction, highlight this interaction as critical for the toxicity of ataxin-3, and emphasize the importance of considering protein context when pursuing suppressive avenues. Based on these findings, we are currently exploring approaches for SCA3 therapy that disrupt the Rad23-ataxin-3 interaction, while leaving ataxin-3's autoprotection intact.

64. Nitric Oxide prevents Aft1 activation and metabolic remodeling in frataxin-deficient yeast

D. Alsina, R. Purroy, J. Ros and J. Tamarit\*

Dept. Ciències Mèdiques Bàsiques, Fac. Medicina, Universitat de Lleida. Lleida. Spain

(\*) Correspondence to: jordi.tamarit@cmb.udl.cat

**Introduction:** In yeast, frataxin deficiency activates Aft1, a transcription factor which induces the expression of proteins involved in iron uptake. The mechanisms causing this activation are not completely understood. It is assumed that loss of iron-sulfur biogenesis may prevent an iron-sulfur dependent signal to retain Aft1 in the cytosol. However, previous research from our group indicates that activation of Aft1 occurs in the absence of iron-sulfur deficiency. Besides Aft1 activation, frataxin deficiency also leads to metabolic remodeling and to induction of Yhb1, a nitric oxide (NO) detoxifying enzyme (Moreno-Cermeño, Alsina et al., BBA 2013;183:3326). In this work, we investigate the relationship between NO and Aft1 activation in frataxin- deficient yeasts.

**Methods:** we have used conditional (tet-regulated) frataxin and Grx5 mutant yeast strains. Increased NO levels have been achieved by null Yhb1 mutations and by exogenous exposure to sodium nitroprusside, an NO donor. Metabolic remodeling has been evaluated by targeted proteomics. Iron quantitation, western blot, qPCR and microscopy have been used to evaluate Aft1 activation.

**Results:** we have observed that increased NO levels prevent Aft1 activation in frataxin-deficient yeasts. This phenomenon is not observed when Aft1 is activated by iron scarcity, oxidative stress or impaired iron-sulfur biogenesis (Grx5 deficiency). In addition, NO also prevents the metabolic remodeling caused by frataxin deficiency.

**Conclusion:** a major conclusion of this work is that the mechanism that leads to Aft1 activation in frataxin-deficient yeasts must differ from the one promoted by iron-sulfur deficiency or iron scarcity. Our hypothesis is that frataxin deficiency leads to the presence of anomalous iron species in mitochondria that can compromise iron bioavailability and activate a signaling cascade that results in Aft1 activation. NO would chelate these iron species and form iron-nitrosyl complexes which would increase iron bioavailability and avoid Aft1 activation.

**Acknowledgments:** This project has been funded by SAF-2013-44820-R from Ministerio de Economía y Competitividad (Spain)

## 65. Deciphering metabolic dysfunctions in Friedreich's ataxia using quantitative proteomic approach

Lorène Télot<sup>1</sup>, Elodie Rousseau<sup>1</sup>, Camille Garcia<sup>2</sup>, Laetitia Collomb<sup>2</sup>, Jean-Michel Camadro<sup>1,2</sup>, Valérie Serre<sup>1</sup>

(1) « Mitochondria, Metals and Oxidative Stress » group and (2) Structural and Functional Proteomics Facility, Jacques Monod Institute, UMR7592 CNRS – Paris Diderot University, 15 rue Hélène Brion, 75013 Paris

Friedreich's ataxia (FRDA) is caused by mutations in the FXN gene encoding frataxin protein arising from an unstable hyperexpansion of GAA triplet repeat in the first intron of the gene. This hyperexpansion leads to FXN gene silencing by epigenetic modifications. Rarely, gene defects found in FRDA patients are loss-of-function mutations. However despite many efforts to overcome any of these abnormalities, there is currently no efficient treatment to cure or even stop the progression of this disease, mostly because many aspects of the pathological consequences of frataxin depletion are still not fully understood. The precise role of frataxin is still under debate. A key function of frataxin in Fe- S cluster biogenesis has now been clearly pointed out, but how its role in this essential cellular pathway correlates with the pathophysiology of FRDA needs to be further investigated.

No systematic quantitative proteomic studies have been reported so far concerning this disease. The use of this metabolomic approach offer an opportunity to screen and analyze

several biochemical pathways at once, and provide a dynamic and a functional integration of metabolism.

To precise the consequences of frataxin depletion, we used a quantitative proteome analysis on heterozygous FRDA lymphoma B-cells (650 and 1300 GAA repeats) compared with controls as a method to study steady-state and perturbation induced-changes in protein profiles. Approximately 200 proteins showed statistically significant fold changes between FRDA and control cells. The differences in selected proteins were verified by Western blotting or enzymatic assays. Differentially abundant proteins were enriched or decreased in cellular pathways previously implicated in FRDA including mitochondrial respiratory chain, oxidative stress and iron homeostasis. Interestingly, new metabolic pathways have been highlighted in our study which could be future targets for novel therapeutic strategies in FRDA, which still lacks a cure.

#### 66. Novel mutation in SETX causes a dominant pleiotropic Tremor-Ataxia phenotype across three generations.

Vasco G1, Nardella M2, Bellacchio E3, Capuano A4, Claps D4, Castelli E1, Bertini E2, Zanni G2.

- 1- Department of Neurosciences, Unit of Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- 2- Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- 3- Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- 4- Department of Neuroscience, Unit of Neurology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

**Introduction:** SETX encodes senataxin, a protein containing a highly conserved C-terminal domain found in the superfamily 1 of DNA/RNA helicases with an important role in gene expression, including transcription termination, RNA processing and DNA damage repair. Mutations in SETX can give rise to both dominant and recessive disorders with partially overlapping features. To date, up to four different SETX-related syndromes have been described: recessive Ataxia oculomotor apraxia type 2 (AOA2), dominant Juvenile Amyotrophic lateral sclerosis (ALS4), Autosomal dominant proximal spinal muscular atrophy (ADSMA) and Tremor ataxia syndrome (TAS) reported in one family with a mother and her daughter displaying symptoms of cerebellar ataxia/atrophy, oculomotor defects, and tremor.

**Methods:** We performed targeted resequencing (Nextera Rapid capture custom kit, Illumina) in a cohort of patients with genetically unsolved early-onset cerebellar atrophy.

**Results:** A novel c.2479A>G missense mutation (p.K827E) in SETX was identified in a boy who started ataxic gait at age 2 years, with tremors and oculomotor deficit, without peripheral neuropathy. Extensive metabolic examinations and serum alpha-fetoprotein levels were normal. Neuroimaging showed a mild global atrophy of the cerebellum with mild signs of supratentorial atrophy. Rapid deterioration occurred with progressive worsening of swallowing function and loss of ambulation. At the age of 4 years the child was admitted to the pediatric intensive care unit for aspiration pneumonitis. Neurological condition rapidly deteriorated to apostural tetraparesis, and generalized dyskynetic movements. Gastrostomy for nutritional support was required. The carrier mother presented unsteady ataxia gait and intentional tremor. The maternal grandmother also was a carrier of the SETX mutation, and developed a progressive dementia and intentional tremor since the age of 50.

**Conclusions:** We report on a novel SETX missense mutation in a family with autosomal dominant tremor and ataxia. RNA processing and gene expression profiling studies will be

performed to compare phenotypic differences and assess the functional consequences of the mutation.

### 67. Dissection of epigenetic mechanisms underlying the GAA-mediated FXN silencing in Friedreich's ataxia to identify FXN up-regulating compounds

Vilema-Enríguez G1, Lufino M1 & Wade-Martins R1

1 Department of Physiology, Anatomy & Genetics - University of Oxford, Oxford, United Kingdom

Several human diseases, including neurodegenerative disorders, are associated with reduced gene expression. In Friedreich's ataxia (FRDA), the molecular mechanisms of pathology are associated with epigenetic silencing of the frataxin gene (FXN). It has been shown that expanded GAA repeats induce a repressive heterochromatin environment at the FXN locus. Silent heterochromatin is characterized by the presence of histone modifications, such as H3K9 methylation and the absence of acetylated histones. Therefore, the epigenetic changes reported at the FXN locus in FRDA, including increased levels of methylated histones H3K9me2 and H3K9me3 and reduced acetylation of histones H3 and H4, clearly demonstrate epigenetic repression of the FXN gene in FRDA.

Our group has been working on the silencing mechanisms of FXN and is particularly interested in the epigenetics driving the pathology. Histone deacetylase 3 (HDAC3) and euchromatic histone-lysine N-methyltransferase 2 (EHMT2/ G9a) have been associated with epigenetic changes of the FXN locus. We are directly targeting these proteins in a human GAA repeat expansion reporter model of FRDA using siRNA knock down to assess FXN expression. Additionally, we are screening an epigenetic probe library containing compounds which target several molecules involved in methylation and demethylation of histones and other proteins, as well as heterochromatin formation and remodelling. Identification of compounds that restore FXN expression will help us to characterize the molecular basis of FXN silencing and will contribute to finding novel therapeutic approaches for this fatal disease.

### 68. Activation of $\alpha$ 1 adrenergic receptors is required and sufficient for stress-induced attacks of motor dysfunction in a mouse model of Episodic Ataxia Type 2

A. Vintenzon

A.V, E.T, C.C, K.K - Dominick P Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461

#### Introduction

Episodic ataxia type 2 (EA2) is a disorder that arises from mutations in the CACNA1A gene encoding for the  $\alpha$ 1 pore forming subunit of P/Q-type voltage-gated calcium channels. In this disorder a mild baseline ataxia is interrupted by attacks of severe motor dysfunction triggered by physical or emotional stress, or caffeine or alcohol consumption. The mechanism by which the stressors trigger the motor attacks is not known. We used the tottering mouse, a faithful model of EA2, to scrutinize the role of adrenergic transmission in triggering attacks of motor dysfunction.

#### Methods

We performed in vivo awake electrophysiology to record from cerebellar Purkinje neurons (PCs) and deep cerebellar nuclei (DCN) neurons during attacks. We also delivered pharmacological agents, either systemically, or via a guide cannula that was stereotaxically

implanted in the cerebellum of the tottering mice. Finally, we used optogenetics to stimulate locus coeruleus.

#### Results

We find that PCs and DCN neurons exhibit high frequency burst firing during attacks, no matter which stressor is used to elicit them, which suggests the triggers share a common mechanism in triggering attacks. We also find that blocking  $\alpha 1$  adrenergic receptors using prazosin, both systemically and in the cerebellum of tottering mice, is sufficient to prevent attacks that were induced by stress, but not by caffeine or alcohol. Finally, we find intracerebellar infusion of norepinephrine, or optogenetic activation of the locus coeruleus to be sufficient in inducing attacks.

#### Conclusion

Using a combination of approaches, we show that local noradrenergic transmission in the cerebellum of tottering mice is sufficient to induce attacks, and necessary for stress, but not caffeine or ethanol-induced attacks. This finding is surprising given our electrophysiology data. As such, this data does not rule out the possibility that all three triggers may still converge downstream at the cell signaling level.

### 69. Physiological and pathophysiological functions of ataxin-3 isoforms and their impact on Machado Joseph Disease

Weishäupl D.1,2,3, Schneider J.1,2, Pinheiro B.1,2, Riess O.1,2, Schmidt T.1,2

1 Institute for Medical Genetics and Applied Genomics, Tübingen, Germany

2 Centre for Rare Diseases, Tübingen, Germany

3 Graduate Training Center of Neuroscience, Tübingen, Germany

**Introduction:** Machado-Joseph disease (MJD) is caused by an expansion of a polyglutamine repeat in the ataxin-3 protein. The encoding gene ATXN3 is spliced alternatively and two full-length isoforms - differing in their number of ubiquitin interacting motifs - could be detected on protein level. Both are modified by single nucleotide polymorphisms (SNPs) that cause amino acid changes and a premature stop in one isoform. In this study we examined the significance of ataxin-3 isoforms and the effect of the premature stop mutation on major components of the physiological function of ataxin-3 as well as their impact on main disease mechanisms.

**Methods:** In order to study these physiological and pathophysiological differences between ataxin-3 isoforms we performed different analyses using in vitro assays and transient transfections of an ATXN3 KO cell culture model.

**Results:** On the physiological level we could show that alternative splicing and the premature stop cause changes in the stability of ataxin-3 isoforms and that ataxin-3 isoforms differ in their enzymatic deubiquitination activity, subcellular distribution and interaction with other proteins. On the pathological level we found that the expansion of the polyglutamine repeat leads to a stabilization of the respective isoform and that they differ in their aggregation properties on multiple levels. Interestingly we could demonstrate for the first time a crosstalk between the normal and the expanded ataxin-3 allele. The interaction of ataxin-3 variants modifies physiological as well as pathophysiological properties of ataxin-3.

**Conclusion:** Together our current data indicates that different aspects of the pathogenesis are affected by alternative splicing as well as the mutual interaction of ataxin-3 isoforms.

Therefore ataxin-3 isoforms could contribute differently to the development of MJD. We hope that our results will lead to the identification of mechanisms that can be used as new targets for a potential treatment of this fatal disease.

## 70. Clinical and genetic characterization of Spinocerebellar Ataxia Type 6

Sarah Wiethoff<sup>1,2</sup>, Emer O'Connor<sup>1</sup>, Henry Houlden<sup>1,3</sup>

<sup>1</sup>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.

<sup>2</sup>Center for Neurology and Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tübingen, Germany.

<sup>3</sup>MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK.

### Introduction

Spinocerebellar Ataxia type 6 (SCA6) is a slowly progressive neurodegenerative disease characterized genetically by a trinucleotide repeat expansion in the CACNA1A gene. This study further defines the genetic and clinical features of this condition.

### Methods

The DNA of sixty-four patients with a known diagnosis of SCA6 were scrutinised by fragment analysis to establish the length of the expanded allele and by Sanger sequencing to examine for interruptions within the CAG repeat sequence. Clinical features were retrospectively analysed using patient records.

### Results

Notably, sequencing of the repeat expansions revealed a pure CAG repeat sequence without interruptions in all cases.

Clinically, twenty-four patients (37.5%) reported paroxysmal vertigo in the period preceding the onset of progressive symptoms. On average, the onset of vertigo predated progressive symptoms by 10.45 years.

The age of onset of progressive symptoms ranged from 23 to 77 with an average age of onset of 55.54 years old. When prodromal vertigo was included, the average age of onset was lowered to 51.41 years. No significant correlation between age of onset and length of repeat expansion was observed in either group ( $R = -0.2128$ ,  $R = -0.20334$  respectively).

### Conclusions

These results confirm that the trinucleotide repeat expansions involved in SCA6 are pure CAG repeats without interruptions. Additionally, we identified episodic vertigo as a common prodromal symptom in SCA6, perhaps representing a phenotypical overlap with allelic episodic ataxia 2. Finally, in our cohort, there was no significant inverse correlation between length of

## 71. De novo T362R mutation in MORC2 (Microorchidia 2) causes early onset cerebellar ataxia and axonal polyneuropathy with diaphragmatic involvement.

Ginevra Zanni<sup>1</sup>, Marta Nardella<sup>1</sup>, Sabina Barresi<sup>2</sup>, Marcello Niceta<sup>2</sup>, Emanuele Bellacchio<sup>3</sup>, Andrea Ciolfi<sup>2</sup>, Stefano Pro<sup>4</sup>, Stefano D'Arrigo<sup>5</sup>, Marco Tartaglia<sup>2</sup>, Enrico Bertini<sup>1</sup>.

<sup>1</sup> Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

<sup>2</sup> Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

<sup>3</sup> Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

<sup>4</sup> Department of Neurosciences, Unit of Neurology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

<sup>5</sup> Developmental Neurology Division, IRCCS Fondazione Istituto Neurologico C. Besta, Milan, Italy.

Introduction: MORC2 belongs to the MORC family proteins that are emerging as key regulators of gene silencing and DNA damage response. MORC2 contains a GHKL (DNA gyrase B, Hsp90, DNA mismatch repair enzyme MutL)-ATPase domain, a CW-type zinc finger domain, and four coiled-coil motifs. MORC2 is highly expressed in the brain and peripheral nerve tissues and downregulates the expression of carbonic anhydrase 9 and Arg kinase-binding protein 2, an adapter protein of actomyosin cytoskeleton localized in cerebellar Purkinje cells., MORC2 mutations have been generally associated to Charcot Marie Tooth type 2 neuropathy. Methods: We performed whole exome sequencing (WES) in a cohort of 22 patients from 17 families with genetically unsolved congenital or early-onset cerebellar atrophy. Results: A de novo c.1085C>G missense mutation (p.T362R) in MORC2 was identified in a 6 year-old girl who developed ataxia, tremors and generalized hypotonia at 15 months of age. The girl never walked without support. Retarded growth, minor facial anomalies such as hypertelorism, anteverted nares, flat philtrum, thick lip, and micrognathia, were present. Neurography revealed axonal motor neuropathy with slightly reduced sensory nerve action potential. Serial brain MRI at 15 and 30 months, showed progressive cerebellar atrophy. Respiratory tract infections triggered respiratory distress that required nocturnal mask ventilation from 4.5 years onwards when right diaphragmatic hypomobility was diagnosed. Griffiths scale testing at 4 years 3 months revealed a developmental age of 14 months. At last examination she was tetraplegic with bradykinesia and difficulties in holding her head. Conclusions: A MORC2-associated disorder should be considered in the differential diagnosis of early onset Spinal Muscular Atrophy-like disorders with diaphragmatic involvement (due to SMARD1, ICGHMBP2 or LAS1L mutations) or early onset ataxia and cerebellar atrophy due to EXOSC3 or TBCE mutations.

#### 198. Repeat expansion at the interface between genomic instability and autophagy

Sherif F. El-Khamisy

University of Sheffield, UK

The human genome is under continuous threat from environmental genotoxins and endogenous sources generated during normal metabolic activities. We have previously shown that failure to repair protein-linked chromosomal breaks (PDBs) lead to neurological disease in man such as ataxia telangiectasia and spinocerebellar ataxia. Whether PDBs are also pathogenic in other neurological disorders remains to be tested. Short tandem nucleotide repeats and microsatellites are common features of mammalian genomes and are predicted to interfere with normal transcriptional activities, causing genomic instability and accumulation of PDBs. For example, expansion of a hexanucleotide repeats G4C2 in the non-coding region of chromosome 9 open reading frame 72 (C9orf72) contributes to a wide spectrum of neurodegenerative diseases such as Huntington's, multiple sclerosis, Parkinson's disease and cerebellar ataxias. It is the most common genetic cause for frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). However, the mechanisms by which C9orf72 repeat expansions cause neurodegeneration are poorly understood. Here, we used a combination of biochemical and genetic approaches in human cells, rodent neurons and in C9orf72-ALS patient spinal cord tissues to reveal mechanistic implications of the expansion on DNA repair pathways. These data will be presented and discussed.

201. A novel mutation in the KCNA1 gene in a patient with episodic ataxia, myokymia, painful contractures and metabolic dysfunctions

1Imbrici P, 1Altamura C, 2Gualandi F, 1Mangiatordi GF, 2Neri M, 3De Maria G, 2Ferlini A, 4Padovani A, 1Sahbani D, 5D'Adamo MC, 1Nicolotti O, 5,6Pessia M, 1Conte D, 4Filosto M and 7 Desaphy J-F

1Department of Pharmacy - Drug Sciences, University of Bari Aldo Moro, Bari, Italy

2Logistic Unit of Medical Genetics, Department of Medical Sciences, University - Hospital of Ferrara, Italy

3Unit of Neurophysiopathology, ASST "Spedali Civili", Brescia, Italy

4Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST "Spedali Civili" and University of Brescia, Brescia, Italy

5Faculty of Medicine, Department of Physiology and Biochemistry, University of Malta, MSD 2080-Msida, Malta

6Department of Experimental Medicine, Section of Physiology & Biochemistry, University of Perugia School of Medicine, Perugia, Italy

7Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy

**Introduction.** Episodic ataxia type 1 (EA1) is a rare dominant neurological syndrome characterized by attacks of ataxia and myokymia triggered by emotional stress and fatigue (D'Adamo et al., 2015). It is caused by missense mutations in the KCNA1 gene coding for the voltage-gated potassium channel Kv1.1, that contributes to nerve cell excitability but is also expressed in the heart, vascular smooth muscle and pancreatic  $\beta$ -cells. We identified a novel KCNA1 mutation, E283K, in an Italian proband presenting with paroxysmal ataxia and myokymia aggravated by painful contractures, glucose intolerance and hypertension. The patient responded well to carbamazepine. The E283K mutation is located in the S3-S4 linker belonging to the voltage sensor domain of Kv channels. The aim of this study is to provide a functional and pharmacological characterization of the E283K mutation.

**Methods.** To reach this purpose, HEK293 cells have been transfected with Kv1.1WT or mutant cDNAs alone or in a 1:1 combination and potassium currents have been recorded through whole-cell patch-clamp.

**Results.** Mutant E283K channels shift the voltage-dependent activation by 10mV toward positive potentials and slow kinetics of activation by 2-fold compared with WT channels. Upon co-expression with WT, E283K shows a weak dominant-negative effect on WT and heteromeric channels display intermediate biophysical behavior. Interestingly, preliminary pharmacological experiments suggest that carbamazepine shifts the voltage dependence of activation of Kv1.1 channels by 10mV toward negative potentials. Finally, homology modeling studies suggest that the replacement of a negatively charged glutamate with a positively charged lysine at position 283 may reduce voltage sensitivity and slow channel opening.

**Conclusions.** We identified a novel KCNA1 mutation associated with a broader EA1 phenotype responsive to carbamazepine. The biophysical changes of E283K channels cause a drop of potassium current that likely accounts for typical EA1 features and possibly for the additional symptoms in the carrier.

D'Adamo MC, Hasan S, Guglielmi L, Servettini I, Cenciarini M, Catacuzzeno L, Franciolini F (2015). New insights into the pathogenesis and therapeutics of episodic ataxia type 1. *Front Cell Neurosci*, 9:317.



## TRANSLATIONAL MODELS OF DISEASE

### 72. Impaired mitochondrial function in SCA1 patient-derived cells

R.A.M. Buijsen<sup>1</sup>, S.L. Gardiner<sup>1</sup>, L.M. van der Graaf<sup>1</sup>, M.M. Evers<sup>2</sup>, B.P.C. van de Warrenburg<sup>3</sup>, W.M.C. van Roon-Mom<sup>1</sup>

<sup>1</sup> Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

<sup>2</sup> UniQure NV, Amsterdam, The Netherlands

<sup>3</sup> Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands

#### Introduction

Spinocerebellar ataxia type 1 (SCA1) is a hereditary neurodegenerative disease caused by a polyglutamine expansion in the ataxin-1 protein that results in aberrant protein aggregation and neuropathology, mainly in the cerebellum (Orr et al, 1993). Recently, it has been shown that the ataxin-1 protein plays a role in the regulation of bioenergetics and metabolic alterations in the cerebellum of SCA1 mouse models (Sanchez et al, 2016).

The aim of our study is to (1) generate patient-specific cell models and (2) determine if mitochondrial dysfunction is present in these newly generated models.

#### Methods

Skin biopsies were obtained from four SCA1 patients and four related healthy controls. Control and disease-specific induced Pluripotent Stem Cell (iPSC) lines were generated using the integration-free Sendai virus based method. The two major energy pathways of the cell, mitochondrial respiration and glycolysis, were measured in both patient-derived fibroblasts and neuronally differentiated iPSCs using the Seahorse XF96 Extracellular Flux Analyzer. Outcome measures were the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) respectively. These results were correlated with mitochondrial activity and ATP production.

#### Results

We successfully generated patient-derived fibroblast and iPSC lines. Preliminary results show decreased maximal respiration and increased glycolysis in patient-derived cells compared to control cells. These results support a role for mitochondrial dysfunction in SCA1 pathogenesis.

#### Conclusion

These results could lead to strategies to correct the metabolic dysregulation observed in SCA1 patient-derived cells. Furthermore, cellular bioenergetics profiles can be used as read out for future therapeutic intervention studies.

### 73. Folate metabolism modifies disease progression in a mouse model for mitochondrial ataxia

Carroll CJ<sup>1</sup>, Nikkanen J<sup>1</sup>, Hokkanen H<sup>1</sup>, Pohjanpelto M<sup>1</sup>, Paetau I<sup>1</sup>, Euro L<sup>1</sup>, Velagapudi V<sup>2</sup> and Suomalainen A<sup>1,3</sup>.

<sup>1</sup> Research Programs Unit, Molecular Neurology, Biomedicum-Helsinki, University of Helsinki, 00290 Helsinki, Finland.

<sup>2</sup>Metabolomics Unit, Institute for Molecular Medicine Finland FIMM, 00290 Helsinki, Finland.

<sup>3</sup>Neuroscience Center, University of Helsinki 00790 Helsinki, Finland

Introduction: We have recently reported the cell-autonomous remodelling of folate- driven one-carbon (1C)-metabolism in mitochondrial disease. Here, we have investigated the impact

of targeting 1C-metabolism in the IOSCA mouse, a newly described model for mitochondrial ataxia.

Methods: Modification of folate intake in mice was achieved by feeding a diet lacking in folate (“folate free”) or by injections of folinic acid. Motor performance and gait analysis was assessed by footprint assay, rotarod, beam walk and pole test. UPLC-MS based metabolomics analyses was done for quantification of +100 metabolites in mouse tissues. Mitochondrial DNA quantification and gene expression analysis was performed by quantitative PCR and protein expression analysis by immunoblotting. Folate uptake assay was performed by in vivo PET scanning using 18F-labelled NOTA-Folate tracer.

Results: IOSCA and wild-type mice fed a folate-free diet both showed reduced body weight, reduced activity and significantly reduced mtDNA copy number in their livers. However, IOSCA mice fed a folate-free diet performed significantly worse in motor performance tests and were anaemic compared to their wild-type littermates on the same folate free diet. Metabolomics analyses revealed genotype-specific alterations in the metabolome of tissues after folate free and folinic acid treatments.

PET analysis revealed increased binding of 18F-labelled NOTA-Folate tracer in the brains of IOSCA mice on normal diet.

Conclusions: Mitochondrial ataxia is associated with increased dependence of the brain for folate, as determined by increased folate binding in the brain and sensitivity to loss of folate in the diet manifested as poor motor coordination. Our study shows that alterations in folate driven 1C-metabolism contribute in the pathogenesis of mitochondrial disorders, and that folate levels in the diet can affect disease progression.

#### 74. Sodium valproate is protective in a novel transgenic zebrafish model of Machado Joseph disease

Maxinne Watchon (1,2) Kristy C. Yuan (1), Nicholas J. Cole (1) , Garth A. Nicholson (1) , Angela S. Laird (1)

1Department of Biomedical Science, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW Australia

2 Sydney Medical School, University of Sydney, Sydney, NSW Australia

3ANZAC Research Institute, Concord Hospital, Sydney, NSW Australia

Introduction: The neurodegenerative disease Machado Joseph disease (MJD, also known as spinocerebellar ataxia-3) is a fatal disease that impairs control and co-ordination of movement. MJD is caused by expansion of a trinucleotide (CAG) repeat region within the ATXN3 gene, encoding a long polyglutamine (polyQ) region within the ataxin-3 protein. We have established the first transgenic zebrafish model of MJD to aid discovery of a treatment for MJD through drug testing studies. Here we present our findings from testing the effect of treating these transgenic MJD zebrafish with a potential treatment, sodium valproate.

Methods: The GAL4/UAS transgenesis system was used to express fluorescently (EGFP) tagged human ataxin-3 protein containing either 23Q (wild-type) or 84Q (MJD) in all neurons. We characterized disease phenotypes that developed in the zebrafish and validated use of the model for drug testing studies.

Results: Phenotypic characterization of our MJD zebrafish revealed that zebrafish expressing EGFP-Ataxin-3-84Q have significantly shorter life span, neuropathology, increased protein cleavage and impaired swimming behavior from 6 days old through to adult stages. Treatment of the EGFP-Ataxin-3-84Q zebrafish with low-dose sodium valproate (3.125 μM) improved the swimming ability of the MJD zebrafish. The sodium valproate treatment increased levels of

acetylated histone 3 and 4 suggesting an increased level of transcription, in line with its hypothesized mode of action.

Conclusion: Transgenic MJD zebrafish develop relevant disease phenotypes, both in aged animals and at early time-points suitable for use in drug testing studies. Sodium valproate treatment had a beneficial effect on the movement of our MJD zebrafish, supporting the importance of investigating its use for the treatment of MJD.

#### 75. Cellular models of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) reveal mitochondrial dysfunction and cytoskeletal reorganisation

E.J. Duncan<sup>1</sup>, T.Y. Bradshaw<sup>1</sup>, L.E.L. Romano<sup>1</sup>, R. Larivière<sup>2</sup>, F. Longo<sup>3,4</sup>, B. Brais<sup>2</sup>, F. Maltecca<sup>3</sup>, and J.P. Chapple<sup>1</sup>

<sup>1</sup> William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, EC1M 6BQ, United Kingdom.

<sup>2</sup> Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4.

<sup>3</sup> Università Vita-Salute San Raffaele and Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy

<sup>4</sup>. Università degli Studi dell'Insubria, Italy.

#### Introduction

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a childhood-onset neurological disease, with pyramidal spasticity and cerebellar ataxia. ARSACS results from mutations in the SACS gene that encodes saccin, a modular protein with conserved domains that indicate a molecular chaperone linked function.

#### Methods

We used ARSACS patient human dermal fibroblasts and saccin knockdown SH-SY5Y cells to investigate the cellular consequences of loss of saccin function.

#### Results

Our cellular models identified that loss of saccin leads to altered organisation and dynamics of the vimentin intermediate filament (IF) cytoskeleton. This is consistent with the observation that neurons from the saccin knockout mouse have neurofilament abnormalities (Larivière et al. 2015; Hum Mol Genet. 24:727-39). The vimentin IF is important for maintenance of cellular architecture, and we observed altered organelle distribution in cells without functional saccin. This included juxtannuclear localisation of lysosomes. This lysosomal repositioning was accompanied by perinuclear accumulation of other proteostasis linked proteins and altered autophagic flux. We have also identified mitochondrial dysfunction as a feature of saccin null cells. Specifically, we have shown that loss of saccin reduces mitochondrial recruitment of the mitochondrial fission factor dynamin-related protein 1, impairs oxidative phosphorylation and leads to increased levels of oxidative stress.

#### Conclusions

These data show that loss of saccin has consequences for intermediate filament networks and mitochondrial health. We will discuss how these phenotypes of ARSACS cellular models may be integrated and their relevance to the molecular pathogenesis of this neurodegenerative disease.

## 76. Characterization of iPS-derived Friedreich ataxia cardiomyocytes

Cotticelli, M.G.<sup>1,2</sup>, Xia, S.<sup>1,2</sup>, Lin, D.<sup>1,2</sup>, Doliba, N.M.<sup>3</sup>, Rozo, A.V.<sup>3</sup>, Shi, J.<sup>4</sup>, Edelstein, H.<sup>4</sup>, Yang, W.<sup>4</sup>, Napierala, J.S.<sup>5</sup>, Napierala, M.<sup>5</sup>, and Wilson, R.B.<sup>1,2</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, PA

<sup>2</sup>The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research

<sup>3</sup>Diabetes Research Center, University of Pennsylvania

<sup>4</sup>Institute for Regenerative Medicine, University of Pennsylvania

<sup>5</sup>Department of Biochemistry and Molecular Genetics, Stem Cell Institute, University of Alabama at Birmingham

**Introduction:** Hypertrophic cardiomyopathy, leading to arrhythmias and/or heart failure, is the leading cause of premature death in Friedreich ataxia (FA) patients. Several groups have successfully derived human cardiomyocytes from FA iPS cells and reported morphological differences compared to normal controls. However, few functional studies have been reported. We derived cardiomyocytes from FA iPS cells in order to 1) study the molecular mechanisms that underlie the pathophysiology of FA cardiomyopathy, and 2) identify phenotypes that might be exploited for drug testing.

**Methods:** iPS cells derived from two FA patients and two control subjects were differentiated into cardiomyocytes. We measured calcium transient concentrations and molecular markers of cardiac hypertrophy by RT-PCR.

**Results:** We confirmed the successful differentiation of iPS cells into cardiomyocytes. Calcium concentrations in the FA cardiomyocytes were consistently higher than in the controls. We also found increased expression levels of GATA-4 and Natriuretic Peptide A, both markers of cardiac hypertrophy. PGC1-alpha was also overexpressed in the FA cardiomyocytes compared to controls.

**Conclusions:** Our study identified increased calcium concentrations, and increased expression of genes associated with cardiac hypertrophy, as markers of iPS-derived FA cardiomyocytes. Recently, Crombie et al. (*Aging* 9:1440, 2017) derived cardiomyocytes from FA iPS cells and found 1) an increase in heart rate variability, and 2) a decrease in intracellular calcium concentrations, which was paradoxically rescued by nifedipine, a calcium channel blocker. The discrepancies between our results and those of Crombie et al. suggest that subtle technical variables may contribute to specific phenotypes in iPS-derived FA cardiomyocytes in culture and that caution should be exercised presently in interpreting results from these cells.

## 77. Understanding Friedreich's ataxia neuropathophysiology using a new conditional neuronal mouse model.

de Montigny C., Piguet F., Diedhiou N. and Puccio H.

Department of Translational Medicine and Neurogenetics, IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), INSERM U596, CNRS UMR 7104, 67400 Illkirch, France, Université de Strasbourg, France.

Friedreich's ataxia (FA), the most common recessive ataxia, is characterized by sensory and spinocerebellar ataxia and hypertrophic cardiomyopathy. Proprioceptive neurons within the dorsal root ganglia (DRG) are one of the primary affected cells in FA patients. FA is caused by reduced levels of frataxin (FXN), an essential mitochondrial protein involved in the biosynthesis of iron-sulfur (Fe-S) clusters. FXN depletion leads to a Fe-S cluster protein deficit, mitochondrial dysfunction, iron dysregulation and cellular dysfunction. The molecular mechanism underlying neuronal degeneration has not been well established. To decipher the pathological

mechanisms in proprioceptive neurons, a new conditional neuronal mouse model (cKO), based on the Cre/LoxP technology, was generated, using the Cre Recombinase expressed under the parvalbumin promoter. Parvlb cKO mice present a FXN depletion in DRG proprioceptive neurons, starting at E17.5, in Purkinje cells of the cerebellum at p40 and in interneurons of the brain at 21.5 weeks. Interestingly, we showed that proprioceptive neurons, which represent only 7.5% of the DRG cell population, express between 50 and 70% of the total FXN of the DRG. Moreover, lumbar DRG express more FXN than cervical DRG. Parvlb cKO mice develop a severe and progressive ataxic phenotype assessed by different behavioural tests and a specific decrease of the sensory wave, revealed by electrophysiological studies. At the molecular level, we identified a deficit of a Fe-S protein, the Succinate Dehydrogenase, in proprioceptive neurons and in Purkinje cells, followed by cellular iron dysregulation, in agreement with elements observed in non-neuronal mouse models. To decipher the downstream events following FXN depletion, RNAseq analysis of DRG was performed and an upregulation of genes known to be expressed by sensory neurons following axonal damage (Regeneration Associated Genes) was identified. Further molecular analyses are ongoing to elucidate the mitochondrial and cellular defects in neurons. Understanding FA neuropathophysiology is critical to develop therapeutical strategies and to identify biomarkers that are essential to validate therapeutical approaches such as gene therapy.

#### 78. A human iPSC-based cardiac model of Friedreich's Ataxia for drug discovery and patient stratification using all-optical electrophysiology

Dempsey G1, Williams L1, Freland L2, Parekh D2, Werley K1, and Cherry JJ2 1 Q-State Biosciences, Cambridge MA, USA

2 RaNA Therapeutics, Cambridge MA, USA

##### Introduction:

Nearly two thirds of all Friedreich's Ataxia (FA) patients present with cardiac impairment or thickening of the myocardium and heart disease is reported as the most common cause of death in FA. Cardiac impairment has been evaluated through traditional analysis of cardiac function in both FA patients and mouse models. Such phenotypes, however, have not yet been recapitulated in in vitro cellular models, limiting the mechanistic understanding of FA and the ability to evaluate new therapeutic approaches.

##### Methods:

Using a proprietary all-optical electrophysiology platform (Optopatch) that enables simultaneous readout of action potentials (APs) and calcium transients (CTs) under paced conditions, we compare the electrophysiological phenotype in cardiomyocytes (CMs) expressing different levels of frataxin protein. To further elucidate the mechanism of cardiac impairment, these cells are treated with chemical stimuli (iron, beta-adrenergic, ryanodine receptor-targeted, etc.) to reveal the possible cause of phenotypic differences between FA and control samples.

##### Results:

We have completed preliminary studies with CMs derived from FA-patient and zinc finger-corrected iPSCs using Optopatch. CMs successfully paced at 1.5 Hz and voltage and calcium waveforms were measured with high fidelity. In addition, we have also made preliminary comparisons between the disease and corrected cell lines. We see an increase in rise time, decrease in AP80 duration, and a decrease in Ca<sup>2+</sup> amplitude of the disease compared to corrected CMs. Work is underway to confirm the correlation between these measurements and FXN expression levels and to identify potential mechanisms of cardiac impairment in FA CMs.

## Conclusions:

Our preliminary data shows the feasibility of using this approach for phenotypic evaluation of electrophysiological changes from FA-patient derived CMs. Broadly, this approach will support the functional validation of increased FXN expression in cardiomyocytes, screening of therapeutics, and open the opportunity for use in patient stratification.

79. Let-7 activates autophagy and alleviates motor and neuropathological deficits in pre and post symptomatic Machado-Joseph disease mouse models.

Sonia Duarte (see oral presentations)

80. Epigenetic editing of the Frataxin (FXN) locus by re-purposing CRISPR/CAS9 – targeted epigenetic editing with heterochromatin antagonists specifically reactivates the FXN gene in living cells?

S Nageshwaran MBBS MRCP1,2, R Festenstein MB BS PhD FRCP2 Harvard Medical School1, Imperial College London2

Email addresses: r.festenstein@imperial.ac.uk sathiji@hms.harvard.edu

## Background:

Aberrant epigenetic silencing is a fundamental disease mechanism in FA. We reasoned that its dynamic nature might permit targeted therapies to reactivate frataxin (FXN) expression through epigenetic editing, which may be more feasible than trinucleotide repeat excision within disease specific tissues. Targeted epigenetic modification of the frataxin locus, through removal of histone methylation (H3K9me3 and H3K27me3), DNA methylation and addition of histone acetylation are a powerful means to identify epigenetic regulators important in gene silencing, and promote frataxin expression without the unwanted secondary effects found to occur with other investigative and therapeutic approaches (e.g. gene knockout and histone deacetylase inhibitors). Recent studies have identified naturally occurring H3.3 mutations as powerful inhibitors of both H3K9me3 and H3K27me3 histone modifications (1-3). This combination of both constitutive and facultative heterochromatin modifications at a single locus is highly unusual and occurs at the FXN gene in FA patients. Recently, such H3.3 mutant peptides have been shown to be powerful inhibitors of H3K9me3 and H3K27me3 and suppressors of heterochromatin-mediated position effect variegation in *Drosophila* in vivo.

Given that the FXN gene is decorated with the unusual combination of both H3K9me3 and H3K27me3 we reasoned that targeting of these mutant H3.3 peptides directly to the FXN locus might be an effective way of overcoming pathological heterochromatin-mediated silencing.

## Methods:

Nuclease dead Cas9 protein fused to several epigenetic modifiers including the histone acetyltransferase, p300, mutant H3.3 peptides and transcriptional activators (VPR) were targeted to either the FXN promoter, upstream or downstream of the GAA expansion within the frataxin locus in FA cell lines. Frataxin expression was assessed by qRT-PCR. Off-target effects and frataxin transcriptional network analysis will be assessed through RNA-Seq and ChIP-Seq. Validated constructs will then be optimised for use with AAV9 for CNS targeting and delivered to FA transgenic mice.

## Results:

Up to a 2-fold increase in Frataxin expression occurred when the frataxin locus was specifically targeted with a transcriptional activator, the histone acetyltransferase, p300 and more recently the novel histone H3.3 peptide mutants, which have been shown to inhibit both

H3K9me3 and H3K27me3. Significant upregulation was noted when H3.3 was targeted downstream of the GAA and H3K9M was targeted to the promoter (two tailed t test,  $p < 0.05$ ). Significant downregulation was noted upon targeting H3K27M to the promoter and downstream of the of the GAA repeat (two tailed t-test,  $p < 0.05$ ). We have, therefore, identified both specific DNA elements within the Frataxin locus within the promoter region and flanking the GAA\_repeat itself as well as novel heterochromatin inhibitors using mutant histone-peptide mimics capable of upregulating FXN expression.

Conclusions:

Epigenetic editing of the frataxin gene and targeted transcriptional activation using dCas9 fusion proteins are a novel and powerful methodology to dissect the epigenetic requirements for FXN silencing and its reversal in FA.

References:

- Herz, H.-M. et al. "Histone H3 Lysine-To-Methionine Mutants As A Paradigm To Study Chromatin Signaling". *Science* 345.6200 (2014): 1065- 1070.
- Lewis, P. W. et al. "Inhibition Of PRC2 Activity By A Gain-Of-Function H3 Mutation Found In Pediatric Glioblastoma". *Science* 340.6134 (2013): 857-861.
- Chan, K.-M. et al. "The Histone H3.3K27M Mutation In Pediatric Glioma Reprograms H3K27 Methylation And Gene Expression". *Genes & Development* 27.9 (2013): 985-990.

#### [81. Elov5 knockout mice recapitulate SCA38 symptoms and cerebellar atrophy](#)

Hoxha E1, Gabriele RMC1, Balbo I1, Masante L1, Ravera F1, Zambelli V1, Mitro N2, Caruso D2, Brusco A3, Boccone L4, Borroni B5, Tempia F1

1Neuroscience Institute Cavalieri Ottolenghi and Dept. of Neuroscience, University of Torino, Italy

2Dept. of Pharmacological and Biomolecular Sciences, University of Milan, Italy

3Medical Genetics Unit, Città della Salute e della Scienza Hospital and Dept. of Medical Sciences, University of Torino, Italy

4Microcitemie Regional Hospital, ASL 8, Cagliari, Italy

5Neurology Unit, Dept. Clinical and Experimental Sciences, University of Brescia, Italy

Spinocerebellar Ataxia 38 (SCA38) is caused by mutations of the ELOVL5 gene (MIM 611805). However, it is not clear whether the mechanism is a loss of function of ELOVL5 or a toxic gain of function of the mutated protein. The first aim was to test the loss of function hypothesis by assessing SCA38 symptoms in Elov5 knockout mice. The second aim was to investigate cellular lesions in the cerebellum of such murine model.

Behavioral tests were used to detect deficits in motor control and olfaction. Histological and immunohistochemical analysis were utilized to detect cellular lesions.

Elov5 knockout mice displayed a significant motor impairment in the balance beam test at 3, 6, 12 months ( $P < 0.001$ ). In accordance with the expression of Elov5 in mitral cells and with the symptoms of SCA38 patients, at 12 months of age Elov5 knockout mice also displayed hyposmia ( $P < 0.05$ ). These results indicate that Elov5 knockout mice recapitulate the principal symptoms of SCA38, in line with the loss of function hypothesis. In order to investigate the cellular mechanisms, we performed a morphological analysis of the cellular layers of the cerebellar cortex of Elov5 knockout mice at 12 months of age, which revealed a reduction in thickness of the molecular layer ( $P < 0.05$ ), containing the dendritic trees of Purkinje cells, which showed a reduced extension with retraction of dendrites.

The loss of Elov5 in knockout mice reproduces the main SCA38 symptoms. The thinning of the molecular layer of Elov5 knockout mice is in line with the cerebellar atrophy of SCA38

patients. These results validate Elov15 knockout mice as a model of ELOVL5 loss of function in SCA38.

## 82. Application of nanotechnology in FRDA drug research.

Swasti Wagh and D.K.Wagh

Swasti Wagh, M.Sc. (Applied Mathematics), Email –swastiwagh@gmail.com

D.K. wagh, Ph.D. retired prof.of mathematics, SGSITS Indore. Email-  
waghdiwakar42@gmail.com

Present age is the age of interdisciplinary collaborative research. The collaboration of different disciplines has advanced research at very fast rate. Nanotechnology is concerned with the synthesis of nano sized material particles, study of their properties and their applications. Nanoparticles have novel optical, electronic, magnetic properties that are not found in individual molecule or bulk solid. The living organisms are made up of cells and proteins which are of nano size. Therefore, nanotechnology finds promising application in medical science. Nanoparticles can be made body compatible by coating them with a suitable surfactant. In recent years nanoparticles have found application in cancer therapy, drug targeting and drug delivery. A targeted drug delivery system (TDDS) releases the drug at a specific bio- site in a controlled way. TDDS can prevent drug degradation and eliminate biological barriers. It has now been possible to prepare magnetic nanoparticles sensitive to specific pH value. The magnetic nanoparticles can control the speed of drug delivery at the destination and it is possible to skip the regions quickly where the drug has adverse effect. For FA there is no cure. Drugs for FA are under trial stage but there is no evidence of nanotherapeutic drug delivery system (NDDS). The use of NDDS shall be effective for FRDA drug trial and it is very essential when the drugs are administered for long period. Joseph F. Nabhan and team made an attempt in which nanoparticles were used to introduce frataxin to maintain frataxin level. Recently the authors of this paper presented a paper on “Magnetic nanoparticles approach to control degeneration in FA” in 14th international conference of Nanotechnology and Nanomaterials. However this theoretically justified approach needs experimental verification.

## 83. A Drosophila cell-based assay for high-throughput screening of genetic modifiers of FXN transcriptional silencing mediated by the GAA repeat expansion.

Llorens JV1, Calap-Quintana P1, Lufino M2, González-Fernández J1, Wade-Martins R2, Martínez-Sebastian MJ1 and Moltó MD1,3.

1 Dpt. Of Genetics, University of Valencia. Burjasot, Spain.

2 Dpt. Of Physiology, Anatomy and Genetics, University of Oxford, England, UK.

3 Cibersam, Incliva, Valencia, Spain.

**Introduction:** The GAA repeats expansion form unusual DNA structures affecting gene expression. These structures include triplexes and a related structure known as sticky DNA that could affect transcription by sequestering transcription factors or RNA polymerase or leading the formation of an RNA:DNA hybrid. It has been also shown that the region flanking the GAA repeats in the FXN gene is enriched for epigenetic marks characteristic of transcriptionally repressed regions of the genome. The FRDA repeats might trigger the formation of heterochromatin that could spread to adjacent sequences.

**Methods:** To identify potential genetic factors involved on the FXN transcriptional repression mediated by the GAA repeat expansion, we obtained a Drosophila cell model containing the FXN intron 1 with a pathological number of the GAA repeats. In the model cells, the expression



of a reporter gene (firefly luciferase) is under the effect of an expansion of  $\approx 300$  GAA repeats. The experimental design is based on the use of the S2R+ *Drosophila* cells and the pACMAN methodology allowing the generation of two stable cell lines, the model line and the control line carrying 300 GAA and 9 GAA repeats respectively. Both lines have a pACMAN-renilla luciferase construct to normalize the results. The expression of luciferases was controlled by the UAS sequences and the system is analyzed by means of the GAL4-UAS methodology, using an inducible GAL4 driver by copper (pMT-GAL4).

Results: Luciferase activity was measured as a ratio of luminescence between firefly and renilla luciferases. This activity was 2.5 lower for the 300 GAA cell lines than the control line with 9 GAA repeats at 1mM Cu. Testing the system, we co-transfected the model cell line with a diap1 dsRNA observing a reduction of 5 times on firefly luciferase activity because diap1 is involved in apoptosis control and its depletion kills the cells, indicating that the RNAi machinery works in this model. We found that the effect of knocking down several genes involved in the heterochromatin formation increase significantly the firefly luciferase expression.

Conclusions: We obtained a cell based-assay useful for high-throughput screening of a large collection of dsRNAs to identify genetic factors involved in the repression mechanisms of FXN in FRDA. We expect to identify *Drosophila* genes which human homologous could change the epigenetic marks associated with the GAA-mediated heterochromatinization.

#### 84. Mouse models of Friedreich's Ataxia

Melissa Osborne, Laurent Bogdanik, Laure Case, Crystal Davis, Aamir Zuberi, Cathleen Lutz  
The Jackson Laboratory, Bar Harbor Maine

Introduction: Friedreich's Ataxia (FRDA) is an autosomal recessive ataxia caused by a mutation in the frataxin gene. This mutation is characterized by an expanded tri-nucleotide (GAA) repeat within the first intron of the gene. This expansion leads to reduced expression of frataxin, a ubiquitously expressed protein that acts in iron sulfur cluster and heme biosynthesis.

Insufficiency in frataxin causes decreased activity of iron-sulfur cluster enzymes such as aconitase and the mitochondrial respiratory chain complexes. The approach to model FRDA in the laboratory mouse entails knocking out endogenous Fxn expression and replacing it with mutant FXN containing large GAA repeats either through transgenesis or a targeted approach.

Methods: The Jackson Lab currently has over 15 different mouse models of FRDA under development or for distribution from the scientific community. These models have been genetically standardized and rederived into high barrier facilities for the scientific community. The repository at The Jackson Lab has performed a comprehensive phenotyping program cross comparing these models. Current publicly available mouse models for FRDA fall short at recapitulating many of the pathological and physiological features of the disease in humans.

Results: The newly available genome editing technologies afford us the opportunity to optimize the current FRDA collection and make new models for FRDA at an efficiency never before seen. These models include new BAC transgenic models that carry human genes expressing low levels of human Frataxin, conditional alleles that do not require licenses, knock-in models with larger repeats, and siRNA approaches to generating relevant alleles.

Conclusion: Our aim at the Rare and Orphan Disease Center at JAX is to genetically standardize the disease collection, delineate phenotypic parameters for each of the available FRDA models, and work to provide better models to the FRDA community to aid in the advancement of therapeutic discovery.

## 85. Histological characterization and drug screening on a *Drosophila* cardiac model of Friedreich Ataxia

Palandri A, Martin E, Rera M, Tricoire H and Monnier V

Unit of Functional and Adaptive Biology (BFA), University Paris Diderot, CNRS UMR8251, Paris, France.

Friedreich Ataxia (FA) is characterised by progressive degeneration of the central and peripheral nervous system, hypertrophic cardiomyopathy and increased incidence of diabetes. FA is caused by reduced levels of frataxin, a highly conserved mitochondrial protein. *Drosophila* appears as an adequate animal model to study pathogenic mechanisms involved in FA and to evaluate therapeutic interventions. We have previously developed a *Drosophila* cardiac model of FA, in which the fly frataxin is inactivated specifically in the heart by RNAi interference using a RU486-inducible system. These flies exhibit cardiac functional defects observed in patients and mouse models of FA, in particular heart dilatation and impaired systolic function. Here, we present further histological characterization of this model. We observed strong sarcomere alterations with loss of striation of actin fibers in cardiomyocytes of *Drosophila* hearts depleted for frataxin, a phenotype reversible following arrest of frataxin inactivation. The microtubule network was also disrupted and, only following strong frataxin inactivation, the mitochondrial network was deeply modified with the presence of enlarged and donut-shaped mitochondria. To identify potential therapeutic compounds, we then screened in vivo the Prestwick Chemical library, composed of 1280 compounds, on more than 20,000 flies. This screen allowed the identification of several drugs reducing the cardiac dilatation. The drug with the strongest protective effects was paclitaxel, a microtubule-stabilizing drug. Thus, our results suggest that frataxin inactivation induces cardiac dysfunction through impaired sarcomere assembly and/or renewal. Considering the protective effect of paclitaxel, microtubule destabilization could be one of the mechanistic link between mitochondrial dysfunction and impaired sarcomere assembly, leading to cardiac dysfunction in FA.

## 86. New *Drosophila* models of Friedreich ataxia with GAA expansions.

Russi M, Martin E, Tricoire H and Monnier V

Unit of Functional and Adaptive Biology (BFA), University Paris Diderot, CNRS UMR8251, Paris, France.

Friedreich Ataxia (FA) is caused by a GAA repeat expansion in the first intron of FXN, the gene encoding frataxin, a small mitochondrial protein, which results in decreased gene expression. Thanks to the high degree of conservation of frataxin throughout evolution, *Drosophila* appears as an adequate animal model to study FA disease and to evaluate therapeutic interventions. The existing *Drosophila* models of FA are mainly based on RNAi-mediated downregulation of fh, the fly ortholog of FXN. Here, we have generated new *Drosophila* models of FA, based on the insertion, in the intron of the fly fh gene, of a portion of the first intron of the human FXN gene carrying GAA triplet expansions. We observed a decrease in frataxin expression of 70% in these fh-GAA flies. Expression of a neighbor gene is also decreased, showing that the GAA expansions also affects gene expression beyond the fh locus. fh-GAA flies exhibit developmental delay and lethality. Interestingly, some individuals reach the adult stage when raised at low temperature but present strong locomotor defects, short lifespan and cardiac dysfunction. Developmental and adult phenotypes are both rescued by frataxin overexpression, showing that they are effectively due to frataxin deficiency. These new *Drosophila* fh-GAA models have multiple interests: they will be used to study

physiopathological mechanisms involved in the disease, and to identify and evaluate therapeutic compounds, in a context that mimicks closer the situation in human patients compared to RNAi models. Moreover, they will allow to evaluate in vivo a gene therapy based on GAA deletion by the CRISPR/Cas9 system. To this purpose, we have already built genetic tools allowing inducible expression of the CRISPR/Cas9 machinery ubiquitously or specifically in affected tissues.

### 87. Inactivation of the Grm5 gene improves motor coordination defects in the Grm1crv4 mouse model of SCAR13 ataxia

Simone Bossi<sup>1</sup>, Ilaria Musante<sup>1</sup>, Tommaso Bonfiglio<sup>2</sup>, Tiziana Bonifacino<sup>2</sup>, Laura Emionite<sup>3</sup>, Maria Cerminara<sup>1</sup>, Chiara Cervetto<sup>2</sup>, Manuela Marcoli<sup>2,4</sup>, Giambattista Bonanno<sup>2,4</sup>, Roberto Ravazzolo<sup>1,4,5</sup>, Anna Pittaluga<sup>2,4</sup>, Aldamaria Puliti<sup>1,4,5</sup>.

<sup>1</sup>Dept. of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, via Gaslini 5, 16148 Genoa, Italy

<sup>2</sup>Dept. of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Viale Cembrano 4 I- 16148 Genoa, Italy

<sup>3</sup>Animal Facility, IRCCS A.U.O. San Martino-IST, Largo Rosanna Benzi 10, Genoa, Italy;

<sup>4</sup>Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Viale Benedetto XV, 9 - 16132, Genoa, Italy

<sup>5</sup>Medical Genetics Unit, Istituto Giannina Gaslini, via Gaslini 5, 16148 Genoa, Italy

**Background.** Deleterious mutations of GRM1 gene were associated with a recessive form of cerebellar ataxia, SCAR13 (MIM614831). Grm1 and Grm5 code for the metabotropic glutamate receptor type 1 (mGlu1R) and type 5 (mGlu5R), which often substitute one each other in cells, but also have different distributions and functional roles in brain. In the cerebellum of Grm1crv4/crv4 mice, a significant overexpression of mGlu5Rs regulating glutamate exocytosis was observed. We proposed that mGlu5Rs overexpression had a role in determining phenotype in the Grm1crv4/crv4 mice so that blockade of mGlu5Rs could improve motor-coordination. To test our hypothesis, we generated double mutant mice lacking both the mGlu1Rs and the mGlu5Rs.

**Methods.** We obtained (Grm1crv4/crv4Grm5ko/ko) mice by crossing Grm1crv4 and Grm5ko mice. SHIRPA analysis on the mice with the following genotypes, namely the Grm1crv4/crv4Grm5ko/ko, the Grm1crv4/crv4Grm5+/+, the control Grm1+/+Grm5ko/ko and the wild type mice, was carried out to quantify the phenotypes. Animal motor activity was recorded in the open field and with rotarod, motor coordination was analyzed in a plexiglas corridor to perform footprint analysis. In the same mice, the release of glutamate from cerebellar nerve endings (synaptosomes) elicited by 12 mM KCl or by (S)AMPA was evaluated. **Results.** In “in vivo” studies, blocking mGlu5 receptors since mouse development elicited ameliorated motor coordination. In “in vitro” studies, a clear restoration of glutamate release efficiency, elicited by both KCl depolarization and activation of presynaptic release-regulating AMPA autoreceptors, was also observed. Finally, the expression of Glu2/3 AMPA receptor subunits in cerebellar synaptosomes, that was significantly reduced in Grm1crv4/crv4Grm5+/+ mice, recovered in double mutant mice.

**Conclusions.** The dysregulation of glutamate transmission observed in the Grm1crv4 mouse model of SCAR13 is reduced by blocking mGlu5 receptors activity, in this supporting the use of pharmacological therapy based on a direct modulation of this receptor for the cure of ataxia.

## 88. Generation of Machado-Joseph disease induced pluripotent cell lines and isogenic controls using the CRISPR/Cas9 technology

Santana MM<sup>1,2,\*</sup>, Lopes SM<sup>1,2,3,\*</sup>, Onofre I<sup>1,3</sup>, Álvaro AR<sup>1,2</sup>, Di Donato R<sup>1</sup>, Mendonça N<sup>4</sup>, Januário C<sup>4</sup>, Pereira de Almeida L<sup>1,5</sup>

<sup>1</sup>CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; <sup>2</sup>Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Portugal; <sup>3</sup>PhD Programme in Experimental Biology and Biomedicine (PDBEB), CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; <sup>4</sup>Neurology Service, University of Coimbra Hospital, Coimbra, Portugal; <sup>5</sup>Faculty of Pharmacy, University of Coimbra, Portugal.

\*Equal contribution

**Introduction:** Machado–Joseph disease (MJD), or spinocerebellar ataxia type 3, is the most common of the dominantly inherited ataxias worldwide. It is caused by the overrepetition of a CAG trinucleotide in the ATXN3/MJD1 gene, which translates into an expanded polyglutamine tract within the protein ataxin-3. Despite important progresses in the knowledge of the pathological mechanisms involved we still miss effective therapies. Disease-specific iPSC, coupled with recent gene editing techniques, are nowadays leading tools for developing physiologically relevant and predictive models of disease. Given the urgency of such models to validate therapeutic approaches for MJD, in this work we aimed at generating MJD patients-derived iPSCs lines and its isogenic controls, engineered using CRISPR-Cas9 technology.

**Methods:** Fibroblasts from MJD patients were transduced with lentiviral vectors encoding the Yamanaka factors: Oct4, Sox2, Klf4 and c-Myc. Three weeks post-infection, MJD-iPSC colonies emerged and were picked for expansion under feeder-free conditions. Morphological and molecular features of MJD-iPSC lines were evaluated by RT-qPCR and immunocytochemistry. To generate MJD-iPSC knock-out isogenic controls, four guide RNA sequences targeting human ATXN3 gene were designed and constructed. After validation in HEK 293T cells, the best sequence was then introduced in MJD-iPSC lines by nucleofection and the editing capacity was confirmed with the surveyor mutation assay.

**Results:** MJD-iPSC lines displayed typical hESC/hiPSC morphology. MJD-iPSC lines were positive for Oct4, Nanog and TRA-1-60 and presented the activation of endogenous expression of pluripotent genes, such as OCT4, SOX2, C-MYC, NANOG, REX1, ABCG2, TERT and GDF3.

Surveyor mutation detection assay revealed the cutting capability of our CRISPR/Cas9 system in HEK 293T cells and MJD-iPSC. As a result, we observed a reduction in hATXN3 mRNA and/or protein levels. **Conclusion:** The iPSC lines generated in this work are promising models for both mechanistic and preclinical studies for Machado-Joseph Disease.

This is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND - [www.jpnd.eu](http://www.jpnd.eu) (Fundação para a Ciência e Tecnologia, Portugal). The project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 643417. This work was also supported by National Ataxia Foundation (Post Doc Fellowship Award 2016) and FEDER (QREN), through Programa Mais Centro under projects CENTRO-07-ST24-FEDER-002006 and through Programa Operacional Factores de Competitividade - COMPETE and National funds via FCT – Fundação para a Ciência e a Tecnologia (Pest-C/SAU/LA0001/2013-2014, PTDC/NEUNMC/0084/2014, E-Rare4/0003/2012 and SFRH/BD/51673/2011).

### 89. Comparison of two GAA repeat expansion-based Friedreich ataxia mouse models: YG8sR and YG8LR

Saqlain, S.1, Chiu, C-S.2, Gketsopoulou, A.1, Al-Mahdawi, S.1, Mikaeili, H.1, Sherzai, M.1, Lewis, P.2 and Pook, M.A.1

1Biosciences, Dept. of Life Sciences, CHLS, and SB Theme, IEHS, Brunel University, London, UK  
2RaNA Therapeutics, Cambridge, Massachusetts, USA

Four GAA repeat expansion-based human FXN YAC transgenic FRDA mouse models have previously been characterised: Y47R (9 GAA repeats), YG8R (90/190 GAA repeats) YG22R (190 GAA repeats) and YG8sR (120-315 GAA repeats). The YG8sR model, which was derived from YG8R breeding, consists of a single copy of the FXN transgene on mouse chromosome 16. The YG8sR founder mouse contained 120 GAA repeats, but due to selective breeding, our colony of YG8sR mice now contains 215 to 315 GAA repeats, with an average length of 270 GAA repeats. YG8sR mice have significant decreases in FXN gene and protein expression, together with a progressive decline in coordination ability, in comparison to C57BL6/J and Y47R controls. Recently, the generation of a newer mouse model, designated YG8LR, has evolved from breeding of the YG8sR mice. The YG8LR founder mouse contained 410 GAA repeats, but due to selective breeding of further GAA repeat expansions our colony of YG8LR mice now contain 400 to 480 GAA repeats, with an average length of 420 GAA repeats. Through rigorous analysis by qRT-PCR, western blots, frataxin dipstick and ELISA analysis, significant decreases in frataxin gene and protein expression levels have been identified in cerebellum, heart, liver, dorsal root ganglia and spinal tissues from YG8LR mice in comparison to YG8sR mice. ELISA analysis showed a decrease of YG8LR frataxin levels by 38% in the liver and 16% in the lumbar spinal cord in comparison to YG8sR. In addition, qRT-PCR analysis of FXN levels showed a 35% decrease in the liver and a 22% decrease in the thoracic spinal cord of YG8LR mice compared with YG8sR mice. Further investigations of YG8LR and YG8sR mice are currently underway to determine the epigenetic status at the FXN transgene (DNA methylation, histone modifications and FAST-1 expression), together with behavioural and histopathological studies.

### 90. High Throughput Screen (HTS) using ARSACS fibroblast cytoskeletal bundling assay

Nicolas Sgarioto, Roxanne Lariviere, Benoit Gentil, Paul Chapple, Eric Shoubridge, Heather D. Durham, Bernard Brais

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is Quebec founder disease caused by mutations in the SACS gene. Our data show that the cytoskeletal defect first observed in *Sacs*<sup>-/-</sup> mice and patient brains, are also found in cultured fibroblasts derived from ARSACS patient skin biopsies (HDF). In both primary and immortalized HDF, vimentin intermediate filaments form in the great majority of cells perinuclear bundles. To search for therapeutic molecules we developed a cellular model for high throughput screen (HTS) by expressing a fluorescent-tagged vimentin protein in patient HDFs. Using high-resolution confocal plate reader, we are in the process of screening 20 000 molecules.

Our first HTS of 2 000 FDA-approved drugs has uncovered 8 active compounds that had the potential to reverse the ARSACS cytoskeletal phenotype. Validation on 6 different patients HDF carrying 4 different mutations as well as a CRISPR/Cas9 SACS knockout line is under way. The identification of compounds that may influence cytoskeletal bundling formation serve as proof of concept that further HTS screens using this model make uncover therapeutic molecules for ARSACS.

## 91. Development of an unbiased standardized gene therapy genotoxicity platform using induced pluripotent stem cells and their reprogrammed derivatives

Themis, M1, Pook, MA1, D.C. Hay2, Wang, W3, Weise, F4, Takeuchi, Y5,5a, Henckaerts, E6, and Schmidt, M3

1. Brunel University London, Uxbridge, Middlesex, UK., 2. Medical Research Council Centre for Regenerative Medicine University of Edinburgh, Edinburgh, Scotland, UK, 3. GeneWerk GmbH, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany., 4. NMI Natural and Medical Sciences Institute at the University of Tuebingen Markwiesenstraße 55, 72770 Reutlingen, Germany., 5. Wohl Virion Centre, Division of Infection and Immunity, University College London, UK., 5a. Advanced Therapy, National Institute for Biological Standards and Control, UK, 6. Department of Infectious Diseases, King's College London School of Medicine at Guy's, UK

We present a human IPS cell based model to evaluate gene therapy (GT) vector associated genotoxicity caused by integrating vectors as an alternative to the currently used in vivo models. Supported by the NC3Rs CRACK-IT Challenge initiative, we have set up a standardized assay for an Individualized Genotoxicity Testing (InGeTox) system that examines both vector safety and efficacy.

### Methods

As the liver is recognised as the 'gold standard' for pharmacological toxicological evaluation, human induced pluripotent stem cells (hiPSc) are differentiated into long-term 3D liver cell cultures whilst being subjected to gene delivery. This approach can use cells derived from the patient and enables the individual's genetic background to be accounted for in toxicological studies.

### Results

We use vector standards that are either considered 'safe' or 'unsafe' to measure vector related adverse effects in order to score the genotoxicity potential of new vectors being considered for GT. In addition to a predictive test for integrative vector safety, we measured the effects of vector integration on gene expression, splicing with host genes to form aberrant transcripts and vector read-through. Furthermore, we measured host methylation level changes associated with infection. For each parameter we show clear differences between vector standards giving us confidence that our personalised genotoxicity model will be useful to provide a clear readout of potential therapeutic vector adverse effects. We are currently proceeding to follow regulator guidelines to establish our model for use by academics and industry to provide vector safety data before advancing to the clinic.

### Conclusion

We are now developing a iPSc/neuron model to include Friedreich Ataxia GT genotoxicity to compare with our data from the liver and to validate our work across different tissue types. This is the first report of an un-biased, human, standardised vector genotoxicity model for GT.

## 92. A human induced pluripotent stem cell (iPSC)-based model of cerebellar ataxia

Maggie M. K. Wong<sup>1</sup>, Lauren M. Watson<sup>1</sup>, Jane Vowles<sup>2</sup>, Sally Cowley<sup>2</sup>, Kevin Talbot<sup>3</sup> and Esther E. Becker<sup>1</sup>

<sup>1</sup>Department of Physiology, Anatomy and Genetics, Medical Sciences Division, University of Oxford, Oxford, United Kingdom

<sup>2</sup>Sir William Dunn School of Pathology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom

3Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom

**Introduction:**

Spinocerebellar ataxia type 14 (SCA14) is a subtype of the autosomal dominant cerebellar ataxias, a group of incurable neurodegenerative disorders characterised by the progressive dysfunction and loss of Purkinje cells. SCA14 is caused by point mutations in protein kinase C gamma (PKC $\gamma$ ), possibly via aberrant calcium signalling in cerebellar Purkinje cells. The precise disease mechanisms underlying SCA14 remains unclear. My work has employed human induced pluripotent stem cells (iPSCs) as a novel tool to dissect the pathogenic mechanisms of SCA14.

**Methods:**

I have reprogrammed and characterised 18 iPSC lines from SCA14 patients using a standardised quality control pipeline. I have then differentiated these SCA14-iPSCs and matched control-iPSCs into human cerebellar Purkinje cells, and performed the subsequent characterisation and functional analyses of these iPSCs and iPSC-derived Purkinje cells.

**Results:**

I have successfully generated a unique disease model of SCA14, namely, cerebellar Purkinje cells derived from SCA14 patient-specific iPSCs. These iPSC-derived neurons express Calbindin, a Purkinje cell marker, and display the characteristic morphologies of Purkinje cells. Interestingly, SCA14-iPSCs are less capable of developing into Purkinje cells during the differentiation, and survive poorly when cultured further in vitro compared to control-iPSCs. Furthermore, the dendritic development of SCA14-Purkinje cells is significantly compromised. Importantly, I have demonstrated that PKC $\gamma$  is expressed in these Purkinje cells, which thus serve as an ideal platform for studying SCA14 pathogenesis. Moreover, I have employed patient-iPSCs to study the cellular phenotypes resulting from the expression of SCA14-PKC $\gamma$  mutants. My results suggest that protein degradation processes in SCA14-iPSCs are impaired following PKC $\gamma$  activation.

**Conclusions:**

I have developed a novel human disease model of SCA14 that help us better understand and ultimately treat the pathogenic processes in this disorder.

93. [Voluntary running prevents onset of symptomatic Friedreich's ataxia in mice.](#)  
Zhen Yan (see oral presentations)

# POSTER SESSION TWO

Friday 29 September  
h. 5.30 – 7.00 pm



## NATURAL HISTORY, BIOMARKERS AND ENDPOINTS

### 94. Systems biology approach to studies of mitochondrial dysfunction for the discovery of Friedreich's ataxia biomarkers

Blair IA, Wang QQ, Guo L, Weng L, Salamatipour A, Strawser CJ, Hwang WT, Lynch DR, Mesaros C.

Penn SRP Center and Center of Excellence in Environmental Toxicology, University of Pennsylvania, Philadelphia, PA 19104 and Departments of Neurology & Pediatrics, The Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104

**Introduction:** Selective cell death in neurodegenerative diseases such Friedreich's ataxia (FRDA), is thought to involve mitochondrial complex 1 dysfunction. FRDA is a devastating genetic disease resulting from elongated GAA repeats in both alleles of the FXN gene, which results in epigenetic inhibition of frataxin protein expression. There are currently no approved treatments for FRDA and there is a need for biomarkers to monitor treatment efficacy

**Methods:** Using stable isotope dilution liquid chromatography-mass spectrometry (LC-MS) coupled with [13C]-labeling and isotopologue analysis, the metabolic derangement in lipid metabolism in freshly isolated human platelets from FRDA patients and controls was established. In addition, highly specific LC-MS assays for serum apolipoprotein A-I (ApoA-I) and tissue frataxin using stable isotope labeled protein internal standards were employed to quantify the proteins in serum and tissue samples.

**Results:** There was a significant increase in labeling from [13C16]-palmitate into M + 4 for HMG-CoA in FRDA platelets ( $13.3 \pm 4.9\%$ ;  $p < 0.001$ ) when compared with controls ( $4.8 \pm 2.6\%$ ). This led to the analysis of serum ApoA-I and the finding that concentrations were reduced in FRDA (129.4 mg/dL serum, n=50) when compared with controls (166.6 mg/dl serum; n=50). Knockdown of the FXN gene in HepG2 cells, caused a significant decrease in ApoA-I biosynthesis. The highly sensitive LC-MS assay for frataxin (limit of detection of 5 amol/ $\mu$ g protein) revealed that the frataxin levels were decreased by > 50 % in the FRDA dermal fibroblasts and platelets when compared with controls

**Conclusions:** Overall, our systems biology approach has facilitated the discovery of in vivo biomarkers for FRDA, a disease of mitochondrial dysfunction. In view of the inverse relationship between serum ApoA-I levels and dilated cardiomyopathy, our novel finding partly accounts for the increased risk of this disease in FRDA.

Supported by P30ES013508 and Penn/CHOP Center of Excellence in FRDA.

### 95. A study of personality, psychopathological features and social adaptation in subjects with the Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay

Gallais, B1, Forgues, G2, Bouchard, J2, Gagnon, C1.

1Université de Sherbrooke

2Université du Québec à Chicoutimi

\*Member or associate of the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN).

Introduction: Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a hereditary progressive neurological disorder, originally identified in Quebec (more specifically in Charlevoix and Saguenay-Lac-Saint-Jean (SLSJ) regions), but is now known to have a worldwide distribution. ARSACS is regarded as the second most common recessive ataxia. Moreover, one in 22 people living in these areas are carriers of the gene involved in ARSACS. ARSACS typically presents with a prominent cerebellar ataxia, spasticity and peripheral neuropathy. Clinicians and patients' proxies frequently evocate "a particular profile" in ARSACS' patients, including personality rigidity and lack of investment in their medical care, as well as difficulties in maintaining paid job. Low openness to experience personality trait has been actually found in 8 ARSACS patients (pilot study). Theoretically, impairments of the cerebellum have been recently associated with cognitive and affective disruptions throughout the so-called "cerebellar cognitive affective syndrome". Then, our objective is to determine whether individuals with the ARSACS present specific personality and emotional features that may alter (correlate with) their social participation.

Methods: 30 participants (age range: 30-59 years) with the c.8844delT mutation of ARSACS will be assessed on personality (NEO Five Factor inventory; Millon clinical multi-axial inventory-3), psychopathological symptoms (The MINI; SCL-90-R), psychological adaptation (Ways of coping checklist) and social adaptation/participation (SAS-SR; Mhavia questionnaire). Descriptive and correlational analyses will be used.

Results: Inclusions are currently on course. Data will be available for presentation at time of the IARC. Additionally, longitudinal data (3 years) will be explored for 8 of the 30 subjects (previous pilot study). Conclusions: The present study may provide for the first time with such a cohort results on the potential association between, on the one hand, cerebellar involvement and the psychological profile, and, on the other hand, psychological features and social restrictions in ARSACS patients.

#### 96. What do we know about personality and cognitive deficits in ARSACS: results from a pilot study

Bouchard, J. UQAC Desmeules, A. UQAC Boucher, A. UQAC Gagnon, C. USherbrooke

Introduction: Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is characterized by an evolutive cerebellar atrophy who lead to major coordination and physical deficits. However, little is known about the cognitive and personality aspects of adults with ARSACS. Recently, some authors have linked cerebellar atrophy with cognitive and affective deficits, to present the cognitivo-affective cerebellar syndrome (CACS). It became thus impelling to make a parallel from this syndrome and many characteristics observed from a long time by clinicians working with ARSACS individuals.

Methods: A pilot study with 8 adults (a women and a man in each decades from 20 years old to 60 years old) was done to evaluate cognitive and personality aspects using a battery of known tests. Extensive case study and comparisons were done to analyze the results.

Results: Even if it was impossible to generalize with only 8 participants, some elements did emerge. For the psychological profile, a psychological distress appear in all individuals, as for traits of mental rigidity. Many others manifestations of CACS were evident in many of our subjects (i.e. emotional arousal, indifference, instability, obsessive-compulsive features). They also present a low openness, a high agreeableness, an extraversion and a nevrotism in the average and a tendency for a low conscientiousness. For the cognitive profile, all individuals of

more than 40 years old demonstrated deficits in information processing speed, sustained attention, language functions and visual logical reasoning.

Conclusion: This is the biggest study done to explore personality and cognitive deficits in ARSACS individuals. Many aspects found can be linked to CACS. It serves to develop a longitudinal study of natural psychological and cognitive history of ARSACS.

#### 97. Applicability of neuropsychological and personality tests in ARSACS

Brassard, K. UQAC Bouchard, J. UQAC Forgues, G. UQAC Boivin-Mercier, A. UQAC Gagnon, C. U Sherbrooke

Introduction: Autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS) is a degenerative spinocerebellar disease with major impacts in different systems including cognition. New pharmacological and genetic treatments are being developed since the last few years. In this context, it is essential to identify appropriate and relevant measures in order to evaluate these treatment’s impacts. Cognitive and personality evaluation can bring relevant information for this purpose. However, it is necessary to take into account the functional limitations of ARSACS patients (e.g., motor disabilities, dysarthria) to select the best instruments. The objective of this study is thus to document in an objective way the applicability of various cognitive and personality tests for this specific population.

Methods: Seventeen cognitive and personality tests were used with eight ARSACS individuals (four women and four men, one on each decade from 20 to 59 years old). A scoring table consisting of a three-level rating scale (A “excellent”, B “acceptable”, or C “reconsider”) was used by the test administrator to assign a score to four applicability criteria (respondent burden, examiner burden, score distribution and format compatibility) for each test.

Results: A table containing the scores for these four applicability criteria for the 17 tests is presented. Researchers and clinicians can thus be informed of the advantages and burdens inherent to each of these tests with ARSACS individuals.

Conclusion: This study can help to develop an efficient and adapted battery of cognitive and personality tests to evaluate ARSACS individuals considering their functional limitations. Evaluation of the incoming pharmacological and genetic treatment’s efficacy will thus be facilitated.

#### 98. Impacts of cognitive deficits and social participation in ARSACS

Brassard, K. UQAC, Bouchard, J. UQAC, Laberge, L. Écobes– Recherche et transfert, Cégep de Jonquière Gagnon, C. U Sherbrooke

Introduction: Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is characterized by a progressive cerebellar atrophy that leads to major coordination and physical deficits. Also, a pilot study found cognitive deficits such as information processing speed, sustained attention, language function, and visual logical reasoning, which could resemble what found in the cognitivo-affective cerebellar syndrome (CACS). Moreover, clinicians noted difficulties in individuals with ARSACS to maintain a satisfactory social participation, including maintaining a paid job and questioned if deficits in the theory of mind or in logical reasoning can explain these difficulties. The objective is thus to specify those cognitive deficits are associated with ARSACS and to explore their relationship with social participation

Methods: Forty adults with the c.8844delT mutation of ARSACS (a woman and a man for each decade between 20 and 59 years old) were given an exhaustive battery of neuropsychological

tests, including measures of the theory of mind and social participation. Descriptive and correlational analyses will be used to answer the objectives of the study.

Results: Data will be available at time of the IARC 2017. In addition, longitudinal data (3 years) will be explored for 8 of the 40 subjects using data gathered during the above-mentioned pilot study.

Conclusion: To the best of our knowledge, this study is the largest to date pertaining to the cognitive function of adults with ARSACS. It may also shed light on the clinician's observation of impacts of these cognitive deficits on their social participation.

#### 99. Investigating feasibility of use of an Android Smart Phone Application (Movelt) as a clinical outcome measure

Ashford, S.L.1, Dowling, L.C. 1, Lake, J. 1, Marshall, M.E. 1, Bell, D. 2, Payne, A. 2, Bunn, L.M. 1  
1: Plymouth University, Devon, UK, 2: Brunel University, Greater London, UK

Introduction: Mobile accelerometry has been validated against gold-standard motion analysis and current low-cost, low-tech clinical (Physiological Profile Assessment) measures of stance stability (Patterson et al., 2014). This could offer a fast, portable, specific and feasible clinical method to the PPA. This study assesses feasibility of use of 'Movelt' for student physiotherapists (Movelt: An android Smart Phone application with a standardised procedure to measure stance stability).

Methods: Project studies ethical approval was obtained from the University of Plymouth's Ethics Committee. Twelve final year student physiotherapists tested participants with 'Movelt' alongside secondary measures of balance; namely the PPA and the Activities of Balance Confidence questionnaire. Participants were recruited via the Plymouth branch of the MS Society and the University of the 3rd Age. Six people with balance impairment and ataxia signs (progressive multiple sclerosis) and 22 older aged adults met study inclusion. PPA scores and Movelt measures of postural sway were collected simultaneously across 3 30 second collections. Brief exit interviews with each student physiotherapist was undertaken to assess feasibility of use.

Results: Students described Movelt App and accompanying standardised clinical procedure feasible in terms of: (1) Ease of use, environmental adaptability and application/use of the equipment with individuals with balance impairment and ataxia signs. Students considered use of Movelt in practice currently limited by: (1) Poor immediate visibility of outcome (requiring offline analysis) (2) Inability of patients to self-don/doff the Smart Phone within current design. PPA and Movelt sway correlated with large-effect across all stance conditions.

Conclusions: Movelt is valid, easy to use, portable and potentially less susceptible to operator error than PPA methods, thus may be a more appropriate clinical choice. Further development of the App is now needed to: (1) Provide fast and reliable visualisation of outcome measures and (2) Adapt methods to enable patients to independently use the App for self-monitoring of balance.

#### 100. How does performance of the Friedreich Ataxia Functional Composite compare to rating scales?

Tai G BBiomedSci (Hons)1, Yiu EM MBBS FRACP PhD1,3,5, Delatycki MB MBBS FRACP PhD1,2,3,6, Corben LA PhD1,2,3,4

1 Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Victoria, 3052, Australia.

2 School of Psychological Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, 3168, Australia.

3 Department of Paediatrics, University of Melbourne, Parkville, Victoria, 3052, Australia.

4 Department of Occupational Therapy, Monash Health, Clayton, Victoria, 3086, Australia.

5 Department of Neurology, Royal Children's Hospital, Parkville, Victoria, 3052, Australia.

6 Victorian Clinical Genetics Services, Parkville, Victoria, 3052, Australia.

## Introduction

Progression of Friedreich ataxia (FRDA) is often measured using neurological rating scales such as the Friedreich Ataxia Rating Scale (FARS). Performance scales comprising functional measures have been used in other conditions due to their increased sensitivity and reproducibility and may replace examination-based measures. The Friedreich Ataxia Functional Composite (FAFC) consisting of the timed 25-foot walk (T25FW), the 9-hole peg test (9HPT) and low-contrast letter acuity (LCLA), has therefore been proposed, and could be effective in assessing the progression of FRDA.

The aims of this study were to examine the relationship between the Friedreich Ataxia Functional Composite (FAFC) measures and characteristics of FRDA to determine if the FAFC is more sensitive to clinical change over time compared to the raw data of its components.

## Methods

One hundred and twenty-two individuals completed all three performance measures at baseline, 63 at Year 1, 34 at Year 2 and 25 at Year 3. Composite scores called Z2 (from the combination of T25FW and 9HPT) and Z3 (from T25FW, 9HPT and LCLA) were created using methods described by Lynch and colleagues<sup>1</sup>. Correlation analyses were conducted. Change in FAFC components were examined over one, two, and three years.

## Results

The FARS, Z2, Z3 and 9HPT showed significant change over all time points compared to baseline. The T25FW demonstrated significant change over three years. The LCLA demonstrated no significant change over any of the time points.

## Conclusions

The FAFC shows significant change over time indicating disease progression, however this may result from individual components driving the differences rather than the robustness of the complete scale. In particular, the LCLA showed no change over time, rendering Z3 redundant. We conclude the FAFC is of limited value in cohorts with non-ambulant individuals and is therefore better suited for use in measuring change in less affected populations.

<sup>1</sup>Lynch, D.R., et al., Measuring Friedreich ataxia: Complementary features of examination and performance measures. *Neurology*, 2006. 66(11): p. 1711-1716.

## 101. Sexual function, intimate relationships and Friedreich Ataxia

Corben LA<sup>1, 2, 3</sup>, Crowe L<sup>1,3</sup>, Hermans MM<sup>1,4</sup>, Marks A<sup>1,5</sup>, Delatycki MB<sup>1,2 3,6</sup>.

<sup>1</sup> Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Vic., Australia

<sup>2</sup> School of Psychological Sciences, Monash University, Clayton, Vic., Australia

<sup>3</sup> Department of Paediatrics, The University of Melbourne, Parkville, Vic., Australia

<sup>4</sup> State University of New York, Albany, USA.

5 Faculty of Science, The University of Melbourne, Parkville, Vic., Australia

6 Victorian Clinical Genetics Service, Parkville, Vic., Australia.

**Introduction:** Sexual dysfunction (SD) is reported in neurological conditions similar to Friedreich ataxia (FRDA) such as multiple sclerosis. Anecdotally individuals with FRDA report difficulty forming intimate relationships and SD including erectile dysfunction and altered genital sensation. To date there has been no formal appraisal of SD in FRDA, nor the impact SD may have on intimate relationships. This study aimed to explore if, and to what extent, people with FRDA experience challenges with sexual function and intimate relationships due to FRDA. **Methods:** A questionnaire including a number of validated scales was purpose designed to explore SD and intimate relationships. Invitations to participate in the study were sent electronically to eligible participants on the Ataxia UK and Friedreich Ataxia Research Alliance databases. Responses were anonymous.

**Results:** One hundred and seventy-seven individuals with FRDA (female=82/150) aged 18 and over returned 118 completed and 59 partial responses. The average age of respondents was 38 years (SD: 12.9), the average age of disease onset was 17.8 years (SD: 9.5) and average score on the Functional Independence Measure was 96/112 (SD: 19.6), indicating mild functional impairment. Sixty-two percent (86/138) respondents reported that FRDA impacted on their ability to enter into intimate relationships. Fifty-nine percent of male respondents (20/34) reported a degree of erectile dysfunction and 31% (14/45) of females reported inadequate vaginal lubrication interfering with sexual responsiveness. Thirty-six percent (42/117) of all participants reported reduced genital sensation, 77% (90/117) reported problems moving their body during sexual activity and 64%, (75/117) reported reduced confidence due to FRDA interfering with sexual satisfaction.

**Conclusion:** This survey confirmed that FRDA impacts on the capacity to both enter into, and enjoy intimate relationships. Understanding the nature and extent of SD is critical to developing interventions and recommendations designed to enhance sexual function and intimate relationships for individuals with FRDA.

## 102. [Keeping the black dog at bay: understanding depression in Friedreich ataxia.](#)

Corben LA<sup>1,2,3</sup>, Tai G<sup>1</sup>, Stagnitti MR<sup>2</sup>, Georgiou-Karistianis N<sup>2</sup>, Delatycki MB<sup>1, 2, 3, 4</sup>

<sup>1</sup> Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Vic., Australia

<sup>2</sup> School of Psychological Sciences, Monash University, Clayton, Vic., Australia

<sup>3</sup> Department of Paediatrics, University of Melbourne, Parkville, Vic., Australia

<sup>4</sup> Victorian Clinical Genetics Service, Parkville, Vic., Australia.

**Introduction.** Despite few published studies, clinical experience indicates individuals with Friedreich ataxia (FRDA) are at a significant risk of developing depression. Left untreated, depression can have a profound effect on quality of life. This study documents the incidence of depression in adults with FRDA and explores possible change in severity of depression over time.

**Method.** Forty-four individuals with FRDA and 44 control participants completed the Beck Depression Inventory (BDI). Of this cohort 21 individuals with FRDA completed the BDI again 24 months later. An additional cohort of 9 individuals completed the BDI on two occasions with a 10 year interval. Demographic information and clinical parameters were collected. A total BDI score of 0-13 is considered in the minimal range for depression, 14-19 is mild depression, 20-28 is moderate depression, and 29-63 indicates severe depression.

Results. The presence of mild to severe depression in 29.55% of individuals with FRDA compared to 4.55% in controls underscored a significant difference between individuals with FRDA (M=10.1; SD=9.3), and control participants (M=4.0; SD=4.3) in the total BDI score ( $F(1.83) = 15.29, p < 0.001$ ). However, there was no significant difference in scores on the BDI for individuals with FRDA when compared over 24 months indicating the symptoms of depression do not alter over this time period. In a smaller cohort there was a significant ( $t(9) = 2.22, p = 0.05$ ) difference in baseline BDI (M=10.5, SD=11.6) compared to the BDI score administered 10 years later (M=7.8; SD= 10.4) indicating a reduction in depression.

Conclusion. This study identified a significantly greater incidence of depressive symptoms in individuals with FRDA compared with controls and underscores the critical need for early screening and management of depression for people with FRDA. The absence of significant change over 24 months and improvement over 10 years suggests that depression, when present may not be progressive.

### 103. Transgenic mouse models of Machado-Joseph disease show cerebellar neurochemical profiles similar to that of patients

Costa M.C.1\*, Radzwion M.1, Utecht L.2, Ashraf N.S.1, Shakkottai V.G.1, Maciel P.3,4, Paulson H.L.1, Öz G.2

1Department of Neurology, University of Michigan, Ann Arbor, MI, USA; 2Center for MR Research, Department of Radiology, Medical School, University of Minnesota, Minneapolis, MN, USA; 3Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; 4ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.

Introduction: No treatment is available for the most common dominant ataxia Machado-Joseph disease (MJD). The emergent identification of therapeutic agents for MJD calls for subsequent preclinical testing in animal models of disease. Successful translation of these trials to human clinical trials, however, depends upon the availability of biomarkers of disease that can be noninvasively tested to ensure efficacy of candidate therapeutics. Noninvasive biomarkers of MJD are nearly unknown in mouse models of this disease. Here, we sought to identify cerebellar neurochemical biomarkers in two MJD mouse models that are conserved in human patients.

Methods: Using magnetic resonance spectroscopy (MRS) we measured levels of several neurochemicals in the cerebellar vermis of symptomatic homozygous YACMJD84.2 (Q84/Q84) and hemizygous CMVMJD135 (Q135) mice. These transgenic mouse models of MJD show early-onset and robust motor phenotypes, and are currently the best models to carry out preclinical trials for this disease. Brains from tested mice were subsequently harvested and collected for protein analysis and pathology assessment.

Results: Levels of total N-acetylaspartate (tNAA) were decreased in both symptomatic MJD transgenic mouse models and MJD patients. Additionally, Q135 mice showed reduced levels of glutamate similar to MJD patients. Furthermore, both Q84/Q84 and Q135 mice displayed reduction of myo-inositol (myo-Ins) and total choline (tCho). Decreased levels of tNAA, myo-Ins and tCho are biomarkers of neurodegeneration but can also be a reflection of demyelination. While these two mouse models show cerebellar neurodegeneration, it was unknown if these mice would also undergo demyelination. Indeed, indicative of demyelination, we observed reduced levels of myelin binding protein and neurofilament components in the cerebellar cortex of both transgenic mouse models and MJD patients.

Conclusions: Q84/Q84 and Q135 transgenic mice show cerebellar neurochemical profiles suggestive of neurodegeneration and demyelination. These noninvasive neurochemical

biomarkers can be monitored during preclinical trials of promising therapeutic agents in these MJD mice and subsequently translatable to human clinical trials for MJD.

#### 104. A unique pattern of left ventricular remodeling in Friedreich ataxia (FRDA) related to frataxin deficiency?

Peverill RE (1), Hassam R (1), Donelan L (1), Corben LA (2), and Delatycki MB (2).

1 Monash Cardiovascular Research Centre, Monash Heart and Department of Medicine (School of Clinical Sciences at Monash Medical Centre), Monash University and Monash Health,

2 Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia

**Introduction:** Cardiac disease is common in FRDA and is a predictor of prognosis. While FRDA cardiac involvement is often described as hypertrophy, the geometric changes in FRDA are complex, appear to be different to what is seen in hypertensive heart disease, aging and the autosomal dominant hypertrophic cardiomyopathies, and may also differ between children and adults. The aim of this study was to define the left ventricular (LV) geometric changes in FRDA.

**Methods:** Echocardiography was performed in 171 subjects, including 52 children (7-18 years) and 119 adults, who were homozygous for a GAA expansion in the FXN gene and had a normal LV ejection fraction. End-diastolic measurements were made of LV internal diameter (LVEDID), septal wall thickness (SWT), posterior wall thickness (PWT), LV length (LVEDL) and LV volume (LVEDV) and calculations were made of LV external diameter (LVEDED = SWT+LVEDID+PWT), relative wall thickness (RWT =  $2 \times \text{PWT}/\text{LVEDID}$ ) and LV mass (LVM).

**Results:** After adjustment for age, sex and BSA, GAA1 was not a correlate of SWT, PWT or LVM, but was inversely correlated with LVEDID, LVEDED, LVEDL and LVEDV ( $p < 0.05$  for all). After adjustment for age, GAA1 was positively correlated with RWT. Age was an independent inverse correlate of PWT, LVEDED, LVEDL, LVEDV, RWT and LVM ( $p < 0.05$  for all). All of the above correlations were also present in separate analysis of the adult group, but none were evident in the children.

**Conclusions:** In FRDA, the degree of genetic abnormality is associated with a smaller left ventricle in adults, but no direct relationship with wall thickness or LVM is evident. An explanation for the variable findings of previous studies may be the lack of similar correlations in children. Progressive LV dilatation and a survivor effect may be contributing factors to the relationship of age with smaller LV size and mass.

#### 105. Monitoring progression of disease in Friedreich's Ataxia: a multimodal electrophysiological approach

V Dhawan 1,3, S R Jaiser 1,3, P F Chinnery 2, S N Baker 3, M R Baker 1,3

1 Department of Clinical Neurophysiology, Royal Victoria Infirmary, Newcastle upon Tyne

2 Clinical Neurosciences Department, University of Cambridge UK

3 Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

**Background:** In Friedreich's Ataxia (FRDA), a lack of functioning Frataxin manifests as a progressive neurological syndrome with features of dorsal root ganglionopathy (DRG), degeneration of the spinocerebellar tracts and corticospinal tracts (CST). Clinical trials of novel/emerging therapies that can correct the underlying molecular defect in FRDA are now planned. However, because of the low prevalence of FRDA (1/100,000) and the relative insensitivity of clinical rating scales (e.g. ICARS, FARS) at detecting treatment effects in small



interventional trials (<120 patients), measures that can detect subclinical disease progression will be needed as trial endpoints.

Aim: To identify potential electrophysiological markers of subclinical disease progression.

Methods: In this preliminary study, 20 patients with a genetically confirmed diagnosis of FRDA (age 4-51 years; disease duration 6-35 years) were recruited prospectively and assessed at six-monthly intervals. Each assessment involved nerve conduction studies, somatosensory evoked potentials, motor evoked potentials (MEPs), Friedreich's Ataxia Rating Scale (FARS) and quantification of Frataxin levels. We also measured beta-band EMG-EMG coherence (BIMC), which is a simple, painless and non-invasive method of assessing the integrity of the CST and sensory afferents using surface EMG.

Results:

1. BIMC is absent or significantly reduced in all FRDA patients compared to controls;
2. There was a significant increase (~20%) in MEP central motor conduction time over 6 months.

Conclusion: EMG-EMG coherence is potential method of screening for the subclinical onset of disease in asymptomatic individuals with a genetic diagnosis of FRDA and identifying when such individuals should initiate disease-modifying therapy. MEPs could provide a method of monitoring subclinical disease progression in FRDA.

Supported by Ataxia UK, GoFAR, FARA, NIHR, Newcastle Healthcare Charity

#### 106. [CARFA \(NCT02840669\): A study to characterize the cardiac phenotype of individuals With Friedreich's Ataxia](#)

Marie-Lorraine Monin 1,2, Virginie Bonnamain 3,4, Lise Legrand 5, Alban Redheuil 5, Stéphane Hatem 5, Françoise Pousset 5, Alexandra Durr 1,2

1 Department of Genetics, Hôpital Pitié-Salpêtrière, APHP, Paris, France

2 ICM (Institut du Cerveau et de la Moelle épinière) Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Paris, France

3 Annapurna Therapeutics SAS, Paris, France

4 Adverum Biotechnologies, Inc., Menlo Park, California, USA

5 Cardiology Institute, Hôpital Pitié-Salpêtrière, APHP, Paris, France

Cardiomyopathy occurs in more than 90% of Friedreich's ataxia (FA) patients, mostly young adults, and is severe in ~60% of them, ultimately leading to heart failure. To date, no marker has been identified to predict the onset or the severity of FA-associated cardiomyopathy and no specific therapy exists to prevent the deterioration of or to restore cardiac function. FXN gene replacement therapy constitutes a promising approach for treatment and one candidate therapy is currently under development at Adverum Biotechnologies.

A multi-parameter, prospective, longitudinal, observational clinical study has been initiated to better characterize the cardiac manifestations of the disease. Cardiac magnetic resonance imaging, echocardiography, serum cardiac biomarkers and fatigue severity are being evaluated over one year to identify markers indicative of disease progression and which could be used to measure treatment efficacy in future interventional clinical studies. In addition, a cardiopulmonary exercise test (CPET) with an arm-bicycle ergometer has been specifically designed for FA patients, with the objective of testing the feasibility, reproducibility and reliability of this test as a functional evaluation of FA at different stages of the evolution of the disease.

At the time of submission of this abstract, 15 FA patients diagnosed with FA-associated hypertrophic cardiomyopathy (10 males, 5 females) and 9 age and gender-matched healthy volunteers have been enrolled in the study (target enrollment: 20 FA patients and 20 healthy volunteers). Average age of FA patients is 30 years old (range 24-47), average duration from first symptom is 13.2 years (range 5-27), and 9/15 patients (60%) are ambulatory. Average SARA score was 20/40 (SD 7.9). Most patients carried two GAA expansions with a shortest allele range of 100 to 800 (mean 464). Two patients were compound heterozygous carriers of a GAA expansion and a point mutation. Baseline data will be presented.

107. [CCFS a quantitative score of cerebellar dysfunction and evolution in Friedreich ataxia](#)

Alexandra Durr (see oral presentations)

108. [Ambulatory status and quality of life in children with Friedreich ataxia](#)

Ejaz R1, Chen S2, Isaacs CJ3,4, Carnevale A1, Wilson J5, George K5, Delatycki MB6, Perlman SL7, Mathews KD8, Wilmot GR9, Hoyle C10, Subramony SH11, Zesiewicz T12, Farmer J3,4, Lynch DR3,4,13, Yoon G1,14

1. Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
2. The Hospital for Sick Children Research Institute, Child Health Evaluative Sciences/Biostatistics Design & Analysis Unit, Toronto, Ontario, Canada
3. Department of Neurology, Children's Hospital of Philadelphia, Philadelphia PA
4. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia PA
5. Cardiomyopathy and Heart Function Program, Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, Canada
6. Murdoch Childrens Research Institute, Victorian Clinical Genetics Services, Victoria, Australia
7. Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA
8. Departments of Neurology and Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA
9. Department of Neurology, Emory University, Atlanta, GA
10. Department of Neurology, Ohio State University College of Medicine, Columbus, OH
11. Department of Neurology, University of Florida, College of Medicine, Gainesville, FL
12. Department of Neurology, University of South Florida, Tampa FL
13. Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA
14. Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

Background: Friedreich ataxia (FRDA) is a recessively inherited neurodegenerative disorder, often of childhood onset. The majority of patients present with ataxia and mobility devices are the mainstay of managing loss of ambulation due to progressive ataxia and muscle weakness. Objective: To determine the impact of loss of independent ambulation and use of a mobility device on quality of life (QOL) scores in children with FRDA.

Methods: Participants were 111 individuals from 9 institutions with genetically confirmed FRDA, who were less than 18 years of age. Data was collected as part of a prospective natural history study and standardized clinical evaluations were carried out across all study sites, including health related QOL using the PedsQL 4.0 Generic Core Module as the main outcome

measure. The association between ambulatory status/use of mobility device and QOL scores was evaluated using univariate and multivariate regression. Longitudinal QOL data available for 16 individuals who transitioned to or between mobility devices was also analyzed.

Results: Mobility device use was associated with worse mean PedsQL total scores and worse mean physical, emotional, social, and academic subscores, after adjusting for gender, age of disease onset, and total Friedreich Ataxia Rating Scale (FARS) score. The magnitude of the difference was greatest for the physical subscore (19.5,  $p=0.0004$ ) and least for the emotional subscore (10.61,  $p=0.031$ ). Transition to or between a mobility device was associated with a worse mean physical subscore (18.13,  $p=0.012$ ); there were no statistically significant changes in emotional (10.4,  $p=0.19$ ), social (2.66,  $p=0.71$ ) or academic subscores (4.0,  $p=0.6$ ), and there was a trend toward improvement in emotional subscore over time (9.55 per year,  $p=0.06$ ). Conclusions: Loss of independent ambulation has a significant impact on QOL in children with FRDA, but appears to affect the physical domain to a much greater extent than psychosocial health.

#### 109. SAOA vs. MSA-C: Structural analysis with VBM and TBSS

J. Faber 1,2, X. Jiang 1, J. Acosta-Cabronero 1, I. Giordano 1,2, H. Jacobi 3, P. Nestor 1, A. Spottke 1,2, L. Scheef 1,4, T.Klockgether 1,2

1: German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; 2: Department of Neurology, University Hospital Bonn, Germany, 3: Department of Neurology, University Hospital Heidelberg, 4: Department of Radiology, University Hospital Bonn

Introduction: Sporadic adult-onset ataxia of unknown etiology (SAOA) denotes the non-hereditary degenerative adult-onset ataxia disorders that are distinct from cerebellar variant of multiple system atrophy (MSA-C). The aim of this study was to investigate the structural alterations of SAOA patients, MSA-C patients and healthy controls by using diffusion tensor imaging and voxel based morphometry.

Methods: T1 and diffusion weighted structural imaging were performed on 3T scanners at two sites in 11 MSA-C (3 male;  $60 \pm 8.6$  years SD), 36 SAOA patients (21 male;  $62 \pm 9.4$  years SD), and 40 healthy control subjects (16 male;  $67 \pm 4.5$  years SD). All patients were participants of the SPORTAX study (clinicaltrials.gov Identifier: NCT02701036). Spatially normalized T1 data were compared voxelwise by using the SPM12 toolbox for voxel based morphometry (VBM8). Diffusion images were analyzed by using tract-based spatial statistics (TBSS) included in FSL

Results: We found a significant volume reduction of gray and white matter for both patient groups in the cerebellum, cerebellar peduncles and the brainstem in comparison to healthy controls ( $p_{FWE} < 0.05$ ). We could not find a volume reduction in gray or white matter between SAOA and MSA-C patients ( $p_{FWE} < 0.05$ ). To study the white matter alterations we used diffusion tensor imaging, focusing on fractional anisotropy (FA). For MSA-C patients, FA was significantly reduced within the mesencephalon, pons, middle cerebellar peduncles, both capsula interna and both corticospinal tracts compared to SAOA patients ( $p < 0.01$ ). There was no significant decrease of FA-values in the SAOA group compared to MSA-C ( $p < 0.01$ ).

Conclusion: Even though the VBM analysis did not show differences between SAOA and MSA-C patients, the TBSS analysis showed a significant decline of FA, as a marker for white matter integrity, in the brainstem, cerebellum and cerebellar peduncles, both capsula interna and the corticospinal tracts of MSA-C patients in comparison to SAOA patients.

#### 110. Healthcare practices and socio-economic impact in Friedreich's Ataxia

Jennifer Farmer<sup>1</sup>, Melissa Blunck<sup>2</sup>, Megan Macri<sup>3</sup> and Dawn Fleck<sup>3</sup>

1 Friedreich's Ataxia Research Alliance, 2Horizon Pharma, 3DeNovo Research Solutions

**Introduction:** The severity of clinical symptoms and progressive nature of Friedreich's Ataxia (FA) are likely to have significant socio-economic and healthcare consequences. This study aimed to understand the actual impact of FA on socio-economics and healthcare received by disease severity.

**Methods:** DeNovo, Horizon, and FARA developed a 47-question survey exploring, demographics and socio-economics, disease severity (ambulatory status), current treatments and supportive care received, and other healthcare practices. DeNovo fielded the online survey which took respondents an average of 40 minutes to complete. FARA recruited a representative mix of FA patients and caregivers enrolled in their U.S. Registry of 1122 individuals. Data were analyzed by total respondents and by ambulation status groups.

**Results:** 203 FA patients or caregivers completed the survey, with a nearly equal distribution of individuals being ambulatory and non-ambulatory. Neurologists are identified as the 'main' diagnosing and treating physicians. The average time from initial physician visit to FA diagnosis was 2-4 years; an average of 3-4 HCPs were seen prior to diagnosis. 53% of FA patients had either Medicare or Medicaid health insurance. Fewer than 20% of adults with FA were employed full-time; median employment time was 7 years. 86% of patients reported needing some help with Activities of Daily Living (ADLs). 65% were determined disabled by the Social Security Administration by the age of 30 years and 30% received Supplemental Security Income.

**Conclusions:** The results provide significant insights into the healthcare practices and socio-economic implications of FA. The time to FA diagnosis and referrals through multiple HCPs reflect the continued need to raise awareness. While individuals with FA are able to achieve high levels of education and professional training, employment time is limited. Most adults require assistance with ADLs and rely on government program support for health insurance and income, reflecting the profound physical effects of FA.

#### 111. [Validation of suitable reference genes for the normalization of qPCR gene expression data in spinocerebellar ataxia type 3.](#)

Ana F. Ferreira<sup>1,2</sup>, Mafalda Raposo<sup>1,2</sup>, Catarina Costa<sup>1</sup>, Manuela Lima<sup>1,2</sup>

<sup>1</sup>Faculdade de Ciências e Tecnologia, Departamento de Biologia, Universidade dos Açores, Ponta Delgada, Açores, Portugal

<sup>2</sup>Instituto de Investigação e Inovação em Saúde (I3S), Porto, Portugal

Molecular biomarkers are urgently needed for spinocerebellar ataxia type 3 (SCA3), an autosomal dominant spinocerebellar ataxia of late onset, which is entering a phase of intense trial activity. We have previously reported results from cross-sectional and longitudinal studies that analyzed expression data from SCA3 subjects, aiming to identify disease biomarkers. Accurate quantification of gene expression levels by fluorescence-based quantitative PCR (qPCR) relies on the normalization of data; although many housekeeping genes are commercially available as endogenous controls, several studies report that expression levels of such genes may vary in multiple biological conditions. This study aimed to analyze the expression behavior of four genes (TRAP1, FPGS, DECR1 and B2M), previously proposed as valid endogenous controls, in blood samples from SCA3 subjects. qPCR was used to determine the expression levels in 10 preataxic SCA3 subjects, 10 patients and 20 age and gender matched controls. Expression stability and ranking analysis was performed using GeNorm and NormFinder algorithms. The most stably expressed gene will be of further use in future qPCR gene expression studies of SCA3, therefore improving data reliability.

112. Autosomal recessive spastic ataxia of Charlevoix-Saguenay: a natural history study over a two-year follow-up

Cynthia Gagnon (see oral presentations)

113. Cognitive deficits in spinocerebellar ataxia type-3/Machado-Joseph disease.

Garcia-Moreno, H (MD; Molecular Neuroscience Department, Institute of Neurology, University College London; National Hospital for Neurology and Neurosurgery, University College London Hospitals); Giunti, P (MD, PhD; Molecular Neuroscience Department, Institute of Neurology, University College London; National Hospital for Neurology and Neurosurgery, University College London Hospitals).

INTRODUCTION.

Spinocerebellar ataxia type-3 (SCA3) is the most common autosomal dominant cerebellar ataxia, caused by an expanded CAG repeat in the ATXN3 gene. The cerebellar cognitive affective syndrome (CCAS) is caused by the interruption of the interconnections between the cerebellum and the association and paralimbic cortex. It consists of executive dysfunction, visuospatial processing impairment, linguistic deficits, and affective dysregulation. We aim to review previous studies reporting neuropsychological deficits in SCA3 patients to characterize the CCAS in this population.

METHODS.

The following systematic search was performed in PubMed: cognitive impairment AND cognition AND dementia AND spinocerebellar ataxia type 3. Only studies which included a control group were selected.

RESULTS.

Different reports revealed visual function deficits (visual processing speed, visual perception) and one of the studies identified a correlation between the Picture Completion Test and the regional cerebral blood flow in the parahippocampal gyrus. Regarding the verbal memory, deficits in consolidation processes were assessed by using the Rey Auditory Verbal Learning Test (RAVLT). In one study, the performance in the RAVLT correlated with cerebral atrophy in bilateral frontotemporal areas and was not correlated with motor disability. Many studies identified poor performance in phonemic fluency and speed processing. Most studies found higher scores in scales for depression and anxiety. Nevertheless, major depression was rarely reported. One study found a clear dysfunction in the Theory of Mind (ToM) tasks and the progression of the cognitive impairment might be specific for each SCA subtype.

CONCLUSIONS.

Despite conflicting evidence (variability in methodologies and populations), SCA3 patients showed visuospatial, verbal memory, and mood impairments. The frontal dysfunction was less affected than the other domains. Neither moderate nor severe cognitive impairment in SCA3 patients were found. Most of the studies could not prove a correlation between neuropsychological deficits and age of onset, duration of disease or length of the CAG repeat. However, they might correlate with cerebellar scores (SARA).

114. Baseline disease severity predicts longitudinal brain atrophy over 2-Years in Friedreich Ataxia: the IMAGE-FRDA Study

Ian H Harding<sup>1</sup>, Louise A. Corben<sup>1,2</sup>, Monique R. Stagnitti<sup>1</sup>, Elsdon Storey<sup>3</sup>, Gary F. Egan<sup>1</sup>, Martin B. Delatycki<sup>2</sup>, Nellie Georgiou-Karistianis<sup>1</sup>

1. Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Monash University, Melbourne, Australia;
2. Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Melbourne, Australia
3. Department of Medicine, Monash University, Prahran, Vic., Australia

**Introduction:** Cross-sectional magnetic resonance imaging (MRI) studies of brain structure in Friedreich Ataxia (FRDA) report atrophy in the cerebellum, subcortical nuclei, and frontal cortices. This study aimed to determine whether MRI could also detect longitudinal volume change over a 2-year period in a large FRDA cohort.

**Methods:** Structural MRI was acquired at two time-points ( $2.02 \pm 0.14$  years apart) in 28 individuals with FRDA and 29 healthy controls. Rate of volume change across the whole brain was calculated using the SPM12 Longitudinal Registration Toolbox. Non-parametric permutation tests, with family-wise error (FWE) cluster-corrected thresholds, were used to infer between-group differences and associations with baseline disease severity (Friedreich Ataxia Rating Scale (FARS); cohort range:19-126).

**Results:** Significantly greater volume loss in FRDA, relative to controls, was evident in the white matter of the midbrain, internal capsules, and splenium of the corpus callosum ( $p_{FWE} < 0.03$ ), and at trend levels in the superior cerebellar peduncle and vermal grey matter ( $p_{FWE} = 0.086$ ). In the FRDA cohort, significant correlations with baseline FARS indicated that diffuse cerebellar grey matter atrophy occurred maximally in individuals at earlier stages of the disorder ( $FARS < \sim 60$ ), followed by later relative stability ( $r = 0.56$ ,  $p_{FWE} = 0.019$ ). Conversely, in the grey and white matter of the sensorimotor and premotor cortices, volume gain was evident in early disease ( $FARS < \sim 60$ ), with later volume loss in these regions ( $FARS > \sim 100$ ;  $r = -0.66$ ,  $p_{FWE} = 0.003$ ).

**Conclusions:** MRI is sensitive to progressive brain atrophy in FRDA over a 2-year period. This atrophy occurs most consistently in the white matter of the cerebellar-thalamic tracts and corpus callosum, consistent with reports of longitudinal microstructural degradation in these same regions. In contrast, disease state plays an important moderating role in patterns of cerebellar and cerebral cortical atrophy, providing insights into the sequelae of the underlying neuropathology. These results support the potential utility of structural MRI as a biomarker of FRDA progression, which may be optimised by accounting for individual disease severity.

#### 115. Prediction of the age at onset in Spinocerebellar ataxia type 3 varies according to population of origin

Leotti VB 1,8, Mattos EP 2,7, Souza GN 3, Furtado GV 2,7, Saraiva-Pereira ML 2,4,6,7, Saute JAM 6, Camey SA 1,8, Jardim LB 2,3,5,6

1 Departamento de Estatística, Universidade Federal do Rio Grande do Sul, Brazil. 2 Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Brazil. 3 Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul, Brazil. 4 Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Brazil. 5 Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul, Brazil. 6 Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Brazil. 7 Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, Brazil. 8 Programa de Pós-Graduação em Epidemiologia, Universidade Federal do Rio Grande do Sul, Brazil.

**Background:** The CAG repeat expansion (CAGexp) correlates with age at onset (AO) in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD). Recently, a specific formula was proposed to predict AO based on CAGexp, based on an European population (Tezenas du Montcel et al, 2014). **Aim:** to test whether the formula proposed by the European study can

predict accurately AO of Brazilian SCA3/MJD patients and to build a new one, addressed to this population. Methods: data of all SCA3/MJD carriers, living in our region, were registered and kept confidential. A survey was performed among affected individuals to confirm information on AO of gait ataxia (AOga). The predicted median AOga from birth were calculated for symptomatic individuals from the survey and for anonymous data about asymptomatic individuals, based on his/her CAGexp value with a critical range (CR) from 5th to 95th percentiles. Equations and estimates presented by Tezenas du Montcel et al (2014) were implemented. Results: 100 symptomatic and 47 asymptomatic SCA3/MJD carriers were studied. Predicted AOga underestimated the actual AOga by 10.41 years (CI 9.01 - 11.80). Underestimations were present in all individuals who received a predicted AOga of 25 years or more. Thirty one (66%) of the 47 asymptomatic carriers were still asymptomatic in an age older than the predicted AOga, based on their CAGexp. A formula addressed to our population was developed. Conclusions: The data obtained from the European cohort was not sufficient to propose a model to predict age at onset for SCA3/MJD in general. These differences pointed to a populational stratification effect operating in SCA3/MJD. Prediction of the AOga should be modelled for each specific population of origin.

Acknowledgements: CNPq; FIPE-HCPA; INAGEMP; FAPERGS.

#### 116. The progression rate of neurological deterioration in spinocerebellar ataxia type 2 changes according to stage of disease

Monte TL 1, 7, Reckziegel ER 10, Augustin MC 10, Locks-Coelho LD 10, Silva ASP 10, Barsottini OP 11, Pedroso JL 11,

Vargas FR 12, 13, Saraiva-Pereira ML 2, 6, 8, Camey SA 4, 9, Leotti VB 4, 9, Jardim LB 2, 3, 5, 7, 8, 10, 14, on behalf of Rede Neurogenética.

1 Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 2 Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 3 Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 4 Departamento de Estatística, Universidade Federal do Rio Grande do Sul, Brazil; 5 Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul, Brazil; 6 Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Brazil; 7 Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul, Brazil; 8 Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Brazil; 9 Programa de Pós-Graduação em Epidemiologia, Universidade Federal do Rio Grande do Sul, Brazil; 10 Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Brazil; 11 Setor de Neurologia Geral e Ataxias. Disciplina de Neurologia Clínica da UNIFESP - Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil; 12 Laboratório de Epidemiologia de Malformações Congênitas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; 13 Departamento de Genética e Biologia Molecular, Universidade Federal do Estado do Rio de Janeiro, Brazil; 14 Instituto Nacional de Genética Médica Populacional, Brazil.

Background: Spinocerebellar ataxia type 2 (SCA2) has heterogeneous symptoms. Previous studies showed progression of ataxic manifestations only, and all used the study entry as the start of the measurements. Aims: to describe the progression of Scale for the Assessment and Rating of Ataxia (SARA), SCA Functional- Index (SCAFI), Composite-Cerebellar-Functional-Score (CCFS), and the Neurological Examination Score for Spinocerebellar Ataxias (NESSCA) in SCA2; to explore whether progression is linear during all the disease duration; and to look for potential modifiers. Methods: 49 subjects were examined. Age at onset and disease duration, CAGexp, and amyotrophy, parkinsonism, dystonia, and cognitive losses at baseline were used

as independent variables. Linear growth curve models were adjusted to model relationships between outcomes and time in two ways: a study duration model (baseline and follow up observations) versus a disease duration model (disease onset according to patient, baseline, and follow up observations). Results: SARA progressed 1.75 versus 0.79 points/year in the study duration and disease duration models. NESSCA progressed 1.45 versus 0.41 points/year in the study duration and disease duration models. Therefore, NESSCA and SARA progression rates were not constant during disease duration. Individuals with less and more than 10 years of disease duration progressed 0.35 and 2.45 points/year in SARA scores ( $p = 0.013$ ) in the study duration model. Conclusions: Early phases of disease were associated with slower SARA and NESSCA progressions. Modelling of future studies should take those parameters into account. Our database was made available online in order to help future meta-analyses intended to clarify SCA2 progression.

Acknowledgements: CNPq; FIPE-HCPA; INAGEMP; FAPERGS.

#### 117. Neurological phenotypes in spinocerebellar ataxia type 2: role of mitochondrial polymorphism A10398G and other risk factors

Monte TL 1,6 , Pereira FS 8, Reckziegel ER 3, Augustin MC 3, Silva ASP 3, Locks-Coelho LD 3, Pedroso JL 10, Barsottini OP 10, Vargas FR 11, Saraiva-Pereira ML 2,4,7,8,9, Jardim LB 1, 2, 3, 5, 7, 8, 9,12, on behalf of Rede Neurogenética.

1 Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul, Brazil; 2 Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Brazil; 3 Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Brazil; 4 Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Brazil; 5 Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul, Brazil; 6 Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 7 Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 8 Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 9 Rede Neurogenética, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 10 Setor de Neurologia Geral e Ataxias. Disciplina de Neurologia Clínica da UNIFESP - Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil; 11 Departamento de Genética e Biologia Molecular, Universidade Federal do Estado do Rio de Janeiro, Brazil; 12 Instituto Nacional de Genética Médica Populacional, Brazil.

Background: Spinocerebellar ataxia type 2 (SCA2) is due to a CAG expansion (CAGexp) at ATXN2. Alongside characteristic ataxia with saccadic slowness, SCA2 presents great clinical variability. Aims: to study parkinsonism, dementia, dystonia, and amyotrophy, as subphenotypes of SCA2, and to explore the effect of CAG repeats at several loci and of mitochondrial polymorphism A10398G as modifiers of phenotype. Methods: Symptomatic subjects were classified by presence/absence of neurological signs mentioned above; SARA and NESSCA scores were obtained. CAG repeats at ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7 and RAI1, and polymorphism A10398G at mtDNA were established. Group characteristics were compared, with a  $p < 0.05$ . Results: Forty-eight SCA2 individuals were included. Age at onset, CAGexp, and disease duration explained 53% and 43% of SARA and NESSCA variations. CAGexp of subjects with and without parkinsonism were different (medians of 42 and 39 repeats) as well as of subjects with and without dystonia (44 and 40 repeats). Amyotrophy was not significantly related to any variable under study. Concerning polymorphism A10398G, 83% of subjects with and 34% of those without cognitive decline carried 10398G at ( $p=0.003$ ). Conclusions: Treating the four phenotypical subgroups as outcomes was a valid strategy to



identify modifiers of disease. Among the correlations found, some confirmed previous reports, such as those between dystonia and CAGexp. Of note was the association between cognitive decline and the variant G at mitochondrial polymorphism A10398G, a variant formerly related to earlier ages at onset in SCA2.

Acknowledgements: CNPq; FIPE-HCPA; INAGEMP; FAPERGS.

#### 118. Validation of the Neurological Examination Score for the assessment of Spinocerebellar Ataxias (NESSCA) and responsiveness of several rating scales in Spinocerebellar Ataxia type 2

Monte TL 1,7, Reckziegel ER 9, Augustin MC 9, Silva ASP 9, Locks-Coelho LD 9, Barsottini OP 10, Pedroso JL 10, Vargas FR 11,12, Saraiva-Pereira ML 2, 3, 6, Leotti VB 4,8, Jardim LB 2, 3, 5, 7, 8, 13, on behalf of Rede Neurogenética.

1 Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 2 Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 3 Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil; 4 Departamento de Matemática e Estatística, Universidade Federal do Rio Grande do Sul, Brazil; 5 Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul, Brazil; 6 Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Brazil; 7 Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul, Brazil; 8 Programa de Pós-Graduação em Epidemiologia, Universidade Federal do Rio Grande do Sul, Brazil; 9 Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Brasil; 10 Setor de Neurologia Geral e Ataxias. Disciplina de Neurologia Clínica da UNIFESP - Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil; 11 Laboratório de Epidemiologia de Malformações Congênitas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; 12 Departamento de Genética e Biologia Molecular, Universidade Federal do Estado do Rio de Janeiro, Brazil; 13 Instituto Nacional de Genética Médica Populacional, Brazil.

Background: Spinocerebellar ataxia type 2 (SCA2), caused by a CAG expansion (CAGexp) at ATXN2, has a complex clinical picture. While validated ataxia scales are available, comprehensive instruments to measure all SCA2 neurological manifestations are required. Aim: to validate the Neurological Examination Score for the assessment of Spinocerebellar Ataxias (NESSCA) to be used in SCA2 and to compare its responsiveness to those obtained with other instruments. Methods: NESSCA, SARA, SCAFI, and CCFS scales were applied in symptomatic SCA2 patients. Correlations were done with age at onset, disease duration, CAGexp, and between scales. Responsiveness was estimated by comparing deltas of stable to worse patients after 12 months, according to Patient Global Impression of change, and the area under the curve (AUC) of the Receiver Operating Characteristics curve of scores range. Results: Eighty-eight evaluations (49 patients) were obtained. NESSCA had an even distribution, and correlated with disease duration ( $r=0.55$ ), SARA ( $r=0.63$ ), and CAGexp ( $\rho=0.32$ ): both explained 44% of NESSCA variance. Deltas (CI 95%) after one year in stable and worse patients were only significantly different for SARA. NESSCA, SARA, SCAFI, and CCFS AUC were 0.63, 0.81, 0.49, and 0.48, respectively. Conclusions: NESSCA is valid to be used in SCA2. However, the only instrument that presented good responsiveness to change in one year was SARA. We suggest that NESSCA can be used as a secondary outcome in future trials in SCA2, due to the burden of neurological disabilities related to disease progression.

Acknowledgements: CNPq; FIPE-HCPA; INAGEMP; FAPERGS.

### 119. CAG repeat numbers seem to influence genetic fitness and meiotic drive of ATXN2 alleles

Lucas Sena<sup>1</sup>, José Luiz Pedroso<sup>2</sup>, Maria Marla Paiva de Amorim<sup>3</sup>, Orlando Barsottini<sup>2</sup>, Clecio Godeiro<sup>3</sup>, Raphael Machado Castilhos<sup>1,5</sup>, Gabriel Vasata Furtado<sup>1,4</sup>, Eduardo Preusser Mattos<sup>1,4</sup>, Maria Luiza Saraiva Pereira<sup>1,4,6,7</sup>, Laura Bannach Jardim<sup>1,4,6,8</sup>

<sup>1</sup> Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul; <sup>2</sup> Setor de Neurologia Geral e Ataxias. Disciplina de Neurologia Clínica da UNIFESP – Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil; <sup>3</sup> Universidade Federal do Rio Grande do Norte, Natal, Brazil; <sup>4</sup> Laboratório de Identificação Genética, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre; <sup>5</sup> Serviço de Neurologia, Hospital de Clínicas de Porto Alegre; <sup>6</sup> Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre; <sup>7</sup> Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul; <sup>8</sup> Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul.

**Background:** Spinocerebellar ataxia type 2 (SCA2) is caused by an expanded CAG repeat tract (CAG<sub>exp</sub>) at ATXN2. CAG<sub>exp</sub> is related to anticipation. Very disabling, SCA2 would be prone to selective forces. However, SCA2 frequency seems to be stable in populations. **Aims:** to estimate fitness and segregation distortion in SCA2. **Methods:** Adult carriers were invited to participate. Informants provided data about all his/her relatives, about their date of birth, parents, order of birth, symptomatic status, and number of children. Numbers of children of affected and unaffected sibs were compared to estimate fitness. Progenies were studied when affected parent was older than 52 years old (yo), and if reproductive history of the individual and his/her affected parent were entirely known. **Results:** Twenty SCA2 families were studied, including 1,017 individuals (164 affected), born from 1840 to 2012. Mean  $\pm$  SD AO was 36.6 $\pm$ 14.9 yo. One hundred sixty four subjects fitted the criteria for fitness analysis: 97 asymptomatic – assumed to be noncarriers and 67, symptomatic individuals – assumed to be carriers. Average numbers of children of the noncarriers and carriers were 2.39 and 3.10 ( $p < 0.025$ ). Fitness of carriers was of 1.29. The number of symptomatic individuals was smaller than the number of asymptomatic subjects in all age groups. To study segregation distortion, we included individuals older than 52 yo with complete sibships, children of affected parents. A total of 230 subjects fitted the criteria: 137 were nonsymptomatic or noncarriers (59.6%) and 93 were carriers (40.4%) ( $p = 0.04$ ). **Discussion:** We raised evidence in favor of increased fitness related to the carrier state at ATXN2. This finding is in agreement with those observed in similar diseases such as SCA3 and Huntington disease. In contrast, results suggested a segregation distortion favoring the normal allele with 22 repeats, which can explain presence of this allele in more than 90% of human chromosomes.

**Funding:** FIPEIHCPA number GPPG 16I0320

### 120. Local gray matter changes in the cerebellum in MSA-C and SAOA: a multicenter VBM study

X. Jiang, J. Faber, I. Giordano, Ch. Schneider, A. Spottke, H. Boecker, T. Klockgether, L. Scheef on behalf of the SPORTAX and DELCODE consortium

**Background:** The cerebellar atrophy patterns in sporadic adult-onset ataxia of unknown etiology (SAOA) are as yet not well defined. Therefore, the aim of this voxel based

morphometry (VBM) study was to characterize the underlying structural changes of SAOA at the cerebellar level by comparison to multiple system atrophy of the cerebellar type (MSA-C) and healthy controls.

**Methods:** Isotropic T1-weighted magnetic resonance imaging (MRI) was acquired in 12 MSA-C patients (7 female, 5 male;  $60.33 \pm 8.40$  years), 45 SAOA patients (17 female, 28 male;  $61.83 \pm 9.43$  years), and 39 healthy control subjects (24 female, 15 male;  $67.43 \pm 4.52$  years). Data preprocessing was performed with SUIT and the VBM8 toolbox. Group differences were calculated with an ANOVA, controlling for age, gender, scanner site, and total intracranial volume ( $p < 0.01$ , FWE-corrected at the cluster level; cluster extent 20 voxels). Differences between groups were analyzed with post-hoc t-tests.

**Results:** Gray matter changes were identified in the right cerebellum in Crus I, Crus II, in the left cerebellum in regions VIIb, VIIIa, VIIIb and the interposed nucleus, and bilaterally in regions IV, VI, IX, X, the dentate nucleus, and the cerebellar vermis. Post hoc t-tests revealed that the atrophy in vermis, left VIIIb, left IX, bilateral X and the dentate nucleus was significant for both groups (MSA-C and SAOA), whereas all other regions were affected exclusively in SAOA group.

**Conclusion:** Although direct between-group comparisons of MSA-C vs. SAOA were not yet significant, most likely do to the small group sizes of this cohort, our data provide initial evidence for different cerebellar atrophy patterns in both sporadic degenerative disease conditions, i.e. SAOA being spatially more extensively affected. Future work is needed in larger cohorts to substantiate these initial findings.

#### 121. Assessing mobility, balance, coordination, and dexterity in ARSACS: Reliability and validity of 7 outcome measures

Lessard, I; Gagnon, C; Lavoie, C., Brais, B., Mathieu, J.

**Introduction:** Selection of outcome measures for natural history studies or clinical trials can be decisive of their success. Determination of metrological properties is therefore essential to know which is the best tool to use in a specific population. In this study, we aimed to assess construct validity and reliability of the Nine-Hole Peg Test (NHPT), Standardized Finger-to-Nose Test (SFNT), grip strength, 10-Meter Walk Test (10mWT), Six-Minute Walk Test (6MWT), Berg Balance Scale (BERG), and Timed Up and Go (TUG) in Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) population.

**Methods:** A total of 42 ARSACS patients were recruited. Subjects were assessed by two experienced physical therapists for three half-day sessions (T1-T2-T3). The first two assessments (T1-T2) were carried out by rater 1, and the third (T3) by rater 2. Test-retest reliability was determined with T1-T2 assessments, and interrater reliability with T1-T3 assessments.

**Results:** Mean age of participants was 38.6 years. Almost all tests have shown to have excellent construct validity, according to their high correlation with age ( $r = 0.64-0.84$ ) and overall disease severity ( $r = 0.70-0.97$ ), and their ability to distinguish between participants in different disease stages (First walking difficulty; Use of walking aid; Wheelchair user) and age groups ( $\leq 29$ ;  $30-39$ ;  $\geq 40$ ). Intrarater reliability of the NHPT and SFNT was excellent ( $ICC = 0.93-0.97$ ), and interrater reliability of the NHPT, SFNT, grip strength, 10mWT, and 6MWT was also excellent ( $ICC = 0.90-0.99$ ). However, reliability of the NHPT in ARSACS is questioned (bias for weaker participants and high standard error of measurement).

Conclusions: All tests have shown to have an excellent construct validity and reliability, except for the NHPT and grip strength. The use of the SFNT, 10mWT, 6MWT, BERG, and TUG in this population is supported.

122. Exercise stress testing on adaptive equipment is feasible and reliable in Friedreich ataxia

Kimberly Lin (see oral presentations)

123. Cardiac magnetic resonance T1 mapping as a window into the myocardium in Friedreich ataxia

198. (FRDA)

Kimberly Lin (see oral presentations)

124. Body Mass Index and Stature in the Friedreich Ataxia Clinical Outcome Measure Study

Ashley McCormick<sup>1</sup>, Jennifer Farmer<sup>1,2,3</sup>, Susan Perlman<sup>4</sup>, Martin Delatycki<sup>5</sup>, George Wilmot<sup>6</sup>, Katherine Matthews<sup>7</sup>, Grace Yoon<sup>8</sup>, Chad Hoyle<sup>9</sup>, S.H. Subramony<sup>10</sup>, Theresa Zesiewicz<sup>11</sup>, David R. Lynch<sup>1,2,3</sup>, Shana E. McCormack<sup>3,12</sup>

<sup>1</sup>Division of Neurology, Children's Hospital of Philadelphia, Philadelphia PA 19104;

<sup>2</sup>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104; <sup>3</sup>Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104;

<sup>4</sup>Department of Neurology, University of California Los Angeles, Los Angeles CA 90095; <sup>5</sup>Department of Genetics, Murdoch Children's Research Institute, Victoria, Australia; <sup>6</sup>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322;

<sup>7</sup>Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA 52242; <sup>8</sup>Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, Canada; <sup>9</sup>Department of Neurology, Ohio State University College of Medicine, Columbus, OH 43210;

<sup>10</sup>Department of Neurology, University of Florida, College of Medicine, Gainesville, FL 32610;

<sup>11</sup>Department of

Neurology, University of South Florida, Tampa FL 33612; <sup>12</sup>Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia PA 19104

Objective: Friedreich Ataxia (FA) is a progressive neuromuscular disorder. Anthropometric measures reflecting weight relative to height (body mass index, BMI) and stature (height) are important indices of health. The objective of this study was to identify factors associated with BMI and stature in FA.

Research Design and Methods: Participants were 769 individuals from 12 international sites in a prospective natural history study (FA Clinical Outcome Measure Study, FACOMS). For this cross-sectional analysis, we used the first visit where simultaneous height and weight measurements were obtained. Age- and sex-specific BMI and height z-scores were calculated using CDC 2000 growth standards for participants <20y. For adults ≥20y, the reference range for 20 year-olds was used to permit comparisons. Detailed clinical information was available (n=471). Multivariable linear regression analyses were used to investigate the associations between factors and outcomes.

Results: Median age of participants was 21.9y (IQR, 14.4-33.6y); 50% (n=379) were female. The shorter GAA repeat length was a median of 680 bp (IQR, 500-800, n=728 with genetic information). 4.8% had point mutations in FXN. 7.3% had diabetes mellitus (DM), 82% had

scoliosis, and 60% had cardiomyopathy. Increasing age ( $\beta=0.024$ ;  $p<0.001$ ) and having a point mutation ( $\beta=0.46$ ;  $p=0.042$ ) were each positively associated with BMI-z. When clinical conditions were added to the model, scoliosis had an independent negative association with BMI-z ( $\beta=-0.40$ ;  $p=0.016$ ). In adults only, increased GAA repeat length ( $\beta=-0.003$ ;  $p=0.05$ ) or having scoliosis ( $\beta=-1.67$ ;  $p=0.013$ ) were negatively associated and having DM ( $\beta=2.19$ ;  $p=0.027$ ), or a point mutation ( $\beta=4.89$ ;  $p=0.006$ ) was positively associated with BMI (kg/m<sup>2</sup>). Increased GAA repeat length ( $\beta=-0.0004$ ;  $p=0.030$ ) is negatively associated and age ( $\beta=0.007$ ;  $p=0.037$ ) is positively associated with relative height.

Conclusions: Anthropometric measurements are independently associated with both genetic and clinical factors, and may reflect overall health in FA. In future, longitudinal analyses will yield important additional insights.

### 125. Acute effects of dietary glycemic index on lactate and glucose homeostasis in individuals with Friedreich's Ataxia and other disorders affecting mitochondria

Ashley McCormick<sup>1</sup>, Ashley M. Whitaker<sup>2</sup>, Kristin Wade<sup>3</sup>, Sara Nguyen<sup>3</sup>, Elizabeth McCormick<sup>4</sup>, Colleen Muraresku<sup>4</sup>, Rui Xiao<sup>5</sup>, Marni J. Falk<sup>4,5</sup>, David R. Lynch<sup>1</sup>, Darko Stefanovski<sup>6</sup>, Shana E. McCormack<sup>3,5</sup>

<sup>1</sup>Department of Neurology, Children's Hospital of Philadelphia, Philadelphia PA; <sup>2</sup>Department of Clinical Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles CA; <sup>3</sup>Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia PA; <sup>4</sup>Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia PA; <sup>5</sup>Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA; <sup>5</sup>Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA; <sup>6</sup>University of Pennsylvania School of Veterinary Medicine, Philadelphia PA

Acknowledgements: NIDDK/K12DK094723 (SEM); NIDDK/K23DK102659 (SEM); CHOP CTRC: NIH National

Center for Advancing Translational Sciences (NCATS): UL1TR000003, UL1TR001878. We appreciate assistance with recruitment from the Friedreich's Ataxia Research Alliance (FARA) and North American Mitochondrial Disease Consortium (NAMDC). We also appreciate Dr. Belinda Lennerz sharing technical details regarding test meal preparation.

Introduction: Individuals with Friedreich's Ataxia (FA) and other disorders affecting the mitochondria are at increased risk of diabetes mellitus, a condition for which nutrition plays a critical role in management. The "glycemic index" (GI) of a food refers to its tendency to raise blood glucose. The objective of this study was to test the effect of low- versus high-GI meals on glucose and lactate homeostasis and cognition in individuals with mitochondrial diseases.

Methods: We performed a randomized, double-blinded, crossover study in adults (n=17) with primary mitochondrial disorders (NCT02284334). On two separate occasions, in random order, participants received a low-GI (37/100) or a high-GI (84/100) test "shake", with identical proportions of energy from carbohydrate (59%), protein (15%), and fat (26%). Measurements were made every 30 minutes for 4 hours of blood glucose and lactate. Cognitive testing (computerized test of sustained attention and vigilance) was administered 2 and 4 hours after each meal.

Results: Ten of 17 participants had FA. 15/17 participants completed both visits. 52% (9/17) were female, mean age was 40 years (SD 14, range, 18 – 62). After the high-GI meal, maximum blood sugar was 150 mg/dL, versus 125 mg/dL after the low-GI meal ( $p=0.00075$ , mixed effects

regression analysis). After the high- GI meal, 61% of participants experienced a late blood sugar decrease to <70 mg/dL, versus 14% after the low- GI meal ( $p=0.0052$ , Fisher's exact test). Using mixed-effects multivariate linear regression analysis, we found a 14% reduction in lactate area under the curve (AUC) following the low-GI meal as compared to the high-GI meal (SE = 6.5%,  $p=0.047$ , accounting for age). With respect to cognitive testing, at the 4-hour time point only, sustained attention (ability to continuously discriminate targets from non-targets) was worse during the high-GI meal (unadjusted  $p$ -value=0.03, by paired t-test).

Conclusions: Low-glycemic index sources of nutrition may offer advantages in individuals with FA. The role of nutrition in the management of conditions affecting the mitochondria should be the focus of future study.

## 126. Motor GABA levels predict clinical impairment in children with Friedreich ataxia

William Gaetz, Tim Roberts, Luke Bloy, Tim Boorady, Sudha Kilaru Kessler, David Lynch

The objective of this study is to observe the relationship between estimates of GABA levels, derived from edited magnetic resonance spectroscopy (MEGAPRESS-MRS), and clinical scores of impairment in children and adults with Friedreich Ataxia (FRDA). FRDA is debilitating life-shortening degenerative neuro-muscular disorder which presents in childhood and leads to progressive ataxia (e.g., lack of muscle coordination affecting speech, sensory and motor impairments of the limbs etc.). While no cure exists, several potential therapies are under development. Direct measurement of the relevant neurophysiologic parameters is necessary in order to understand the specific effects of different therapies on the pathways involved in FRDA. Our pilot work suggests that MRS GABA/Cr concentration from primary motor regions may yield correlates of impairment shown in FRDA.

Spectrally-edited MEGAPRESS (TE 80ms) MRS from left-hemisphere MI 3x3x3 cm<sup>3</sup> voxels were obtained in a cross-section of children and adults with FRDA ((N=13; age 11.3 to 34.6 years). Clinical measures of impairment included the Friedreich Ataxia Rating Scale (FARS) battery which includes: timed 25 foot walk, 9-hole peg test, low contrast letter acuity, quality of life measures, ataxia disability score, and ataxia activities of daily living (ADL). Pearson correlation of the GABA/Cr value and corresponding FARS score shows a non-significant trend  $p<0.11$ . Future work will attempt to determine 1. The degree to which these scores are due to changes in cortical thickness within the prescribed GABA voxel 2. The functional (neural and behavioral) correlates of GABA/Cr downregulation in motor regions in FRDA.




Figure 1: MRS Motor voxel GABA. Left: GABA concentration from primary motor cortex (MI) is associated with Friedreich Ataxia Rating Scale values (FARS; large numbers = greater impairment). This demonstration of MI GABA predicting baseline FARS scores represents a novel and promising biomarker for gene therapy.

127. [Biomarkers in FRDA cardiomyopathy to monitor disease progression](#)

Martin, AS1,2, Wagner, G1, Cui, H1, Muehlbauer, MJ1, Payne, RM3, and Hirschey, MD1,2,4  
 1Duke Molecular Physiology Institute, Duke University Durham, NC; 2Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC; 3Department of Medicine, Division of Pediatrics, Indiana University, Indianapolis, IN; 4Department of Medicine, Division of Endocrinology, Metabolism, & Nutrition, Duke University Medical Center, Durham, NC

Background/Hypothesis: A clinical hallmark of Friedreich's Ataxia (FRDA) is severe cardiomyopathy, which is the most frequent cause of death in FRDA patients (1). Treatments for FRDA cardiomyopathy are limited by our inability to monitor changes in disease progression with therapeutic intervention. Thus, we measured protein biomarkers coupled with metabolite profiling to identify serum markers that accurately reflect the stages in FRDA cardiomyopathy progression.

Methods: 5 controls and 11 FRDA patient serum samples were provided by Dr. Mark Payne with clinical information (e.g. parameters: clinical profiling, electrocardiography, EKG; echocardiography, ECHO). We used mass spectrometry to identify acylcarnitines (ACs) and amino acid (AAs), and ELISA multiplex technology to identify protein metabolites. Mean difference statistical analysis was used to identify parameters with significant difference between controls and FRDA patients. These select parameters were then used as the predictor variables in our linear regression models. To determine statistical significance, Bonferroni and Benjamini-Hochberg adjustments were performed at level  $\alpha = 0.05$ ,  $\alpha = 0.25$  and  $\alpha = 0.50$ .

Results/Conclusions: In addition to the EKG and ECHO measures identified as predictor variables, we also used the FRDA-specific parameters age of onset and repeat length. In contrast to the literature, repeat length (long or short allele) poorly correlated with the other clinical parameters and the response variables. Cardiac-specific measures EKG measures and ECHO left ventricular wall thickness demonstrated a strong ( $\alpha = 0.05$ ), positive correlation with even-chained acylcarnitines (ACs). This indicates increased ACs with left ventricular

hypertrophy and abnormal shifts in cardiac conduction. These findings are consistent with the literature which describes a strong association between elevated serum even-chained ACs and increased risk of cardiovascular death in patients with stable angina pectoris (2).

Future Studies: We are currently conducting a two-stage analysis, validating our findings with more serum collections from new patients.

1. Koeppen AH, Becker AB, Feustel PJ, Gelman BB, Mazurkiewicz JE. The significance of intercalated discs in the pathogenesis of Friedreich cardiomyopathy. *Journal of the Neurological Sciences* 2016;367:171–176.

2. Strand E et al. Serum Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in Patients With Stable Angina Pectoris. *Journal of the American Heart Association* 2017;6(2):e003620.

### 128. Correlation between GAA expansion length and frataxin upregulation in Friedreich's ataxia

McAteer S1, Bayot A, Abeti R1, Giunti P1

1 Department of Molecular Neuroscience, Institute of Neurology, UCL, Ataxia Centre, London UK

Introduction: Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disorder resulting from an unstable GAA repeat expansion situated in intron 1 of the frataxin (FXN) gene, which encodes the mitochondrial protein frataxin (FXN). This pathogenic expansion causes epigenetic silencing of FXN resulting in a reduced production of frataxin in patients leading to the FRDA disease phenotype. Specifically, the size of the shorter expanded allele is inversely correlated with disease onset and progression, where late-onset and slower progressing cases are associated with smaller GAA expansions. Various compounds have been shown to upregulate the levels of FXN in FRDA, either in vivo or in vitro, including several histone deacetylase (HDAC) inhibitors and vitamins. We identified four compounds (Nicotinamide, Thiamine, BIX-01294, benzamide HDAC inhibitor 109) that although have been proven to upregulate FXN, have reported variable efficacy, which has been suggested to be due to different expansion lengths in FRDA patients. Therefore, we investigated the correlation between the efficacy of these compounds in upregulating FXN and different GAA repeats expansion lengths present in FRDA patients.

Methods: To this purpose, peripheral blood mononuclear cells (PMBCs) were extracted from several FRDA patients and controls. PMBCs were treated with each compound. FXN mRNA and protein levels were assessed in untreated and treated PMBCs via qPCR and Western Blot. To determine the length of GAA repeats expansion, long-range PCR was applied.

Results: Based on previous investigations and initial data we report that the pathogenic expansion length in FRDA patients appears to have an inverse correlation with FXN upregulation.

Conclusions: Our findings demonstrate that future treatments aimed at upregulating frataxin in FRDA should be determined by personalised medicine based on the genetic profile of individual patients.



129. Targeted quantitation of coenzyme A metabolites and serum apolipoprotein A-I by LC-MS for monitoring mitochondrial dysfunction in Friedreich's ataxia

Wang QQ1, Guo L1, Mesaros C1, Strawser CJ2, Hauser L2, Hwang WT1, Lynch DR2, Blair IA1  
1 Penn SRP Center and Center of Excellence in Environmental Toxicology, University of Pennsylvania, Philadelphia, PA 19104

2 Departments of Neurology & Pediatrics, The Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104

Introduction: Friedreich's ataxia (FRDA) is associated with decreased levels of frataxin mRNA and mature frataxin protein. There is increasing evidence from studies with frataxin-deficient cells, mouse models and human tissues that this results in mitochondrial dysfunction together with changes in fatty acid oxidation and lipid metabolism.

Methods: Stable isotope dilution liquid chromatography-mass spectrometry (LC-MS) coupled with [13C]-labeling and isotopologue analysis were used to characterize the metabolic derangement in lipid metabolism in FRDA platelets. Highly specific and accurate LC-MS assay for serum apolipoprotein A-I (ApoA-I) using a stable isotope labeled protein internal standard was employed to quantify ApoA-I in serum samples from FRDA patients.

Results: A significant decrease in labeling from [13C6]-glucose to into M+2 for 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA, an intermediate in the mevalonate and ketogenesis pathways) was revealed in FRDA platelets ( $10.3 \pm 7.3\%$ ,  $P < 0.05$ ) when compared to controls ( $16.7 \pm 4.8\%$ ). In contrast, there was a significant increase in labeling from [13C16]-palmitate into M+4 for HMG-CoA in FRDA platelets ( $13.3 \pm 4.9\%$ ,  $p < 0.001$ ) when compared to controls ( $4.8$

$\pm 2.6\%$ ). These metabolic changes led us to analyze serum Apo A-I, which revealed that levels were reduced in FRDA ( $129.4 \pm 26.0$  mg/dL,  $n=50$ ) when compared to controls ( $166.6 \pm 37.2$  mg/dL,  $n=50$ ). Experiments conducted in FXN knock-down HepG2 cells, showed a significant decrease in ApoA-I biosynthesis. A pilot study of statins in FXN knock-down HepG2 cells also revealed an increase of ApoA-I level along with decreased HMG-CoA.

Conclusions: Targeted quantitation of platelet acyl-CoA thioester metabolites and serum ApoA-I by LC-MS has provided biomarkers for monitoring the treatment of mitochondrial dysfunction in FRDA. The reduced serum ApoA-I levels found in FRDA can potentially be normalized by statin treatment.

Supported by NIH grant P30ES013508 and The Penn/CHOP Center of Excellence in Friedreich's ataxia.

130. Living with Ataxia in Ireland 2016—a nationwide survey of 130 Irish patients with inherited Ataxia

Petya Bogdanova-Mihaylova1, Richard A Walsh & Sinéad M Murphy1,2

1National Ataxia Clinic, Department of Neurology, Adelaide & Meath Hospital Dublin incorporating the National Children's Hospital, Tallaght, Dublin 24, Ireland

2Academic Unit of Neurology, Trinity College Dublin, Ireland

Introduction

Background: In Ireland a handful of neurologists manage the majority of people with inherited ataxia. With little information in the literature and with the support of the national patient organisation people with different types of ataxia were asked to complete a comprehensive survey to evaluate disability, resource use and QoL.

Objective: To collect real-life data from a large cohort of patients with inherited ataxia in Ireland, with special attention to the individual ataxia-related healthcare resources and costs, disability due to the disease and quality of life (QoL) measures. We aimed to compare responses of patients from a heterogeneous population across groups of all ages, different underlying genetic causes and disease durations.

#### Methods

Over 250 anonymous surveys were distributed in clinics, by post and at ataxia meetings nationwide. We report observational descriptive data and compare groups using non-parametric statistics.

#### Results

One hundred and thirty patients (45% males) responded. Seventeen percent were <25 years of age, 31% were >60 years old. Nine percent were working full or part time, 47% were unable to work or retired early due to ataxia. Thirty-nine percent were wheelchair-bound. Fifty-nine percent had symptom onset <20 years, 23% had late onset >40 years. As expected, the majority (42%) had Friedreich's ataxia, 28% did not have genetic diagnosis. Forty-five percent relied on professionally paid care. Group comparisons and QoL data will be reported.

#### Conclusions

To date this is the first study in Ireland and the largest single-country 'real-life' patient survey in Europe looking at patients with various types of inherited ataxia with comprehensive data on disability, healthcare resource use and QoL.

### 131. Longitudinal change of gait and balance in individuals with Friedreich ataxia

Milne SC1,2,3, Kim SH4, Murphy A2,5, Zesiewicz T4, Danoudis M2,5, Shaw J4, Malapira R4, Yiu E1,6,7, Georgiou-Karistianis N3, Delatycki MB1,3,8, Corben LA1,3,6.

1Murdoch Childrens Research Institute, Bruce Lefroy Centre, Australia.

2Monash Health, Australia.

3Monash University, Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Australia.

4University of South Florida, Tampa, Florida, USA.

5Monash University, Monash Ageing Research Centre, Australia.

6The University of Melbourne, Department of Paediatrics, Australia.

7The Royal Children's Hospital Melbourne, Department of Neurology, Australia.

8Victorian Clinical Genetics Services, Australia.

Introduction: Gait ataxia and instability are common presenting features of Friedreich ataxia (FRDA). Mobility declines with disease progression until ambulation is no longer possible, approximately 10- 15 years following initial symptoms. This study aims to determine valid and responsive gait and balance outcome measures to detect progressive change over 12 months for individuals with FRDA. Methods: Forty-two individuals with FRDA underwent assessment at baseline and six months (12- month data is being collected). Measures included (i) gait parameters at preferred and fast speeds using the GAITrite® instrumented walkway, (ii) Biodex Balance System™ SD postural stability test (PST) and limits of stability (LOS), (iii) Berg Balance Scale (BBS), (iv) Timed 25 Foot Walk Test and (v) Dynamic Gait Index. Correlations between objective measures, the Friedreich Ataxia Rating Scale (FARS) neurological exam, Scale for the Assessment and Rating of Ataxia (SARA) and disease characteristics were examined. The standardised response mean was reported as the effect size index for comparison of internal responsiveness. Results: Significant correlations were found between the BBS and SARA ( $p<0.001$ ). A lower LOS score was associated with earlier disease onset ( $p=0.002$ ) and a higher

FARS score ( $p < 0.001$ ). The SARA and FARS did not detect a significant change over six months. However, the BBS significantly decreased with an effect size index (ES) of  $-2.36$  ( $p = 0.026$ ) over this time period. Similarly, the PST anterior-posterior index with eyes-closed detected balance decline ( $ES = 1.00$ ,  $p = 0.026$ ). A significant decrease in normalized stride length during fast walking was also evident ( $ES = -0.54$ ,  $p = 0.040$ ). Conclusions: The BBS, PST anterior-posterior index with eyes-closed and normalized stride length are more sensitive to the decline in individuals with FRDA as compared to previously validated measures of disease severity, the SARA and FARS. These gait and balance measures may provide sensitive, objective, and clinically meaningful measurements for use in clinical trials and therapeutic interventions.

### 132. Allelic CACNA1A disorders: a retrospective cohort analysis on clinical course and overlapping features

Wolfgang Nachbauer<sup>1</sup>, Patrick Dorin<sup>1</sup>, Elisabetta Indelicato<sup>1</sup>, Andreas Eigentler<sup>1</sup>, Sylvia Boesch<sup>1</sup>.

<sup>1</sup> Department of Neurology, Medical University Innsbruck, Austria.

#### Objective

To (1) retrospectively study emerging clinical symptoms and disease course in a cohort of patients with genetically proven CACNA1A mutations and (2) to define occurrence and frequency of overlapping clinical features.

#### Background

The CACNA1A gene encodes for the pore forming alpha 1A subunit of the P/Q-type voltage-gated calcium channel (Cav2.1). Mutations in the CACNA1A gene are known to cause the three allelic disorders spinocerebellar ataxia type 6 (SCA6), episodic ataxia type 2 (EA2) and familial hemiplegic migraine type 1 (FHM1).

#### Methods

Patients with genetically proven CACNA1A mutations were identified from the clinical database of the Department of Neurology at the Medical University Innsbruck. Medical records were systematically analyzed for demographics, clinical manifestations at onset and in later disease course. Characterization of episodic symptoms was carried out using a standardized protocol considering frequency, duration and associated symptoms.

#### Results

46 patients with a mean age of 50 years (range: 6 – 86) were identified from the database. Mean age of onset was 26 years with significant lower onset in EA2 and FHM1 as compared to SCA6. Frequency of attacks was highest in the EA2 group, whereas duration of attacks was considerable longer in FHM1. 14% of SCA6 patients exhibited episodic symptoms mainly short lasting vertigo and gait ataxia, which were evident in early disease and preceded the chronic cerebellar syndrome. Triggers for attacks were mainly identified in EA2 comprising emotional stress, physical exercise and caffeine. Most common ictal symptoms were gait ataxia and dysarthria, which also occurred in one third of FHM1 patients during attacks. Conversely 50% of EA2 patient had a history of migraine associated with attacks or occurring independently. Interictal cerebellar signs were observed in 85% of EA2 and 71% of FHM1 patients. Gaze evoked nystagmus therefore was the most prominent cerebellar feature. Progression of cerebellar syndrome in EA2 and FHM1 was mild over the observation period.

#### Conclusion

This retrospective analysis further demonstrates high phenotypic variability in allelic CACNA1A disorders. Distinctive clinical manifestations are present in some mutations. In a greater part

overlap between these disorders is observed in both ictal as well as interictal symptoms and most prominent between EA2 and FHM1.

### 133. The autonomic nervous system in Friedreich's Ataxia: preliminary findings

Indelicato E1, Fanciulli A1, Nachbauer W1\*, Wanschitz J1, Wenning GK1 and Boesch S1

1Department of Neurology, Medical University Innsbruck

\*Presenting author

**Introduction:** FRDA is a hereditary neurodegenerative disorder characterized by progressive gait ataxia, dysmetria and dysarthria. Further features are hypertrophic cardiomyopathy and diabetes mellitus. The disease is caused by an intronic GAA expansion in the FXN gene. Age at onset and disease severity strongly correlates with the length of the shorter GAA repeat (GAA1). The neurodegeneration in FRDA primarily involves the dorsal root ganglia and large myelinated nerve fibers in peripheral sensory nerves. Recently an involvement of small unmyelinated fibers has been demonstrated in skin biopsy of FRDA and it has been correlated with disturbances in temperature and pain perception. The presence of autonomic correlates was not investigated yet in genetically confirmed cases.

**Methods:** Eighteen genetically confirmed FRDA patients were consecutively enrolled. Each patient underwent a laboratory work-up and echocardiography to rule out diabetes and cardiomyopathy respectively. Disease severity was quantified through the SARA scale. Autonomic function was investigated by means of a cardiovascular tests battery (head-up tilt, active standing, Valsalva maneuver and deep breathing), the skin sympathetic reflex and the SCOPA-aut autonomic questionnaire.

**Results:** Mean age at examination was  $40 \pm 14$  years and mean SARA score was 22. The average GAA1 repeats were  $500 \pm 310$  and mean disease duration was  $19 \pm 10$  years. Two patients had impaired glucose tolerance and were excluded from autonomic evaluation. Abnormal autonomic findings were found in 8 patients (50%). Two out of 10 patients (20%) had delayed orthostatic hypotension, while 3/10 (30%) and 4/12 (33%) had abnormal Valsalva and Deep Breathing ratio respectively. Skin sympathetic reflex was absent in 4/12 patients (33%). The mean SCOPA-AUT was 12 (range: 3-27). No difference regarding age at examination, GAA1 repeats, disease duration and severity, was found in the comparison between the patients with or without abnormal autonomic findings.

**Conclusion:** We observed subtle alterations of autonomic function in our FRDA cohort independently from disease severity. That could be attributed to multiple determinants as well as to an impairment of peripheral autonomic relays.

### 134. Peripheral blood gene expression biomarkers in Friedreich's ataxia patients

Nachun, D.1, Gao, F.1, Isaacs, C.2, Yang, Z.1, Dokuru, D.1, Van Berlo, V.1, Sears, R.1, Farmer, J.3, Perlman, S.4, Lynch, D.2, Coppola, G.1,4

1UCLA Department of Psychiatry and Semel Institute, Los Angeles, CA

2Children's Hosp. of Philadelphia, Philadelphia, PA 3Friedreich's Ataxia Res. Alliance,

Downingtown, PA 4UCLA Department of Neurology, Los Angeles, CA

**Introduction:** Advances in the understanding of disease pathology in Friedreich's ataxia (FRDA) have led to the development of a large number of candidate treatments. However, evaluating the effectiveness of these treatments is challenging because the disease progresses relatively slowly and clinical scales lack the sensitivity to identify short term changes in disease state. The purpose of this study is to find biomarkers in peripheral blood gene expression which can serve as more precise quantifications of disease state in FRDA patients.

Methods: RNA was extracted from peripheral blood from 409 FRDA patients, 226 carriers and 90 unaffected controls. Gene expression was quantified using Illumina HT-12 v4 microarrays. Differential expression analysis was used to identify genes whose expression was significantly different between diagnostic groups, and linear regression was used to identify genes which were correlated with shorter repeat length in patients (GAA1). Network analysis (WGCNA) was used to identify modules of co-expressed genes associated with diagnostic group or GAA1. Machine learning was also used to identify a set of genes which predicted diagnostic group (classification) or GAA1 (regression).

Results: 215 genes were found to be differentially expressed between patients and controls, and 669 genes between patients and carriers. 368 genes were found to be significantly positively or negatively correlated with GAA1. Network analysis identified two modules were significantly different in patients and one module was found to be positively correlated with GAA1. Finally, classifiers for patient vs. control and patient vs. carrier identified 243 genes and 466 genes, respectively, which predicted diagnostic class with high accuracy. The predictive regression model for GAA1 identified 277 genes which predicted GAA1 with low error.

Conclusions: A large number of peripheral biomarkers for FRDA were identified that will be helpful in quantifying disease state and treatment effectiveness.

135. [Corticokinematic coherence in patients with Friedreich ataxia correlates with GAA1 repeat expansion and SARA score](#)

Gilles Naeije (see oral presentations)

136. [Cortical responses and change detection to auditory and somatosensory stimuli in Friedreich ataxia](#)

Naeije G1, Marty B2, Wens V2, Goldman S2, Pandolfo M1, De Tiège X2

1 Service of Neurology, ULB-Hôpital Erasme, Belgium

2 Laboratoire de Cartographie fonctionnelle du Cerveau (LCFC), ULB Neuroscience Institute, Belgium

Introduction

Neurophysiological assessment of the proprioceptive and cerebellar systems, whose dysfunction and degeneration underlie the afferent and cerebellar ataxia characterizing Friedreich ataxia (FRDA), may define the severity and timing of their involvement, guide the identification of therapeutic targets, and provide biomarkers reflecting disease status, progression and response to treatments.

Previous studies on evoked potentials (EPs) in FRDA proposed that impairment in somatosensory EPs (SSEPs) correlates with GAA1 and does not change with disease progression, while impairment in brainstem auditory EPs (BAEPs) was reported to correlate with disease duration, suggesting an early and stable deficit in somatosensory processing and a progressive involvement of the auditory system. However, a limitation of SSEP studies is the complete loss of these responses in most FRDA subjects, even at a young age, a finding we could confirm with our patients.

Methods

We used magnetoencephalography (MEG) to study cortical evoked responses of FRDA subjects to somatosensory and auditory stimuli, with the assumption that this technology might allow to detect responses even when traditional EPs cannot be measured, and add temporal and spatial resolution to the analysis. We also explored MEG signals generated by sensory change detection, which are thought to be modulated by the cerebellum. In traditional EP protocols,

an increased evoked response, called mismatch negativity (MMN), is observed when a deviant stimulus occurs amongst a sequence of repeated standard stimuli. MMN is the correlate of pre-attentional change detection in sensory cortices. An equivalent signal can be measured by MEG. Of notice, unilateral cerebellar lesions lead to near absent MMN for ipsilateral deviant somatosensory stimuli, but have no effect on auditory change detection.

We studied 16 FRDA patients (10 females, 6 males), with a mean age of 30 years (range 9-53) and a mean SARA score of 23.4 (range 9.5-37.5), and 16 healthy controls (9 females, 7 males), with a mean age of 29 years (range 10-55). We recorded whole-scalp MEG (Elekta, Oy) while undergoing (1) a tactile oddball paradigm where standard stimuli consisted of pneumatic stimulation of the right forefinger fingertip and deviant stimuli of simultaneous stimulation of the first two phalanxes; and (2) a monaural auditory oddball paradigm where standard stimuli consisted of audible tones of 540 Hz and deviant stimuli were 600 Hz tones, presented in the right ear. Inverse modelling was done using the Minimum Norm Estimate (MNE). For group analysis, individual source power time series were normalized by the maximum amplitude of standards responses before group averaging, to exclude individual subjects' amplitude effect. We temporally realigned time series on the first peak activation to control for individual responses latencies. We used non-parametric permutation statistic tests to assess significance of evoked responses.

#### Results

Cortical somatosensory evoked responses were found in all subjects at left primary somatosensory cortex (S1). In FRDA subjects their mean latency was significantly longer (53 vs 28 ms;  $p < 0.001$ ), and their mean amplitude was significantly smaller (0.285 vs 0.513;  $p = 0.0041$ ) than in controls. GAA1 negatively correlated with the amplitude of individual S1 responses ( $r = -0.74$ ,  $p = 0.0032$ )

Cortical auditory evoked responses were found in all subjects at primary auditory cortex (A1), bilaterally. In FRDA patients their mean latency was significantly longer than in controls (107 vs 87 ms;  $p < 0.001$ ), but their amplitude was comparable in FRDA and controls (0.507 vs 0.45;  $p = 0.25$ ). GAA1 negatively correlated with individual A1 responses ( $r = -0.56$ ,  $p = 0.036$ ) of FRDA subjects.

Larger amplitude responses to deviant stimuli, the MEG equivalent of MMN, were found in controls and FRDA patients at left secondary somatosensory cortex (S2), with a delay of 100-200 ms; but also at left S1 in FRDA patients, with a delay of 50-78ms.

The normalized magnitude of deviant stimuli responses was significantly smaller for FRDA patients, and negatively correlated with GAA1 ( $r = -0.6$ ,  $p = 0.023$ ).

Similarly, responses to deviant auditory stimuli were found in patients and controls over the left superior temporal lobe, with a delay between 150-200ms and comparable normalized magnitudes for both groups.

#### Conclusions

MEG allows to detect cortical responses to tactile stimuli in all FRDA patients, even when SSEPs are absent. These responses are delayed and reduced in amplitude. Cortical auditory responses are not decreased in amplitude, but show increased latency. In both cases, impairment is seemingly unrelated to disease progression and only correlates with mutation severity, indicating that these parameters are biomarkers of early sensory damage. Cortical responses to deviant somatosensory stimuli (corresponding to MMN) are normally measured at S2 only, as it was the case with our controls, but in FRDA subjects they occurred in S1 as well.

137. Causal factors behind early- and late-onset Machado-Joseph disease patients do not interfere with the rate of neurological deterioration

Camila Maria de Oliveira<sup>1,2</sup>, Estela Rosa Reckziegel<sup>1,2</sup>, Marina Coutinho Augustin<sup>1,2</sup>, Anastácia Guimarães Rocha<sup>1,2</sup>, Gabriela Bolzan<sup>1,2</sup>, José Augusto dos Santos<sup>1,2</sup>, Gabriel Vasata Furtado<sup>1,3,4</sup>, Eduardo Preusser Mattos<sup>1,3,4</sup>, Maria Luiza Saraiva-Pereira<sup>1,3</sup>, Harm H. Kampinga<sup>5</sup>, Jonas Alex Morales Saute<sup>1,3,6</sup>, Laura Bannach Jardim<sup>1,3,4,6</sup>.

<sup>1</sup>Medical Genetics Service, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil; <sup>2</sup>Faculty of Medicine, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; <sup>3</sup>Genetic Identification Laboratory, HCPA, Porto Alegre, Brazil; <sup>4</sup>Postgraduation program, UFRGS, Porto Alegre, Brazil; <sup>5</sup>Department of Cell Biology, University Medical Center Groningen, Groningen University, Netherlands; <sup>6</sup>Internal Medicine Department, UFRGS, Porto Alegre, Brazil.

**Introduction:** Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion (CAGexp) at ATXN3. CAGexp strongly correlates with age of onset (AO) and protein aggregation propensity. Furthermore, extreme phenotype sampling is a powerful approach to discover additional factors that modulate phenotype. The aim of the present study was to analyse the disease progression in patients with extremely early and late AO.

**Methods:** Extreme outliers for AO-CAGexp were identified within the Rio Grande do Sul SCA3/MJD cohort. Distribution of AO and CAGexp were obtained for the overall cohort (n=431) and patients with AO more than one standard deviation (SD) above (AOlate) or below (AOearly) their expected AO according to CAGexp were recruited. AOlate (n=15) and AOearly (n=15) groups were examined at baseline and 15±4.7 months later with Neurologic Examination Score for Spinocerebellar Ataxia (NESSCA) and with Scale of Assessment and Rating of Ataxia (SARA). Parametric tests were used in all comparisons.

**Results:** Mean AO were 23.1±9.9 years for AOearly and 47.9±9.2 years for AOlate, which was respectively -1,67±0.55 and +1,60±0.42 SD different from the expected AO of the overall cohort (p<0.0001). Correlation between CAGexp and AO was r=-0.79 (p<0.0001). NESSCA and SARA correlated well with disease duration at baseline (r=0.66 and 0.69, p<0.0001). However, differences in NESSCA and SARA scores at baseline and at follow-up were similar between early- and late-onset groups.

**Conclusion:** Early- and late-onset SCA3/MJD patients showed the same progression rates of disease, as measured with both NESSCA and SARA. This implies that causal factors behind early/late-onset cases, albeit still unknown, are different from those that modulate the speed of neurological deterioration. This finding has large implications for experimental studies on aggregation prevention and disease-onset delay toward clinical utilizations, in terms of preventive or therapeutics applications.

**Funding:** CNPq (project 402968/2012-3), CAPES (project CAPES/NUFFIC 061/15), FIFE 13-303. CMO and GB were supported by FAPERGS; ERR, MCA, GVF, EPM, MLSP and LBJ were supported by CNPq.

138. ARSACS in the UK

MH Parkinson<sup>1,2</sup>, J Hersheson<sup>1</sup>, R Pfund<sup>3</sup>, MM Reilly<sup>2,4</sup>, H Manji<sup>2</sup>, H Houlden<sup>1,2</sup>, NJ Wood<sup>1,2</sup>, SR Hammans<sup>5</sup>, PF Chinnery<sup>6</sup>, F Bremner<sup>2</sup>, P Giunti<sup>1,2</sup>

Contact details: Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK

Email: m.parkinson@ucl.ac.uk; michael\_h\_parkinson@hotmail.com

- 1 Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
- 2 National Hospital for Neurology & Neurosurgery, Queen Square, London, UK.
- 3 Department of Human Genetics, Radboud University, Nijmegen Medical Centre, Nijmegen, Netherlands.
- 4 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK. Include Newcastle and Southampton collaborators
- 5 Wessex Neurological Centre, Southampton General Hospital, Southampton, UK.
- 6 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

**Introduction:** Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a rare, early-onset neurodegenerative disorder characterized by progressive neuropathy, ataxia, spasticity and other pyramidal signs. The condition was first described in Québec where a small number of mutations was responsible. There is evidence that the condition differs genetically and phenotypically outside Québec. Private mutations are common. Little is known about the clinical and genetic profile of ARSACS in the UK.

**Methods:** Patients with ARSACS were recruited from around the UK. A structured history was elicited and details of associated symptoms were recorded. Functional disability was assessed using the 9-field Activities of Daily Living (ADL) section of the Friedreich's Ataxia Rating Scale (FARS) and the Spinocerebellar Degeneration Functional Score (SDFS). Physical signs were assessed using the Scale for the Assessment and Rating of Ataxia (SARA) and the Inventory of Non-Ataxic Symptoms (INAS). Details of imaging and neurophysiology were collected. SACS gene mutations were identified using standard sequencing techniques as well as an Illumina MiSeq parallel sequencing panel.

**Results:** Twenty-six patients with ARSACS were recruited from 16 families (mean age at onset  $15.0 \pm 17.4$ , range 0-51; mean disease duration  $28.5 \pm 12.9$ , range 8-56). They carried 30 different mutations which were a mixture of missense and nonsense point mutations and large deletions. They included 9 novel mutations. The mean ADL score was  $15.9 \pm 7.7$  out of 36. The mean SARA was  $16.0 \pm 7.7$  out of 40. The INAS revealed hyperreflexia in 46.2%, areflexia in 73.1%, extensor plantar reactions in 84.6%, spasticity in 88.5%, paresis in 76.9% and amyotrophy in 42.3%. Only 19.6% required a wheelchair in the SDFS. 92.3% had skeletal foot abnormalities. 30.8% had hearing problems. 19.2% had epilepsy. 26.9% complained of urinary problems. Nerve conduction studies showed evidence of mixed sensorimotor neuropathy. Neuroimaging commonly showed superior vermal cerebellar atrophy and spinal cord thinning. Pontine hypodensities were only seen in 25%.

**Conclusions:** This study considerably extends knowledge of the genetic diversity and phenotypic spectrum of ARSACS in patients from the UK and is the first large prospective study in the UK. It confirms previous descriptions of ARSACS as causing early onset gait disturbance, followed by spasticity, ataxia and distal sensory loss predominantly affecting the lower limbs. The deep tendon reflexes show a mixed pattern with areflexia commoner than hyperreflexia. Plantar reflexes are typically extensor. Skeletal foot abnormalities are very common. The cohort includes atypical late-onset cases and a higher prevalence of epilepsy than has previously been described.

### 139. Searching for neuroimaging biomarkers in SCA1

Camila C. Piccinin<sup>1</sup>, Carlos R. Martins Jr<sup>1</sup>, Thiago J. R. Rezende<sup>1</sup>, Iscia Lopes- Cendes<sup>2</sup>, Marcondes C. França Jr<sup>1</sup>

Departments of Neurology<sup>1</sup> and Medical Genetics<sup>2</sup>, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil



Introduction: Spinocerebellar ataxia type 1 (SCA1) is characterized pathologically by cerebellar and brainstem damage. Despite that, there are very few neuroimaging studies that addressed simultaneously cerebellar cortex (gray matter – GM) and cerebellar connections (white matter – WM). Our objective was to characterize structural abnormalities in these areas using a multimodal imaging approach. We were ultimately interested in exploring these parameters as possible biomarkers for the disease. Methods: Images of 29 genetically confirmed SCA1 patients (mean-age  $45.6 \pm 9.6$ ) and 29 age-gender-matched healthy controls (HC) ( $45.3 \pm 9.7$ ) were acquired on a 3T scanner. Multi-atlas segmentation was used for brainstem analysis while SUIT tool (Spatial Unbiased Infratentorial Template) for voxel-based morphometry performed a detailed evaluation of the cerebellar GM. WM integrity was assessed using Diffusion tensor imaging (DTI) and specific tracts were segmented using the multi-atlas approach. Groups were compared using Analysis of Covariance.

Age and gender were taken as covariates as well as total intracranial volume in Multi-atlas analyses. Pearson correlation was performed between the altered areas and the Scale for the assessment and rating of ataxia (SARA). Results: There was a significant volumetric reduction in the pons and medulla in SCA1 patients ( $p < .001$ ). SUIT tool analyses showed widespread GM reduction in cerebellar lobules and vermis (FWE-corrected  $p < 0.05$ ). DTI identified significant changes ( $p < .001$ ) of fractional anisotropy, axial diffusivity, mean diffusivity and radial diffusivity in all structures analyzed. Finally, SARA scale showed a significant correlation with most of the injured areas. Conclusions: By performing a multimodal evaluation, our study confirmed and well-delineated GM and WM changes in the cerebellum and connections in SCA1. It also unraveled microstructural WM abnormalities in the cerebellar peduncles. The correlation with SARA favors the hypothesis of using image parameters as future biomarkers of the disease.

#### 140. BCL2 and HSPB1 as potential molecular biomarkers of Spinocerebellar Ataxia Type 3 progression: results from a longitudinal study.

Raposo M1,2,3, Bettencourt C4, Vasconcelos J5 & Lima M1,2,3

1. Departamento de Biologia, Faculdade de Ciências e Tecnologia, Universidade dos Açores (UAc), Ponta Delgada, Portugal
2. Instituto de Investigação e Inovação em Saúde (I3S), Porto, Portugal
3. Instituto de Biologia Molecular e Celular (IBMC), Porto, Portugal
4. Department of Molecular Neuroscience and Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
5. Serviço de Neurologia, Hospital do Divino Espírito Santo (HDES), Ponta Delgada, Portugal

Introduction: Whereas spinocerebellar ataxias (SCAs) remain without treatment, testing disease-modifying compounds in interventional trials has started; methods to detect subtle therapeutic benefits are needed though. Efforts are being made to find a battery of potential sensitive outcome measures, including molecular biomarkers (MBs), capable of fine tracking disease progression and contribute to further understanding of the pathogenic processes underlying these disorders. Our group has been identifying novel MBs of spinocerebellar ataxia type 3 (SCA3)/Machado-Joseph disease (MJD); in a previous cross-sectional study HSPB1 and BCL2 mRNA levels were significantly reduced in blood samples of SCA3 patients, when compared to controls. In this work, expression levels of these two genes were further evaluated using a longitudinal design to test their potential as biomarkers of SCA3 progression.

Methods: Blood samples from 33 SCA3 patients were collected at the baseline of the study and at a second visit. mRNA levels of BCL2 and HSPB1 were measured by fluorescence-based quantitative real-time PCR (qPCR) and statistical procedures for related samples were applied. Unstandardized residuals from a linear regression test were used to account for irregular intervals of blood sampling and disease duration between patients.

Results: BCL2 and HSPB1 adjusted mRNA levels were found to be significantly increased from the baseline to the second moment. Noteworthy, an increase in the expression levels was observed for BCL2 in all 33 patients analysed ( $t(32)=-23.728$ ,  $p<0.005$ ); up-regulation of HSPB1 mRNA levels was obtained in 32 of the 33 patients ( $t(32)=-9.335$ ,  $p<0.005$ ).

Conclusions: This is the first longitudinal study investigating molecular alterations in blood samples of SCA3 patients. A clear pattern of BCL2 and HSPB1 dysregulation during disease progression strongly suggests they are good MBs for SCA3. To further assess this hypothesis, validation in a larger cohort as well as in an independent set of patients is warranted.

#### 141. MR imaging of the spinal cord and brain in Friedreich's Ataxia

Imis Dogan<sup>1,2</sup>, Sandro Romanzetti<sup>1,2</sup>, Shahram Mirzazade<sup>1,2</sup>, Carsten Saft<sup>3</sup>, Matthis Synofzik<sup>4,5</sup>, Dagmar Timmann<sup>6</sup>, Ilaria A. Giordano<sup>7,8</sup>, Thomas Klockgether<sup>7,8</sup>, Jörg B. Schulz<sup>1,2</sup>, Kathrin Reetz<sup>1,2</sup>

1Department of Neurology, RWTH Aachen University, Aachen, Germany / 2JARA-BRAIN Institute Molecular Neuroscience and Neuroimaging, Forschungszentrum Jülich GmbH and RWTH Aachen University, 52074 Aachen, Germany / 3Department of Neurology, Huntington-Centre NRW, St. Josef Hospital, Ruhr-University of Bochum, Germany / 4Department of Neurodegeneration, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany, / 5German Center for Neurodegenerative Diseases (DZNE), Tübingen / 6Department of Neurology, Essen University Hospital, Essen, Germany / 7Department of Neurology, University Hospital of Bonn, Bonn, Germany / 8German Center for Neurodegenerative Diseases (DZNE), Bonn

##### Introduction:

Friedreich's ataxia (FRDA), the most common inherited ataxia, is a spinocerebellar neurodegenerative disorder. Neuronal loss mainly affects the spinal cord, medulla and cerebellum, but also supratentorial cortical areas. The aim was to evaluate the extent of both spinal cord and brain degeneration in FRDA using magnetic resonance imaging (MRI).

##### Methods:

21 genetically confirmed FRDA patients (mean age  $35.0\pm 12.2$  years, 10 male) and 21 age- and gender-matched healthy controls ( $34.4\pm 12.0$  years, 10 male) underwent 3T MRI of the spinal cord and brain using 3-dimensional T1-weighted gradient-echo sequences. Semiautomatic segmentation procedures were applied to measure the cross-sectional area and volume of each section of the cervical and thoracic spinal cord (C1-C7, T1-T10), as well as of volumes of the brainstem, cerebellum, and cortical lobes. Associations of volumetric data with ataxia severity (Scale for the Assessment and Rating of Ataxia, SARA) and ataxia behavioral measures (Spinocerebellar Ataxia Functional Index, SCAFI) were assessed using partial correlations adjusted for age.

##### Results:

The entire spinal cord in patients with FRDA was flattened showing large effect sizes compared to controls (cervical: Cohen's  $d = 0.87$  [C7] to  $1.75$  [C3], thoracic:  $0.82$  [T10] to  $1.90$  [T2]). For brain measures, most pronounced atrophy was observed in the medulla ( $d=1.80$ ), pons ( $d=0.91$ ), midbrain ( $d=1.06$ ), and cerebellar white matter ( $d=0.86$ ). Cortically, we found volume reductions in frontal ( $d=0.87$ ) and occipital lobes ( $d=0.76$ ). While both spinal

data and cerebellar white matter correlated with SARA ( $r=-0.47$  to  $-0.56$ ), brainstem and cerebellar volumes were also associated with SCAFI performances (9-hole-peg-test:  $-0.46$  to  $-0.64$ ).

Conclusions:

Our results demonstrate the extent of atrophy not only of the spinal cord, but also of the cerebellum and brainstem associated with different aspects of disease severity in FRDA. Thus, if confirmed in longitudinal studies, both spinal and brain MRI may serve as surrogate endpoints in future clinical trials.

#### 142. Structural signature of classical vs late-onset Friedreich's ataxia by multimodality brain MRI

Thiago Junqueira R. Rezende<sup>1</sup>, Msc, Alberto Rolim M. Martinez<sup>1</sup>, MD, Ingrid Faber<sup>1</sup>, MD, Karen Giroto<sup>1</sup>, MD Msc, José Luiz Pedroso<sup>2</sup>, MD PhD, Orlando G. Barsottini<sup>2</sup>, MD PhD, Iscia Lopes-Cendes<sup>3</sup>, MD PhD, Fernando Cendes<sup>1</sup>, MD PhD, Andreia V. Faria<sup>4</sup>, MD PhD, Marcondes C. França Jr<sup>1</sup>, MD PhD.

<sup>1</sup> Department of Neurology and Neuroimaging Laboratory, School of Medical Sciences, University of Campinas (UNICAMP), Campinas SP, Brazil

<sup>2</sup> Division of General Neurology and Ataxia Unit, Federal University of São Paulo, São Paulo SP, Brazil

<sup>3</sup> Department of Medical Genetics, School of Medical Sciences, University of Campinas (UNICAMP), Campinas SP, Brazil

<sup>4</sup> Department of Radiology, Johns Hopkins University School of Medicine, Baltimore MD, USA

**Introduction:** Friedreich's ataxia (FRDA) is the most common autosomal-recessive ataxia worldwide. It is clinically characterized by sensory abnormalities, slowly progressive ataxia and early onset, mostly in childhood and adolescence. However, there is a sub-group of patients with FRDA that manifest the disease after the age of 25 years and is classified as late-onset FRDA (LOFA). Therefore, we propose a transversal multimodal MRI-based study to investigate which anatomical substrates are involved in the classical (cFRDA) and LOFA.

**Methods:** We enrolled 36 patients (13 with LOFA) and 29 healthy controls. All subjects underwent magnetic resonance imaging in a 3T device, three-dimensional high resolution T1-weighted and diffusion tensor images were used to assess gray (GM) and white matter (WM) respectively. We used T1 multi-atlas approach to assess deep GM and thickness measures to evaluate cerebral cortex. We also used DTI multi-atlas approach to assess WM. All analyses were corrected for multiple comparisons.

**Results:** Group comparison showed that in both groups there was GM atrophy mostly in the motor cortex. Regarding WM, we found abnormalities in the cerebellar peduncles, pyramidal tracts, midbrain, pons and medulla oblongata for both groups, but the microstructural abnormalities in the cFRDA group were more widespread and severe. However, we found that the corticospinal tract presented more severe microstructural damage in the LOFA group. In addition, the midbrain volume of the cFRDA group correlated with disease duration ( $R=-0.552$ ,  $p=0.012$ ) and severity ( $R=-0.783$ ,  $p<0.001$ ).

**Conclusion:** The cFRDA and LOFA have similar, but not identical neuroimaging damage pattern. The corticospinal tract showed more severe compromise in the LOFA group, which is in line with the more prominent pyramidal signs found in these patients. Midbrain volume is a promising neuroimaging biomarker for clinical trials in cFRDA patients.

143. Differences in cognition between Spinocerebellar Ataxias and Multiple System Atrophy-Cerebellar Type

S Roeske<sup>1</sup>, J Machts<sup>2,5</sup>, I Giordano<sup>1,3</sup>, J Faber<sup>1,3</sup>, H Jacobi<sup>1,6</sup>, IR Vogt<sup>1</sup>, C Schneider<sup>1,3</sup>, I Frommann<sup>1,4</sup>, L Wattenberg<sup>2</sup>, S Vielhaber<sup>2,5</sup>, A Spottke<sup>1,3</sup>, M Wagner<sup>1,4</sup>, T Klockgether<sup>1,3</sup>  
1German Center for Neurodegenerative Diseases, Bonn, Germany 2German Center for Neurodegenerative Diseases, Magdeburg, Germany 3Department of Neurology, University Hospital of Bonn, Bonn, Germany  
4Department of Psychiatry and Psychotherapy, University Hospital of Bonn, Bonn, Germany 5Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany 6Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany

Introduction:

Multiple System Atrophy, cerebellar type (MSA-C) and Spinocerebellar ataxia (SCA) are sporadic and hereditary types of ataxia and share many clinical features but have distinct underlying pathophysiologies leading to progressive neuronal dysfunction. We examined the cognitive performance of these patient groups and of healthy controls (HC) to investigate the impact of these pathophysiological differences on cognition, and also to learn more about cerebellar involvement in cognitive function.

Methods:

We examined 73 MSA-C patients (age 62.0±11.8 years(y), 31 male, disease duration 4.4±2.9y, SARA score 13.4±6.3), 40 SCA patients (age 56.9±13.4y, 25 male, disease duration 9.6±7.3y, SARA score 12.6±6.0) and 21 HC (age 60.2±12.8y, 9 male) with a broad neuropsychological test battery and analyzed the data by multivariate analysis of covariance and partial correlation analysis.

Results:

Compared to HC, both ataxia patient groups were significantly impaired regarding verbal learning, digit span, attentional tasks, working memory, visual-spatial function, verbal fluency and cognitive sequencing. MSA-C patients performed worse than SCA patients in verbal recognition memory and cognitive sequencing (WAIS picture ordering). Analyzing only subjects with normal global cognitive status revealed significantly worse cognitive sequencing performance in ataxia patients; this sequencing impairment was correlated significantly with disease duration in SCA but not in MSA patients.

Conclusions:

Sequencing impairments appear to occur early in SCA and MSA-C, before progressive neurodegeneration affects other functions. The present data indicate a cerebellar contribution not only to motor sequence learning but also to cognitive sequencing independent of general cognitive deterioration. Different cerebellar pathophysiologies that distinguish the ataxia groups seem to influence this impact. In further investigations the corresponding brain structures need to be taken into consideration.

144. Detailing the natural history of Friedreich's ataxia – loss of ambulation in the CCRN-FA study

Christian Rummey (see oral presentations)

145. Analysis of correlations among four measures of disease progression in Friedreich's ataxia.

Harry J. Saal, Retrotape, Frederic Heerinckx, Retrotape; Theresa Zesiewicz, Univ of South Florida; Omid Omidvar, CNS. harry.saal@retrotape.com

**INTRODUCTION:** Friedreich's ataxia (FA) is a neurodegenerative disorder characterized by cardiomyopathy; approximately two-thirds of patients with FA die from cardiac causes. FA is commonly assessed primarily using the Friedreich Ataxia Rating Scale (FARS), a subjective neurological measure. Alternatively, timed 25-foot walk (T25FW), peak VO<sub>2</sub>, and peak workload measures are considered. These three alternative measures are compared with FARS scores to determine whether they reflect FARS and thus reflect FA progression.

**METHODS:** Baseline data were taken from a phase I clinical trial in which 19 patients with FA were administered the FARS Neurological, the T25FW test, and a recumbent exercise bike test for peak workload and peak VO<sub>2</sub>. Spearman's rank correlation coefficients on the FARS scale, the inverse of T25FW time (T25FW-1), peak workload, and peak VO<sub>2</sub> were calculated. Linear regression was used to approximate the rates of decline of the measures as a function of FARS.

**RESULTS:** The FARS Neurological scores negatively correlated with peak workload (R=0.82), peak VO<sub>2</sub> (R=0.60), and T25FW-1 (R=0.91). Increasing FARS Neurological score by 3 points corresponded with a 0.15 points decline in log peak workload, a 0.09 points decrease in peak VO<sub>2</sub>, and 0.012 points decrease in T25FW-1.

**CONCLUSION:** The three alternative measures correlated highly with FARS increase and should be considered as an addition to or substitution for FARS as they also measure cardiopulmonary and skeletomuscular decline. A study on exercise capacity in children and adolescents with FA found similar correlations between peak workload and FARS (R=0.64), and peak VO<sub>2</sub> and FARS (R=0.46). Replicating this study longitudinally, in a larger population, is suggested, in which correlations should be observed in sub-stratified populations.

#### 146. [Cognition in Friedreich Ataxia: a neuropsychological and RS-fMRI study.](#)

Saccà F1, Coccozza S2, Costabile T1, Liguori A1, Abate F1, Paciello F1, Russo C2, Tedeschi E2, Quarantelli M3, Brunetti A2, Filla A1.

1 Department of Neurosciences and Reproductive and Odontostomatological Sciences, University "Federico II", Naples, Italy

2 Department of Advanced Biomedical Sciences, University "Federico II", Naples, Italy

3 Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy

#### Introduction

Several studies have evaluated cognitive impairment in Friedreich Ataxia (FRDA) reporting a modest and discordant cognitive dysfunction. Previous activation fMRI studies showed the presence of low activation patterns during motor and behavioral tasks. Unfortunately, no resting-state fMRI (RS-fMRI) analysis has been performed in FRDA.

#### Methods

We tested FRDA patients and sex, age, and education matched controls with an extensive neuropsychological battery. All MRI studies were performed on the same 3 Tesla scanner. For each subject, BOLD signal time course was calculated over 44 different regions, chosen because linked to the specific tested cognitive functions. The resulting functional connectivity (FC) maps were entered in a second level analysis to test for differences between the two groups. Differences were considered significant for  $P < 0.0011$ , corrected for multiple comparisons.

#### Results

We enrolled 24 FRDA patients and controls. Neuropsychological tests showed impairment in all areas except for language, intelligence, and some memory tests. Nineteen patients and twenty controls were enrolled in the RS-fMRI study. Two were excluded because of motion artifacts. For the remaining 37 studies, clusters of significant difference in FC between the two groups

were observed for the following tested regions: the right (r\_PaCiG) and left paracingulate gyri (l\_PaCiG), the right superior frontal gyrus (r\_SFG), the right medial frontal gyrus (r\_MFG) and the left middle temporal gyrus (l\_MTG).

Conclusion

FRDA showed a worst than expected and diffuse cognitive impairment with widespread alterations of FC. The paradigm of FRDA patients being cognitively normal should be revised in favor of a non-demented, but diffusely impaired phenotype.

#### 147. Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests

Saccà F1, Costabile T1, Abate F1, Liguori A1, Paciello F1, Pane C1, De Michele G1, Filla A1  
1Department of Neurosciences, Odontostomatological and Reproductive Sciences, University Federico II, Naples, Italy

Introduction: Despite neurological patients show frequent physical impairment, timed neuropsychological tests do not take this into account during scoring procedures. We propose a normalization method based on the Pata Rate Task (PRT) and on the Nine-Hole Pegboard Test (9HPT) as a measure of dysarthria and upper limb dysfunction.

Methods: We defined the time spent on phonation or on hand movement during neuropsychological testing as Verbal Effort Fraction (VEF) and Motor Effort Fraction (MEF). Both were measured experimentally on 65 healthy controls on timed neuropsychological tests (Attentional Matrices, Trail Making Test, Symbol Digit Modalities Test, Verbal Fluencies). We developed correction formulas to normalize VEF and MEF considering the patient's PRT/9HPT, their normality limits, and the test timing. We tested the method on 24 patients with Friedreich Ataxia (FRDA), as a model of motor and speech impairment.

Results: In healthy controls, VEF and MEF ranged between 13.5% and 61.7% of total test time. In FRDA patients, the effect of normalization improved all test results (range: 0.51-48.4%;  $p < 0.001$ ). FRDA patients had worst scores in all tests when compared to controls, and the difference remained significant after correction except for the Attentional Matrices. At the individual level, the normalization method improved equivalent scores with fewer patients showing impaired scores after correction.

Conclusions: We propose an innovative normalization method to reduce the impact of neurological disability on timed neuropsychological tests. This could be easily integrated in a clinical setting, as it requires a simple preliminary test with the PRT and 9HPT.

#### 148. Ataxia, 50 clinical case series

Paula Saffie<sup>1</sup>, Pedro Chaná-Cuevas<sup>2</sup>

<sup>1</sup> CETRAM, Clínica Universidad de los Andes. 94417634. psaffie@gmail.com

<sup>2</sup> CETRAM, Universidad de Santiago de Chile.

Introduction

Ataxias are included in orphan diseases. This study tries to determine if there is any feature, allowing to guide the etiology of ataxia, because the genetic test is not available in Chile.

Methods

We conducted a retrospective study in a movement disorder clinic. Clinical, para-clinical, electrophysiological, imaging, and molecular data from patients with the diagnose of ataxia

were collected, together with the diagnosis of the treating neurologist. The cases of acquired ataxia and of ataxia as a minor feature of other neurodegenerative disease were excluded.

## Results

4282 records are reviewed, finding 50 cases with the diagnose of ataxia. 33 cases were excluded, 20 because they had another degenerative disease and 13 had acquired ataxia. The 50 cases correspond to 1.2 % of visits to the center.

The characteristics of the 50 cases are summarized in Table 1. They were compared by etiology, excluding FXTAS because it was only one case. The findings in which statistical significance was found is family history, parkinsonism, autonomic dysfunction and polyneuropathy. No statistically significant difference was found in eye movements, dysphagia / dysarthria, pyramidal tract involvement, cognitive decline and cerebellar atrophy (summarized in Table 2).

## Conclusions

A significant number of cases are studied, in which only 26 % the genetic test could be made (sending the samples to other countries). The etiology of the other cases was determined by family history or by clinical features, and in almost 50 % no diagnose could be made. This situation is common in Chile because we don't have access to the genetic test. It is a priority in Chile to get this kind of study.

When analyzed by groups, statistical differences were found, and may help guide the clinical approach. Family history and polyneuropathy oriented to a genetic cause, and parkinsonism and autonomic dysfunction to MSA.

## References

1. Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. Elsevier/Saunders; 2011. 548 p.

149. [Expression of GSK3B, BDNF, ENO2, and HDAC6 genes in patients with Machado-Joseph disease before and after lithium treatment.](#)

Furtado, G.V.1,2, Mattos, E.P.1,2, Gheno, T.C.1,2, Saute JA3, Souza, G.3, Castilhos R.3, Monte TL4, Schumacher-Schuh AF4, Donis KC3, D'Ávila R3, Souza GN3, Russo AD3, de Souza DO5, Portela LV5, Camey SA6, Leotti VB6, de Mello Rieder CR4, Jardim LB3,7, Saraiva-Pereira M.L.1,2,3,5

1Genetic Identification Laboratory – Centro de Pesquisa Experimental – Hospital de Clinicas de Porto Alegre (HCPA); 2Post-Graduation Program of Genetics and Molecular Biology – Universidade Federal do Rio Grande do Sul (UFRGS); 3Medical Genetics Service – HCPA; 4Neurology Service – HCPA; 5Department of Biochemistry – UFRGS; 6Department of Mathematics and Statistics – UFRGS; 7Department of Internal Medicine – UFRGS, Porto Alegre, RS, Brazil.

Machado-Joseph disease/spinocerebellar ataxia type 3 (MJD/SCA3) is an autosomal dominant genetic disease caused by CAG expansions in the ATXN3 gene. MJD/SCA3 is characterized by neurodegeneration with progressive gait ataxia and additional neurological signs. Although the ATXN3 gene is the main contributor of age of onset (AO) and severity of symptoms, other modifiers can play a role in disease phenotype. The aim of this study was to evaluate expression of GSK3 $\beta$ , BDNF, ENO2, and HDAC6 genes in MJD/SCA3 patients before and after

lithium treatment and compare to some clinical parameters, such as AO, age, disease duration as well as clinical scales. Sample consisted of MJD/SCA3 patients (n=63) of both genders and different CAG expansions length (patient group) and healthy volunteers (n=20) (control group). Clinical parameters were previously described (Saute et al, 2014).

Total RNA was isolated from leukocytes using LeukoLOCK®, mRNA was converted to cDNA, and relative expression of GSK3β, BDNF, ENO2, and HDAC6 genes was performed using TaqMan™ gene expression assays. Selection of genes was based on previous data reporting association to other neurodegenerative diseases. Analysis of the patient group showed no difference in the expression of any of the four genes evaluated when compared to controls (p>0.05) and no correlation with the expanded CAG allele or AO at baseline. Analysis of patients' groups according to AO of symptoms (early, middle, and late onset) did not reveal differences in patterns of expression at baseline (p>0.05). Expression of GSK3β was higher in treated patients than in the placebo group after 6 months treatment (p=0.002). We have also observed an increase in HDAC6 expression following lithium treatment (p=0.032). No further changes were identified in our sample population. Although those markers were evaluated in peripheral tissue, results obtained here can be a guide for further studies, including specific expression analyses in neuronal cells.

Key-words: Machado-Joseph disease, biomarkers, gene expression Financial Support: FIPE-HCPA, CNPq, FAPERGS.

#### 150. [Reduced cerebral white-matter integrity in Friedreich ataxia is associated with diminution in myelin integrity: The IMAGE-FRDA study](#)

Selvadurai, L. P.1, Georgiou-Karistianis, N.1, Corben, L. A.1, 2,3, Stagnitti, M. R.1, Storey, E.4, Egan, G. F.1, 5, Delatycki, M. B.2, 6, Harding, I. H.1

1. Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Monash University, Clayton, Vic., Australia
2. Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Vic., Australia
3. Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
4. Department of Medicine, Monash University, Prahran, Vic., Australia
5. Monash Biomedical Imaging, Monash University, Clayton, Vic., Australia
6. Clinical Genetics, Austin Health, Heidelberg, Vic., Australia

#### Introduction:

In Friedreich ataxia (FRDA), white-matter deficits have been observed in the cerebellum, brain stem, cerebrum, and spinal cord, indicating widespread abnormalities in anatomical brain connectivity. However, the underlying pathophysiology of these abnormalities remains unclear (e.g. axonal vs. myelin-related deficits). Understanding white-matter pathology in FRDA has important implications for therapy and biomarker development. This study aimed to characterise white-matter integrity in a large FRDA cohort, and to investigate the extent to which abnormalities may be related to loss of axonal integrity and/or myelin integrity.

#### Methods:

Thirty-six individuals with genetically-confirmed FRDA and 36 age- and gender-matched healthy control individuals undertook brain Magnetic Resonance Imaging. Diffusion-tensor and magnetisation-transfer imaging protocols were used to undertake whole-brain between- group comparisons of 1) overall white-matter integrity (fractional anisotropy), 2) myelin integrity (radial diffusivity; magnetic-transfer ratio), and 3) axonal integrity (axial diffusivity). Overall white-matter integrity was correlated against the measures of myelin and axonal integrity.



Furthermore, each measure was correlated against disease severity, determined by the Friedreich Ataxia Rating Scale (FARS).

Results:

Individuals with FRDA showed significant diffuse deficits in measures of overall white-matter integrity, myelin integrity, and axonal integrity compared with controls, primarily within the cerebellum, brainstem, peri-thalamic regions, corpus callosum and corticospinal tracts. Reductions in overall cerebral white-matter integrity, particularly within the corpus callosum and peri-thalamic regions, were significantly associated with reduced myelin integrity in the FRDA group. Greater FARS scores in the FRDA group were associated with significantly greater abnormalities across all white-matter measures, predominantly within cerebellar and peri-thalamic regions.

Conclusions:

FRDA is associated with cerebellar and cerebral white-matter abnormalities, which preferentially impact cerebello-thalamo-cortical and cortico-spinal pathways. Furthermore, cerebral white-matter deficits may be particularly driven by myelin damage, indicating a potential treatment target. Measures of white-matter integrity are related to measures of disease severity in FRDA, and therefore warrant further study as disease biomarkers.

#### 151. Sleep and fatigue in Friedreich's Ataxia

Patterson A1, Almeida L1, Monari E1, Farmer J2, Subramony SH1

1Department of Neurology, University of Florida, Gainesville, FL, United States, 32607

2Friedreich's Ataxia Research Alliance

Introduction:

In addition to neurologic symptoms, Friedreich's Ataxia (FA) patients experience poorly characterized systemic symptoms such as impaired sleep, obstructive sleep apnea (OSA), restless legs syndrome (RLS), and fatigue.

Methods:

We recruited subjects from the FA Research Alliance registry with a self-reported diagnosis of FA who resided in the United States to participate in an online survey. Subjects provided demographics and disease state information and completed the Pittsburgh Sleep Quality Index, the Fatigue Severity Scale, and the Visual Analog Fatigue Scale (VAFS).

Results:

Of 171 participants, 42% were male, average onset of symptoms was 17.9y (range 4-51), disease duration was 20.3y (range 2-61), and current age was 38.3y (range 9-77). Average sleep latency was 31.6 minutes (range 2-180) and average sleep duration was 7.4 hours (range 2-12). OSA was endorsed by 16.4%, RLS by 29.8%, and any sleep disorder by 19.9%. Only 25.7% had a sleep study and 20.5% had seen a sleep provider. Presence of OSA correlated with male gender, increased age, disease duration, and FA functional stage. RLS did not correlate with these factors. Average VAFS score was 4.71 (0=worst global fatigue, 10=normal). Presence of OSA, RLS, or other sleep disorders did not predict VAFS score. Smaller GAA repeat expansion correlated with older age of onset and better functional capacity but also with a higher risk of OSA and other sleep disorders.

Conclusions:

Patients with FA experience RLS and OSA with greater frequency than the general population and report significant levels of fatigue. Expected demographic factors correlated with a higher risk of OSA but not RLS. GAA repeats did not correlate as expected with a higher risk of sleep

disorders within this small sub- population that was younger, less disabled by FA, and less affected by sleep disorders than the overall study population. Insomnia was not a major issue.

152. [Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome \(CANVAS\), a novel vestibulo-cerebellar ataxia: clinical phenotype, pathology, imaging abnormalities, differential diagnoses and a quantitative bedside test.](#)

Szmulewicz DJ<sup>1,2,3</sup>, MacDougall<sup>4</sup>, McLean CA<sup>5</sup>, Roberts L<sup>6</sup>, Halmagyi GM<sup>7</sup>, Storey E<sup>8</sup>

1. Balance Disorders and Ataxia Service, Royal Victorian Eye and Ear Hospital, Melbourne, Australia
2. Cerebellar Ataxia Clinic, Neuroscience Department, AlfredHealth, Melbourne, Australia
3. Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
4. Faculty of Science, University of Sydney, Sydney, Australia
5. Department of Anatomical Pathology Alfred Hospital, Melbourne, Australia
6. Department of Neurology, Royal Prince Alfred Hospital, New South Wales, Australia
7. Medicine, Nursing and Health Sciences Department, Monash University,
8. University of Sydney, Royal Prince Alfred Hospital, Sydney Australia

david.szmulewicz@neurologyvictoria.com.au

**Introduction:** As investigative modalities evolve it has become increasingly apparent that a greater number of patients with imbalance have a multifactorial cause for their dizziness. Whilst a number of these patients may have accrued multiple independent causes of their imbalance, our improved diagnostic methods have highlighted the possibility of further single diseases with multiple underlying foci of pathology.

**Objective:** To elucidate the underlying pathology and clinical characteristics in patients who present with a combination of a bilateral vestibulopathy, cerebellar impairment and peripheral sensory loss.

**Methods:** Prospective examination and investigation of 80 patients identified with idiopathic cerebellar ataxia and bilateral vestibulopathy, who were also found to have a somatosensory loss. Investigation included quantitative neuro-otologic oculomotor evaluation, MRI brain and spine imaging, post-mortem neuro- and otopathology, and neurophysiology.

**Results:** We describe a novel balance disorder, Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome (CANVAS), which is characterized by the triad of a bilateral peripheral vestibulopathy, cerebellar ataxia and a somatosensory deficit. The bilateral peripheral vestibulopathy has been quantified using rapid video- oculography and has been pathologically demonstrated to be a vestibular neuronopathy (ganglionopathy). The characteristic pattern of cerebellar atrophy has been elucidated (on MRI and validated by post-mortem samples), whilst the sensory deficit has been shown to be a neuronopathy, with marked dorsal root ganglia neuronal loss.

**Conclusion:** CANVAS is a newly described balance disorder with clear clinico- pathological correlations, diagnostic criteria and given the existence of 13 kindred amongst the 80 patients described, is most likely a late-onset recessive disorder. Clinically, CANVAS may be a differential diagnosis for various spinocerebellar ataxias, particularly SCA 3 and 6, and Friedreich's ataxia.

153. [A novel oculomotor biomarker in Friedreich's Ataxia](#)

Szmulewicz DJ. 1,2,3, MacDougall HG. 4, Storey GM. 5, Halmagyi GM. 6, Cremer P. 7, Corben L. 8,9,10, Delatycki M. 8,9,10,11.

1. Balance Disorders and Ataxia Service, Royal Victorian Eye and Ear Hospital, Melbourne, Australia
2. Cerebellar Ataxia Clinic, Neuroscience Department, AlfredHealth, Melbourne, Australia
3. Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
4. Faculty of Science, University of Sydney, Sydney, Australia
5. Medicine, Nursing and Health Sciences Department, Monash University,
6. Department of Neurology, Royal Prince Alfred Hospital, New South Wales, Australia
7. Department of Neurology, Royal North Shore Hospital, New South Wales, Australia
8. Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Vic., Australia
9. School of Psychological Sciences, Monash University, Clayton, Australia
10. Department of Paediatrics, University of Melbourne, Parkville, Australia
11. Victorian Clinical Genetics Service, Parkville, Vic., Australia.

**Introduction:** To investigate the vestibulo-cerebellar interaction in Friedreich's ataxia (FA) to further elucidate the neuro-otological manifestations of this disease and elucidate a possible bio-marker for FA clinical treatment trials.

**Background:** Friedreich's ataxia (FA) is the most commonly occurring inherited ataxia, and involves widespread neurodegenerative sequelae. Whilst oculomotor, vestibular and cerebellar affects have been documented, little is understood about the clinical consequences of pathology affecting these interacting systems. Impairment of the visually enhanced vestibulo-ocular reflex (VVOR; also called the "doll's head", "doll's eye" or oculo- cephalic reflex) reveals a compound deficit in the three compensatory reflexes involved in eye movement, namely the vestibulo-ocular reflex, smooth pursuit, and the optokinetic reflex.

**Materials and methods:** A prospective observational study.

**Results:** We report 20 patients with genetically confirmed FA and uniformly reduced VVOR gain on rapid video-oculography, that is, eye velocity which failed to match head velocity, resulting in gaze position errors, which were corrected with bursts of saccades and perceptible as the clinical sign of an impaired VVOR.

**Conclusions:** This study further elucidates the pathophysiology of the neuro-otological manifestations of FA. Given the robust and uniform nature of these results, the VVOR is a biomarker planned for implementation in FA treatment trials.

#### 154. [Tracking progression in Friedreich's Ataxia \(FRDA\) to establish biomarkers for clinical trials.](#)

Thomas-Black G, Baker M, Festenstein R, Nemeth A, Giunti P

**Introduction:** Clinical trials using a variety of promising therapeutic compounds have been carried out in FRDA. The primary endpoints have included well established measures such as; clinical rating scales, echocardiography and one study included MRI of iron deposition in the dentate nucleus of the cerebellum, but none have demonstrated statistically significant improvement despite patients reporting subjective benefits (Perlman, 2012). This has led the scientific community to investigate novel trial designs and explore the identification of new biomarkers that could more reliably capture progression of disease.

**Methods:** This study aims to investigate new ways of measuring disease progression in Friedreich's Ataxia. Innovative and quantitative MRI measures in the brain and spinal cord of up to 24 patients and 6 control subjects will be analysed alongside high resolution imaging of the retina using optical coherence tomography (OCT) and visual acuity checks performed on

up to 70 patients. The procedures will be carried out across 3 time points, spanning 22 months. This will be the largest study of its kind to date and should assist in clinical trial development. Results: We will have collected and analysed data from the first time point and will be able to re- port on the following:

Comparison of controls vs FRDA patients using our novel MRI measures. Confirm/negate findings of previous studies looking at OCT data in FRDA.

Novel methodology for analysing frataxin levels in peripheral blood mononuclear cells.

Conclusions: Correlations between the new measures obtained in this study will be sought. We will also seek to discover if there are any relationships between these new data and the following: age of onset, GAA repeat sequence length, SARA score and Activites of Daily Living Score.

#### 155. Swallowing function declines over 12 months in Friedreich ataxia

Megan Keage<sup>1</sup> (PhD), Martin B Delatycki<sup>2,3</sup> (MBBS, PhD), Jessamy Dyer<sup>1</sup> (MSc), Louise A Corben<sup>2,3,4,5</sup> (PhD) & Adam P Vogel<sup>1,2,6</sup> (PhD)

<sup>1</sup> Centre for Neuroscience of Speech, The University of Melbourne, Victoria, Australia

<sup>2</sup> Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Melbourne, Australia

<sup>3</sup> Victorian Clinical Genetics Service, Melbourne, Australia

<sup>4</sup> School of Psychological Sciences, Monash University, Melbourne Australia

<sup>5</sup> Department of Paediatrics, The University of Melbourne, Melbourne, Australia

<sup>6</sup> Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany

Background: Dysphagia is common in Friedreich ataxia (FRDA). It can lead to aspiration pneumonia and results in reduced quality of life. It is characterised by tongue dysfunction, reduced pharyngeal clearance, delayed pharyngeal swallow, and aspiration. Dysphagia is associated with disease duration and severity, however there are no natural history studies of swallowing in FRDA.

Methods: Twenty-three individuals with FRDA and dysphagia (confirmed via videofluoroscopy, VFSS) were assessed twice 12 months apart. The assessment battery included VFSS, a standardised oral-motor assessment (Frenchay Dysarthria Assessment-2, FDA-2) and a quality of life questionnaire (SWAL-QOL).

Results: Data from the VFSS revealed a significant decline in tongue function, pharyngeal clearance and cricopharyngeal function on solid food. However, severity of penetration/aspiration did not increase. Swallowing-related quality of life and oral-motor function remained stable over the 12 month period.

Conclusions: A decline in function was observed at three anatomical sites important for safe and effective swallowing (tongue, pharyngeal, cricopharyngeal). However, these deficits did not appear to translate into any meaningful difference to the patient and their swallowing related health. The fluctuating nature and general progression of FRDA, level of patients' dysphagia-awareness at follow-up assessment, and psychometric limitations of the assessment tools may have impacted on the results of this study.

#### 156. Anti-MAG associated cerebellar ataxia

Zis P, Rao DG, Sarrigiannis PG, Hoggard N, Hadjivassiliou M  
Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

Myelin-associated glycoprotein (MAG) is a glycoprotein specific to Schwann cells. Schwann cells produce myelin for nerve cells in the peripheral nervous system. MAG also plays a role in the central nervous system (CNS) by maintaining myelin integrity and inhibiting CNS axonal regeneration. Presence of anti-MAG antibodies is frequently associated with distal acquired demyelinating symmetric neuropathy (DADS). Such patients often complain of ataxia, originally attributed to the distal sensory loss resulting from the neuropathy. We describe a series of 5 patients with anti-MAG antibodies and cerebellar rather than sensory ataxia including our experience of treatment with rituximab.

#### Methods

Cerebellar ataxia was clinically suspected and confirmed using magnetic resonance spectroscopy (MRS) of the cerebellum. All patients underwent detailed nerve conduction studies (NCS). All patients had extensive immunologically tests and all were anti-MAG positive.

#### Results

Four patients were male. The ages ranged from 64 to 82 years. Case #1 was diagnosed with cerebellar ataxia and no neuropathy. Cases #2-#4 were initially diagnosed with DADS, however they developed cerebellar ataxia few years later (latency between the two diagnoses was 4-10 years). Case #5 was diagnosed simultaneously with DADS and cerebellar ataxia.

All patients were treated with rituximab. Case #1, though reported no immediate clinical effect, showed MRS improvement after the first Rituximab infusion. Although case #2 reported clinical improvement, also confirmed via the MRS, he had to discontinue the treatment as he developed a vasculitic rash thought to be related to rituximab. Case #3 showed no improvement after the first Rituximab infusion and he discontinued the treatment. Cases #4 and #5 showed clinical improvement and currently continue Rituximab infusions every 9 months.

#### Conclusion

Anti-MAG antibodies might be involved in the pathogenesis of idiopathic sporadic ataxias, even in the absence of DADS. Rituximab seems to be a promising therapeutic intervention for those cases.

### 157. Causes of cerebellar ataxia with sensory ganglionopathy

Zis P, Sarrigiannis PG, Rao DG, Hoggard N, Sanders DS, Hadjivassiliou M Affiliation: Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

#### Background and purpose.

Cerebellar ataxia with sensory ganglionopathy (SG) is a disabling combination of neurological involvement usually seen as part of some hereditary ataxias e.g. Friedreich's ataxia, SCA4, SCA25.

However, patients may present with this combination without a genetic cause. Methods We reviewed records of all patients that have been referred to the Sheffield Ataxia Centre who had neurophysiological and imaging data suggestive of SG and cerebellar ataxia respectively. We excluded patients with Friedreich's ataxia, a common cause of this combination. The majority of patients were screened for genetic causes (NGS ataxia panel) including screening for mitochondrial diseases (genetic testing and muscle biopsy). All patients underwent extensive immunological screening.

#### Results.

We identified 36 patients (55.6% females, mean age 58.4±11.1 years, range 29 – 81). The commonest symptom at presentation was unsteadiness (58.1%), followed by patchy sensory symptoms (19.4%) and a combination of unsteadiness and sensory symptoms (16.1%). The first

diagnosis was cerebellar ataxia in 48.4% and SG in 29.0% of the patients. In 22.6% both diagnoses were made at the same time. The latency between the two diagnoses varied from less than 1 year to 23 years (mean 5.9±6.7 years).

Seventeen patients (47.2%) had gluten sensitivity (positive antigliadin antibodies). Other abnormal immunological tests were present in another 13 patients (i.e. GAD, ANA etc.). Two more patients developed cancer within 5 years (one prostate and one ovarian) and their syndrome was considered to be paraneoplastic. In 1 patient genetic testing revealed a variant of unclear clinical significance, involving genes implicated in SCA 11. Only 3 (8.3%) patients were classified as truly idiopathic.

Conclusion.

Our case series highlights that amongst patients with the unusual combination of cerebellar ataxia and sensory ganglionopathy, immune pathogenesis predominates. The majority of such patients have gluten sensitivity, and a gluten free diet has already been shown to be beneficial.

## THERAPEUTICS AND CLINICAL TRIALS

158. Highly specific ubiquitin-competing molecules promote frataxin accumulation in Friedreich ataxia iPSC-derived neuronal cells.

Alaimo G.1,#, Caroleo A.1,#, De Martino G.1, Fortuni S.1, Condò I.1, Alfedì G.1, Benini M.1,2, Malisan F.1, Bellanda M.3, Maso L.4, Costantini P.4, Santos J.5, Testi R.1,2, Rufini A.1,2,\*.

1. Laboratory of Signal Transduction, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
2. Fratagene Therapeutics Srl, Viale dei Campioni 8, 00144 Rome, Italy.
3. Department of Chemical Sciences, University of Padova, via Marzolo 1. 35131, Padova, Italy.
4. Department of Biology "Biochemistry, Biology and Mitochondrial Pathophysiology" Unit, University of Padova, Viale G. Colombo, 3, 35131 Padova (PD) - Italy
5. Instituto de Química y Físicoquímica Biológicas (IQUIFIB), Universidad de Buenos Aires, Junín 956, (C1113AAD), Buenos Aires, Argentina

# share first authorship

\*email: rufini@med.uniroma2.it

**Introduction:** Friedreich ataxia (FRDA) is mainly caused by reduced expression of frataxin, therefore our therapeutic approach aims at increasing frataxin levels in patients' cells. Since we have previously shown that frataxin levels are controlled by the ubiquitin-proteasome system, our therapeutic strategy is based on the possibility to increase frataxin levels by preventing its degradation. We have previously characterized a set of small molecules that promote frataxin accumulation by docking on its ubiquitination site thus protecting frataxin from degradation. These compounds are called ubiquitin-competing molecules (UCMs) (Rufini et al., 2011; Rufini et al., 2015). **Methods:** In order to increase the potency and the efficacy of the identified compounds, we have performed iterative cycles of lead optimization, based on in silico studies, synthesis and in cell validation. Moreover, the effect of the compounds in elevating frataxin levels was evaluated in lymphoblastoid cell lines from FRDA patients, primary FRDA patients' fibroblasts and in FRDA iPSC- derived neuronal cells.

**Results:** We have now identified a set of new molecules that show improved efficacy in promoting frataxin accumulation in several lymphoblastoid cell lines and in primary fibroblasts derived from FRDA patients. In particular, these compounds are effective at 1  $\mu$ M, a concentration 10 times lower than the one described for the previously identified compounds (Rufini et al., 2015). Noteworthy, one of these compounds, UCM166, promotes frataxin accumulation also in FRDA iPSC-derived neuronal cells.

**Conclusion:** These data strongly support the therapeutic potential of this class of compounds and encourage the further development of this therapeutic approach.

Rufini A, Cavallo F, Condo I, Fortuni S, De Martino G, Incani O, Di Venere A, Benini M, Massaro DS, Arcuri G, Serio D, Malisan F, Testi R. 2015. Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the aconitase defect in Friedreich ataxia cells. *Neurobiol Dis* 75:91-99.

Rufini A, Fortuni S, Arcuri G, Condo I, Serio D, Incani O, Malisan F, Ventura N, Testi R. 2011. Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia. *Hum Mol Genet* 20:1253-1261.

#### 159. [FDA-approved drug screening for Friedreich Ataxia: FDA11 promotes frataxin accumulation at near- physiological levels in FRDA patient-derived cells.](#)

Alfedi G.1, Massaro D.S.1, Alaimo G.1, Condò I.1, Luffarelli R. 1, Malisan F.1, Testi R.1,2, Rufini A.1,2,\*

1. Laboratory of Signal Transduction, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.

2. Fratagene Therapeutics Srl, Viale dei Campioni 8, 00144 Rome, Italy.

\* email: rufini@med.uniroma2.it

**Introduction:** Friedreich Ataxia (FRDA) is an autosomal recessive cerebellar ataxia caused by mutation of the FXN gene, resulting in decreased frataxin expression, mitochondrial dysfunction and oxidative stress. In this work we present one of the possible therapeutic approaches, using a drug repositioning strategy, to find compounds that increase frataxin protein levels.

**Methods:** To identify drugs able to increase frataxin levels we performed a high-throughput screening of a library containing 853 FDA-approved drugs in HEK-293. Through the use of a transfected frataxin-reporter system that allows a chemiluminescent measure of frataxin levels, we focused our efforts on drugs that function at a post-transcriptional level. Nineteen

potential candidate drugs were isolated from the screening. The identified compounds were individually validated and tested for their ability to increase frataxin levels both in HEK-293 cells and in cells derived from patients.

Results: Among the candidates, we focused our attention on compound FDA11. This drug, while showing no significant toxic effects on cell viability, has a substantial impact on frataxin levels. Indeed, FDA11 promotes frataxin accumulation in several FRDA lymphoblastoid cell lines and in primary fibroblasts derived from FRDA patients. Moreover, frataxin accumulation in treated patients cell lines is comparable to frataxin levels in unaffected carrier sibling cells, suggesting that this accumulation could be significant for the purpose of restoring the physiological conditions. Currently, we are testing the efficacy of FDA11 treatment on patients iPSCs-derived neurons.

Conclusions: The evidence presented indicates that FDA11 promotes frataxin accumulation at near-physiological levels in FRDA patient-derived cells, suggesting that this drug could be an interesting candidate for pre-clinical studies as a therapy for FRDA.

#### 160. TAT-MTScs-FXN protects frataxin-deficient neurons and is targeted, processed and functional in mice models of Friedreich ataxia.

Britti E.a\*, Delaspre F.a\*, Feldman A.b, Osborne M.c, Greif H.b, Tamarit J.a , Ros J.a #

(a) Departament de Ciències Mèdiques Bàsiques, IRBLleida, Universitat de Lleida, Lleida, Spain. (b) BioBlast-Pharma Ltd., Israel.(c)The Jackson Laboratory, Bar Harbor, Maine, USA. (\*)

Both authors contributed equally to this work

(#) Correspondence to: joaquim.ros@cmb.udl.cat

Introduction: One of the approaches to treat Friedreich Ataxia aims to restore frataxin (FXN) function based on frataxin replacement therapies. One of these strategies is based on using TAT-MTScs-FXN, a construct consisting of mature form of frataxin fused to TAT, a peptide enabling membranes crossing and the mitochondrial target sequence from citrate synthase (MTScs) enabling to penetrate the mitochondria (1). In a previous publication, we reported that frataxin-deficient dorsal root ganglia neurons showed altered calcium homeostasis, neurite degeneration and apoptotic cell death (2)

Methods: In this work, we used frataxin-depleted neurons obtained from dorsal root ganglia (DRG), one of the most affected tissues, as cell model of the disease. Reduction of frataxin in DRGs was achieved by transduction with lentivirus containing shRNA silencing sequences. Using this model, we have analyzed the effect of TAT-MTScs-FXN at 1, 3 and 7  $\mu$ g/mL on decreasing neurodegeneration markers and survival. Mice models of the disease have been also used to test the ability of the fusion protein to reach muscle tissue and its effect on lifespan.

Results: The results show that, treatment with TAT-MTScs-FXN increased cell survival, decreased neurite degeneration and reduced  $\alpha$ -fodrin cleavage, an indicator of apoptotic cell death. Also, we show that HSP60, a molecular chaperone targeted to mitochondria, suffered an impaired processing in frataxin-deficient neurons that was relieved by TAT-MTScs-FXN addition. In mice models of the disease, TAT-MTScs-FXN was able to penetrate muscle mitochondria, restore the activity of the mitochondrial succinate dehydrogenase and significantly increase lifespan.

Conclusion: These results support the use of TAT-MTScs-FXN as a treatment for Friedreich Ataxia.



Acknowledgments: This work was supported by BioBlast-Pharma Ltd. and SAF2013-44820-R from MINECO (Spain) grant. We also thank The Jackson Laboratory, Bar Harbor In Vivo Service for animal care and testing.

#### References:

- (1) Marcus D. et al. 2016. *Int J Biochem Cell Biol.* 81(Pt A):48-56
- (2) Mincheva-Tasheva S. et al. 2014. *Hum Mol Genet.* 23:1829-41

#### 161. [Physiotherapy management of the ataxias towards best clinical practice: 2016 guideline update](#)

Lisa Bunn, Jonathan Marsden, Elizabeth Cassidy, Cherry Kilbride

Institutions: 1: Plymouth University, Devon UK, 2: Brunel University, Greater London, UK

**Introduction:** The principal aim of this systematic review of the literature was to update the physiotherapy section of the Ataxia Management Guidelines (Ataxia UK). The aim of this report is to review the evidence for physical therapy based intervention studies for people with ataxia. PROSPERO registration 2013:CRD42013004323.

**Methods:** A literature search (v2: 2008-2013) replicated a previous review of: 7 databases (CINAHL, PsycINFO, PubMed Central, British Nursing Index, AMED, EMBASE, SCOPUS), the Web of Knowledge and the Cochrane Data Base of Systematic Reviews with hand-searching of references (v1: 1980-2009). Search-terms (physiotherapy or physical therapy and ataxia; rehabilitation or exercise or training and ataxia). Criteria included intervention studies (including case studies), opinion pieces or reviews (primarily about ataxia and the role or efficacy of physiotherapy). Scoring of methodological quality was based on the quantitative review form produced by Law et al (1998). Reviewers scored papers independently and final agreed scores achieved through consensus. Three independent physiotherapists developed clinical practice guidance based on their review of the identified papers and clinical experience.

**Results:** Twenty studies were eligible to add to those original 40 highlighted in the v1 search. One systematic review and 24 research papers were identified: These ranged from randomised controlled trials (n=2) to single case studies (n=8). Methodological quality scores ranged from 4 to 11 (of a maximum 16). Participants had wide-ranging cerebellar pathology.

**Conclusions:** Dynamic task practice both challenging stability and aiming to reduce upper limb weight bearing seems an important intervention to improve gait and balance. Strength and flexibility training may be indicated in conjunction with these interventions. Whilst there is now modest evidence to support the effectiveness of physiotherapy, insufficient evidence remains to support the efficacy of any one specific intervention. Consistent adoption of valid and reliable outcome measures for this population would improve methodological rigor and interpretation of research.

#### 162. [Role of microRNAs in Machado-Joseph disease: from pathogenesis to therapy](#)

Vitor Carmona (see oral presentations)

#### 163. [Clinical Trial Readiness for Friedreich's Ataxia Gene Therapy](#)

Corti M, Tschosik ML, Nair J, Meyer BP, Pope MK, Gay CA, Subramony, Byrne BJ.  
University of Florida, College of Medicine, Gainesville, FL, USA.

Introduction: The overall goal of our Friedreich's Ataxia program is to correct frataxin deficiency in the heart and central nervous system (CNS) by delivery of AAV9 human frataxin (FXN).

Method: We assessed the efficacy of intravenous (IV) delivery of rAAV9-CBA-FXN in a novel conditional knock-down mouse model to prevent and correct the cardiac and neurological disease phenotype. We also compared the efficiency of IV delivery with the combined IV and intrathecal (IT) delivery of rAAV9-CBA-FXN in non-human primates. In parallel, we have been conducting a single-site longitudinal study to identify additional sensitive outcome measures evaluating the cardiac, metabolic and neuromuscular function in individuals with FA in preparation of the current clinical trial. Results: Preliminary data from our preclinical proof of concepts studies showed that: 1) intravenous (IV) injection of AAV9-CBA-hFXN prevents cardiac abnormalities, weight loss and death in the frataxin knock-down model; the combination of IV and intrathecal (IT) AAV9-CBA-hFXN injections in NHPs is safe and leads to human frataxin detection in cerebellum, DRGs and heart tissues. Studies evaluating the effect of IT injections alone in the knock-down model are still ongoing. For the clinical longitudinal study, we enrolled 20 FA subjects and 10 controls. The preliminary data suggests that FA subjects have reduced exercise tolerance during maximal exercise testing as shown by reduced VO2Max. Further, VO2Max correlates well with both the GAA repeat length and the Friedreich's Ataxia Rating Scale (FARS). Conclusion: Based on our observations and ongoing studies, we are planning to conduct GLP toxicology and biodistribution studies in NHP and rodents in support of an IND submission to the FDA. In addition, we are also planning to work with the EU regulatory agencies for a multicenter study.

164. [Friedreich's ataxia patients and mice have less mitochondria, and the EMA and FDA-approved drug dimethyl fumarate raises frataxin in cells and mice, and mitochondrial number in mice and humans](#)

Gino Cortopassi<sup>1</sup>, Genki Hayashi<sup>1</sup>, Susan Perlman<sup>3</sup>, Marissa McMackin<sup>1</sup>, Francesco Sacca<sup>2</sup>, Mittal Jasoliya<sup>1</sup>.

<sup>1</sup>University of California, Davis. <sup>2</sup>University "Federico II", Naples, Italy <sup>3</sup> University of California, Los Angeles.

Background and Specific Objectives. The pathophysiological mechanism of Friedreich's Ataxia (FA) is initiated by the deficiency of the mitochondrial protein frataxin, and we studied the consequences of frataxin deficiency on mitochondrial biogenesis in cells, KIKO mice and blood from Friedreich's patients. In addition, we after screening 1600 drugs that went through clinical trials, we studied the mechanism by which Dimethyl Fumarate (DMF) protects Friedreich's cells from death, and demonstrate that DMF increases mitochondrial biogenesis in cells, mice and in human MS patients dosed in vivo, and also dose-dependently increases frataxin in cells.

Methods. Clinical methods were used to dose MS patients with the DMF drug. QRT-PCR, QPCR, animal drug dosing, cell culture and siRNA-mediated gene knockdown were used to demonstrate the dependence of mitochondrial biogenesis on frataxin, and the dependence of the mitobiogenic effect of DMF on the Nrf2 target.

Results. We observed deficient mitochondria in FA patient cells, which is dependent on repeat number and frataxin level. Transient knockdown of frataxin in cells produced a defect in mitobiogenesis, that could be rescued by transfection of frataxin. Furthermore we show that human FA patients have a significant defect in mitochondrial biogenesis in blood lymphocytes,

and this could be used as an FA biomarker. With DMF, we observe a dose-dependent increase in mitochondrial biogenesis in fibroblasts in the 10 micromolar range, which is the same range that fumarates reach in human plasma after 480mg DMF dosing. In cells at these concentrations there is a consequent increase in mitochondrial biogenesis by Seahorse. Dosing mice in vivo 2 weeks with DMF produces about a 40% increase in mitochondrial biogenesis. DMF has two known targets, i.e. the Keap1/Nrf2 complex, and the HCAR2/Niacin/Betahydroxybutyrate receptor. siRNA-mediated knockdown of these demonstrated that the Nrf2 target is more important for DMF's mitobiogenic effect. DMF also dose-dependently increases frataxin expression.

Conclusions. The mitobiogenesis results demonstrate that Friedreich's and frataxin deficiency cause a specific defect in mitochondrial biogenesis, in FA cells, KIKO mice, and in human FA patients, that could be part of the pathophysiological neurodegeneration mechanism. Secondly since mitochondrial biogenesis is dependent on frataxin level, and taking of blood is considered a less-invasive practice, our results suggest that mitochondrial copy number in blood (or tissues) could now be used as a clinical biomarker of FA disease severity, and could be used in clinical trials of FA's therapeutic development.

The DMF results demonstrate that DMF drug dosed in cells, mice and humans increase mitochondrial biogenesis.

This is the first FDA&EMA clinically-approved drug that has been demonstrated to increase mitochondrial biogenesis. Increasing mitochondrial biogenesis is a general therapeutic strategy in mitochondrial disease, and given the defect in mitochondrial biogenesis in FA observed above, is now a specific therapeutic strategy in FA. We also demonstrate that DMF dose-dependently increases frataxin in human FA patient cells and mice at the same doses it is approved for use in humans. Because DMF has passed through extensive safety testing already, and because it increases frataxin whose deficiency is the only cause of FA, and because it reverses the mitochondrial biogenesis that occurs in Friedreich's, we believe that it should be considered for therapy in Friedreich's ataxia. Some of these results have been peer-reviewed and are in press, others are in preparation for submission, please consider this as a late-breaking abstract.

Frataxin Deficiency Impairs Mitochondrial Biogenesis in Cells, Mice and Humans.

Jasoliya MJ, McMackin MZ, Henderson CK, Perlman SL, Cortopassi GA. *Hum Mol Genet.* 2017 Apr 21. doi: 10.1093/hmg/ddx141. [Epub ahead of print]

Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and

Humans. Hayashi G, Jasoliya M, Saccà F, Pane C, Filla A, Marsili A, Puorro G, Lanzillo R, Brescia Morra V, Cortopassi G. *Hum Mol Genet.* 2017 Apr 28. doi: 10.1093/hmg/ddx167. [Epub ahead of print]

#### 165. Citalopram reduces aggregation of ATXN3 in a YAC transgenic mouse model of Machado-Joseph disease

Ashraf N.S.1, Duarte-Silva S.2,3, Maciel P.2,3, Paulson H.L.1, Teixeira-Castro A.2,3\*, Costa M.C.1\*

1Department of Neurology, University of Michigan, Ann Arbor, MI, USA; 2Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; 3ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal

\*Shared correspondence

Introduction: Machado-Joseph disease (MJD) is a fatal polyglutamine disease and the most common autosomal dominant ataxia worldwide. No preventive or disease-modifying treatment is available for MJD. The commonly used selective serotonin reuptake inhibitor, citalopram, was shown to be a good candidate to be re-purposed for MJD therapeutics. Here, we aimed to confirm the efficacy of citalopram to decrease ATXN3 aggregation in a different mouse model of MJD - the YACMJD84.2 (Q84) transgenic mice - expressing the full-length human disease gene. Methods: Groups of 4-week old hemizygous Q84 mice (n=10) were orally treated with citalopram 8 mg/Kg or drinking water (vehicle) during 10 weeks. At the end point, mice were sacrificed and left and right brain hemispheres were, respectively, frozen for protein analysis and fixed for pathology assessment. Counting of cells containing ATXN3-positive intranuclear inclusions was performed blindly to treatment.

Results: Brains from citalopram-treated Q84 mice showed a robust decrease to about 50% of cells containing ATXN3-positive inclusions in pontine, vestibular and facial nuclei compared with controls. No differences in ATXN3 inclusion load were found, however, in deep cerebellar nuclei of mice from the two treatment groups. These results were corroborated by protein analysis.

While protein lysates from midbrain/brainstem and cervical spinal cord from citalopram-treated mice showed a decrease of all soluble forms of ATXN3 and a trend for reduction of insoluble ATXN3 compared with controls, no differences in ATXN3 levels were found between cerebella of citalopram-treated and vehicle-treated mice. Furthermore, citalopram treatment selectively led to altered levels of specific components of cellular protein homeostasis that could be involved in a potential increase of mutant ATXN3 folding and/or degradation.

Conclusions: Ten-week treatment of Q84 mice with citalopram was effective to reduce aggregation and abundance of ATXN3 in selective brain regions. Whereas citalopram did not show a broad neuronal effect in Q84 mice, the reproducibility of its efficacy in regions affected in MJD of a second mouse model of disease strengthens its potential as a drug to be re-purposed for this disorder.

#### 166. Calcitriol, the active form of Vitamin D, reduces apoptotic markers in a neuron model of Friedreich ataxia

Delaspre F., Britti E., Mincheva S., Llovera M., Tamarit J. and Ros J.\*.

Dept. of Ciències Mèdiques Bàsiques. Fac. Medicina. University of Lleida. Lleida. Spain (\*)  
correspondence to: joaquim.ros@cmb.udl.cat

Introduction: Previous data published by our group showed that cultured frataxin-deficient dorsal root ganglia neurons show neurite degeneration, apoptotic cell death and alterations in calcium homeostasis. Frataxin depletion caused activation of CREB to its phosphorylated form and fodrin cleavage by calpain and caspase3, which are markers of apoptotic process (1). Several evidences suggested as that vitamin D could be able to protect frataxin-deficient DRGs from neurodegeneration because anti-apoptotic and neuroprotective effects of the active form of Vitamin D ( $1\alpha,25(\text{OH})_2\text{D}_3$  or calcitriol), have been observed in several neuropathological conditions (2). Also, the last step in the synthesis of the active vitamin D form depends on CYP27B1, a mitochondrial enzyme that hydroxylates  $25\text{OHD}_3$  (or calcidiol) to  $1\alpha,25(\text{OH})_2\text{D}_3$ . This enzyme has been localized in neurons and glial cells (3) and is induced when levels of  $1\alpha,25(\text{OH})_2\text{D}_3$  are low meaning that calcitriol acts as a repressor (4).

Methods: We tested the effect calcitriol in frataxin-deficient dorsal root ganglia neurons. Reduction of around 80% of frataxin levels in these cells was achieved by transduction with lentivirus containing shRNA silencing sequences.

Results: The results show that when cultures of frataxin-depleted neurons were treated with doses of 10 and 20 nanomolar, markers of apoptotic cell death such as fodrin cleavage or neurite degeneration were clearly reduced. Additionally, a marked increase in CYP27B1 levels observed in frataxin-deficient cultures -thus suggesting low levels of  $1\alpha,25(\text{OH})_2\text{D}_3$ - were reverted to normal values.

Conclusion: These results open an easy therapeutic approach to be considered for patients with Friedreich Ataxia.

Acknowledgments: This work is funded by Ataxia UK., Ataxia Ireland and ACAH (Associació Catalana d'Ataxies Hereditaries)

#### References

- (1) Mincheva-Tasheva S. et al. 2014. *Hum Mol Genet.* 23: 1829-41
- (2) Berridge M. J. 2015. *Biochem Biophys Res Commun.* 460: 53-71
- (3) Eyles DW et al. 2005. *J. Chem. Neuroanat.* 29: 21-30.
- (4) Turunen MM., et al. 2007. *Nucleic Acids Res.* 35: 2734–2747

#### 167. Long-term treatment with thiamine in Friedreich ataxia

Fancellu R<sup>1,2</sup>, Laureti T<sup>3</sup>, Pala M<sup>4</sup>, Cavalieri S<sup>5</sup>, Pozzi E<sup>5</sup>, Brusco A<sup>5,6</sup>, Colangeli M<sup>7</sup>, Salvarani S<sup>2</sup>, Serrati C<sup>1</sup>, Costantini A<sup>4</sup>

<sup>1</sup> Unit of Neurology – IRCCS San Martino University Hospital –Genoa – Italy <sup>2</sup> Unit of Neurology – ASL3 Villa Scassi Hospital – Genoa – Italy

<sup>3</sup> Department of Economics and Management – University of Tuscia – Viterbo – Italy <sup>4</sup>

Department of Neurological Rehabilitation – Villa Immacolata Clinic – Viterbo – Italy <sup>5</sup>

Department of Medical Sciences – University of Turin – Turin – Italy

<sup>6</sup> Medical Genetics Unit – Città della Salute e della Scienza University Hospital – University of Turin – Turin –Italy

<sup>7</sup> University Studies Abroad Consortium – University of Tuscia – Viterbo – Italy

**INTRODUCTION.** Thiamine (vitamin B1) is a cofactor of fundamental enzymes for the energetic cellular metabolism. Previous studies reported low thiamine levels in the cerebrospinal fluid and pyruvate- dehydrogenase dysfunction in the cells of patients with Friedreich ataxia (FRDA). FRDA is an autosomal recessive disease caused by mutations in FXN gene, which encodes a protein named frataxin that is extremely reduced but qualitatively normal. We investigated in an open trial the effect of long-term treatment with thiamine on the neurological symptoms and the variation of blood FXN mRNA levels in FRDA.

**METHODS.** Thirty-four FRDA patients were administered with intramuscular thiamine 100 mg twice a week for a long period (mean±sd, 402±257 days). Mean age was 36.3±11.1 years, mean age of onset was 17.1±9.9 years. Basal levels of plasma thiamine were normal. All patients were evaluated with the Scale for the Assessment and Rating of Ataxia (SARA) at baseline and every three months. Thirteen patients performed echocardiogram before and during treatment, after 450±276 days from baseline. FXN mRNA levels were measured in the blood of six patients with quantitative Real Time RT-PCR at baseline and after 12 months of treatment.

**RESULTS.** Total SARA score improved from 26.6±7.7 to 21.5±6.2 (p=0.019). Moreover, we detected deep tendon reflexes in 57% of patients with areflexia at baseline, and swallowing improved in 63% of patients with dysphagia. At the echocardiogram, interventricular septum thickness reduced significantly (from 9.54±1.76 to 8.85±2.00 mm; p=0.016). FXN mRNA blood

levels were modestly increased in 50% of patients. CONCLUSIONS. Long-term and continuous thiamine administration was safe and effective in ameliorating neurological symptomatology and echocardiographic parameters in our series of FRDA patients. This improvement was stable over time in all patients, even after three years of treatment. Further studies are required to verify the thiamine role on FXN regulation and to confirm our results.

#### 168. Riluzole spinocerebellar ataxia type 7: report on two families

Ferraldeschi M (1), Tzekov R. (2), Romano S. (1), Pegoraro E.(3), Sato G. (4), Maritan V. (5), Codogno C.(6), Suppiej A. (7), Zesiewicz T.(8), Ristori G. (1),

1. Department of Neurosciences, Mental Health and Sensory Organs (NESMOS Department), Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital-site, "Sapienza" University of Rome;
2. Department of Ophthalmology, Advanced Visual Function Testing Service , University of South Florida , Tampa, FL, USA
3. Institute of Neurology, University of Padua
4. Center for Low Vision Rehabilitation of adult, ULSS 16. Padua
5. Center for Low Vision Rehabilitation of childhood. Pediatric clinic. Padua
6. Robert Hollman Foundation. Padua
7. Child Neurology, Clinical Neurophysiology and Neuroophthalmology, Paediatric University Hospital Padua.
8. Department of Neurology, USF Ataxia Research Center, University of South Florida, Tampa, FL, USA

#### Introduction

SCA7 is a very rare form of autosomal-dominant cerebellar ataxia, caused by the expansion of a CAG repeat within the ataxin 7 (ATXN7) gene. Encouraging data on riluzole effects in patients with cerebellar ataxias (1, 2) prompted us to try an off-label use of riluzole in an Italian and an American family with SCA7.

#### Methods and Results

A 41-year old woman, followed at Padua Center, had 40 triplets at ATXN7 gene and was referred at age 36 with visual deterioration and cerebellar signs with progressive course. She started riluzole in late 2014 when visual loss was overt, and SARA score was 30. After 2 years of riluzole therapy SARA score was 16, while no improvement in vision occurred (deterioration from 1/100 to light perception). Her 22-year old daughter started riluzole in the past four months, and she is currently stable with a SARA score of 16.

Two female siblings (63 and 73 year-old), assessed at USF (US) reported visual disturbances and were diagnosed as SCA7 (39 and 40 repeats, respectively). They were followed up by ophthalmological examinations and neurological examination for several years. In late 2010 they started riluzole After one year of therapy cerebellar and visual functions improved (respectively from 8 to 6 at SARA score and from 0.6 to 0.4 at logMAR) in both siblings. SARA score remained stable for 3 years and then started to increase (13 at the last evaluation - 6 years after the beginning of the treatment in both siblings), while ophthalmologic status remained practically stable in both siblings, since they started the drug.

#### Conclusions

Data from these patients suggest some efficacy and safety of riluzole, even after long-term follow-up. This prompted us to propose a project to verify riluzole effects in an informative number of SCA7 patients to the Agenzia Italiana del Farmaco.

## References

1. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. *Neurology* 2010, 74: 839-45.
2. Romano S, Coarelli G, Marcotulli C, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* 2015;14(10):985-91.

### 169. Patient Reported Outcomes in Friedreich's Ataxia after withdrawal from Treatment with Idebenone

Arran Cook, MBBS, Sylvia Boesch, MD<sup>2</sup> Thomas Klopstock, MD<sup>3, 3a, 3b</sup>, Ewout Brunt, MD<sup>4</sup>, Thomas Klockgether, MD<sup>5</sup>. Ludger Schols, MD<sup>6, 6a</sup>, Angela Schulz, MD<sup>7</sup>, Paola Giunti MD PhD<sup>1</sup>.

- 1: Department of molecular neuroscience, Ataxia center, UCL Institute of Neurology
- 2: Neurologische Klinik, Universitätsklinik, Innsbruck
- 3: Department of Neurology, Friedrich-Baur-Institute, University Hospital of LMU Munich
- 4: German Center for Neurodegenerative Diseases (DZNE)
- 5: Munich Cluster for Systems Neurology (SuNergy)
- 6: Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tübingen
- 6a: German Center for Neurodegenerative Diseases (DZNE)
7. Ethik-Kommission der Ärztekammer Hamburg

## Introduction

Friedreich's ataxia is the most common inherited ataxia, and pathogenesis is known to involve mitochondrial oxidative stress. Idebenone as a potent antioxidant, which has already been evaluated in several clinical trials in FRDA, with inconclusive results. For the first time in an FRDA population, we have employed a treatment withdrawal design to assess whether patients could correctly assess their blinded allocation on either placebo or idebenone continuation.

## Methods

Patients taking idebenone for at least 12 months as part of the open-label MICONOS Extension Study were randomised to receive either placebo or idebenone continuation for two-month treatment cycles. The primary endpoint was patient assessment of treatment assignment, and secondary endpoints included early study withdrawal, clinical performance measures and ataxia rating scales. This trial is registered with ClinicalTrials.gov number NCT01303406.

## Results

A total of 29 patients were screened and randomised in the study, forming the idebenone group (n=16) and the placebo group (n=13). No significant differences were detected between the idebenone and placebo groups on assessment of treatment assignment or early study withdrawal. A small but significant difference in ataxia rating scale scores was detected between treatment groups when considering ambulatory patients only. Speech intelligibility showed a significant difference between treatments, in favour of the idebenone group.

## Conclusions

This study provides no data to suggest that FRDA patients can correctly determine their treatment assignment (idebenone or placebo) over a 2 month period. Future studies with

larger cohorts and longer treatment durations should include comprehensive speech assessments and consider sample stratification based on ambulatory status.

170. Morpholino directed alternative splicing of mismatch repair protein mMLH3 in an FRDA mouse model

Ed Grabczyk and Kayla B. Fuselier

Department of Genetics, LSU Health Sciences Center, New Orleans, Louisiana USA

Dozens of ataxias and other neurodegenerative disorders are caused by DNA repeat expansion. There is no treatment or cure for any DNA repeat expansion disease. We are studying the mechanism underlying the GAA•TTC repeat expansion that causes Friedreich ataxia (FRDA). Our hypothesis is that selective somatic expansion of GAA•TTC repeats in disease relevant tissues contributes to disease progression. The FRDA mouse model (Tg(FXN)YG22Pook) exhibits region specific GAA•TTC repeat expansion chiefly in the CNS and most markedly in the cerebellum, consistent with this hypothesis. Our work in human cells indicates that somatic expansion of GAA•TTC repeats requires three sequential steps involving: 1) transcription through the DNA repeat 2) MutS $\beta$  (MSH2/MSH3 heterodimer) and 3) MutL $\gamma$  (MLH1/MLH3 heterodimer). MLH3 is expressed in humans as two isoforms. MLH3 isoform 1 includes a conserved endonuclease domain, while MLH3 isoform 2 lacks this cutting domain. We have shown that MLH3 isoform 2 does not promote repeat expansion in human cells. Skipping the exon encoding the endonuclease domain in both mice and men retains the MLH3 reading frame and effectively shifts MLH3 to isoform 2. We targeted the mouse MLH3 gene with two types of morpholino splice-switching oligonucleotides (SSOs), which were well tolerated. In some tissues, such as kidney, we can reliably alter mMLH3 splicing via tail-vein injection. In the CNS we had to resort to intracerebroventricular (ICV) administration via osmotic pump to effect splice switching in the cerebellum. Although at the time of submission we have yet to sustain mMLH3 isoform switching in the cerebellum sufficiently long to change the GAA•TTC repeat expansion rate we remain optimistic given the recent success of intrathecal delivery of splice switching reagents such as nusinersen for spinal muscular atrophy in humans.

171. RT001 First-in human Clinical Trial Demonstrates Safety, Favorable Pharmacokinetics, and Early Signals of Efficacy in Friedreich's Ataxia

F. Heerinckx<sup>1</sup>, J. Shaw<sup>2</sup>, M. Shchepinov<sup>1</sup>, O. Omidvar<sup>3</sup>, T. Zesiewicz<sup>2</sup> 1 Retrotope, 2 University of South Florida, 3 CNS Network

Contact Info: frederic@retrotope.com

Introduction: RT001 is a deuterated linoleic acid ester that inhibits lipid peroxidation, reducing cellular damage and recovering mitochondrial function in degenerative diseases such as Friedreich's Ataxia (FRDA). A first-in-human study was conducted to evaluate the safety, pharmacokinetics, and preliminary efficacy of RT001 in FRDA patients.

Methods: We conducted a double-blind, comparator controlled trial with 2 doses in FRDA patients. Subjects were randomized 6:3 to receive either RT001 (1.8 g/d or 9.0g/day), or a matching dose of linoleic acid ester as comparator for 28 days. Patients were counseled to observe a low polyunsaturated fatty acid (PUFA) diet (3-5 g/day) throughout the study. The primary endpoints were safety, tolerability and pharmacokinetics. Secondary endpoints included the Friedreich's Ataxia Rating Scale (FARS)-NEURO, timed 25-foot walk (T25FW) with electronic motion sensing, and cardio-pulmonary exercise testing (CPET).



Results: 19 patients enrolled in the trial, and 18 completed all study measurements (12 on active drug and 6 on comparator), median age 35 years, median baseline FARS NEURO = 58. RT001 was found to be safe and tolerable, with plasma levels approaching saturation by 28 days. Patients recorded food intake in a diary and were compliant with diet restrictions. Deuterated arachidonic acid (a brain penetrant metabolite of linoleic acid) was present in plasma. One patient with low BMI experienced steatorrhea taking high dose RT001. There was an improvement in peak workload in the drug group compared to placebo ( $p = 0.02$ ), and a strong improvement trend in peak  $\dot{V}O_2$ , gait in the T25FW-1 measured by electronic sensors, and FARS- NEURO.

Conclusions: RT001 was found to be safe and tolerable over 28 days, and appeared to improve multiple clinical measures in this study. Longer-term evaluation of RT001 in FRDA is warranted.

## 172. Stimulating neural repair through bone marrow stem cell fusion in models of ataxia

Kemp K, Usowicz M, Scolding N and Wilkins A  
University of Bristol

### Introduction

Neuronal cell loss is a critical feature in both genetic and acquired ataxic conditions. Strategies to attenuate neuronal cell injury are crucial to reducing the clinical burden of ataxia and accumulation of neurological disability. A major conceptual consideration in central nervous system repair is how damaged neurons, given their enormous complexity, can possibly be replaced or restored. The phenomenon of cell fusion between infiltrating, healthy bone marrow-derived cells and injured neural cells offers a tantalising solution; it may also provide an opportunity to introduce therapeutic 'donor' genetic material to boost cell survival.

### Methods

Using both in vitro and in vivo experimental techniques and analysing human brain tissue, we have explored in-depth the process of cell fusion in animal models of ataxia and in patients with cerebellar disease.

### Results

In animal models of ataxia and human post-mortem brain tissue, we provide evidence of disease-related increases in neuronal cell fusion and heterokaryon formation. We show that in genetic and acquired models of ataxia, post fusion, genes derived from the donated bone marrow-derived cell nucleus are expressed within the host neuronal cell, demonstrating proof of concept of a potential gene therapy within the nervous system. Moreover, we show that fusion between bone marrow-derived cells and existing neuronal cells leads to the formation of electrically active neurons, restoring their function.

### Conclusion

Our studies have provided novel and fundamental insights into the ways in which nerve cells can be protected and their survival prolonged. Given this potential solution to repairing neurons in adult life, harnessing fusion as a potential gene therapy and/or neuro-regenerative treatment could be clinically valuable to a wide range of patients with otherwise untreatable neurological diseases.

## 173. Evaluation of AMX0035, a novel combination therapy for the treatment of neurodegenerative diseases, in cellular models of Friedreich's Ataxia

Kent Leslie<sup>1</sup>, Justin Klee<sup>1</sup>, Joshua Cohen<sup>1</sup>, Marek Napierala<sup>2</sup>, Jordi Magrane<sup>3</sup>

1Amylyx Pharmaceuticals, Cambridge, MA, USA, 2Stem Cell Institute, University of Alabama at Birmingham, Birmingham, AL, USA 3Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA

Introduction: Amylyx Pharmaceuticals has developed a novel therapeutic, AMX0035, for the treatment of neurodegenerative diseases. AMX0035 is a combination of two small molecules, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), designed to block neuronal death and neuroinflammation through simultaneous inhibition of ER and mitochondrial stress.

Amylyx discovered a synergy between these two compounds when administered in combination across multiple preclinical models. The combination showed a synergistic increase in neuronal viability in an H<sub>2</sub>O<sub>2</sub>-mediated oxidative insult model. Additionally, AMX0035 has been evaluated in in vivo models of ALS and Alzheimer's disease (AD) and shown to have neurobiological effect and strong blood-brain barrier permeability.

Furthermore, AMX0035 was evaluated in preliminary in vitro studies in Friedreich ataxia patient derived fibroblasts and isolated sensory neurons derived from the KIKO FA mouse model.

Methods and Results: FA patient fibroblasts were grown in culture media containing beta-hydroxybutyrate, a selection media for mitochondrial dysfunction that has been shown to cause primary FRDA fibroblasts to grow poorly and lose viability over several days.<sup>1</sup> Treatment with AMX0035 improved cell viability relative to control under BHB-culture conditions.

KIKO-derived sensory neurons develop a relevant pathogenic phenotype for FA: the fragmentation of mitochondria and reduced mitochondrial mass. AMX0035 treatment at the combination dose of 50uM TUDCA + 500uM PB, was effective in reversing mitochondria fragmentation and loss of mitochondrial mass.

Conclusion: These studies demonstrate that AMX0035 promotes cell viability, including protecting frataxin-deficient cells from metabolic stresses, potentially through a mitochondrial-targeted mechanism of action, and may have application as a therapeutic for FA. Additional evaluation of the molecular mechanisms by which AMX0035 protects frataxin-deficient cells are underway in vitro and in vivo models of mitochondrial dysfunction. Further, AMX0035 will enter clinical trials in ALS and AD in mid-2017

1 Cotticelli, M. Grazia, et al. "Phenotypic screening for Friedreich ataxia using random shRNA selection." *Journal of biomolecular screening* 20.9 (2015): 1084-1090.

199.

174. TALEN and CRISPR gene-editing for treatment of Machado-Joseph disease  
Sara Lopes (see oral presentations)

175. Rationale and Trial Design of a Study of the Efficacy and Safety of Omaveloxolone in Patients with Friedreich's Ataxia (MOXIe)

Lynch, D1; Farmer, J2; Meyer, C3; Boesch, S4.; Chin, M.3; Delatycki, M5; Giunti, P6; Goldsberry, A3; Hoyle, JC7; McBride, M1.; O'Grady, M.3; Perlman, S8; Subramony, S9; Wilmot, G10; Zesiewicz, T11

Institution

1. Children's Hospital of Philadelphia, Philadelphia, PA
2. Friedreich's Ataxia Research Alliance, Downingtown, PA
3. Reata Pharmaceuticals, Irving, TX
4. Innsbruck Medical University, Innsbruck, Austria
5. Murdoch Children's Research Institute, Melbourne, Australia
6. University College of London, London, England
7. The Ohio State University, Columbus, OH
8. University of California Los Angeles, Los Angeles, CA
9. University of Florida, Gainesville, FL
10. Emory University, Atlanta, GA
11. University of South Florida, Tampa, FL

INTRODUCTION:

Omaveloxolone, an Nrf2 activator and NF- $\kappa$ B suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways. Efficacy data for omaveloxolone from Part 1 of a Phase 2 study in Friedreich's ataxia (MOXIe, NCT02255435) showed statistically significant improvement in neurological function assessed using the modified Friedreich's ataxia rating scale (mFARS), with a subgroup of patients without musculoskeletal foot deformities (pes cavus) having greater improvement. A randomized, placebo-controlled, double-blind portion of the trial (MOXIe), which could support registration, has been designed to assess the efficacy and safety of omaveloxolone in Friedreich's ataxia patients.

METHODS:

Approximately 100 Friedreich's ataxia patients will be randomized 1:1 to either omaveloxolone 150 mg or placebo to be administered once daily for 24 weeks. Patients with pes cavus will comprise no more than 20% of patients enrolled. Randomization will be stratified by pes cavus status. An independent data safety monitoring board will monitor the study.

RESULTS:

The primary endpoint is change from baseline in mFARS score relative to placebo at Week 24. Secondary endpoints are the change from baseline in peak work during maximal exercise testing relative to placebo at Week 24, and the proportion of patients "much improved" or "very much improved" relative to placebo in the Patient Global Impression of Change and Clinical Global Impression of Change scales. Exploratory efficacy endpoints will include the proportion of patients at Week 24 with mFARS improvements at or better than specified cutoff values (e.g., -2, -3, etc), change in FA Activities of Daily Living score, SF-36, change in performance on a 9-hole peg test, change in performance on a 25-foot timed walk test and frequency of falls.

CONCLUSIONS:

The Part 2 MOXIe trial design is a robust, registrational, placebo-controlled study that includes evaluation of a variety of clinically relevant endpoints; many of these endpoints correlate with FA disease progression.

### 176. Serotonergic signaling suppresses ataxin-3 proteotoxicity

Andreia Teixeira-Castro (1,2,3), Ana Jalles (1, 2), Sofia Esteves (1, 2), Liliana da Silva Santos (1, 2), Stéphanie Oliveira (1, 2), Sara Duarte-Silva (1, 2), Richard I. Morimoto (3) and Patrícia Maciel (1, 2)

(1) Life and Health Sciences Research Institute (ICVS), School of medicine, University of Minho, 4710-057 Braga, Portugal; (2) ICVS/3Bs - PT Government Associate Laboratory, Braga/Guimarães, Portugal; (3) Department of Molecular Biosciences, Northwestern University Evanston, Illinois 60208, USA.

**Introduction:** Our previous results support a therapeutic role for enhanced serotonergic signaling in Spinocerebellar ataxia type 3 (SCA3). In a *C. elegans* screen of FDA-approved small molecules for suppressors of mutant ataxin-3 (ATXN3) induced neurotoxicity, a selective serotonin re-uptake inhibitor (SSRI) was found to rescue mutant ATXN3-mediated toxicity in vivo. SSRI chronic and early symptomatic treatment in SCA3 mice led to a striking amelioration of motor symptoms, to a reduction of mutant ATXN3 aggregation and neuronal loss. Questions to be addressed for improved translation of these findings to the clinical context include the following: How late in disease progression can treatment be initiated? How is this antidepressant rescuing SCA3 pathogenesis? Is this relevant for other neurodegenerative diseases associated with protein misfolding?

**Methods and Results:** In a pre-clinical trial in CMVMJD135 mice, treatment initiated after symptom onset still ameliorated motor coordination and balance, in parallel with restoration of cerebellar calbindin positive neurons, even if it did not reduce ATXN3 inclusions in neurons, and had a reduced effect when compared to earlier treatment initiation. We are currently using genetic, pharmacological and transcriptomic approaches to determine which components of 5-HT signaling are key for the offsetting of neurodegeneration. Suppression of ATXN3 aggregation suggests that the increase in 5-HT availability, early in disease progression, affects folding and/or conformational stability of ATXN3. Using transgenic *C. elegans* strains expressing different aggregation-prone mutant proteins, we found that the beneficial effect of enhanced serotonergic signaling on animals' behavior is extended to other neurodegenerative disease associated proteins. This is accompanied by activation of discrete proteostasis subnetworks and increased folding capacity in live neuronal cells, as seen by employing *C. elegans* reporter and tissue-specific folding sensor strains.

**Conclusions:** Our results suggest that small molecule modulation of serotonergic signaling represents a promising therapeutic approach for conformational disorders, and supports the emerging role of this signaling pathway in the modulation of proteostasis. Post-symptomatic SSRI treatment is beneficial, however early initiation of treatment leads to increased efficacy, strengthening the conceptual basis for future human clinical trials.

### 177. Docosahexaenoic acid (DHA) supplementation as a therapy for Spinocerebellar ataxia 3 (SCA38)

Marta Manes (see oral presentations)

### 178. Effect of Diazoxide on Friedreich ataxia models

Antonella Santoro<sup>1¶</sup>, Sara Anjomani Virmouni<sup>2¶</sup>, Eleonora Paradies<sup>1</sup>, Valentina L. Villalobos Coa<sup>3</sup>, Sahar Al-Mahdawi<sup>2</sup>, Mee Khoo<sup>2</sup>, Vito Porcelli<sup>3</sup>, Angelo Voza<sup>3</sup>, Mara Perrone<sup>4</sup>, Nunzio Denora<sup>4</sup>, Franco Taroni<sup>5</sup>, Giuseppe Merla<sup>6</sup>, Luigi Palmieri<sup>3</sup>, Mark A. Pook<sup>2</sup>, Carlo M.T. Marobbio<sup>3\*</sup>

- 1 Consiglio Nazionale delle Ricerche, Institute of Biomembranes and Bioenergetics, Bari, Italy
- 2 Department of Life Sciences, College of Health & Life Sciences, Brunel University, London, UK
- 3 Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari "A. Moro", Bari, Italy
- 4 Department of Pharmacy - Drug Sciences, University of Bari "A. Moro", Bari, Italy
- 5 I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy
- 6 I.R.C.C.S. Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

\*Corresponding author

E-mail: carlomarya.marobbio@uniba.it

¶These authors contributed equally to this work.

Friedreich ataxia (FRDA) is an inherited recessive disorder caused by a deficiency in the mitochondrial protein frataxin. In this study, we tested diazoxide, a drug commonly used as vasodilator in the treatment of acute hypertension, on cellular and animal models of FRDA. Diazoxide is able to increase frataxin protein levels in FRDA lymphoblastoid cell lines, via the mTOR pathway. Moreover, prolonged oral administration of 3mpk/d diazoxide in frataxin-deficient transgenic YG8sR mice was found to be safe, but produced variable effects concerning efficacy. YG8sR mice showed improved beam walk coordination abilities and footprint stride patterns, but a generally reduced locomotor activity. Moreover, they showed significantly increased frataxin expression, improved aconitase activity and decreased protein oxidation in cerebellum and brain mitochondrial tissue extracts. Further studies are needed before this drug should be considered for FRDA clinical trials.

#### 179. [Ibuprofen improves neuropathology and increases neural progenitors proliferation, synaptic function and neurite growth in Machado-Joseph disease](#)

Mendonça LS 1, Nóbrega C1, Tavino S1, Brinkhaus M1, Matos C1, Tomé S1, Kaspar B2 and Pereira de Almeida L1,3

1. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. 2. The Research Institute at Nationwide Children's Hospital, Ohio State University School of Medicine, Columbus, USA. 3. Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.

**Introduction:** Machado-Joseph disease (MJD) is a neurodegenerative disease caused by an expanded polyglutamine tract within the ataxin-3 protein. This mutated ataxin-3 causes neuronal degeneration leading to severe motor symptoms. Ibuprofen is an anti-inflammatory drug that has been tested in neurodegenerative diseases, promoting reduction of the neuroinflammation, increasing synaptic function and neurite growth. Therefore, in this work we investigated whether treatment with ibuprofen reduces neuroinflammation and improves MJD-associated neuropathology.

**Methods:** MJD patient's iPSCs-derived neural cultures and two MJD mouse models, a lentiviral (Lv) model, in which mice were injected with lentivirus expressing full-length human mutant ataxin-3 and, a transgenic model expressing a truncated human mutant ataxin-3, were used. Ibuprofen-treated mice were fed with chow containing 375 mg of ibuprofen /Kg chow. The impact of the treatment in neuroinflammation was assessed through the evaluation, in mouse brain samples, of IL1 $\beta$  and TNF $\alpha$  mRNA and IKB- $\alpha$  phosphorylation levels by qRT-PCR and western blot, respectively. Neuronal survival and cerebellar atrophy were evaluated by immunohistochemistry and cresyl violet staining, respectively. Moreover, MJD patient's iPSCs-derived neural cultures incubated with 500  $\mu$ M of ibuprofen were evaluated for Msi1, Syp and

Ki67 levels, as well as for excitatory synapses numbers and neurite length. Additionally, Msi1, Syp and Ki67 levels were also assessed in ibuprofen-treated mice.

Results: In the Lv model, ibuprofen administration significantly reduced the mRNA levels of pro-inflammatory IL1 $\beta$  and TNF $\alpha$  interleukins and the phosphorylated IKB- $\alpha$  protein. Moreover, a significant neuronal preservation was observed for both mouse models, and for the transgenic mice cerebellar atrophy was also reduced. MJD patient's iPSCs-derived neural cultures treated with ibuprofen exhibited higher levels of synaptic and neural progenitors proliferation markers, as well as increased numbers of excitatory synapses and longer neurites. Finally, the synaptic and neural progenitors proliferation markers were also increased in ibuprofen-treated mice.

Conclusions: This work demonstrates that ibuprofen positively modulates MJD decreasing neuroinflammation and improving neuropathology, namely by increasing neural progenitors proliferation, synaptic function and neurite growth.

Acknowledgements: This work was supported by the National Ataxia Foundation, the Association Francaise Contre les Myopathies (AFM)-Téléthon, by FEDER through Programa Mais Centro (CENTRO-07-ST24-FEDER-002006) and COMPETE and by FCT funds.

## 180. Rehabilitation improves health and well-being in individuals with Friedreich ataxia.

Milne SC1,2,3; Corben LA1,3,4; Roberts M2; Murphy A5,6; Tai G1; Georgiou-Karistianis N3; Yiu EM1,4,7; Delatycki MB1,3,4,8.

1Murdoch Childrens Research Institute, Bruce Lefroy Centre, Australia.

2Monash Health, Physiotherapy Department, Australia.

3Monash University, Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Australia.

4The University of Melbourne, Department of Paediatrics, Australia.

5Monash University, Monash Ageing Research Centre, Australia.

6Monash Health, Clinical Research Centre for Movement Disorders and Gait, Australia.

7The Royal Children's Hospital Melbourne, Department of Neurology, Australia.

8Victorian Clinical Genetics Services, Australia.

Introduction: Progressive mobility decline, upper limb ataxia, muscle weakness and spasticity have a significant impact on the ability to perform activities of daily living and the quality of life for individuals with Friedreich ataxia (FRDA). Primary treatment of FRDA is based on symptom management and maintenance of function, which includes rehabilitation. We aimed to compare the effectiveness of a six-week rehabilitation program in individuals with FRDA to no therapy. The effects of a home exercise program (HEP) following rehabilitation were also examined. Methods: We conducted a single-blinded randomised controlled trial. Nineteen participants with FRDA were randomised to an immediate rehabilitation group or a six-week delayed-start control group. Rehabilitation involved outpatient land and aquatic physiotherapy. This was followed by a six-week HEP. The primary outcome was the Functional Independence Measure (FIM). Secondary outcome measures included the motor domain of the FIM (m-FIM), Friedreich Ataxia Impact Scale (FAIS), Berg Balance Scale (BBS) and Friedreich Ataxia Rating Scale (FARS). Outcomes were administered at baseline and six weeks.

Additionally, response to the HEP was measured for all participants. Results: There was a significant within-group increase in the m-FIM for the immediate group ( $t(9)=2.41$ ,  $p=0.039$ ) indicating that individuals undergoing rehabilitation made functional gains. Participants in the immediate group had an average 12.4% improvement in health and well-being at six weeks, compared to a 3.5% worsening in the control group ( $t(17)=3.40$ ,  $p=0.003$ ), as indicated by the

FAIS body movement subscale. Collated data from both groups (n=18) identified a reduction in the FARS (p=0.016), and an increase in the BBS for non-ambulant participants (p=0.026) after the HEP, both indicating improvement. Conclusions: This study found that rehabilitation improves function as well as the health and wellbeing of individuals with FRDA, providing compelling evidence that short-term rehabilitation should be offered to individuals with FRDA.

### 181. Non-invasive and allele-specific silencing of mutant ataxin-3 alleviates neuropathology and motor deficits of Machado–Joseph disease

Nobre, Rui Jorge 1,2 ; Saraiva, J 2; Fusco, Clelia 2; Paixão, Susana

2; Santana, Magda 2; Sena-Esteves, Miguel 3; Pereira de Almeida, Luis 1,4.

AFFILIATIONS: 1Center for Neuroscience and Cell Biology, University of Coimbra, Portugal;

2Institute for Inter-disciplinary Research, University of Coimbra, Portugal; 3Neurology

Department, Gene Therapy Center, University of Massachusetts Medical School, MA, USA;

4Faculty of Pharmacy, University of Coimbra, Portugal.

Introduction: Machado-Joseph disease (MJD) is the most common dominantly- inherited ataxia worldwide. Although there is no cure, our group and others showed that RNA interference holds great promise for its treatment. However, all previous experiments involved craniotomy and in situ injection of vectors in the brain. There is therefore a need for less invasive procedures.

Objective: The aim of the present study was to develop an adeno-associated virus (AAV)-based system that enables: delivery of RNA interference-based treatments to the brain, the specific silencing of mutant ataxin-3 (mutATAX3) and alleviation of the disease by intravenous (iv) injection.

Methods: For that, we generated AAV9 vectors encoding an artificial microRNA that targets the mutant form of ataxin-3 mRNA (AAV9-mirATAX3). Its efficacy and specificity were firstly confirmed in neuronal cell models and viral-based mouse models and the therapeutic potential was then tested in a severely impaired transgenic mouse model of MJD. Mice were intravenously injected at postnatal day one (PN1); were submitted to behavioral tests at 3 different ages and sacrificed at PN95.

Results: AAV9-mirATAX3 vectors efficiently spread throughout the brain, transducing regions affected in MJD, such as the striatum, cerebellum, brainstem and spinal cord. AAV9-mirATAX3's treatment reduced the number of mutATAX3 aggregates and the cerebellar neuropathology, and treated animals showed a better performance in all behavioral tests.

Conclusion: Overall, this study provides compelling evidence that a single iv injection of AAV9-mirATAX3 at PN1 is able to transverse the BBB, silence mutATAX3 and alleviate MJD motor phenotype. To our knowledge, this is the first time that a non-invasive iv administration of rAAV9 vectors had significant impact on motor deficits of a polyglutamine disorder.

This work was supported by the National Ataxia Foundation and by funds from FEDER (COMPETE) and by national funds through the Portuguese Foundation for Science and Technology (COMPETE:POCI-01-0145-FEDER-007440, EXPL/NEU-NMC/0331/2012, and SFRH/BPD/66705/2009).

### 182. Clinical trials in Friedreich ataxia: pre-clinical evidence of efficacy is essential

Pandolfo M

Université Libre de Bruxelles (ULB) - Hôpital Erasme, Brussels, Belgium.

## Introduction

When a new treatment is tested in humans, safety is the primary concern of regulatory agencies and Ethics Committees (or IRBs). They impose appropriate pre-clinical assessment of potential toxicity and strict rules for first-in-human trials, with safety monitoring remaining an essential requirement throughout all phases of therapeutic development. However, as pointed out in a recent Comment in the journal *Nature* (Kimmelman J and Federico C, *Nature* 2017; 542:25-27), robust pre-clinical evidence of efficacy is equally essential to justify testing an experimental therapeutic in people.

## Methods

Results of past clinical trials in Friedreich ataxia (FRDA), published in peer-reviewed journals or disclosed in press releases, have been reviewed along with the pre-clinical evidence of efficacy that supported the trial.

Criteria considered for any proposed therapeutic for FRDA include: 1) target a biological process with a major pathogenic role, as supported by robust, consistent and reproducible evidence; 2) interfere with such process, partially or entirely interrupting the pathogenic cascade as early as possible; 3) correct key phenotypic abnormalities in cellular and animal models of the disease; 4) have appropriate pharmacological properties, such as lack of off-target effects, favorable pharmacokinetics (PK), good blood-brain barrier (BBB) penetration.

## Results

Clinical trials in Friedreich ataxia (FRDA) have so far failed to identify any effective treatment, leaving a major unmet medical need. While flaws in the way trials have been designed and conducted are often cited as a major factor, I would argue that lack of appropriate evidence of efficacy, obtained in well conducted pre-clinical studies, has been largely responsible of these repeated failures.

A few examples can illustrate these points.

Trials of antioxidants in FRDA have so far been disappointing. Looking back at the preclinical evidence for their use, it is often flagrantly insufficient. Idebenone was never tested in appropriate model systems before moving to human trials. A study in a cardiac mouse model only followed several human trials, with only modestly positive results despite the very large doses utilized (Seznec H et al. *HMG* 2004; 13:1017-1024). Even evidence that antioxidants target a relevant pathogenic mechanism is questionable. While oxidative stress does occur in several model systems (e.g. Codazzi et al., *HMG* 2016; 25:4847-4855), it does not appear to be needed for neurodegeneration induced by frataxin deficiency (e.g. Seznec H et al., *HMG* 2005; 14:463-474, and more recently Chen et al. *eLife* 2016; 5:e20732), suggesting that antioxidants are not likely to interrupt the pathogenic cascade at an early step. While it can be argued that these are relatively benign drugs, it must be carefully assessed if they may be worth testing when the expected benefit is likely to be limited.

Although frataxin restoration appears to be the best possible therapeutic approach for FRDA, several compounds supposed to upregulate frataxin expression, such as erythropoietin (EPO) or gamma interferon (IFNG), failed in clinical trials. Again, they had limited preclinical evidence of efficacy. Frataxin-inducing properties were usually modest. Model systems did not closely reproduce the human disease, so evidence of correction of a relevant phenotype was lacking. Furthermore, no mechanism of action was identified.

Considerations about PK properties, BBB penetration, and receptor distribution should also have induced caution.

## Conclusion

Even if it always provides some useful information, a failed trial has a very high human and financial cost. It breaks hopes and wastes resources. Furthermore, analysis of disease



progression in large patient cohorts demonstrated that proof of efficacy in FRDA requires long trials with a substantial number of participants, limiting the number of studies that can be performed at any given time. We must therefore avoid committing patients and time, the most precious resources, to test treatments whose potential efficacy is not supported by strong enough experimental evidence.

### 183. [CAT-4001 improves mitochondrial function in a Friedreich's ataxia model](#)

John F. Reilly<sup>1</sup>, Giuseppe Yañez<sup>2</sup>, Pradeep Bista<sup>1</sup>, Dominic Picarella<sup>1</sup>, Diana Lee<sup>1</sup>, Chi Vu<sup>1</sup>, Andrew Nichols<sup>1</sup>, and Jordi Magrane<sup>2</sup>

<sup>1</sup>Catabasis Pharmaceuticals, Cambridge, MA, US; <sup>2</sup>Brain and Mind Research Institute, Weill Cornell Medical College, New York, US

The frataxin deficiency that underlies Friedreich's ataxia (FA) leads to oxidative stress and decreased mitochondrial function, which may play significant roles in disease pathology. Impaired nuclear translocation of Nrf2 may be the causative factor for oxidative neuronal damage in FA. CAT-4001 is a novel, CNS-penetrant small molecule conjugate of monomethyl fumarate (MMF), which activates Nrf2, and the omega-3 fatty acid, docosahexaenoic acid (DHA), which inhibits NF-κB, coupled via a linker designed to be enzymatically cleaved, enabling simultaneous intracellular release of the active components with concomitant synergistic pharmacology.

Degeneration of large sensory neurons is a hallmark of FA, and associated defects can be observed in dorsal root ganglion (DRG) derived neurons from frataxin-deficient mice (KIKO). KIKO DRG neurons show mitochondrial abnormalities in terms of mitochondrial fragmentation and altered bioenergetics. Treatment of DRG neurons from normal (WTWT) or KIKO mice with CAT-4001 increased expression of the Nrf2-target gene, Hmox1, indicating pharmacological modulation of the target pathway. To assess CAT-4001 effects on mitochondrial abnormalities, cultures were treated with CAT-4001 and mitochondrial lengths were measured using fluorescence microscopy. Compared to WTWT neurons, KIKO neurons showed a decreased mitochondria length within their axons, consistent with mitochondrial fragmentation. However, the axonal mitochondria in CAT-4001 treated KIKO neurons were longer, and of comparable lengths to the mitochondria in WTWT neurons, suggesting that CAT-4001 could prevent mitochondrial fragmentation.

We evaluated mitochondrial respiration in a mouse muscle cell-line (C2C12). Treatment with a pro-oxidant stressor leads to markedly decreased oxygen consumption in these cells. CAT-4001 reversed the H<sub>2</sub>O<sub>2</sub>-mediated decreases in oxygen consumption in a concentration-dependent manner. Combined with the effects in reversing mitochondrial fragmentation seen in the KIKO neurons, these results suggest that CAT-4001 is likely to improve mitochondrial bioenergetics. In conclusion, CAT-4001 may represent an effective approach to improve mitochondrial function for the treatment of FA.

### 184. [Modification of Frataxin with BBB-shuttles to increase brain access](#)

Sánchez-Navarro, M.a Arranz, P.a Teixidó, M.a Giralt, E.a,b

a) Institute for Research in Biomedicine (IRB Barcelona), 08028, Barcelona, Spain;

b) Department of Organic Chemistry, University of Barcelona, 08028, Barcelona Spain  
macarena.sanchez@irbbarcelona.org

#### Introduction

The development of an efficient protein replacement therapy for Friedreich ataxia (FA) is hampered by the presence of the Blood-Brain barrier (BBB). The natural protection of the brain

is also the main obstacle when delivering therapeutics. BBB-peptide shuttles are compounds able to circumvent the BBB increasing the transport of substances linked to them. We propose the modification of expressed Frataxin (FXN) with various protease resistant BBB-shuttles in order to improve its BBB penetration. BBB cell-based models are used to test and compare the constructs prepared.

#### Methods

Mature FXN with and without a selected mitochondrial localization signal (FXN81-210 and MLS-FXN81-210) were expressed in E. Coli. Modification with the BBB-shuttles of choice was carried out by site-selective modification strategies or by modifying the most reactive solvent exposed residues. All the constructs were conveniently characterized. BBB-cell based models, both endocytosis and transcytosis, were used to establish the BBB transport capabilities of the different constructs.

#### Results

When challenging a human BBB cell-based model with the designed FXN constructs differences in transport were observed when comparing number, type and location of the BBB-shuttles. Endocytosis experiments allowed for intracellular distribution of the constructs. Those that reached the mitochondria on selected cells lines and had good transport were selected for further experiments.

#### Conclusions

Modification of FXN with protease resistant BBB-shuttles is an attractive approach to develop an efficient protein replacement therapy since the newly designed FXN derivatives have better BBB permeability in cell-based in vitro models of the BBB.

### 185. Biophysical Characterization of the Recombinant Human Frataxin Precursor

Ignacio H. Castro<sup>1</sup>, Alejandro Ferrari<sup>1</sup>, Georgina Herrera<sup>1</sup>, Martín E. Noguera<sup>1</sup>, Lorenzo Maso<sup>2</sup>, Alessandra Rufini<sup>3</sup>, Roberto Testi<sup>3</sup>, Paola Costantini<sup>2</sup> and Javier Santos<sup>1</sup>

<sup>1</sup>Instituto de Química y Físicoquímica Biológicas (IQUIFIB), CONICET, Universidad de Buenos Aires, Junín 956, (C1113AAD), Buenos Aires, Argentina

<sup>2</sup>Department of Biology University of Padova, Viale G. Colombo 3, 35131 Padova, Italy

<sup>3</sup>Laboratory of Signal Transduction, Medical Physics Section, Department of Biomedicine and Prevention, University of

Rome "Tor Vergata," Via Montpellier 1, 00133 Rome, Italy

**Introduction:** One outstanding strategy to increase the concentration of active frataxin (FXN) inside the mitochondria is the production of recombinant variants of FXN with the capability to cross cell membranes using a TAT-derived peptide fused to FXN precursor [1-4]. For an eventual TAT-FXN-based therapy, the integrity of protein conformation is essential. Not enough information is available about the conformation of precursor FXN1-210. Here, we investigated the conformation and stability of a recombinant precursor (TAT-His6-FXN1-210), which includes a TAT peptide in the N-terminal region plus a histidine tag.

**Methods:** His6-TAT-FXN1-210 was expressed in Escherichia coli codon plus ROSETTA2pLysDE3 cells and purified to  $\geq 95\%$  (SDS-PAGE). Mass and aggregation state were evaluated by ESI-MS and MALS/DLS. Circular dichroism and fluorescence measurements were performed. GdmCl- and temperature-induced unfolding experiments were carried out. Cysteine desulfurase NFS1/ISD11 activation by FXN was investigated (methylene blue method). Protein transduction was studied using FITC-labeling TAT-His6-FXN1-210. Immune response against TAT-His6-FXN1-

210 (0.05 or 0.25 nmol) was measured using C57 mice. Specific antibodies to FXN variants were tested by ELISA.

Results: We optimized expression and purification conditions that maintain the protein soluble, even after freezing and thawing, free of aggregation, oxidation or degradation. His6-TAT-FXN1-210 is monomeric, with the N-terminal stretch (residues 1-89) mostly unstructured, and the C-terminal domain folded. GdmCl-induced unfolding of the precursor is reversible, cooperative and the protein is stable. Temperature-induced unfolding/aggregation was not reversible but the addition of low concentrations of GdmCl makes it reversible. His6-TAT-FXN1-210 activates desulfurase in vitro. Precursor was translocated across cell membranes and our results support the notion that the C-terminal fragment is not immunogenic at these concentrations.

Conclusions: His6-TAT-FXN1-210 exhibits an enhanced propensity to aggregate. Conditions were set that keep the protein stable and soluble after freeze/thaw, with minimal auto-proteolysis. Low GdmCl concentration prevents N-terminal-mediated aggregation.

1. Marcus, D., et al., Heterologous mitochondrial targeting sequences can deliver functional proteins into mitochondria Therapeutic approaches for the treatment of Friedreich's ataxia. *Int J Biochem Cell Biol*, 2016. 81(Pt A): p. 48-56.
2. Vyas, P.M., et al., A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. *Hum Mol Genet*, 2012. 21(6): p. 1230-47.
3. Kim, M.J., et al., Tat-Frataxin protects dopaminergic neuronal cells against MPTP-induced toxicity in a mouse model of Parkinson's disease. *Biochimie*, 2012. 94(11): p. 2448-56.
4. Strawser, C.J., K.A. Schadt, and D.R. Lynch, Therapeutic approaches for the treatment of Friedreich's ataxia. *Expert Rev Neurother*, 2014. 14(8): p. 949-57.

#### 186. [Autologous haematopoietic stem cell transplantation in a patient with paraneoplastic-related ataxia](#)

PD Shanmugarajah<sup>1</sup>, M Hadjivassiliou<sup>1</sup>, ASJE Barker<sup>2</sup>, DG Rao<sup>2</sup>, N Hoggard<sup>3</sup>, AD Chantry<sup>4</sup>, JA Snowden<sup>4</sup>

Departments of <sup>1</sup>Neurology, <sup>2</sup>Neurophysiology, <sup>4</sup>Haematology and Oncology, Royal Hallamshire Hospital, Sheffield, UK and University of Sheffield, UK <sup>3</sup>Academic Unit of Radiology, University of Sheffield, UK

#### Introduction

Paraneoplastic syndromes are immune mediated and can manifest as cerebellar disorders or demyelinating neuropathies. We describe the presentation and management of a patient with rapid onset ataxia.

#### Methods

A 40 year old male patient presented with a 3 month history of rapid deterioration in balance and distal limb sensory symptoms. There was nystagmus, upper limb tremor, gait and limb ataxia with sensory and cerebellar components. He was areflexic with extensor plantars and had asymmetrical distal lower limb weakness and sensory loss. Paraneoplastic antibodies were normal. Serum protein electrophoresis revealed dual abnormal IgG lambda monoclones. The neurophysiology study demonstrated multifocal acquired demyelinating sensory and motor neuropathy (MADSAM). MR spectroscopy of cerebellum showed dysfunctioning of the cerebellum. MRI spine displayed abnormal multifocal vertebral bone disease with bone

marrow infiltration. CSF protein was raised. PET scan revealed multiple lytic and sclerotic lesions. Sacral and bone marrow trephine biopsies confirmed plasma cell myeloma.

#### Results

Treatment with intravenous immunoglobulins provided no benefit. He became wheelchair dependent in view of worsening ataxia and lower limb weakness. He received 4 cycles of cyclophosphamide, thalidomide and dexamethasone (CTD). He proceeded to have autograft conditioning with melphalan and was successfully treated with autologous stem cell transplantation. Post treatment haematology related investigations and PET scan results showed good response. Clinically he improved from wheelchair dependent to mobilising independently with one walking aid. Repeat MR spectroscopy of cerebellum and neurophysiology study parameters demonstrated objective stability. He continues to remain well and in remission more than one year post stem cell transplant and is now on mycophenolate.

#### Conclusions

Clinical, imaging, immunology and neurophysiology studies can help correctly identify the cause for a specific paraneoplastic syndrome. This case provides support for the role of autologous haematopoietic stem cell transplantation as a potential therapeutic intervention in patients presenting with paraneoplastic-related ataxia.

#### 187. DAO inhibitor preclinical therapeutic studies for FRDA

Sherzai, M. 1, Fradley, R. 2, Harrison, D.C. 2, Miller, D. 2, Pook, M.A. 1

1 Division of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge, Middlesex, UK

2 Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge, UK

Friedreich ataxia (FRDA) is an inherited progressive neurodegenerative disorder caused by a trinucleotide (GAA) repeat hyper-expansion within intron 1 of the of the frataxin gene, FXN, which instigates transcriptional deficiency. The neurological defect in FRDA is primarily caused by the degeneration of dorsal root ganglia and cerebellar neurons and degeneration of axons in peripheral nerves, dorsal roots, and posterior columns, depriving the cerebellum of sensory input to coordinate movement.

It is speculated that high levels of D-amino acid oxidase (DAO) enzyme activity affects regular neural transmission extensively in the cerebellum, by degrading D- serine and in turn inducing stereotyped behavior and ataxia. In this study, a small molecule inhibitor of DAO, TAK-831, was investigated using FRDA (YG8sR) mice. Two chronic dosing experiments were performed by administering either vehicle or 3mpk TAK-831 by daily gavage for 14 days on groups of ten FRDA mice at approximately 4 months of age and again at 9 months of age, with a 97 day interval between experiments. Age and sex matched vehicle-treated WT mice were also used as controls.

Results indicated no significant FRDA-like disease or TAK-831 effects for the 4 month old mice. However, a progressive FRDA-like disease effect was seen for the 9 month-old vehicle-treated FRDA mice versus WT mice, whilst the TAK-831-treated FRDA mice showed significantly improved motor coordination ability compared with vehicle-treated FRDA mice. Moreover, the dose of TAK-831 used was well tolerated, with no effect on mouse weight and qRT-PCR results showed no effect of TAK-831 on FXN gene expression. The outcomes of this study encourage the continued study of TAK-831 as a potential therapy for FRDA; however more research needs to be carried out to understand the effects of this DAO inhibitor therapeutic compound.

## 188. HMTase inhibitor preclinical therapeutic studies for FRDA

Sherzai, M., Anjomani-Virmouni, S., Saqlain, S., Mikaeili, H., Al-Mahdawi, S. and Pook, M.A. Division of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge, UK

Friedreich ataxia (FRDA) is an inherited progressive neurodegenerative disorder caused by an intronic GAA trinucleotide repeat expansion within the frataxin gene (FXN), which encodes a mitochondrial protein, frataxin. This abnormal GAA expansion plays a role in histone modification, subjecting the FXN gene to heterochromatin silencing. Therefore, inducing a more relaxed chromatin structure at the FXN gene by inhibiting various histone markers may have beneficial therapeutic outcome.

Recent studies have shown that histone H3 lysine 9 trimethylation (H3K9me3) and histone H3 lysine 27 trimethylation (H3K27me3) are enriched in the flanking regions of expanded GAA repeats, where acetylation marks are correspondingly reduced.

Here we have studied two histone methyltransferase (HMTase) inhibitor compounds, BIX01294 and GSK-126, to specifically target and reduce H3K9me3 and H3K27me3 levels, respectively, in FRDA human and mouse model (Y47R, YG8R, YG8sR and YG8LR) fibroblast cells, using concentrations ranging from 1nM to 10µM.

Potential cell toxicity for each drug was assessed using the PrestoBlue cell viability assay, followed by collection of cells for biochemical and molecular analysis. Thus far, we have detected lack of cell toxicity and a consistent 1.6-fold increases in FXN mRNA and frataxin protein levels when using BIX-01294 at concentration from 1nM to 1µM. In contrast, GSK126 induced inconsistent changes of FXN mRNA and frataxin protein levels in different cell types at non-toxic concentration, including decreases in FXN expression. For further analysis, we are currently investigating the levels of methylated histone marks at the FXN locus after BIX01294 or GSK-126 treatment by performing chromatin immuno-precipitation (ChIP). Additionally, we are combining BIX01294 and GSK-126 together to detect any potential synergistic effect on FXN gene expression.

## 189. BBB-shuttle decorated DNA nanocarriers to treat Friedreich's ataxia.

Teixidó, M. 1, Garcia, J. 1, Sánchez-Navarro, M.1, Giralt, E.1,2

1) Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, 08028, Barcelona, Spain;

2) Department of Organic Chemistry, University of Barcelona, 08028, Barcelona Spain  
meritxell.teixido@irbbarcelona.org

### Introduction

Brain delivery is one of the major challenges in drug development, as the blood–brain barrier (BBB) prevents most drugs from reaching their central nervous system targets. BBB-shuttle peptides with their capacity to cross the BBB and transport cargoes of distinct sizes and types that can not cross unaided – offer great promise to safely overcome this formidable obstacle.<sup>1-3</sup>

In the case of Friedreich's ataxia (FA), we envisaged to go significantly beyond the state-of-the-art in gene delivery by combining the properties of two well-known DNA nanocarriers (such as viral vectors and PLGA nanoparticles) with the targeting properties of our peptides that function as BBB-shuttles.

### Methods

We have chemically decorated these two DNA nanocarriers (viral and non-viral) with synthetic protease-resistant BBB-shuttle peptides. Also, we have incorporated some cell penetrating peptides (CPPs) at the surface of the PLGA NPs to help on their internalization at the target cells.

We have characterized the physicochemical (Z-potential, size and encapsulation efficiency) and gene delivery properties of the obtained nanoconstructs, including in vitro and in vivo evaluation of the transfection of the encapsulated DNA, as well as, transport evaluation using BBB cell-based models. All these tools have been used to optimize the set of nanoconstructs prepared and the most promising and robust have been selected to be further developed and studied.

#### Results and Conclusions

Based on our obtained results, we have decided to focus our future efforts in the transport of synthetic BBB-shuttle decorated PLGA nanoparticles. These systems are highly advantageous as delivery vehicles since they are simple to prepare, scale-up and can be decorated in a more controlled and reproducible manner. In addition, they generally have less pro-inflammatory effects than viral particles. Although some optimization is still required, our nanoparticles are not only able to encapsulate the cDNA encoding for Frataxin but also the complete Frataxin gene.

#### References

- 1.- B. Oller-Salvia, M. Sánchez-Navarro, E. Giralt, M. Teixidó, *Chem. Soc. Rev.*, 2016, 45, 4690-4707.
- 2.- R. Prades, B. Oller-Salvia, S.M. Schwarzmaier, J. Selva, M. Moros, M. Balbi, V. Grazú, J.M. de La Fuente, G. Egea, N. Plesnila, M. Teixidó, E. Giralt, *Angew. Chem. Int. Ed.*, 2015, 54, 3967-3972.
- 3.- B. Oller-Salvia, M. Sánchez-Navarro, S. Ciudad, M. Guiu, P. Arranz-Gibert, C. Garcia, R.R. Gomis, R. Cecchelli, J. García, E. Giralt, M. Teixidó, *Angew. Chem. Int. Ed.*, 2016, 55, 572- 575.

190. [Ataxin-3 exon skipping as a treatment strategy for Spinocerebellar ataxia type 3](#)

Lodewijk Toonen (see oral presentations)

191. [Combining multiple therapeutic strategies for Friedreich's ataxia \(FRDA\): antioxidant metallic nanoclusters as coadjuvants for gene and stem cell therapy.](#)

Meregalli M.1,2, Villa C. 1, Banfi S. 1, Belicchi M. 1,2, Erratico S. 2 and Torrente Y 1,2.

1 Stem Cell Laboratory, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Centro Dino Ferrari, Via F. Sforza 35, Milan

2 Novastem Srl, Viale Piave 21, Milan

Introduction FRDA pathology is caused by guanine–adenine–adenine trinucleotide repeat expansion within the first intron of frataxin (FTX) gene, leading to epigenetic silencing. Since mitochondrial FTX controls cellular iron use and redox status maintenance, its lack causes an increased level of reactive oxygen species. We report an effective lentivirus FXN gene delivery to FTX deficient mesenchymal stem cells (MSCs), inducing improvement of neurological functionalities when transplanted in vivo. We also identify antioxidant nanoclusters (NCs) able to block ROS–dependent apoptotic pathways in the FRDA pathology. Methods MSCs from

FRDA patient bone marrows were transduced with a lentiviral vector for FXN expression. After LV transduced MSC characterization by FACS, IF, and WB analyses, engineered cells were systemically injected in Fxntm1MknTg (FXN)YG8Pook/2J mice. Behaviour tests (rotarod and treadmill) were performed. Brain tissues were harvested for IF staining and WB. FRDA MSCs labelled with AuAg NCs were characterized to evaluate mitochondrial ROS scavenger activity. Results After LV transduction, MSCs showed the preservation of mesenchymal marker expression (CD73, CD44, CD90 and CD105), colony forming abilities, and capacity to differentiate into multilineages. Comparison with untreated animals revealed i) in vivo FTX rescue; ii) increased number of cerebellar cells expressing Tuj1 neuronal marker; and iii) improvement trend of motor skills in mice injected with engineered MSCs. In addition, AuAg NCs entered the mitochondria of FRDA MSCs where they reduce ROS levels lowering cell sensitivity to oxidative stress. Conclusions The results confirm the gene and stem cells-based therapeutic applicability to treat the neuronal degeneration in FRDA. The suitability of metallic NCs as anti oxidant agents represents a crucial point as implemental strategy for further ameliorating the progressive ROS mediated degeneration. Indeed, a combined approach based on NCs nasal inhalation in autologous transplanted FRDA patients may be considered as a step further into a clinically relevant treatment.

192. Increased frataxin expression induced in Friedreich ataxia cells by new TALEs fused with a transcription activation domain.

Khadija Cherif, Catherine Gérard and Jacques P. Tremblay

Centre de Recherche du CHU de Québec-Université Laval and Département de Médecine Moléculaire de l'Université Laval

Québec, Canada

Introduction: The FXN gene expression is reduced in Friedreich ataxia (FRDA) patients due to an increase in the number of GAA trinucleotides in intron 1. The frataxin protein, coded by that gene, plays an important role in the iron metabolism in the mitochondria. TALE (proteins targeting the regulatory region of the FXN gene, fused with transcription factors (TF) were used to increase the expression of that gene.

Methods: Thirty one (31) different TALEs targeting 14 sequences of the FXN gene were produced.

Results: The best 3 TALEs increased FXN gene expression by up to 19-folds in different FRDA fibroblasts. An AAV9 virus was used to deliver the selected TALE-TF genes to the YG8R mouse model to validate the efficacy of these effectors in vivo.

Conclusion: The results show that these selected TALE-TFs induced the transcriptional activity of the endogenous FXN gene as well as the expression of the frataxin protein in vitro and in vivo in the heart and the skeletal muscles. The higher frataxin expression increased the aconitase activity, which is reversibly modulated by the frataxin level in mitochondria.

193. In vivo deletion of the GAA repeats from the intron 1 of the human frataxin gene using the CRISPR system delivered with PHP.B-serotyped AAV in the YG8R mouse model.

Dominique L. Ouellet, Catherine Gérard and Jacques P. Tremblay

Centre de Recherche du Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada and Département de Médecine Moléculaire, Faculté de Médecine, Université Laval, Québec, Québec, Canada.

**Introduction:** The CRISPR system has been proved to efficiently modify DNA molecules both in vitro and in vivo. The system allows to specifically target genome sequences with minimal off-target effects. The actual CRISPR technology toolbox is constantly growing and many different nucleases are available for a broad range of gene editing and modification purposes.

**Methods:** In order to remove the GAA repeat expansion, a major mutation of the FXN gene known to be involved in the Friedreich Ataxia, we designed sgRNA and used either *S. pyogenes* or *S. aureus* Cas9 nuclease to cut in intronic regions flanking the repeat. In vitro experiments have been done using mouse YG8sR isolated fibroblasts containing a human FXN mutated transgene while in vivo experiments were performed on YG8sR mice injected with adeno-associated viruses (AAV).

**Results:** In vitro results showed a 2-fold increase of the frataxin protein expression following correction of the mutation in YG8sR fibroblasts. Therefore, the aconitase activity in treated cells was restored to wild-type level. In vivo results in YG8sR mice showed efficient delivery of a PHP.B-serotyped AAV encoding CRISPR components in tissues of the central nervous system, including the cerebellum and the dorsal root ganglia. The deletion of the GAA repeat expansion (200 repeats) was detected using digital droplet PCR (ddPCR) and percentages of edited molecules varied between the analyzed tissues, with a range between 0.2 and 2.1% after one-month injection. Long-term experimentations are ongoing and will be further discussed.

**Conclusion:** The CRISPR system can be used to remove the GAA repeat expansion from a mutated FXN gene and could represent a one-time treatment for the Friedreich Ataxia, a monogenic disease for which there is no cure.

200.

194. [Combining transcranial direct current stimulation and intensive physiotherapy in patients with Friedreich's Ataxia: a pilot study.](#)

Vavla, M; Paparella, G; Merotto, V; Comiotto, J; Piai, J; Martinuzzi, A  
IRCCS E. Medea Scientific Institute, Conegliano and Pieve di Soligo, Italy

Friedreich's ataxia (FRDA) is a neurodegenerative disorder affecting primarily the dorsal columns of the spinal cord and cerebellum. FRDA leads to progressive disability and reduced lifespan. No cure is currently available. The effect of physiotherapy in FRDA has been debated with no definitive recommendation either in favor or against it. The transcranial Direct Current Stimulation (tDCS) is a safe and non-invasive technique applying small-intensity currents directly to the scalp leading to cortical excitability. tDCS has been applied to various neurological conditions, including ataxias, with promising results. However, the use of tDCS to potentiate the effects of rehabilitative-intervention has never been tested. We propose a pilot randomized double-blind study in FRDA undergoing intensive-physiotherapy treatment and randomly allocated into active- vs sham-tDCS. We recruited 4 patients: 3F/1M; aged  $20.25 \pm 3.86$  years; disease duration  $10.75 \pm 3.77$  years; GAA1  $662.5 \pm 159.87$ , Friedreich's Ataxia Rating Scale (FARS) staging 1-4 and no contraindication to tDCS. The intensive-physiotherapy program consisted in 5-weeks of 2 sessions/day targeting balance and core-stability. The anodal-stimulation was applied over M1 and cerebellar cortex bilaterally once/day for 2-weeks, 20 minutes, 2mA intensity in the active-tDCS. Patients were assessed at pre-/post-treatment with FARS, 6-minute walking test (6-MWT), MiniBEST, BERG. Descriptive analysis was performed to compare the differences between pre- and post-treatment results in all patients and each group separately.



All patients tolerated the treatments protocol and showed post-treatment functional improvement in all the scales applied. Active-tDCS showed a greater improvement in the FARStot score, upright- stability section and in 6MWT when compared to sham-tDCS group. Intensive-physiotherapy in FRDA ambulatory patients results in measurable improvements in functional scales. The effect on walking and upright-stability is potentiated by tDCS to M1 and cerebellum. This difference might be due to the effect of the cortical stimulation in pathways involved in the motor control. Larger RTC are needed to confirm these results.

#### 195. [Speech Rehabilitation in Friedreich ataxia](#)

Adam P. Vogel 1,2 (PhD)\*, Natalie Rommel 1,3 (MSc), Matthis Synofzik 1,4 (MD)

1 Department of Neurodegeneration, Hertie Institute for Clinical Brain Research & Center for Neurology, University Hospital Tübingen, Germany

2 Centre for Neuroscience of Speech, The University of Melbourne, Victoria, Australia

3 TherapieZentrum, University Hospital Tübingen, Germany

4 Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Germany

**Introduction:** The loss of the ability to speak is a devastating and inevitable outcome of many neurodegenerative diseases. It results in daily disadvantage, stigmatisation, social marginalisation and underemployment. Disordered speech is an inevitable consequence of hereditary ataxias.

**Methods:** We have designed a home-based, intensive four-week speech exercise programme designed to improve speech in people with hereditary ataxia. The treatment protocol is based on principles of motor learning and neuroplasticity with a focus on improving speech intelligibility and vocal control. Exercises and feedback were created to enhance self-monitoring and include computer based aural, visual and results feedback and self-management. 17 patients with a degenerative ataxia (7x ARSACS, 5x SCA6, 2 x SCA1, 2 x SCA3) have completed the study so far. Efficacy was measured by an expert listener blinded to time-point rating intelligibility of speech samples from the study participants using Direct Magnitude Estimation. (DME). DME dictates that samples are compared to a pre-identified anchor.

**Results:** In these 17 participants, mean (SD) intelligibility was 98.0 (29.8) points at baseline and 119.5 (25.4) 4-weeks post-baseline with Pearson's correlation coefficient of 0.9. The relative (%) increase in speech intelligibility from baseline to post-treatment was statistically significant (geometric mean of the post-treatment/baseline ratio 1.25, 95% CI [1.16, 1.35],  $p < 0.0001$ ) using a two-sided paired t-test on base-2 log-transformed outcome data. Relative improvements from baseline in intelligibility of 5-10% represent clinically meaningful change in participants' speech including significant change in voice quality and naturalness in a variety of tasks (eg. conversation). We saw individual relative increases in intelligibility between -7-80% in our pilot data. On an individual level, 16/17 (94%) patients responded to treatment.

**Conclusions:** Our preliminary speech rehabilitation data has yielded promising results. Our pilot data shows that even mild dysarthria improves with our intervention. The relative improvement is larger for those ataxia participants (SCA) with more severe dysarthria. A larger trial continues.

#### 196. [EPI-743 \(Alpha-tocotrienol Quinone\) Demonstrates Long-Term Improvement in Neurological Function and Disease Progression in Friedreich's Ataxia](#)

Theresa Zesiewicz<sup>1</sup>, Susan Perlman<sup>2</sup>, Kelly Sullivan<sup>3</sup>, Yangxin Huang<sup>4</sup>, Jason Salemi<sup>5</sup>, Matthew Klein<sup>6</sup>, Charles Isaacs<sup>7</sup>, Clifton Gooch<sup>1</sup>, Jessica Shaw<sup>1</sup>, David Lynch<sup>7</sup>

1 - Department of Neurology, University of South Florida; 2-Department of Neurology, University of California, Los Angeles; 3 - Georgia Southern University; 4 - Department of Biostatistics, University of South Florida; 5 - Baylor College of Medicine; 6 – BioElectron Technology Corporation; 7 - CHOP University of Pennsylvania  
Study Supported by: Edison Pharmaceuticals, Mountainview, CA, provided all study support and investigational product.

**Introduction:** FRDA is an inherited ataxia caused by impairment of mitochondrial iron-sulfur-cluster protein assembly. EPI-743 is a compound that targets oxidoreductase enzymes essential for redox control of metabolism. The objective of this study was to evaluate the long-term safety and clinical effects of EPI-743 in Friedreich's Ataxia (FRDA).

**Methods:** We conducted a multicenter trial that included a 6-month multiple dose placebo controlled phase, followed by an 18-month phase in which all subject received treatment with EPI-743. The primary study objective was low contrast visual acuity as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS). The key secondary study endpoint was neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS) – NEURO.

**Results:** A total of 63 subjects were enrolled in the trial; 61 completed the initial phase. EPI-743 was found to be safe and well tolerated, and demonstrated consistent pharmacology. During the placebo- controlled phase, there were no significant improvements in the primary or secondary endpoints using raw scores. However, significantly more patients taking low-dose EPI-743 had a 3-point or greater improvement (equivalent to one year of symptom progression in natural history cohorts) in the FARS NEURO than patients taking placebo ( $p = 0.047$ ).

Longitudinal modeling at 24 months revealed significantly improved disease progression in all drug groups when compared to natural history data. Using FA Clinical Outcome Measure data, the mean FARS increase (worsening) in untreated patients over 24 months is 4.8 points, compared to a mean decrease (improvement) in all patients taking EPI-743 of 1.8 points (2-tailed t-test with equal variance  $p=0.00001$ ).

**Conclusions:** EPI-743 was safe and well tolerated, and although it did not reach the primary endpoint following six months, long-term treatment resulted in significantly improved neurological outcome after 24 months compared to natural history data.

#### 197. RNA therapeutics for Friedreich's Ataxia

Zucchelli Silvia<sup>1,2</sup>, Bon Carlotta<sup>1</sup>, Fimiani Cristina<sup>1</sup>, Tigani Wendalina<sup>1</sup>, Fortuni Silvia<sup>3</sup>, Luffarelli Riccardo<sup>3</sup>, Condò Ivano<sup>3</sup>, Mallamaci Antonello<sup>1</sup> and Gustincich Stefano<sup>1,4</sup>.

<sup>1</sup>Area of Neuroscience, SISSA, Trieste, Italy

<sup>2</sup>Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy <sup>3</sup>Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata', Roma, Italy <sup>4</sup>Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy

Friedreich's ataxia (FRDA) is a fatal untreatable neurodegenerative disease caused by expansions of guanine-adenine-adenine (GAA) repeats in intron 1 of the frataxin (FXN) gene. Homozygous GAA repeat expansion leads to significantly decreased quantities of frataxin mRNA and protein. In principle, any molecular manipulation eliciting an increase in frataxin levels should be beneficial. Recent studies of mammalian transcriptomes have identified new classes of small and long non-coding regulatory RNAs that may be used as therapeutics. Here we describe the application of recently discovered classes of small RNA molecules, RNAa, and long non-coding RNAs, SINEUP, to respectively increase transcription and translation of frataxin and rescue the disease phenotype in FRDA cellular models.

We show that four independent artificial miRNAs targeting FXN promoter (FXN- RNAa) are able to elicit a moderate, however reliable, upregulation of frataxin mRNA in HEK293T cells. The transcriptional upregulation activity of the best-performing FXN-RNAa was further validated in immortalized peripheral lymphocytes, obtained from FRDA patients, and in patients' fibroblasts.

In a parallel approach, upon screening in HEK 293T cells, we selected a number of FXN-specific SINEUPs that increase frataxin protein quantities acting at a post- transcriptional level. SINEUP-FXN activity is retained when tested in human neuroblastoma cells. Most importantly, SINEUP-FXNs could elicit a 2-fold increase in frataxin protein quantities in fibroblasts derived from FRDA patients.

Our results pave the way for new therapeutic strategies to cure FRDA and provide new classes of RNAs for molecular medicine.

### 199. What to look for in a clinical trial? How clinical trials can be interpreted differently in reviews.

Mary G Kearney<sup>1,2</sup>, Richard W Orrell<sup>3</sup>, Michael Fahey<sup>4</sup>, Massimo Pandolfo<sup>2,5</sup>

<sup>1</sup> General Practice, Irish College of General Practitioners, Dunlavin, Ireland. <sup>2</sup>European Patient Advocate for European Reference Network, (ERN-RND) [www.ern-rnd.eu](http://www.ern-rnd.eu) <sup>3</sup>Department of Clinical Neurosciences, University College London Institute of Neurology, London, UK.

<sup>3</sup>Department of Paediatrics, Monash University, Clayton, Australia.,<sup>5</sup>Department of Neurology, Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium Massimo Pandolfo.

#### INTRODUCTION:

Before changing your practice in the light of a recently published clinical trial or review, it is important to assess if the clinical trial or review is relevant, valid and appropriate for the population you are treating. In particular, did the author just use reviews from people known to him or did the author do a systematic search? Is it an objective review?

Every year, researchers and scientists publish more than three million new articles in scientific journals. It has been estimated that a health professional would need to read 20 articles every day just to stay on top of their field. These articles range from background information, expert opinion, case series, case controlled studies, cohort studies, randomised controlled trials, critically appraised individual articles, critically appraised topics to systematic reviews at the top of the mountain. A systematic review gives a thorough yet abridged view of the evidence in a particular field.

#### OBJECTIVES:

- 1) To explore different types of clinical trials and reviews
- 2) To critical appraise clinical trials which are used in reviews
- 3) To look at the framework for systematic reviews

#### RESULTS:

This poster aims to:

- 1) summarise what to look for in a clinical trial,
- 2) give a framework to assess reviews,
- 3) explain the theory of pooling the results of small studies to form a meta-analysis,
- 4) help resolve contradictory findings among different studies on the same question.

Example of quantitative summary known as meta-analysis from systematic review

#### DISCUSSION:

Systematic Reviews were conceived as early as the 17th century when astronomers began to see the value of combining data sets instead of choosing between one and the other.

Increasingly, medicine required some sort of synthesis, particularly in simplifying the eventual clinical decisions of medical practitioners. Cochrane Systematic Reviews aim to answer a particular research question using a structured approach, explicitly formulated, reproducible, are constantly updated.

Systematic reviews are prepared by a team of at least two reviewers who have a thorough understanding of the clinical area and review methodology to minimize bias and significantly reduce human error.

Keywords: Review, Bias, meta-analysis

200. Gene-targeted synthetic molecules stimulate transcription through repressive GAA-repeats in patient-derived Friedreich's ataxia cells.

Matthew Grieshop (see oral presentations)